

# *The Second Report of the National Eye Database 2008*

## **Includes reports on:**

Cataract Surgery Registry 2002, 2003, 2004, 2007 and 2008

Diabetic Eye Registry 2007, 2008

Contact Lens Related Corneal Ulcer 2007, 2008

Age-related Macular Degeneration Registry 2008

Retinoblastoma Registry 2008

Ophthalmology Service Census 2002 to 2008

## **Edited by:**

Goh Pik Pin

Bethel Livingstone

Elias Hussein

Mariam Ismail




## **With contributions from:**

Aziz Salowi, Zuraidah Mustari, Shamala Retnasabapathy, Ong Poh Yan, Jamalia Rahmat,

Tara Mary George, Nor Fariza Ngah, Chandramalar T Santhirathelgan,

Loh Swee Seng, Radzlian Othman, Ang Ee Ling, Poh Eu Ping



# *The Second* — *Report of the National* *Eye Database* **2008**

**Edited by:**

Goh Pik Pin

Bethel Livingstone

Elias Hussein

Mariam Ismail

[www.acrm.org.my/ned](http://www.acrm.org.my/ned) January 2010  
© National Eye Database

**Published by the**  
National Eye Database (NED)  
Registry Coordinating Centre  
c/o Clinical Research Centre  
Level 4, Specialist Office  
Hospital Selayang  
Lebuhraya Selayang -Kepong  
68100 Batu Caves Selangor  
Malaysia

**Contact**  
Chairperson: Dr Goh Pik Pin  
General Line: 603-61203233 Ext.: 4169  
Fax: 603-61207564  
Email: [ned@acrm.org.my](mailto:ned@acrm.org.my)  
Website: <http://www.acrm.org.my/ned>

**Disclaimer**  
Data reported here are supplied by the NED.  
Interpretation and reporting of these data are the responsibility of the editors and in no way should be seen  
as an official policy or interpretation of the NED.  
This report is copyright. However it can be freely reproduced without the permission of the NED. However,  
acknowledgement would be appreciated.

**Suggested citation**  
The suggested citation for this report is as follows:  
Goh Pik Pin, Bethel Livingstone, Elias Hussein, Mariam Ismail (Eds)  
THE SECOND ANNUAL REPORT OF THE NATIONAL EYE DATABASE, 2008  
Kuala Lumpur, Malaysia 2010

**Electronic version**  
The electronic version of this report can be downloaded at <http://www.acrm.org.my/ned>

|                |
|----------------|
| ISSN 1985-7489 |
|----------------|

## **ACKNOWLEDGEMENTS**

The National Eye Database (NED) thank the following:

Director-General of Health for the permission to publish the report.

Heads of ophthalmology departments, site coordinators and doctor in-charge at 37 MOH hospitals and resident optometrists at three district hospitals without ophthalmologists. They are source data providers to NED.

Staff Nurse Teng Kam Yoke, NED clinical registry manager at Registry Coordinating Centre.

Dr Lim Teck Onn, Director of Network of Clinical Research Centre (CRC), MOH.

Dr Jamaiah Haniff, Head of Clinical Epidemiology Unit of CRC.

Information technology personnel namely Ms Lim Jie Ying, database administrator, Ms Teo Jau Shya, clinical data manager, Ms Amy Porle, web application programmer, Ms Azizah Alimat, desktop publisher and Ms Huziana Fauzi, clinical data assistant.

Statisticians Ms Lena Yeap Lay Ling and Ms Siti Norhazrina Binti Abd Wahab.

Matron Wakia Abdul Wahab, CRC Manager and Ms Sujahila bt Zulkipli, assistant administrator at Clinical Research Unit, Selayang Hospital.

Dr Hjh Siti Zaleha Mohd Salleh, Director of Selayang Hospital.

Pfizer, Novartis, Alcon Laboratories Sdn Bhd and Allergan for providing financial support.

Many others, whose names are not listed here, for their support.

Thank you.

NED Steering Committee Members  
Jan 2010

## NED STEERING COMMITTEE MEMBERS 2007-2008

|             |   |
|-------------|---|
| Advisor     | Dr Bethel Livingstone<br>Head, Ophthalmology Service, MOH<br>Head & Consultant Ophthalmologist,<br>Ophthalmology Department, Hospital Tuanku Jaafar, Seremban   |
| Chairperson | Dr Goh Pik Pin<br>Public Health Ophthalmologist/ Consultant Ophthalmologist<br>Ophthalmology Department, Hospital Selayang<br>Principal Investigator for Cataract Surgery Registry  |
| Members     | <p>Dr Mariam Ismail<br/>Head &amp; Vitreoretinal Consultant, Ophthalmology Department, Hosp. Selayang</p> <p>Dr Elias Hussein<br/>Consultant Ophthalmologist, Primary Eye Care Service<br/>Ophthalmology Department, Hospital Selayang<br/>National Coordinator for Key Performance Indicators</p> <p>Dr Radzlian Othman<br/>Head &amp; Consultant Ophthalmologist, Oculoplasty Service<br/>Ophthalmology Department, Hospital Serdang<br/>National Coordinator for Monthly Ophthalmology Service Census, MOH</p> <p>Dr Shamala Retnasabapathy<br/>Consultant Ophthalmologist, Corneal Service<br/>Ophthalmology Department, Hospital Sungai Buloh<br/>Principal Investigator for Contact Lens-related Corneal Ulcer Surveillance</p> <p>Dr Ong Poh Yan<br/>Consultant Ophthalmologist, Glaucoma Service<br/>Ophthalmology Department, Hospital Selayang<br/>Principal Investigator for Glaucoma Registry</p> <p>Dr Nor Fariza Ngah<br/>Consultant Ophthalmologist, Medical Retina Service<br/>Ophthalmology Department, Hospital Selayang<br/>Principal Investigator for Diabetic Eye Registry</p> <p>Dr Zuraidah Mustari<br/>Head &amp; Consultant Ophthalmologist<br/>Ophthalmology Department, Hospital Sultanah Nur Zahirah, K. Terengganu<br/>Principal Investigator for Tele-Diabetic Retinopathy</p> <p>Dr Mohd Aziz Salowi<br/>Ophthalmologist, Hospital Umum Sarawak</p> <p>Puan Che Rohani<br/>Head of Optometry Service, Optometrist, Hospital Kuala Lumpur</p> |
| Secretariat | Teng Kam Yoke<br>Ophthalmic trained staff nurse<br>NED Clinical Registry Manager  |

### Technical Support Personnel

|                                      |   |
|--------------------------------------|---|
| Statistician                         | Ms Lena Yeap Lay Ling<br>Ms Siti Norhazrina Binti Abd Wahab |
| Database Administrator               | Mrs Lim Jie Ying  |
| Clinical Data Manager                | Ms Teo Jau Shya   |
| Web Application Developer            | Ms Amy Porle  |
| Clinical Data Management Assistant   | Ms Huziana Fauzi  |
| Desktop Publisher & Website Designer | Mrs Azizah Alimat   |

## **ABOUT NATIONAL EYE DATABASE**

### **Introduction**

The National Eye Database (NED) is an eye health information system supported by MOH. It is a clinical database consisting of six patient registries and a monthly ophthalmology service census. The patient registries are Cataract Surgery Registry, Diabetic Eye Registry, Contact Lens-Related Corneal Ulcer Surveillance, Glaucoma Registry, Retinoblastoma Registry, and Age Related Macular Degeneration Registry. The source data producers are eye care providers, currently from the public. Information collected, both clinical and epidemiological, are very useful in assisting the MOH, Non-Governmental Organizations, private healthcare providers and industry in the planning, evaluation and continuous improvement of eye care services, leading to prevention and control of blindness in the nation.

### **Vision**

An accessible eye health information.

### **General Objectives of the National Eye Databases**

1. To establish and maintain a web based eye health information system on natural history of visual threatening eye diseases, which are of public health importance. The information is useful in the planning and evaluation of eye care service.
2. To determine the effectiveness of treatment, both clinical outcomes and cost, and to identify factors influencing outcomes. This serves the needs of outcome assessment.
3. To provide information necessary to evaluate ophthalmology services through census and key performance indicators, as well as on safety or harm of products and services used in the treatment of a disease. This contributes to continuous quality initiative.
4. To evaluate the accessibility and equity in health care provision. This information enhances accountability.
5. To provide a mean of prompt and wide dissemination of epidemiological and clinical information through web such as real time registries reports and notification of epidemic of contact lens-related corneal ulcer. This is essential for public health advocacy.
6. To stimulate and facilitate research on eye diseases.

### **Specific Objective of Individual Registry and Census**

#### **Cataract Surgery Registry**

The Cataract Surgery Registry (CSR) was initiated in 2002 and collects data pertaining to patients who have had cataract surgery. Data collected include demography, medical history, operative events, post-operative visual outcomes and probable causes for poor outcome. Since 2008, data on posterior capsular rupture, visual outcome and post-operative endophthalmitis were linked to online key performance indicator for monitoring centre performance while data on incidence of posterior capsular rupture and patients with poor visual outcome are linked to online cumulative sum (CUSUM) to monitor competency of individual surgeon. Annual reports for the year 2002, 2003, 2004 and 2007 are available at [www.acrm.org.my/ned](http://www.acrm.org.my/ned), under the section of publication.

#### Specific Objectives

1. To determine the frequency, distribution and practice pattern of cataract surgery in Malaysia.
2. To determine the outcomes and factors influencing outcomes of cataract surgery.
3. To evaluate cataract surgery services based on rate of posterior capsular rupture, post-operative infection, post-operative visual outcome and induced astigmatism.
4. To stimulate and facilitate research on cataract and its management.

#### Diabetic Eye Registry

Diabetic eye registry collects data on patients who are seen for the first time at MOH ophthalmology clinics and some optometry clinics at hospitals without ophthalmologists. All MOH ophthalmology clinics participated in 2007 and 2008. From 2009 onwards, participation is optional.

#### Specific Objective

1. To evaluate the status of diabetic retinopathy at the first diabetic eye screening at Ophthalmology clinics.

#### Contact Lens-Related Corneal Ulcer Surveillance

Contact lens-related corneal ulcer surveillance was initiated in 2007 following the global outbreak of fusarium keratitis related to contact lens cleaning solution in 2006. Surveillance for the years 2007 and 2008 only cover MOH ophthalmology clinics and the findings were similar for both the years. Therefore, unless private and university ophthalmology clinics also take part in this active surveillance, the findings will not be comprehensive. Thus the surveillance will stay dormant from 2009 onwards. The web application can be activated when necessary in the future.

#### Specific Objectives

1. To detect outbreak of contact lens-related corneal ulcer.
2. To determine pattern of causative organism of corneal ulcer.
3. To study the characteristics of patients in terms of demography, risk factors and contact lens type and wearing patterns.
4. To monitor the outcome of patients with contact lens related corneal ulcer.

#### Glaucoma Registry

Glaucoma registry captures data on patient demography, types of glaucoma, risk factors and mode of management. The participation to this registry is optional.

#### Specific Objectives

1. To study the demographic characteristics of glaucoma patients, glaucoma suspects and patients with ocular hypertension.
2. To determine the types of glaucoma.
3. To assess risk factors associated with glaucoma, glaucoma suspects and patients with ocular hypertension.
4. To evaluate the pattern of management among glaucoma patients.

### **Retinoblastoma Registry**

Retinoblastoma registry collects data on the pattern of clinical presentation, mode of treatment and outcome of patients with retinoblastoma seen at ophthalmology clinics with paediatric ophthalmology service. The main SDP is Hospital Kuala Lumpur.

#### **Specific Objectives**

1. To determine the incidence and distribution of retinoblastoma in different states in Malaysia.
2. To determine the ethnic-specific prevalence of retinoblastoma in Malaysia.
3. To study characteristics of RB patients in terms of clinical presentation and stage of disease based on International Intraocular Retinoblastoma Classification.
4. To evaluate types of treatments and monitor treatment trends.
5. To evaluate treatment outcomes including complications related to treatment.

### **Age Related Macular Degeneration Registry**

Age Related Macular Degeneration (AMD) registry collects data on demographics, risk factors, clinical features and methods of treatment used in newly diagnosed patients with AMD. Hospital Selayang is the only SDP in 2008.

#### **Specific Objectives**

1. To determine patients' characteristics, risk factors and clinical presentation of AMD.
2. To study types of AMD based on clinical and investigative examinations.
3. To evaluate quality of life among AMD patients.
4. To evaluate types of treatments given to patients.

### **Monthly Ophthalmology Service Census**

Since 2002, Ophthalmology Service of MOH has been collecting annual census from all the hospitals with ophthalmology departments. Data include essential service census and key performance indicators for ophthalmology service. There are 13 sections in the census return, namely out-patients, inpatients, major eye operations, cataract service, diabetic service, glaucoma service, and optometry service, and subspecialty services which include vitreoretinal, corneal, paediatric ophthalmology, oculoplasty, medical retinal, and a public health ophthalmology, and data on training records and prevention of blindness activities. Data are entered monthly by staff at sites via on-line data entry. Heads of ophthalmology department can view their own and other hospitals' real-time reports.

#### **Specific Objectives**

1. To evaluate service output in all ophthalmology departments.
2. To study trends in service output and service patterns.
3. To get baseline and norm from services provided by MOH ophthalmology departments.
4. To determine norm and set standards for performance indicators for centres which differ in strength of physical and human resources.

### **Cusum- Ophthalmology**

Cataract surgery is the most common procedure done in ophthalmology departments. The procedure is quite consistent and outcome is measured by visual acuity. Cataract surgery outcome depends greatly on surgeons' skill. With advancement in technology and intraocular lens implantation, good visual outcome is almost certain among patients without pre-existing ocular co-morbidity. Hence, monitoring and evaluating surgeons' competency, especially trainees' performance, are essential in ensuring standard of care.

Cumulative Sum (CUSUM) software auto-mine data on occurrence of posterior capsular rupture and patients with post-operative vision worse than 6/12 from cataract surgery registry on surgery done by individual surgeon using unique surgeon ID. From 2008, by using individual unique username and password, surgeon can access his/her own CUSUM charts via eCUSUM web page. Consultant ophthalmologists can view their own as well as their trainees' charts. By doing so, monitoring on surgeons' competency in cataract surgery is made most effectively and easily.

### Key Performance Indicator

The Ministry of Health (MOH) launched the implementation of Key Performance Indicators (KPIs) in February 2008 with the aim to assess the overall performance of services provided by Clinical Departments in MOH. The MOH Ophthalmology Service has identified eight KPIs which measure clinical performance of core ophthalmology service such as out-patient service, cataract surgery and diabetic eye screening.

Key Performance Indicators related to cataract surgery such as rate of infectious endophthalmitis following cataract surgery, posterior capsular rupture and postoperative visual acuity better than 6/12 in patients without ocular co-morbidity are data mined from cataract surgery registry.

#### Ophthalmology Service KPIs:

| Aspect of Performance : QUALITY & SAFETY             |   |  |
|--|---|--|
| Dimension : Patient-focused Care                     |   | Optimal Target / Standard  |
| No. 1  | Waiting time to see a doctor at the Specialist Clinic   | > 90% of the patients are seen within ninety (90) minutes                            |
| No. 2  | Waiting Time to get an appointment for First Consultation for Diabetic Patients at the Specialist Clinic                                  | > 80% of the patients are given an appointment for First Consultation within 6 weeks |
| No. 3  | Waiting Time for Cataract Surgery   | > 80% of patients have appointment given for cataract surgery within 16 weeks        |
| Dimension : Clinical Effectiveness & Risk Management |   |  |
| No. 4  | Rate of Infectious Endophthalmitis following Cataract Surgery   | < 0.2% (2 cases per 1000 operations)   |
| No. 5  | Rate of Posterior Capsular Rupture during Cataract Surgery  | < 5 % (50 cases per 1000 operations)   |
| No. 6  | Rate of Post-operative Visual Acuity of 6/12 or better within 3 months following Cataract Surgery in Patients without Ocular Co-morbidity | > 85 % (850 cases per 1000 operations)*  |
| No. 7  | Average Frequency of Mortality / Morbidity Review being Conducted in Ophthalmology Department Monthly                                     | At least 6 times in 6 months   |
| Aspect Of Performance : PRODUCTIVITY                 |   |  |
| Dimension : Workload                                 |   |  |
| No. 8  | Percentage of Out-patients seen by Specialist in specialist clinic per Month  | To be decided  |

In 2009, we added two new features i.e. interactive online charting and intraocular lens (IOL) defect notification. The interactive online charting allows public users to identify findings they want to display in tables. While IOL defect notification acts as a mean for all public and private eye care providers to notify IOL defect, an initiative to promote patient safety.

### **Methods of the National Eye Database**

The National Eye Database is designed as a cohort study. It is an online clinical database hosted at the Association of Clinical Registry Malaysia website at [www.acrm.org.my/ned](http://www.acrm.org.my/ned). Its protocol was approved by the Medical Research Ethical Committee of MOH on 2<sup>nd</sup> September 2008 (reference number NMRR 08-552-1707) and is accessible at the NED website.


Data collection and data entry are done at SDP sites. Data are collected either using case report forms (CRF) (refer to appendix), which are later entered into the web application, or are directly entered into the web application during the course of clinical work.

Data management using data query are set in the web application to reduce inconsistency, out-of-range or missing values. Authorised staff at each SDP are given passwords to perform data entry. Individual SDP reports and aggregated reports based on cumulative data of all SDPs are available real-time at NED website. These reports are only accessible by heads of department, doctors-in-charge and site coordinators via authorised password. The web reports are descriptive analysis of data which have been entered. Annual statistical report will be produced based on data collected for a specific year. The statistical reports will be published yearly and distributed to users in MOH divisions and units, all the ophthalmology departments, universities, other relevant public agencies and non-governmental organisations.

The NED has high level of security for protection of its data. Data protection is ensured at all times through strict compliance with regulatory requirements such as authentications of users and web application owners, access control, encryption, audit trail, control of external communication links and access, as well as system backup and disaster recovery.

NED Organization

Organisation Chart



## NED SOURCE DATA PROVIDERS

### List of doctors in charge & site coordinators for 2008-2009

| Northern Zone |  |                                       |                            |
|---------------|--|---------------------------------------|----------------------------|
| No.           | SDP  | Doctor-in-charge                      | Site Coordinator           |
| 1.            | Hospital Kangar                            | Dr Noram Azian bin Ramli              | Roslinda bt Rahman         |
| 2.            | Hospital Sultanah Bahiyah                  | Dr Lee Annie                          | Nur Diana Mohd Zani        |
| 3.            | Hospital Sungai Petani                     | Dr Rosnita binti Alias                | Juliana Md Desa            |
| 4.            | Hospital Pulau Pinang                      | Dr Ang Ee Ling                        | Noor Asmah Md Azmi         |
| 5.            | Hospital Bukit Mertajam                    | Dr Ng Seok Hui                        | Maria Mohamad Muhayadin    |
| 6.            | Hospital Ipoh                              | Dr Poh Eu Ping                        | Noraini Harith             |
| 7.            | Hospital Taiping                           | Dr Ng Sok Lin                         | Rohaiza bt Abdul Hamid     |
| 8.            | Hospital Teluk Intan                       | Dr Noram bt Mat Saad                  | Adawiyah Ismail            |
| 9.            | Hospital Sri Manjung                       | Dr Yushaniza Yaacob                   | Juhaida bt Zahri           |
| Central Zone  |  |                                       |                            |
| No.           | SDP  | Doctor-in-charge                      | Site Coordinator           |
| 10.           | Hospital Selayang                          | Dr Shelina Oli Mohamed                | Nurul Aini Yusoff          |
| 11.           | Hospital Kuala Lumpur                      | Dr Rohanah Alias                      | Intan Khususiah Abd Rahman |
| 12.           | Hospital Tengku Ampuan Rahimah             | Dr Haireen Kamaruddin                 | Najihah Muhammad Sharif    |
| 13.           | Hospital Putrajaya                         | Dr Salmah Othman                      | Lily Muhanifa Mustafa      |
| 14.           | Hospital Serdang                           | Dr Zaida Mohd Kasim                   | Yusrina Mohamat Hata       |
| 15.           | Hospital Sungai Buloh                      | Dr Shamala Retnasabapathy             | Puan Majidah Zainal Abidin |
| 16.           | Hospital Ampang                            | Dr Zalifa Zakiah bt Asnir             | Noriah binti Abdullah      |
| Southern Zone |  |                                       |                            |
| No            | SDP  | Doctor in charge                      | Site Coordinator           |
| 17.           | Hospital Tuanku Jaafar                     | Dr Norlelawati Abu                    | Normalisa Muhammad Som     |
| 18.           | Hospital Tuanku Ampuan Najihah Kuala Pilah | Dr Khairul Husnaini binti Mohd Khalid | Fadhilah Mohd Hilmi        |
| 19.           | Hospital Melaka                            | Dr Juliana Jalaluddin                 | Eryanti Md Omar            |
| 20.           | Hospital Sultanah Aminah                   | Dr Kevin Ong                          | Nurazilah Ismail           |
| 21.           | Hospital Pakar Sultanah Fatimah            | Dr Ngim You Siang                     | Roziana Sumardi            |
| 22.           | Hospital Batu Pahat                        | Dr Jawiah bt Hassan                   | Nur Adilah Abdullah        |
| 23.           | Hospital Sultan Ismail                     | Dr Hooi Siew Tong                     | Puan Nursalinah bt Adam    |

| 24.                                | Hospital Tengku Ampuan Afzan | Dr. Mohamad Aziz Husni     | Noor Azhari bin Ahmad |
|------------------------------------|------------------------------|----------------------------|-----------------------|
| 25.                                | Hospital Temerloh            | Dr Thevi Thanigasalam      | Nor Hanim Ahmad Adnan |
| 26.                                | Hospital Kuala Terengganu    | Dr Nor Anita Che Omar      | Noor Hayati Mohammad  |
| 27.                                | Hospital Kota Bharu          | Dr Azma Azalina Ahmad Alwi | Rossaidah bt Mustapa  |
| 28.                                | Hospital Kuala Krai          | Dr Salazahrin Salleh       | Farawahida Fakaruddin |
| <b>East Malaysia Zone –Sarawak</b> |                              |                            |                       |
| No                                 | SDP                          | Doctor-in-charge           | Site Coordinator      |
| 29.                                | Hospital Umum Sarawak        | Dr Mohd Aziz Salowi        | Nazirin bin Arshad    |
| 30.                                | Hospital Sibu                | Dr Peter Chong             | Suzzana Abdul Karim   |
| 31.                                | Hospital Bintulu             | Dr KM Reddy                | Nurulain Mat Zain     |
| 32.                                | Hospital Miri                | Dr Chieng Lee Ling         | Nur Hafizah Mat Jalil |
| <b>East Malaysia Zone –Sabah</b>   |                              |                            |                       |
| No                                 | SDP                          | Doctor-in-charge           | Site Coordinator      |
| 33.                                | Hospital Queen Elizabeth     | Dr Shuaibah Ab Ghani       | Iramayanah Ambo Mase  |
| 34.                                | Hospital Duchess Of Kent     | Dr Suriana Suaibun         | Norhafizah Abd Razik  |
| 35.                                | Hospital Tawau               | Dr Ajit Majumder           | Nurliyana binti Ishak |
| 36.                                | Hospital Keningau            | Dr Christina Lee Lai Ling  | Hr Shredznear         |
| 37.                                | Hospital Queen Elizabeth     | Dr Shuaibah Ab Ghani       | Iramayanah Ambo Mase  |

## CONTRIBUTING EDITORS

|   | Title  | Editors                                | Institution  |
|---|--|--|--|
| 1 | Cataract Surgery Registry                          | Dr Goh Pik Pin                         | Public Health Ophthalmologist<br>Consultant Ophthalmologist<br>Hospital Selayang |
|   |  | Dr Aziz Salowi                         | Ophthalmologist<br>Hospital Umum Sarawak   |
|   |  | Dr Loh Swee Seng                       | Head, Ophthalmology Department<br>Hospital Sultanah Aminah                       |
|   |  | Dr Poh Eu Ping                         | Ophthalmologist<br>Hospital Raja Permaisuri Bainun                               |
|   |  | Dr Ang Ee Ling                         | Ophthalmologist<br>Hospital P .Pinang  |
| 2 | Diabetic Eye Registry                              | Dr Zuraidah Mustari                    | Head & Consultant Ophthalmologist<br>Hospital Sultanah Nur Zahirah               |
|   |  | Dr Nor Fariza Ngah                     | Consultant Ophthalmologist<br>Medical Retina Service<br>Hospital Selayang        |
| 3 | Contact Lens-Related<br>Corneal Ulcer Surveillance | Dr Shamala<br>Retnasabapathy           | Consultant Ophthalmologist<br>Corneal Service<br>Hospital Sungai Buloh           |
|   |  | Dr Chandramalar T.<br>Santhirathelagan | Consultant Ophthalmologist<br>Corneal Service<br>Hospital Sungai Buloh           |
| 4 | Glaucoma Registry                                  | Dr Ong Poh Yan                         | Consultant Ophthalmologist<br>Glaucoma Service<br>Hospital Selayang              |
|   |  | Dr Vivian Gong                         | Consultant Ophthalmologist<br>Glaucoma Service<br>Hospital Ipoh                  |
| 5 | Age Related Macular<br>Degeneration Registry       | Dr Tara Mary George                    | Consultant Ophthalmologist<br>Medical Retina Service<br>Hospital Selayang        |
| 6 | Retinoblastoma Registry                            | Dr Jamalia Rahmat                      | Consultant Ophthalmologist<br>Paediatric Ophthalmology<br>Hospital Kuala Lumpur  |
| 5 | Ophthalmology Service<br>Census                    | Dr Mariam Ismail                       | Head, Ophthalmology Department<br>Vitreoretinal Service<br>Hospital Selayang     |
|   |  | Dr Goh Pik Pin                         | Consultant Ophthalmologist<br>Hospital Selayang                                  |
|   |  | Dr Radzlian Othman                     | Head & Consultant Ophthalmologist<br>Oculoplasty Service<br>Hospital Serdang     |
|   |  | Dr Elias Hussein                       | Consultant Ophthalmologist<br>Hospital Selayang                                  |

## FOREWORD

The National Eye Database (NED) web application established in 2007, is now in its fourth year. The Malaysian Society of Ophthalmology is now a co-sponsor, together with the ophthalmology service of MOH. The NED also receives financial support from Pfizer, Novartis, Allergan and Alcon Laboratories Sdn Bhd.

This second annual report contains report of cataract surgery registry (CSR) from 2002 to 2008, diabetic eye registry 2008-2009, contact lens-related corneal ulcer surveillance 2008-2009, glaucoma registry 2008-2009, ophthalmology service census 2002-2008, and reports of two new registries, i.e. age-related macular degeneration and retinoblastoma registry.

Over the years, we see an increased level of ascertainment for cataract surgery registry, based on the number of cataract surgeries recorded in the service census. Source data producers can access real-time reports for all the data entered for their hospitals as well as the aggregated reports.

From 2009, we have incorporated the ophthalmology service key performance indicator (KPI) into the web application. Out of the eight KPIs, we are able to mine data from CSR of the three KPIs that are related to cataract surgery, which means we will save time and effort in data collection. The other new features in 2009 include interactive online charting and IOL defect notification.

There are many challenges faced by NED. To overcome these challenges, we need the leadership and commitment of head of departments (HOD) to lead their staff to work towards the success of NED. The following are the challenges we faced and the actions we need to take:-

1. Ascertainment rate for cataract surgery- HODs need to ensure their staff enter data of all the patients who have had cataract surgeries into the CSR, since data from CSR are used for competency monitoring through CUSUM and also for calculation of department KPI.
2. Data quality- staff in-charge of NED should ensure case report forms are completely filled, i.e. no missing values, and ensure data are accurate as stated in the definition of data which falls within the range of variables.
3. Prompt data entry, especially for the outcome of cataract surgery and service census.
4. Use of report- real-time report from service census, eKPI and cataract surgery registry can be used for department audit and planning.
5. Review eCUSUM chart- Head of department should review trainee's CUSUM charts for the purpose of competency monitoring.
6. Maintenance of web application- we need to seek financial support from professional bodies and industry.

As data collected for contact lens-related corneal ulcer surveillance, diabetic eye registry and glaucoma registry for 2007 and 2008 show consistent trends, we have stopped data entry from 2009 onwards.

The future of NED is challenging. Research assistants at some state hospitals had to be terminated due to lack of funds, and with a reduction in research grant allocation, NED needs commitment and support from all relevant stakeholders.

NED Advisor

Dr Bethel Livingstone  
Head, Ophthalmology service (2009-2010)  
Hospital Tuanku Jaafar

NED Chairperson

Dr Goh Pik Pin  
Public Health Ophthalmologist  
Hospital Selayang

## ABBREVIATION

|       |                                      |       |  |
|-------|--------------------------------------|-------|--|
| ADED  | Advanced Diabetic Eye Disease        | NED   | National Eye Database                  |
| AMD   | Age related Macular Degeneration     | NPDR  | Non Proliferative Diabetic Retinopathy |
| CAI   | Carbonic Anhydrase Inhibitor         | NPL   | No Perception Of Light                 |
| CF    | Counting Finger                      | OT    | Operating Theatre                      |
| CLRCU | Contact Lens-Related Corneal Ulcer   | PCO   | Posterior Capsule Opacification        |
| CSMO  | Clinically Significant Macular Odema | PCR   | Posterior Capsule Rapture              |
| CMO   | Cystoid Macular Oedema               | PDR   | Proliferative Diabetic Retinopathy     |
| CSR   | Cataract Surgery Registry            | Phaco | Phacoemulsification                    |
| DER   | Diabetic Eye Registry                | PL    | Perception Of Light                    |
| DM    | Diabetes Mellitus                    | PI    | Principal Investigator                 |
| DR    | Diabetic Retinopathy                 | RB    | Retinoblastoma                         |
| ECCE  | Extracapsular Cataract Extraction    | RCC   | Registry Coordinating Centre           |
| FU    | Follow Up                            | SD    | Standard Division                      |
| HM    | Hand Movement                        | SDP   | Source Data Producers                  |
| HPT   | Hypertension                         | VA    | Visual Acuity                          |
| ICCE  | Intracapsular Cataract Extraction    | VR    | Vitreoretinal Surgery                  |
| IOL   | Intraocular Lens                     | ZD    | Zonular Dialysis                       |
| MOH   | Ministry Of Health                   |       |  |



# CONTENTS

|   |             |
|---|-------------|
| <b>ACKNOWLEDGEMENTS .....</b>   | <b>iii</b>  |
| <b>NED STEERING COMMITTEE MEMBERS 2007-2008 .....</b>                         | <b>iv</b>   |
| <b>ABOUT NATIONAL EYE DATABASE .....</b>                                      | <b>v</b>    |
| <b>NED SOURCE DATA PROVIDERS .....</b>  | <b>xi</b>   |
| <b>CONTRIBUTING EDITORS .....</b>   | <b>xiii</b> |
| <b>FOREWORD .....</b>   | <b>iv</b>   |
| <b>ABBREVIATION .....</b>   | <b>xv</b>   |
| <b>CONTENTS .....</b>   | <b>1</b>    |
| <b>LIST OF TABLES .....</b>   | <b>4</b>    |
| <b>LIST OF FIGURES .....</b>  | <b>7</b>    |
| <b>REPORT SUMMARY .....</b>   | <b>9</b>    |
| <b>CHAPTER 1 CATARACT SURGERY REGISTRY .....</b>                              | <b>16</b>   |
| 1.1 STOCK AND FLOW .....  | 17          |
| 1.2 CHARACTERISTICS OF PATIENT .....  | 20          |
| 1.2.1 Patient Demography .....  | 20          |
| 1.2.2 Medical history .....   | 21          |
| 1.2.2.1 Systemic co-morbidity .....   | 21          |
| 1.2.2.2 Causes of cataract .....  | 22          |
| 1.2.2.3 First or Fellow Eye Surgery .....                                     | 23          |
| 1.2.2.4 Past ocular surgery of the operated eye .....                         | 23          |
| 1.2.2.5 Pre-existing ocular co-morbidity .....                                | 24          |
| 1.2.2.6 Pre-operative vision .....  | 26          |
| 1.2.2.7 Target refractive power .....   | 28          |
| 1.3 CATARACT SURGICAL PRACTICES .....   | 29          |
| 1.3.1 Number of Cataract Surgeries Registered by SDP, CSR 2002-2008 .....     | 29          |
| 1.3.2 Number of Cataract Surgeries by Month, CSR 2002-2008 .....              | 29          |
| 1.3.3 Number of cataract surgeries registered by state .....                  | 30          |
| 1.3.4 Surgeon Status .....  | 31          |
| 1.3.5 Duration of surgery .....   | 31          |
| 1.3.6 Distribution of cataract surgery performed under day care setting ..... | 32          |
| 1.3.7 Distribution of types of cataract surgery .....                         | 35          |
| 1.3.8 Distribution of combined surgery .....                                  | 39          |
| 1.3.9 Anaesthesia in cataract surgery .....                                   | 42          |
| 1.3.10 Intraocular lens implantation .....                                    | 49          |
| 1.4 INTRA-OPERATIVE COMPLICATIONS .....                                       | 52          |
| 1.4.1 Intra-operative complications by years .....                            | 52          |
| 1.4.2 Intra-operative complication by type of surgery .....                   | 53          |
| 1.4.3 Intra-operative complications by combined surgery .....                 | 54          |
| 1.4.4 Intra-operative complications by types of local anaesthesia .....       | 56          |
| 1.4.5 Intra-operative complications by surgeon status .....                   | 57          |
| 1.4.6 Rate of posterior capsular rupture by SDPs .....                        | 59          |
| 1.4.7 Rate of posterior capsular rupture by type of cataract surgery .....    | 61          |

|  |  |            |
|--|--|------------|
| 1.5  | CATARACT SURGERY OUTCOME.....  | 61         |
| 1.5.1  | Post-operative Complications.....  | 61         |
| 1.5.1.1  | Post-operative infectious endophthalmitis .....  | 62         |
| 1.5.1.2  | Unplanned return to operating theatre (OT) .....   | 64         |
| 1.5.1.3  | Post-operative follow-up period .....  | 65         |
| 1.5.2  | Post-operative Visual Acuity .....   | 66         |
| 1.5.2.1  | Post-operative visual acuity for all patients .....  | 66         |
| 1.5.2.2  | Post-operative visual acuity for patients without ocular co-morbidity .....                  | 69         |
| 1.5.2.3  | Post-operative visual acuity 6/12 or better among patients without ocular co-morbidity ..... | 72         |
| 1.5.3  | Reasons for no records of visual acuity.....   | 81         |
| 1.5.4  | Factors contributing to post-operative refracted visual acuity of worse than 6/12.....       | 81         |
| 1.5.5  | Actual or residual refractive power .....  | 82         |
| <b>CHAPTER 2 DIABETIC EYE REGISTRY .....</b>                           |  | <b>87</b>  |
| 2.1  | STOCK AND FLOW .....   | 88         |
| 2.1.1  | Number of cases registered by states .....   | 88         |
| 2.1.2  | Number of cases registered by month.....   | 89         |
| 2.2  | CHARACTERISTICS OF PATIENTS.....   | 89         |
| 2.2.1  | Patient demography .....   | 90         |
| 2.2.2  | Source of Referral .....   | 90         |
| 2.3  | MEDICAL HISTORY AND PRACTICE PATTERN .....   | 90         |
| 2.3.1  | Type of Diabetes.....  | 90         |
| 2.3.2  | Duration of Diabetes .....   | 90         |
| 2.3.3  | Type of Treatment.....   | 90         |
| 2.3.4  | Systemic co-morbidity .....  | 90         |
| 2.3.5  | Risk Factors.....  | 91         |
| 2.3.6  | Ocular co-morbidity .....  | 91         |
| 2.3.7  | Pregnancy and eye examination .....  | 92         |
| 2.3.8  | Previous eye examinations.....   | 92         |
| 2.4  | STATUS OF THE EYES .....   | 93         |
| 2.4.1  | Status of visual acuity .....  | 93         |
| 2.4.2  | Status of diabetic retinopathy and maculopathy.....  | 96         |
| 2.5  | TREATMENT PLAN.....  | 98         |
| <b>CHAPTER 3 CONTACT LENS RELATED CORNEAL ULCER SURVEILLANCE .....</b> |  | <b>99</b>  |
| 3.1  | STOCK AND FLOW .....   | 100        |
| 3.2  | DISTRIBUTION OF CASES BY CENTRE .....  | 101        |
| 3.3  | PATIENTS DEMOGRAPHY.....   | 103        |
| 3.4  | DATA ON CONTACT LENS RELATED CORNEAL ULCER AT PRESENTATION.....                              | 105        |
| 3.5  | OUTCOME BY ONE MONTH AFTER PRESENTATION .....  | 114        |
| <b>CHAPTER 4 GLAUCOMA REGISTRY .....</b>                               |  | <b>116</b> |
| 4.1  | INTRODUCTION .....   | 117        |
| 4.2  | CHARACTERISTICS OF PATIENTS.....   | 117        |
| 4.3  | MEDICAL HISTORY .....  | 117        |
| 4.4  | CLINICAL FEATURES.....   | 117        |
| 4.4.1  | Visual acuity .....  | 117        |
| 4.4.2  | Cup disc ratio.....  | 117        |
| 4.4.3  | Types of Glaucoma.....   | 118        |
| 4.5  | MANAGEMENT OF GLAUCOMA .....   | 118        |

|   |            |
|---|------------|
| <b>CHAPTER 5 AGE RELATED MACULAR DEGENERATION REGISTRY.....</b> | <b>120</b> |
| 5.1 PATIENTS DEMOGRAPHY.....                                    | 121        |
| 5.2 RISK FACTORS .....  | 122        |
| 5.3 QUALITY OF LIFE.....  | 122        |
| 5.4 MEDICAL HISTORY .....                                       | 122        |
| 5.5 VISION STATUS.....  | 123        |
| 5.7 INVESTIGATION .....   | 125        |
| 5.8 DIAGNOSIS.....  | 126        |
| 5.9 TREATMENTS .....  | 128        |
| <b>CHAPTER 6 RETINOBLASTOMA REGISTRY .....</b>                  | <b>130</b> |
| 6.1 STOCK AND FLOW .....  | 131        |
| 6.2 PATIENTS DEMOGRAPHY.....                                    | 131        |
| 6.3 OCULAR HISTORY AND PRESENTATION .....                       | 132        |
| 6.4 INVESTIGATION AND CLASSIFICATION .....                      | 134        |
| 6.5 MANAGEMENT .....  | 134        |
| <b>CHAPTER 7 OPHTHALMOLOGY SERVICE CENSUS .....</b>             | <b>136</b> |
| <b>APPENDIX: CASE REPORT FORMS .....</b>                        | <b>144</b> |

## LIST OF TABLES

|                   |  |    |
|-------------------|--|----|
| Table 1.1(a)      | Stock and Flow.....  | 17 |
| Table 1.1(b):     | Ascertainment Rate for MOH Hospitals, CSR 2002-2008 .....  | 18 |
| Table 1.1(c):     | Ascertainment Rate for Cataract Surgery Registry by SDP in 2008 .....  | 18 |
| Table 1.2.1:      | Age and Gender Distributions, CSR 2002-2008 .....  | 20 |
| Table 1.2.2.1:    | Distribution of Systemic Co-Morbidity, CSR 2002-2008.....  | 21 |
| Table 1.2.2.2:    | Causes of Cataract, CSR 2002-2008.....   | 22 |
| Table 1.2.2.3:    | First or Fellow Eye Surgery, CSR 2002-2008 .....   | 23 |
| Table 1.2.2.4:    | Past Ocular Surgery of the Operated Eye, CSR 2002-2008.....  | 23 |
| Table 1.2.2.5     | Distribution of Pre-existing Ocular Co-Morbidity, CSR 2002-2008.....   | 25 |
| Table 1.2.2.6:    | Distribution of Pre-Operative Vision, CSR 2002-2008 .....  | 26 |
| Table 1.2.2.7(a): | Distribution of Target Refractive Power, CSR 2007-2008 .....   | 28 |
| Table 1.2.2.7(b): | Distribution of Target Refractive Power, CSR 2007-2008 .....   | 28 |
| Table 1.3.1:      | Range of Cataract Surgeries Registered by SDP per year, CSR 2002-2008 .....  | 29 |
| Table 1.3.2:      | Number of Cataract Surgeries by Month, CSR 2002-2008.....  | 29 |
| Table 1.3.4:      | Surgeon Status, CSR 2002-2008.....   | 31 |
| Table 1.3.5(a):   | Duration of Surgery by Types of Cataract Surgery in minutes,<br>CSR 2007-2008 .....  | 31 |
| Table 1.3.5(b):   | Duration of Surgery by Surgeon Status, CSR 2007-2008.....  | 31 |
| Table 1.3.6(a):   | Distribution of Cataract Surgeries Performed Under Day Care Setting,<br>CSR 2003-2008 .....                                    | 32 |
| Table 1.3.6(b):   | Distribution of Cataract Surgery (Excluding Children and Combined Surgery)<br>Performed as Day Care by SDP, CSR 2003-2008..... | 33 |
| Table 1.3.7(a):   | Distribution of Types of Cataract Surgery, CSR 2002-2008.....  | 35 |
| Table 1.3.7(b):   | Distribution of Types of Cataract Surgery by SDP, CSR 2008 .....   | 37 |
| Table 1.3.7(c):   | Distribution of Phaco by SDP, CSR 2002-2008 .....  | 38 |
| Table 1.3.7(d):   | Distribution of ECCE by SDP, CSR 2002-2008.....  | 39 |
| Table 1.3.8(a):   | Distribution of Combined Surgery for all SDPs, CSR 2002-2008 .....   | 40 |
| Table 1.3.8(b):   | Distribution of Combined Surgery by SDP, CSR 2008.....   | 41 |
| Table 1.3.9(a):   | Types of Anaesthesia all SDPs, CSR 2002-2008 .....   | 42 |
| Table 1.3.9(b):   | Types of Anaesthesia by SDPs, CSR 2008 .....   | 43 |
| Table 1.3.9(c):   | Types of Local Anaesthesia by SDPs, CSR 2008.....  | 44 |
| Table 1.3.9(d):   | Subtenon Anaesthesia by SDPs, CSR 2002-2008 .....  | 45 |
| Table 1.3.9(e):   | Topical Anaesthesia by SDPs, CSR 2002-2008.....  | 46 |
| Table 1.3.9(f):   | Types of Sedation by among Patients Given Local Anaesthesia by SDPs,<br>CSR 2008.....  | 47 |
| Table 1.3.9(g):   | Oral Sedation by SDPs, CSR 2002-2008 .....   | 48 |
| Table 1.3.9(h):   | Intravenous Sedation by SDPs, CSR 2002-2008 .....  | 49 |
| Table 1.3.10(a):  | Intraocular Lens Implantation, CSR 2002-2008 .....   | 50 |
| Table 1.3.10(b):  | Distribution of IOL Placement by SDPs, CSR 2008.....   | 51 |
| Table 1.4.1:      | Distribution of Type of Intra-operative Complications, CSR 2002-2008.....  | 52 |
| Table 1.4.2(a):   | Intra-operative Complications by Types of Cataract Surgery, CSR 2002-2008 ...  | 53 |
| Table 1.4.3(a):   | Distribution of Intra-operative Complications by Any Combined Surgery,<br>CSR 2002-2008 .....                                  | 54 |
| Table 1.4.3(b):   | Distribution of Intra-operative Complications by Specific Combined Surgery,<br>CSR 2008.....                                   | 55 |
| Table 1.4.3(c):   | Distribution of Intra-operative Complications when Combined with Filtering<br>Surgery, CSR 2002-2008 .....                     | 55 |
| Table 1.4.3(d):   | Distribution of Intra-operative Complications when Combined with VR Surgery,<br>CSR 2002-2008 .....                            | 56 |
| Table 1.4.4:      | Intra-operative Complications by Types of Local Anaesthesia, CSR 2008 .....  | 56 |
| Table 1.4.5(a):   | Percentage of Intra-operative Complications by Surgeon Status,<br>CSR 2002-2008 .....  | 57 |
| Table 1.4.6(a):   | Rate of PCR by SDPs, CSR 2007-2008 .....   | 59 |
| Table 1.4.7       | Rate of PCR by Type of Cataract Surgery, CSR 2002-2008.....  | 61 |

|                    |   |     |
|--------------------|---|-----|
| Table 1.5.1:       | Distribution of Cataract Surgery with Post-operative Complication Record, CSR 2002-2008 .....   | 62  |
| Table 1.5.1.1(a):  | Rate of Post-operative Infectious Endophthalmitis, CSR 2002-2008.....   | 62  |
| Table 1.5.1.1(b):  | Time from Surgery to Diagnosis of Post-operative Infectious Endophthalmitis, CSR 2007-2008.....   | 62  |
| Table 1.5.1.2(a):  | Rate for Unplanned Return to OT, CSR 2004-2008.....   | 64  |
| Table 1.5.1.2(b):  | Reasons for Unplanned Return to OT, CSR 2004-2008 .....   | 64  |
| Table 1.5.1.3(a):  | Median Follow-up Period for Patients who had only Unaided Vision (in weeks) by Types of Surgery, 2008 .....   | 65  |
| Table 1.5.1.3(b):  | Median Follow-up Period for Patients who had Refracted Vision (in weeks) by Types of Surgery, 2008 .....  | 66  |
| Table 1.5.2.1:     | Post-operative Visual Acuity for All Patients, CSR 2002-2008.....   | 67  |
| Table 1.5.2.2:     | Post-operative Visual Acuity for Patients without Ocular Co-morbidity, CSR 2002-2008 .....  | 70  |
| Figure 1.5.2.2(a): | Post-operative Visual Acuity for Patients without Ocular Co-morbidity, CSR 2003-2008 .....  | 71  |
| Table 1.5.2.3(a):  | Post-operative Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by Types of Surgery, CSR 2002-2008.....                          | 73  |
| Table 1.5.2.3(b):  | Post-operative Refracted Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by Complications and Types of Surgery, CSR 2008 .....  | 75  |
| Table 1.5.2.3(c):  | Post-operative Refracted Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by Surgeon Status and Types of Surgery, CSR 2008 ..... | 75  |
| Table 1.5.2.3(d):  | Post-operative Refracted Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by SDP and Types of Surgery, CSR 2008.....             | 77  |
| Table 1.5.3        | Reasons for No Records of Visual Acuity, CSR 2002-2008.....   | 81  |
| Table 1.5.4(a)     | Factors Contributing to Post-operative Refracted VA of Worse than 6/12 in All Patients, CSR 2002-2008.....  | 81  |
| Table 1.5.4(b)     | Factors Contributing to Post-operative Refracted VA of Worse than 6/12 Among Patients without Pre-existing Ocular co-morbidity, CSR 2004-2008.....      | 82  |
| Table 1.5.5(a)     | Distribution of Target and Actual Refractive Power in ECCE and Phaco, CSR 2007-2008 .....   | 83  |
| Table 1.5.5(b)     | Percentage Distribution of Target and Actual Refractive Power in ECCE and Phaco, CSR 2007-2008 .....  | 84  |
| Table 1.5.5(c)     | Difference in Target and Actual Refractive Power for Patients who had Phacoemulsification Only, CSR 2007-2008 .....                                     | 86  |
| Table 2.1.1        | Number of cases of diabetic patients registered to Diabetic Eye Registry (DER) .....  | 88  |
| Table 2.1.2        | Number of cases registered by month .....   | 88  |
| Table 2.2.1        | Demographics of diabetic patients .....   | 89  |
| Table 2.2.2        | Sources of referral for diabetic patients .....   | 90  |
| Table 2.3.6        | Past medical and ocular history .....   | 91  |
| Table 2.3.7        | Female diabetic patients who were pregnant.....   | 92  |
| Table 2.3.8        | Distribution of previous eye examination .....  | 93  |
| Table 2.4.1(a)     | Distribution of unaided visual acuity by eyes .....   | 93  |
| Table 2.4.1(b)     | Distribution of presenting visual acuity by eyes .....  | 94  |
| Table 2.4.1(c)     | Status of visual acuity among diabetic patients with and without DR .....   | 95  |
| Table 2.4.2(a)     | Status of diabetic retinopathy, by individuals .....  | 96  |
| Table 2.4.2(b)     | Status of diabetic retinopathy, by eyes.....  | 97  |
| Table 2.4.2 (c)    | Level of severity of diabetic retinopathy by eyes.....  | 97  |
| Table 2.5          | Treatment plans .....   | 98  |
| Table 3.1          | Number of cases .....   | 100 |
| Table 3.2          | Distribution of cases by centre .....   | 101 |
| Table 3.3.1        | Distribution of patients by age.....  | 103 |
| Table 3.3.2        | Distribution of patients by gender.....   | 104 |
| Table 3.3.3        | Distribution of patients by ethnicity.....  | 104 |

|                |   |     |
|----------------|---|-----|
| Table 3.4.1    | Affected eye(s) .....   | 105 |
| Table 3.4.2    | History of trauma .....   | 105 |
| Table 3.4.3    | Types of contact lens worn at diagnosis .....   | 106 |
| Table 3.4.4    | Contact lens wearing pattern at diagnosis .....   | 106 |
| Table 3.4.5    | Types of cleaning solution used at diagnosis .....  | 107 |
| Table 3.4.6(a) | Vision at presentation .....  | 108 |
| Table 3.4.7    | Presumptive causative organism .....  | 110 |
| Table 3.4.8    | Types of Laboratory investigations .....  | 110 |
| Table 3.4.9    | Results of laboratory investigations .....  | 111 |
| Table 3.4.10   | Bacteria specify for each types of lab investigation .....  | 113 |
| Table 3.4.11   | Results of laboratory investigations (PCR) .....  | 113 |
| Table 3.5.1    | Vision by one month .....   | 114 |
| Table 3.5.2    | Vision outcomes from presentation to one month after presentation .....   | 115 |
| Table 3.5.3    | Patients requiring surgical intervention .....  | 115 |
| Table 4.1:     | Distribution of medical co-morbidity .....  | 117 |
| Table 4.2:     | Distribution of visual acuity and cup disc ratio .....  | 118 |
| Table 4.3:     | Types of antiglaucoma agents prescribed .....   | 118 |
| Table 4.4:     | Types of laser procedures performed .....   | 119 |
| Table 5:       | Types of surgical procedures performed .....  | 119 |
| Table 5.1.1    | Demography .....  | 121 |
| Table 5.1.2    | Affected eye .....  | 121 |
| Table 5.2.1    | Risk factors by person .....  | 122 |
| Table 5.2.2    | Risk factors in the affected eye .....  | 122 |
| Table 5.3      | Quality of Life that may be related with the problem .....  | 122 |
| Table 5.4      | Ocular History of the affected eye .....  | 122 |
| Table 5.6(b)   | Status of vision in the affected eyes .....   | 123 |
| Table 5.6(c)   | Status of unaided vision in the affected eyes, by age .....   | 124 |
| Table 5.6(d)   | Fundus examination .....  | 124 |
| Table 5.7(a)   | OCT findings in the affected eyes .....   | 125 |
| Table: 5.7(b)  | FFA findings in the affected eyes .....   | 125 |
| Table 5.7(c)   | ICG findings in the affected eyes .....   | 125 |
| Table 5.8.1    | Diagnosis .....   | 126 |
| Table 5.8.2    | Distribution of diagnosis of affected eyes, by age .....  | 126 |
| Table 5.8.3    | Risk factors by diagnosis .....   | 127 |
| Table 5.8.4    | Diagnosis based on OCT findings .....   | 127 |
| Table 5.9.1    | Treatment .....   | 128 |
| Table 5.9.2    | Treatment in affected eyes, by age .....  | 128 |
| Table 5.9.2    | Treatment by age .....  | 129 |
| Table 6.1      | Stock and flow .....  | 131 |
| Table 6.2(a)   | Distribution of patients by age .....   | 131 |
| Table 6.2(b)   | Distribution of patients by gender .....  | 131 |
| Table 6.3(c)   | Distribution of patients by ethnicity .....   | 132 |
| Table 6.3.1    | Clinical presentation .....   | 132 |
| Table 6.3.2    | Age of onset .....  | 132 |
| Table 6.3.3    | Duration of disease at the time of presentation .....   | 132 |
| Table 6.3.4    | Eyes affected .....   | 133 |
| Table 6.3.5    | Family history of RB .....  | 133 |
| Table 6.3.6    | Vision Presentation .....   | 133 |
| Table 6.4      | Classification of Retinoblastoma based on International Intraocular<br>retinoblastoma Classification (IIRC) ..... | 134 |
| Table 6.5      | Chemotherapy by patient .....   | 135 |
| Table 7.1:     | Number of ophthalmology departments which have census return .....  | 137 |

## LIST OF FIGURES

|                    |  |    |
|--------------------|--|----|
| Figure 1.1(a):     | Stock and Flow.....  | 17 |
| Figure 1.1(c):     | Ascertainment Rate for Cataract Surgery Registry by SDP in 2008 .....  | 18 |
| Figure 1.2.1:      | Age Distribution, CSR 2002-2008 .....  | 20 |
| Figure 1.2.2.1:    | Percentage of Patients with Specific Ocular Co-morbidity, CSR 2002-2008 .....  | 21 |
| Figure 1.2.2.4:    | Percent Distribution of Past Ocular Surgery of the Operated Eye,<br>CSR 2002-2008 .....  | 23 |
| Figure 1.2.2.5:    | Percent Distribution of Patients with Diabetic Retinopathy,<br>Glaucoma or Lens-induced Glaucoma , CSR 2002-2008.....  | 25 |
| Figure 1.2.2.6:    | Distribution of Pre-Operative Vision, CSR 2002-2008 .....  | 26 |
| Figure 1.3.2:      | Number of Cataract Surgery by Month, CSR 2002-2008.....  | 29 |
| Figure 1.3.3:      | Number of Cataract Surgery Registered to NED by State, CSR 2002-2008 .....   | 30 |
| Figure 1.3.6(a):   | Distribution of Cataract Surgery Performed as Day Care by SDP, CSR 2008.....   | 32 |
| Figure 1.3.6(b):   | Distribution of Cataract Surgery Performed as Day Care and In-patient<br>by SDP (Excluding Surgery Done in Children and Combined Surgery),<br>CSR 2008.....        | 35 |
| Figure 1.3.6(c):   | Distribution of Cataract Surgeries Performed as Day Care all SDPs<br>(Excluding Surgery Done in Children and Combined Surgery),<br>CSR 2002-2008 .....             | 38 |
| Figure 1.3.7:      | Distribution of type of cataract surgery , CSR 2002-2008.....  | 36 |
| Figure 1.3.8(a):   | Distribution of Combined Surgery all SDP, CSR 2002-2008.....   | 40 |
| Figure 1.3.10:     | Intraocular Lens Implantation, CSR 2002-2008 .....   | 50 |
| Figure 1.4.1:      | Distribution of Specific Type of Intra-operative Complications,<br>CSR 2002-2008 .....   | 52 |
| Figure 1.4.2:      | Intra-operative Complications by Types of Cataract Surgery,<br>CSR 2002-2008 .....   | 53 |
| Figure 1.4.5:      | Percentage Distribution of Intra-operative Complications by Surgeon Status,<br>CSR 2003-2008 .....   | 57 |
| Figure 1.4.6(a):   | Rate of PCR by SDP, CSR 2007-2008-Bar Cchart<br>(National KPI set at < 5%).....  | 59 |
| Figure 1.4.6(b):   | Rate of PCR by SDP, CSR 2007-2008-Radar Chart<br>(National KPI set at < 5%).....   | 60 |
| Figure 1.4.7:      | Rate of PCR by Type of Cataract Surgery, CSR 2002-2008.....  | 61 |
| Figure 1.5.1.1(a): | Rate of Post-operative Infectious Endophthalmitis, CSR 2002-2008.....  | 62 |
| Figure 1.5.1.1(b): | Rate of Post-operative Infectious Endophthalmitis, by SDP CSR 2007-2008 .....  | 63 |
| Figure 1.5.1.1(c): | Rate of Post-operative Infectious Endophthalmitis, by SDP CSR 2007-2008 .....  | 63 |
| Figure 1.5.1.2:    | Reasons for Unplanned Return to OT, CSR 2004-2008 .....  | 65 |
| Figure 1.5.2.1(a): | Percent Distribution of Post-operative Unaided and Refracted Vision.....   | 68 |
| Figure 1.5.2.1(b): | Post-operative Visual Acuity by Visual Category for All Patients,<br>CSR 2002-2008 .....   | 69 |
| Figure 1.5.2.2(b): | Post-operative Visual Acuity by Visual Category for Patients<br>without Ocular Co-morbidity, CSR 2003-2008 .....   | 72 |
| Figure 1.5.2.3(a): | Post-operative Visual Acuity 6/12 or Better for Patients<br>without Ocular Co-morbidities by ECCE and Phaco, CSR 2002-2008 .....                                   | 74 |
| Figure 1.5.2.3(b): | Post-operative Refracted Visual Acuity 6/12 or Better for Patients<br>without Ocular Co-morbidities by Surgeon Status and Types of Surgery,<br>CSR 2002-2008 ..... | 76 |
| Figure 1.5.2.3(c): | Post-operative Refracted Visual Acuity 6/12 or Better for Patients<br>without Ocular Co-morbidities by SDP and All Surgeries, CSR 2008<br>(national KPI->85%)..... | 79 |
| Figure 1.5.2.3(d): | Post- Phaco Refracted Visual Acuity 6/12 or Better for Patients<br>without Ocular Co-morbidities by SDP, CSR 2008.....   | 79 |
| Figure 1.5.2.3(d): | Post- ECCE Refracted Visual Acuity 6/12 or Better for Patients<br>without Ocular Co-morbidities by SDP , CSR 2008 .....  | 80 |

|                 |   |     |
|-----------------|---|-----|
| Figure 1.5.4(a) | Factors Contributing to Post-operative Refracted VA of Worse than 6/12 in All Patients, CSR 2002-2008.....          | 82  |
| Figure 1.5.5(a) | Percentage Distribution of Actual Refractive Power in ECCE and Phaco, CSR 2007-2008 – redo .....                    | 85  |
| Figure 1.5.5(b) | Difference in Target and Actual Refractive Power for Patients who had Phacoemulsification Only, CSR 2007-2008 ..... | 86  |
| Figure 2.3.6    | Systemic co-morbidities .....   | 92  |
| Figure 3.1      | Number of cases .....   | 100 |
| Figure 3.2(a)   | Distribution of cases by centre, 2007 .....   | 102 |
| Figure 3.2(b)   | Distribution of cases by centre, 2008 .....   | 102 |
| Figure 3.3.1    | Age distribution .....  | 103 |
| Figure 3.3.2    | Gender distributions .....  | 104 |
| Figure 3.3.3    | Ethnic distributions .....  | 105 |
| Figure 3.4.3    | Types of contact lens worn at diagnosis .....   | 106 |
| Figure 3.4.4    | Contact lens wearing pattern at diagnosis .....   | 107 |
| Figure 3.4.5    | Types of cleaning solution used at diagnosis.....   | 108 |
| Figure 3.4.6(a) | Vision at presentation, January-December 2007 .....   | 109 |
| Figure 3.4.6(b) | Vision at presentation, January-December 2008 .....   | 109 |
| Figure 3.4.7    | Presumptive causative organism .....  | 110 |
| Figure 3.4.8    | Types of Laboratory investigations.....   | 111 |
| Figure 3.4.9(a) | Results of laboratory investigations, January-December 2007 .....   | 112 |
| Figure 3.4.9(b) | Results of laboratory investigations, January-December 2008.....  | 112 |
| Figure 3.5.1(a) | Vision by one month, 2007.....  | 114 |
| Figure 3.5.1(b) | Vision by one month, 2008.....  | 114 |
| Figure 3.5.2    | Vision Outcome-from presentation to one month after presentation.....   | 115 |
| Figure 6.3.3    | Duration of disease at the time of presentation.....  | 133 |

## REPORT SUMMARY

### CATARACT SURGERY REGISTRY

#### 1. Stock and Flow

- Number of SDP increased from 25 SDPs in 2002 to 36 SDPs in 2008.
- Total number of cataract surgery registered to CSR increased from 12798 in 2002 to 21496 in 2008.
- CSR ascertainment rates for MOH SDP, calculated based on census return were maintained above 80.0% (84.6% in 2008).
- More than 80% of cataract surgeries registered had outcome data except for the year 2004 (only 33.9%).

#### 2. Characteristics of Patients

- Mean age of patients at the time of cataract surgery maintained at 64 years. This is much younger compared to age at mid-70s as reported by Swedish National Cataract Register.
- Larger percentage of patients presented within the age group of 65-74 years old (38.6%).
- Increasing trend in the proportion of patients who had systemic co-morbidity, from 56.8% in 2002 to 68.7% in 2008.
- Increasing trend in the specific systemic co-morbidities; hypertension (from 35.4% in 2002 to 50.9% in 2008), diabetes mellitus (from 28.9% in 2002 to 38.1% in 2008), ischaemic heart disease (from 9.0% in 2002 to 9.5% in 2008) and renal failure (from 1.6% in 2002 to 2.9% in 2008).
- Senile cataract was the most common cause of primary cataract (98.4%).
- Trauma was the most common cause of secondary cataract (62.3%).
- Only one-third of patients returned for cataract surgery for the fellow eye (68.0%).
- Majority of the eyes had no prior surgery (96.8%). The most common surgery performed among eyes which had prior eye surgery was vitreoretinal surgery (0.8%).
- One-third of the eyes had ocular co-morbidity (33.8%). The most common ocular co-morbidity was diabetic retinopathy in any forms (10.6%).
- 52.7% of patients had unaided vision and 32.5% had refracted vision in the blindness category (2/60-NPL). This trend was the same over the years.
- Refraction was not done prior to cataract surgery in more than 2/3 of the eyes (73.6%).
- Bimodal pattern of pre-operative vision observed over the years with one peak at the range between 6/18 to 6/36 and another peak at CF-HM.
- In terms of choice of IOL power, majority of the cataract surgeons choose target or intended refractive power as -0.5D (SD 0.4), in 2007 and -0.1D (SD 0.4) in 2008. This means most surgeons aimed to give patients either emmetropic or slightly myopic refraction post-operatively.

#### 3. Cataract Surgery Practice Patterns

- Number of cataract surgery performed by SDPs varied. Approximately 50% of the SDPs performed less than 500 surgeries a year and 20% performed more than 1000 cataract surgeries a year. Hospitals which perform low number of surgery need to identify ways to increase the number so as to reduce cost per surgery.
- Each year, the number of cataract surgeries performed was lower than average in the month of February, October, September and December.
- Selangor, Perak, Johor, Penang and Sarawak performed higher number of cataract surgeries.
- Specialists performed more than 2/3 of total cataract surgeries (78.4%).
- Mean duration of surgery was 34.1 min for phaco and 45.8 min for ECCE. Surgeons at MOH hospitals need to find ways to shorten time taken for cataract surgery, especially when performing phaco.

- The proportion of patients (excluding children and combined surgeries) operated in day care was only 42.6%. Four out of 33 SDPs did not do any surgery as day care at all. Sixteen SDPs with Day Care Service performed less than 50% of the surgeries under Day Care. This reflects under-utilisation of day care services. As day care surgery is much more cost-effective, ways to increase day care surgery should be sought.
- Phaco has become the preferred method of cataract surgery since 2004 and has increased from 39.7% in 2002 to 69.1% in 2008. ECCE has dropped from 54.0% in 2002 to 26.3% in 2008.
- The rate of phaco converted to ECCE was 2.4%. The value stayed constant over the years. This may indirectly reflect the competency of new phaco surgeons during their learning curve. A better competency monitoring of individual surgeon is through CUSUM monitoring.
- Proportion of cataract surgery performed in combination with VR surgery reduced from 2.4% in 2007 to 1.1% in 2008. This may reflect individual VR surgeons' practice pattern.
- Majority of cases were done under local anaesthesia (94.3%). The preferred type of local anaesthesia was subtenon injection (54.6%).
- There is a constant increase in the usage of topical anaesthesia (11.7% in 2002 to 33.1% in 2008) and decrease in the use of peribulbar anaesthesia (21.7% in 2002 to 6.1% in 2008) and in the use of retrobulbar anaesthesia (25.9% in 2002 to 5.9% in 2008).
- There is a decreased use of sedation (33.3% in 2002 to 14.5% in 2008). Data by SDP showed that the practice of prescribing oral sedation to patients before cataract surgery was specific to certain hospitals and thus indicating practice pattern of specific doctors working in those hospitals.
- Majority of the patients had IOL implantation (98.2%). Out of this proportion, 96.3% had posterior chamber IOL.
- Acrylic and foldable IOL were the preferred choice of IOL implanted.

#### **4. Intra-operative Complications**

- The rate of all intra-op complication has been decreasing from 10.4 % in 2002 to 7.6% in 2008.
- There is a decreasing trend in the specific intra-operative complications; PCR (from 6.0% in 2002 to 3.7% in 2008), vitreous loss (from 5.7% in 2002 to 2.8% in 2008) and zonular dehiscence (from 1.9% in 2002 to 1.5% in 2008).
- The rates of any complication were higher in phaco converted to ECCE (45.8%) and ICCE (46.5%).
- The rate of any complication was higher in surgeries performed by the gazetted specialists (11.9%).
- As for rate of PCR, 27 SDPs achieved the national KPI standard, which is below 5%.

#### **5. Cataract Surgery Outcome**

- The rate of post-operative endophthalmitis was 0.11% (1.1 cases in 1000 cataract surgeries). It demonstrated a decreasing trend over the years.
- The rate of unplanned return to OT was 0.43%. The common reasons were iris prolapse, wound dehiscence and IOL related problem. IOL related problem showed an increasing trend over the years.
- For visual outcome among patients who were without ocular co-morbidity, the outcome based on unaided visual outcome was not satisfactory. Only 27.8% of patients following ECCE and 40.0% following phaco achieved unaided VA 6/12 or better. This may be due to refractive error (IOL power related to biometry or surgically induced astigmatism) rather than ocular co-morbidity because the proportion of patients with VA 6/12 or better increased double folds following refraction. With refraction, 80.8% of patients following ECCE and 91.3% of patients following phaco achieved VA 6/12 or better.
- The visual outcome results reflect that following cataract surgery, a large number of patients need to wear glasses in order to see better.
- Patients who had phaco had better visual outcome when compared to patients who had other forms of cataract surgery. The rate for VA 6/12 or better increased from 86.8% in 2002 to 91.3% in 2008.

- Post-op VA 6/12 or better for patients who had ECCE has also increased from 77.5% in 2002 to 80.8% in 2008.
- In all types of surgeries, visual outcome became less favourable following occurrence of intra-operative complications.
- In all types of surgeries, visual outcomes were better in eyes with IOL implantation, especially with foldable IOL and IOL made of Acrylic.
- The main contributing factor for eyes with post-operative refracted VA worse than 6/12 was pre-existing ocular co-morbidity followed by high astigmatism and PCO.
- When patients with pre-existing ocular co-morbidity were excluded from analysis, high astigmatism was the major cause of poor vision followed by pre-existing ocular co-morbidity (not detected preoperatively).
- Although more surgeons aimed for their patients to have near emmetropia after surgery, the final refraction for patients who had phaco was at -0.8D in 2007 and 0.0 D in 2008, and for patients who had ECCE, it was -1.1 D in 2007 and -0.2 in 2008.
- Eyes that had ECCE had more myopic shift than eyes that had phaco.
- There was a large disparity between the targeted and the actual refraction. Only one-quarter of the patients achieved what was aimed for pre-operatively.

## **DIABETIC EYE REGISTRY**

### **1. Stock and Flow**

- A total of 22870 new diabetic patients were registered to DER from 2007-2008. The number increased from 10856 in 2007 to 12014 in 2008.
- Average number of cases registered per month increased from 905 to 1001 in 2008.
- Number registered by SDP varied widely.

### **2. Characteristic of Diabetic Patients**

- Mean age of patient was 57.3 years.
- More than half were of working age group (between 30 and 60 years).
- More females were registered (56.2% in 2008)
- More Malays were registered (55.0% in 2008).
- No difference in the mean age for those with DR (56.6 years) and without DR (57.1 years).
- Percentage of DR was higher among females. It increased from 53.6% in 2007 to 55.3% in 2008.
- Proportion of patients screened and registered was similar to national ethnic distributions, highest in Malay, followed by Chinese, Indians and others.
- In contrast to 2007 where the proportion of those with DR were similar among the three main ethnic groups, data in 2008 showed the proportion to be highest among the Malays (41.3%) followed by Chinese (36.6%) and Indians (32.6%).
- Government hospitals and primary health clinics were the main source of referral (93.2%). Only 2% were referred from private care providers.

### **3. Medical History and Practice Pattern**

- Majority of patients had type II DM.
- Percentage of patients with DM 10 years or less was more than 60.0%.
- Percentage of patients with DM more than 20 years was 3.1% in both 2007 and 2008.
- Percentage of patients on oral medication was 80.0%.

- Percentage of patients on insulin was 10.6%.
- Hypertension was one of the most common systemic co-morbidity (63.4%) followed by hypercholesterolaemia (18.1%), ischaemic heart disease (10.3%), and renal impairment (5.5%).
- Of those screened, 7.1% were smokers.
- Cataract was detected in 43.1% of patients.
- Glaucoma was detected in 2.3% of patients.
- More pregnant diabetic patients were registered in 2008. (148 or 2.5% of females in 2007 to 208 or 3.1% of females in 2008).
- Although the percentage of pregnant diabetics registered to DER during the first trimester was still not satisfactory in both years (40.7%), the number has increased from 36.5% in 2007 to 43.8% in 2008.
- In contrast to year 2007 where most of pregnant diabetic were registered during 2<sup>nd</sup> trimester, most of them were registered during 1<sup>st</sup> trimester in 2008.
- Large percentage of patients with no previous eye examinations - 70.9% in 2007 and 72.0% in 2008).
- Among patients with previous eye examination, more than 60.0% had the examination 1 year prior to being registered to DER.

#### **4. Eye Status**

- Percentage of patients with presenting VA in the low vision category (6/18-3/60) was approximately 30.0%-40.0%.
- Percentage of patients with presenting VA in the blindness category (2/60-NPL) was approximately 9.0%.
- Eyes with DR presented with worse vision as compared with eyes without DR.
- Among patients screened, more than half had no apparent DR in both their eyes (60.4% in 2007 and 50.8% in 2008).
- Up to 38.2% in 2007 and 36.1% in 2008 had some form of DR in either eye and 11.9% in 2007 and 9.6% in 2008 had maculopathy.
- Percentage of mild – moderate NPDR was 67.3% in 2007 and 76.8% in 2008.
- Percentage of severe NPDR was 8.6% in 2007 and 18.7% in 2008.
- Percentage of PDR was 18.1% in 2007 and 11.4% in 2008.
- Percentage of ADED was 5.9% in 2007 and 4.8% in 2008.
- Percentage of patients with vision threatening DR (PDR and maculopathy) was 15.6% in 2007 and 11.5% in 2008.

#### **5. Treatment Plan**

- Majority of patients did not require treatment (83.0%).
- Laser photocoagulation was required in approximately 10.0% of patients.
- Vitrectomy was required in 3.1% of patients in 2007 and 0.5% patients in 2008.
- Further assessment such as FFA was required in approximately 0.5% of patients.

### **CONTACT LENS RELATED CORNEAL ULCER SURVEILLANCE**

#### **1. Stock and Flow**

- A total of 103 cases reported in the 2007 and 99 cases reported in 2008.
- No outbreak of contact lens related keratitis in the MOH Hospitals during the year 2007 and 2008.

## **2. Distribution of Cases by Centre**

- Hospital Melaka, Hospital Kuala Lumpur and Hospital Sultanah Aminah Johor Bahru reported the highest number of contact lens related keratitis in 2007.
- Hospital Melaka, Hospital Selayang and Hospital Sungai Buloh reported the highest number of contact lens related keratitis in 2008.

## **3. Patient Demography**

- Median age was 25 in 2007 and 24 in 2008.
- Majority of patients were females and Malays.

## **4. Data on Contact Lens-Related Corneal Ulcer at Presentation**

- Bilateral involvement was reported in six cases in 2007 and ten cases in 2008.
- Majority of cases occurred among those who used monthly disposable contact lens.
- Most popular choice of contact lens cleaning solution was from Bausch and Lomb.
- Approximately 1/3 had unaided vision of 3/60 or worse at the time of presentation.
- Eighty-seven percent of the cases were presumptively treated as bacterial corneal ulcer at presentation.
- Cornea scraping was performed in 80% of the eyes. The contact lens and contact lens cleaning solution were sent for microbiological examination in less than half of the cases.
- Rate of positive culture results for corneal scraping was 37.4% in 2007 and 36.9% in 2008.
- Pseudomonas was the most common bacterial isolate from corneal scraping, contact lens and contact lens solution.

## **5. Outcome by One Month After Presentation**

- About 30% had corrected vision of 6/12 or better at one month after presentation.
- In 2008, three cases were complicated by corneal perforation. Two cases were managed by corneal gluing and one by penetrating keratoplasty.

## **GLAUCOMA REGISTRY**

### **1. Stock and Flow**

- In 2008, a total of 23 SDPs from MOH ophthalmology departments collected data for the glaucoma registry.
- A total of 4481 patients were registered, 88.2% were follow-up cases and 11.2% were new cases.

### **2. Characteristics of Patients**

- Median age was within the range of 60-69 years.
- There was a slight female preponderance (54.0%).
- Majority of patients were unemployed (77.4%).
- Proportion of patients registered differed from the national ethnic distributions; Chinese was the highest (41.5%), followed by Malays (36.0%), Indians (17.8%) and others (4.7%).

### **3. Medical History**

- Percentage of patients with systemic co-morbidity was 67.7%; Hypertension was the most common (43.0%) followed by diabetes mellitus (39.4%).
- A total of 113 patients had family history of glaucoma and 55 patients had history of steroid usage.

#### **4. Clinical Features**

- Proportion of patients with vision 6/12 or better was 65.9%.
- Proportion of patients with low vision (6/18-4/60) was 21.6%.
- Proportion of patients in the blindness category (3/60-PL) was 7.5%.
- Proportion of patients with NPL was 5%.
- Proportion of eyes with CDR 0.5 or larger was more than 76.4%.
- Proportion of eyes with CDR 0.9/1.0 was 18.5%.

#### **5. Types of Glaucoma**

- Majority of the eyes had primary type of glaucoma (69.1%) followed by secondary glaucoma (10.0%) and glaucoma suspect (15.6%).
- Among the primary type of glaucoma, POAG was the most common (67.5%) followed by PACG (15.5%), ocular hypertension (4.8%), PAC (1.5%), PACS (0.8%) and others (9.9%).
- Among the secondary type of glaucoma, the few common types of glaucoma were post-surgery (15.9%), pseudoexfoliative (14.9%), rubeotic (14.5%), post-trauma (11.7%), steroid-induced (6.5%) and inflammatory (6%).

#### **6. Management of Glaucoma**

- The most common mode of management was medical treatment (either mono or combined therapy).
- The most frequent eye drop prescribed was beta blockers, followed by prostaglandin analog and topical Carbonic Anhydrase Inhibitors.

### **AGE RELATED MACULAR DEGENERATION REGISTRY**

#### **1. Stock and Flow**

- A total of 52 AMD patients with 104 eyes were registered.

#### **2. Patient Demography and Vision**

- Mean age was 65.6 years.
- Mean duration of symptoms was 15.4 months.
- Proportion of eyes with VA of 6/12 or better was 38.5, VA 6/18-3/60 was 23.1% and with VA 3/60 or worse was 38.5%.

#### **3. Status of AMD**

- Half of the eyes had exudative AMD.
- Disciform scar was present in 27.2% of eyes.
- Central geographic atrophy was present in 8.6 % of eyes.
- Polypoidal choroidal vasculopathy was present in 14.8 % of eyes.
- Active choroidal neovascularization was present in 18.5% of eyes.
- Majority of patients present late to the tertiary referral centre.

### **RETINOBLASTOMA REGISTRY**

#### **1. Stock and Flow**

- A total of 24 patients registered; 12 patients were diagnosed in 2007.

#### **2. Patients Demography**

- Mean age at presentation was 2.19 years.
- Youngest age was 1 month and oldest was 5.5 years.

- About half (45.8%) of these patients were in the age group of 13 to 24 months.
- More boys than girls were affected.
- Majority were of Malay ethnicity (62.5%), followed by Chinese (12.5%) and Indians (8.3%).

### **3. Ocular History and Presentation**

- Leukocoria was the most common presentation feature.
- Highest percentage (30.4%) presented between 13 and 24 months of age.
- Mean duration of disease from onset of symptoms to presentation was 5.4 months with the majority (73.9%) within 1 to 6 months.
- Five patients (20.8%) presented with bilateral retinoblastoma.
- All patients had no positive family history of retinoblastoma.
- Most eyes were blind at presentation.

### **4. Investigation and Classification**

- Based on CT scan, 26 eyes had presence of mass; 24 eyes had calcifications and five eyes showed evidence of extraocular extension.
- Two-thirds (65.52%) of the patients presented with Group E Retinoblastoma.

### **5. Management**

- Enucleation was done in 19 patients.
- Systemic chemotherapy was given in 11 patients.
- Subtenon injection of chemotherapy combined with systemic chemotherapy were given in two patients.
- Focal therapy was given together with chemoreduction.
- No patients had focal therapy only.
- No patient had radiotherapy.

# **CHAPTER 1**

## **CATARACT SURGERY REGISTRY**

### **Contributing Editors**

**Dr Goh Pik Pin  
Dr Aziz Salowi  
Dr Loh Swee Seng  
Dr Poh Eu Ping  
Dr Ang Ee Ling**

## CHAPTER 1 CATARACT SURGERY REGISTRY

### 1.1 STOCK AND FLOW

The number of cataract surgery registry (CSR) source data provider (SDP) continued to increase over the years – from 25 SDPs in 2002 to 36 SDPs in 2008. The number of cataract surgeries being registered to CSR has also increased from 12798 in 2002 to 21496 in 2008.


From 2002-2004, CSR was a paper-based registry. During this period, there was a constant decrease in the percentage of patients with visual outcome recorded in CSR. However when the web-based registry was implemented in 2007, there could be a beginning of an increasing trend when it showed a moderate improvement in the percentage within 2 years i.e. from 85.7% in 2007 to 88.7% in 2008.

Table 1.1(a) Stock and Flow

| Year   | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|--|-------|------|-------|------|-------|------|-------|------|-------|------|
| Number of SDP                                      | 25*   |      | 32*   |      | 33*   |      | 32    |      | 36    |      |
| Total number of cataract surgery registered to CSR | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
| Cataract surgery with visual outcome records       | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
|  | 12512 | 97.7 | 14683 | 87.3 | 6228  | 33.9 | 15786 | 85.7 | 19063 | 88.7 |

\*SDP in 2002, 2003 and 2004 included private centre and University Hospital

Figure 1.1(a): Stock and Flow



The ascertainment rate was maintained at more than 80% for the past 7 years. The reduced ascertainment rate which was observed in 2007 could be due to the change from a paper-based to a web-based registry. The rate improved to 84.6% in 2008.

Table 1.1(b): Ascertainment Rate for MOH Hospitals, CSR 2002-2008

| Year   | 2002  | 2003  | 2004  | 2007  | 2008* |
|--|-------|-------|-------|-------|-------|
| Total number of cataract surgery performed at MOH Hospitals (Source: MOH census returns) | 14316 | 16498 | 18884 | 22051 | 25393 |
| Total number of cataract surgery performed at MOH hospitals and registered to CSR        | 12552 | 16039 | 17536 | 18426 | 21496 |
| Ascertainment rate (%)   | 87.6  | 97.2  | 92.9  | 83.6  | 84.6  |

\*Four hospitals had less than 50% of ascertainment


In terms of ascertainment rate by SDP, five SDPs have higher than 100% as they reported more cataract surgery to CSR than to census. Twenty five SDP obtained higher ascertainment rate than aggregate average at 84.6%. Hospital D, L, T and AG had < 50.0% ascertainment rate in CSR. Hospital D, F, AD and AG had ascertainment rates of <50.0% in terms of outcome with refracted vision. These hospitals were excluded in certain analysis particularly on visual outcome.

Table 1.1(c): Ascertainment Rate for Cataract Surgery Registry by SDP in 2008

|                    | Ascertainment Rate                                     |  |   |  |  |                                       |  |   |   |
|--------------------|--|--|---|--|--|---------------------------------------|--|---|---|
|                    | Total no. of cataract surgery (based on census)<br>(a) | Total no. of cataract surgery registered to CSR (based on operative record)<br>(b) | Total no. of outcome form submitted (c) | Total no. of outcome form with unaided vision<br>(d) | Total no. of outcome form with refracted vision<br>(e) | % Ascertain ment for CSR<br>(b/a*100) | % Ascertain ment for Outcome form submitted<br>(c/b*100) | % Ascertain ment for Outcome with unaided vision<br>(d/c*100) | % Ascertain ment for Outcome with refracted vision<br>(e/c*100) |
| <b>All Centres</b> | 25393  | 21496  | 20521                                   | 19064  | 17240  | 84.6                                  | 95.5   | 92.9  | 84.0  |
| <b>A</b>           | 1754   | 986  | 941                                     | 909  | 804  | 56.2                                  | 95.4   | 96.6  | 85.4  |
| <b>B</b>           | 259  | 208  | 208                                     | 197  | 192  | 80.3                                  | 100  | 94.7  | 92.3  |
| <b>C</b>           | 608  | 573  | 541                                     | 482  | 456  | 94.2                                  | 94.4   | 89.1  | 84.3  |
| <b>D</b>           | 152  | 30   | 29                                      | 29   | 11   | 19.7                                  | 96.7   | 100.0   | 37.9  |
| <b>E</b>           | 492  | 487  | 487                                     | 435  | 426  | 99.0                                  | 100  | 89.3  | 87.5  |
| <b>F</b>           | 150  | 137  | 136                                     | 136  | 54   | 91.3                                  | 99.3   | 100.0   | 39.7  |
| <b>G</b>           | 1817   | 1723   | 1560                                    | 1482   | 1330   | 94.8                                  | 90.5   | 95.0  | 85.3  |
| <b>H</b>           | 354  | 400  | 400                                     | 398  | 363  | 113.0                                 | 100  | 99.5  | 90.8  |
| <b>I</b>           | 57   | 34   | 20                                      | 19   | 18   | 59.6                                  | 58.8   | 95.0  | 90.0  |
| <b>J</b>           | 782  | 739  | 630                                     | 594  | 586  | 94.5                                  | 85.3   | 94.3  | 93.0  |
| <b>K</b>           | 172  | 170  | 168                                     | 135  | 135  | 98.8                                  | 98.8   | 80.4  | 80.4  |
| <b>L</b>           | 1113   | 40   | 40                                      | 39   | 33   | 3.6                                   | 100  | 97.5  | 82.5  |
| <b>M</b>           | 305  | 282  | 275                                     | 267  | 220  | 92.5                                  | 97.5   | 97.1  | 80.0  |

|           | Total no.<br>of cataract<br>surgery<br>(based on<br>census)<br>(a) | Total no.<br>of cataract<br>surgery<br>registered<br>to CSR<br>(based on<br>operative<br>record)<br>(b) | Total no. of<br>outcome<br>form<br>submitted<br>(c) | Total no.<br>of<br>outcome<br>form with<br>unaided<br>vision<br>(d) | Total no.<br>of<br>outcome<br>form with<br>refracted<br>vision<br>(e) | %<br>Ascertain<br>ment for<br>CSR<br>(b/a*100) | %<br>Ascertain<br>ment for<br>Outcome<br>form<br>submitted<br>(c/b*100) | %<br>Ascertain<br>ment for<br>Outcome<br>with<br>unaided<br>vision<br>(d/c*100) | %<br>Ascertain<br>ment<br>Outcome<br>with<br>refracted<br>vision<br>(e/c*100) |
|-----------|--|---|---|---|---|--|---|---|---|
| <b>N</b>  | 731  | 726   | 714   | 695   | 648   | 99.3   | 98.3  | 97.3  | 90.8  |
| <b>O</b>  | 1768   | 1681  | 1656  | 1608  | 1405  | 95.1   | 98.5  | 97.1  | 84.8  |
| <b>P</b>  | 548  | 396   | 372   | 275   | 296   | 72.3   | 93.9  | 73.9  | 79.6  |
| <b>Q</b>  | 406  | 338   | 337   | 318   | 290   | 83.3   | 99.7  | 94.4  | 86.1  |
| <b>R</b>  | 1421   | 1357  | 1281  | 1272  | 1168  | 95.5   | 94.4  | 99.3  | 91.2  |
| <b>S</b>  | 239  | 256   | 256   | 253   | 234   | 107.1  | 100   | 98.8  | 91.4  |
| <b>T</b>  | 824  | 351   | 351   | 340   | 273   | 42.6   | 100   | 96.9  | 77.8  |
| <b>U</b>  | 1488   | 1429  | 1429  | 1388  | 1082  | 96.0   | 100   | 97.1  | 75.7  |
| <b>V</b>  | 639  | 696   | 695   | 683   | 601   | 108.9  | 99.9  | 98.3  | 86.5  |
| <b>W</b>  | 321  | 263   | 202   | 196   | 195   | 81.9   | 76.8  | 97.0  | 96.5  |
| <b>X</b>  | 353  | 350   | 350   | 89  | 332   | 99.2   | 100   | 25.4  | 94.9  |
| <b>Y</b>  | 196  | 180   | 180   | 178   | 176   | 91.8   | 100   | 98.9  | 97.8  |
| <b>Z</b>  | 1408   | 1376  | 1213  | 1092  | 1064  | 97.7   | 88.2  | 90.0  | 87.7  |
| <b>AA</b> | 393  | 319   | 319   | 301   | 274   | 81.2   | 100   | 94.4  | 85.9  |
| <b>AB</b> | 654  | 633   | 618   | 605   | 506   | 96.8   | 97.6  | 97.9  | 81.9  |
| <b>AC</b> | 378  | 379   | 379   | 377   | 369   | 100.3  | 100   | 99.5  | 97.4  |
| <b>AD</b> | 438  | 317   | 279   | 209   | 123   | 72.4   | 88  | 74.9  | 44.1  |
| <b>AE</b> | 599  | 588   | 588   | 531   | 528   | 98.2   | 100   | 90.3  | 89.8  |
| <b>AF</b> | 532  | 531   | 531   | 433   | 415   | 99.8   | 100   | 81.5  | 78.2  |
| <b>AG</b> | 796  | 395   | 265   | 132   | 35  | 49.6   | 67.1  | 49.8  | 13.2  |
| <b>AH</b> | 1325   | 1217  | 1217  | 1196  | 1115  | 91.8   | 100   | 98.3  | 91.6  |
| <b>AI</b> | 860  | 898   | 844   | 778   | 743   | 104.4  | 94  | 92.2  | 88.0  |
| <b>AJ</b> | 1061   | 1011  | 1010  | 993   | 740   | 95.3   | 99.9  | 98.3  | 73.3  |

Figure 1.1(c): Ascertainment Rate for Cataract Surgery Registry by SDP in 2008



## 1.2 CHARACTERISTICS OF PATIENT

### 1.2.1 Patient Demography

The mean age of patients presented for cataract surgery has been consistent at 64 years over the years and in 2008, it was 64.6 years. The minimum age, was similar to previous years, at 1 month old but the maximum age increased to 102 years old.


A larger percentage of patients presented within the age group of 65-74 years old except for the year 2007. There was no marked gender difference over the last 7 years. The slight female preponderance reflected higher female ratio in the aging population.

Table 1.2.1: Age and Gender Distributions, CSR 2002-2008

| Year                             | 2002* |       | 2003* |       | 2004* |       | 2007  |       | 2008  |       |
|----------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Total number of cataract surgery | 12798 |       | 16815 |       | 18392 |       | 18426 |       | 21496 |       |
| Age,                             |       |       |       |       |       |       |       |       |       |       |
| Mean (years)                     | 64.0  |       | 63.7  |       | 63.5  |       | 64.3  |       | 64.6  |       |
| Median (years)                   | 66    |       | 66    |       | 66    |       | 66    |       | 66    |       |
| Minimum (month)                  | 1     |       | 1     |       | 1     |       | 1     |       | 1     |       |
| Maximum (years)                  | 97    |       | 100   |       | 104   |       | 97    |       | 102   |       |
| % Distribution                   |       |       |       |       |       |       |       |       |       |       |
| Age group, years                 | No.   | %     | No.   | %     | No.   | %     | No.   | %     | No.   | %     |
| <1                               | 21    | 0.16  | 23    | 0.14  | 50    | 0.3   | 18    | 0.10  | 34    | 0.2   |
| 1-14                             | 171   | 1.34  | 202   | 1.2   | 266   | 1.5   | 50    | 0.27  | 116   | 0.5   |
| 15-24                            | 101   | 0.79  | 139   | 0.83  | 134   | 0.7   | 141   | 0.77  | 133   | 0.6   |
| 25-34                            | 115   | 0.9   | 147   | 0.87  | 207   | 1.1   | 120   | 0.65  | 167   | 0.8   |
| 35-44                            | 376   | 2.94  | 575   | 3.42  | 526   | 2.9   | 157   | 0.85  | 539   | 2.5   |
| 45-54                            | 1,472 | 11.5  | 1,974 | 11.74 | 2,238 | 12.2  | 499   | 2.71  | 2407  | 11.2  |
| 55-64                            | 3,415 | 26.68 | 4,496 | 26.74 | 4,882 | 26.5  | 2,135 | 11.59 | 6037  | 28.1  |
| 65-74                            | 4,880 | 38.13 | 6,480 | 38.54 | 7,051 | 38.3  | 5,031 | 27.30 | 8307  | 38.6  |
| 75-84                            | 2,041 | 15.95 | 2,511 | 14.93 | 2,722 | 14.8  | 7,103 | 38.55 | 3391  | 15.8  |
| >=85                             | 206   | 1.61  | 264   | 1.57  | 316   | 1.7   | 2,889 | 15.68 | 344   | 1.6   |
| Missing                          | NA    | -     | 4     | 0.02  | NA    | -     | 283   | 1.54  | 21    | 0.1   |
| Gender                           |       |       |       |       |       |       |       |       |       |       |
| Male                             | 6308  | 49.29 | 8397  | 49.94 | 9034  | 49.12 | 8820  | 47.87 | 10295 | 47.89 |
| Female                           | 6490  | 50.71 | 8418  | 50.06 | 9358  | 50.88 | 9606  | 52.13 | 11168 | 51.95 |
| Missing                          | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 0     | 33    | 0.15  |

\*2002, 2003 and 2004 included private centres and university hospitals

Figure 1.2.1: Age Distribution, CSR 2002-2008



## 1.2.2 Medical history

### 1.2.2.1 Systemic co-morbidity


About half to two-third of the patients who came for cataract surgery had systemic co-morbidity. The most common being hypertension, followed by diabetes mellitus, ischaemic heart disease and renal failure. The proportions were increasing over the years.

Table 1.2.2.1: Distribution of Systemic Co-Morbidity, CSR 2002-2008

| Year   | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|--|-------|------|-------|------|-------|------|-------|------|-------|------|
| No of patients (N)   | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
| Percentage of patients with any systemic co-morbidity      | 56.8  |      | 59.1  |      | 59.9  |      | 67.5  |      | 68.7  |      |
| Percentage of patients with specific systemic co-morbidity |       |      |       |      |       |      |       |      |       |      |
|  | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
| 1.Hypertension   | 4529  | 35.4 | 6408  | 38.1 | 7425  | 40.4 | 8630  | 46.8 | 10932 | 50.9 |
| 2.Diabetes Mellitus  | 3694  | 28.9 | 5136  | 30.5 | 5800  | 31.5 | 6869  | 37.3 | 8188  | 38.1 |
| 3.Ischaemic Heart Disease                                  | 1148  | 9.0  | 1538  | 9.1  | 1782  | 9.7  | 1668  | 9.1  | 2037  | 9.5  |
| 4.Renal Failure  | 211   | 1.6  | 303   | 1.8  | 351   | 1.9  | 461   | 2.5  | 624   | 2.9  |
| 5.Cerebrovascular accident                                 | 106   | 0.8  | 165   | 1.0  | 174   | 0.9  | 0     | 0.0  | 29    | 0.1  |
| 6.COAD/Asthma  | 669   | 5.2  | 907   | 5.4  | 955   | 5.2  | 798   | 4.3  | 955   | 4.4  |
| 7.Others   | 935   | 7.3  | 2409  | 7.2  | 861   | 4.7  | 1399  | 7.6  | 1974  | 9.2  |

Number or Percentage may be more than total or 100% as patients might have more than one systemic co-morbidity

Figure 1.2.2.1: Percentage of Patients with Specific Ocular Co-morbidity, CSR 2002-2008



### 1.2.2.2 Causes of cataract

Majority of the patients presented with primary cataract. Among eyes with primary cataract, senile or age-related cataract was the most common. Among eyes with secondary cataract, trauma was the most common cause. This pattern remained unchanged over the years.

Table 1.2.2.2: Causes of Cataract, CSR 2002-2008

| Year                   | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|------------------------|-------|------|-------|------|-------|------|-------|------|-------|------|
| No of patients (N)     | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
|                        | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
| Primary cataract       | 12294 | 96.1 | 16161 | 96.1 | 17697 | 96.2 | 17410 | 94.4 | 20329 | 94.6 |
| Secondary cataract     | 499   | 3.9  | 654   | 3.9  | 695   | 3.8  | 557   | 3.0  | 530   | 2.5  |
| Missing value          | -     | -    | -     | -    | -     | -    | 460   | 2.5  | 637   | 3.0  |
| Primary Cataract (n)   | 12294 |      | 16161 |      | 17697 |      | 17410 |      | 20329 |      |
| • Senile/age-related   | 11960 | 97.3 | 15623 | 96.7 | 17290 | 97.7 | 17075 | 98.1 | 19995 | 98.4 |
| • Congenital           | 130   | 1.1  | 175   | 1.1  | 173   | 1.0  | 129   | 0.7  | 124   | 0.6  |
| • Development          | 155   | 1.3  | 317   | 2.0  | 209   | 1.2  | 169   | 1.0  | 156   | 0.8  |
| • Others               | 49    | 0.4  | 46    | 0.3  | 25    | 0.1  | 37    | 0.2  | 54    | 0.3  |
| Secondary Cataract (n) | 499   |      | 654   |      | 695   |      | 557   |      | 530   |      |
| • Trauma               | 325   | 65.1 | 399   | 61.0 | 440   | 63.3 | 355   | 63.7 | 330   | 62.3 |
| • Drug induced         | 53    | 10.6 | 81    | 12.4 | 84    | 12.1 | 55    | 9.9  | 76    | 14.3 |
| • Surgery induced      | 23    | 4.6  | 67    | 10.2 | 56    | 8.1  | 82    | 14.7 | 39    | 7.4  |
| • Others               | 98    | 19.6 | 107   | 16.4 | 115   | 16.5 | 65    | 11.7 | 85    | 16.0 |

### 1.2.2.3 First or Fellow Eye Surgery

Two-third of the patients came for the first time for cataract surgery, i.e. had operation in their first eyes. Only one-third of the patients returned for fellow eye surgery. This pattern remained unchanged since 2002. Only 5% had fellow eye surgery in the same year. The mean duration between first and fellow eye surgery was between 16 to 23 months.

Table 1.2.2.3: First or Fellow Eye Surgery, CSR 2002-2008

| Year  | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|---|-------|------|-------|------|-------|------|-------|------|-------|------|
| No of patients (N)  | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
|   | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
| First eye surgery   | 8958  | 70.0 | 11851 | 70.5 | 12911 | 70.2 | 12810 | 69.5 | 14610 | 68.0 |
| Fellow eye surgery  | 3840  | 30.0 | 4964  | 29.5 | 5481  | 29.8 | 5559  | 30.2 | 6849  | 31.9 |
| Missing   | NA    | -    | NA    | -    | NA    | -    | 57    | 0.3  | 37    | 0.2  |
| Patients who had second surgery in the same year                        | 573   | 4.5  | 713   | 4.2  | 825   | 4.5  | 759   | 4.1  | 1135  | 5.3  |
| <b>Period of time between first and fellow eye surgery (Months)</b>     |       |      |       |      |       |      |       |      |       |      |
| N   | 2716  |      | 3322  |      | 3673  |      | 4860  |      | 5953  |      |
| Mean  | 16.7  |      | 16.3  |      | 16.9  |      | 23.4  |      | 22.0  |      |
| SD  | 18.0  |      | 17.1  |      | 18.8  |      | 24.3  |      | 22.8  |      |
| Median  | 10.3  |      | 10.1  |      | 10.5  |      | 13.3  |      | 13.1  |      |
| Patients who had cataract surgery before                                | 9092  |      | 11894 |      | 12924 |      | 12867 |      | 15994 |      |
|   | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
| Eyes with intra-operative complications during surgery in the first eye | 939   | 10.3 | 1179  | 9.91 | 1235  | 9.6  | 313   | 2.43 | 298   | 1.86 |

### 1.2.2.4 Past ocular surgery of the operated eye


Most eyes to be operated had no prior ocular surgery. Among eyes with past ocular surgery, the most common was vitreoretinal surgery followed by pterygium excision.

Table 1.2.2.4: Past Ocular Surgery of the Operated Eye, CSR 2002-2008

| Year   | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|--|-------|------|-------|------|-------|------|-------|------|-------|------|
| No of patients (N)   | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
| No of patients who had data on past ocular surgery (denominator) | 12798 |      | 16782 |      | 18372 |      | 17379 |      | 20674 |      |
|  | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
| Patients with no past ocular surgery                             | 12414 | 97.0 | 16178 | 96.4 | 17711 | 96.4 | 16545 | 95.2 | 20010 | 96.8 |
| Vitreoretinal surgery  | 8959  | 0.7  | 1510  | 0.9  | 1653  | 0.9  | 261   | 1.4  | 161   | 0.8  |
| Pterygium excision   | 77    | 0.6  | 1177  | 0.7  | 92    | 0.5  | 869   | 0.5  | 140   | 0.7  |
| Filtering surgery  | 77    | 0.6  | 1007  | 0.6  | 1102  | 0.6  | 1043  | 0.4  | 57    | 0.3  |
| Penetrating keratoplasty   | 13    | 0.1  | 168   | 0.1  | 184   | 0.1  | 1738  | 0.1  | 14    | 0.1  |
| Others   | 1408  | 1.1  | 235   | 1.4  | 276   | 1.5  | 417   | 2.4  | 304   | 1.5  |

Number or Percentage may be more than total or 100% as patients might have more than one past ocular surgery

Figure 1.2.2.4 Percent Distribution of Past Ocular Surgery of the Operated Eye, CSR 2002-2008



#### 1.2.2.5 Pre-existing ocular co-morbidity

One-third of the eyes to be operated had ocular co-morbidities. The most common was diabetic retinopathy in any forms followed by glaucoma. The percentage of eyes with diabetic retinopathy appeared to be increasing over the years. However these figures might not be accurate because the posterior segment could not be assessed in 1/10 of the eyes.

Although in a downward trend, there were still a significant number of patients presented with lens-related complication.


Table 1.2.2.5 Distribution of Pre-existing Ocular Co-Morbidity, CSR 2002-2008

| Year  | 2002 |      | 2003 |      | 2004 |      | 2007 |      | 2008 |      |
|---|------|------|------|------|------|------|------|------|------|------|
| No of patients (N)                              | No   | %    | No   | %    | No   | %    | No   | %    | No   | %    |
| Patients with any ocular co-morbidity           | 3691 | 28.8 | 6068 | 36.1 | 6993 | 38.0 | 5973 | 32.4 | 7269 | 33.8 |
| Patients with specific ocular co-morbidity      |      |      |      |      |      |      |      |      |      |      |
| <b>Anterior segment</b>                         |      |      |      |      |      |      |      |      |      |      |
| 1.Glaucoma                                      | 795  | 6.2  | 1096 | 6.5  | 1238 | 6.7  | 1126 | 6.1  | 1408 | 6.6  |
| 2.Pterygium involving the cornea                | 342  | 2.7  | 393  | 2.3  | 349  | 1.9  | 288  | 1.6  | 319  | 1.5  |
| 3.Pseudoexfoliation                             | 184  | 1.4  | 254  | 1.5  | 209  | 1.1  | 221  | 1.2  | 253  | 1.2  |
| 4.Corneal opacity                               | 184  | 1.4  | 200  | 1.2  | 183  | 1.0  | 176  | 1.0  | 194  | 0.9  |
| 5.Chronic uveitis                               | 54   | 0.4  | 48   | 0.3  | 80   | 0.4  | 81   | 0.4  | 63   | 0.3  |
| <b>Lens-related complication</b>                |      |      |      |      |      |      |      |      |      |      |
| 1.Phacomorphic                                  | 106  | 0.8  | 152  | 0.9  | 118  | 0.6  | 89   | 0.5  | 85   | 0.4  |
| 2.Phacolytic                                    | 61   | 0.5  | 63   | 0.4  | 79   | 0.4  | 44   | 0.2  | 45   | 0.2  |
| 3.Subluxated/Disclosed                          | 87   | 0.7  | 110  | 0.7  | 86   | 0.5  | 101  | 0.5  | 89   | 0.4  |
| <b>Posterior segment</b>                        |      |      |      |      |      |      |      |      |      |      |
| 1.Diabetic Retinopathy: Non Proliferative       | 642  | 5.0  | 965  | 5.7  | 956  | 5.2  | 1125 | 6.1  | 1273 | 5.9  |
| 2.Diabetic Retinopathy: Proliferative           | 218  | 1.7  | 366  | 2.2  | 510  | 2.8  | 465  | 2.5  | 614  | 2.9  |
| 3.Diabetic Retinopathy: CSME*                   | 96   | 0.8  | 177  | 1.1  | 163  | 0.9  | 198  | 1.1  | 221  | 1.0  |
| 4.Diabetic Retinopathy: Vitreous haemorrhage    | 66   | 0.5  | 106  | 0.6  | 138  | 0.8  | 176  | 1.0  | 165  | 0.8  |
| 5.ARM   | 145  | 1.1  | 215  | 1.3  | 308  | 1.7  | 231  | 1.3  | 259  | 1.2  |
| 6.Other macular disease (includes hole or scar) | 77   | 0.6  | 106  | 0.6  | 140  | 0.8  | 118  | 0.6  | 148  | 0.7  |
| 7.Optic nerve disease, any type                 | 43   | 0.3  | 76   | 0.5  | 78   | 0.4  | 71   | 0.4  | 69   | 0.3  |
| 8.Retinal detachment                            | 70   | 0.5  | 177  | 1.1  | 247  | 1.3  | 218  | 1.2  | 204  | 0.9  |
| 9.Cannot be assessed                            | 884  | 6.9  | 1962 | 11.7 | 2290 | 12.5 | 1357 | 7.4  | 2092 | 9.7  |
| <b>Miscellaneous</b>                            |      |      |      |      |      |      |      |      |      |      |
| 1.Amblyopia                                     | 64   | 0.5  | 61   | 0.4  | 78   | 0.4  | 71   | 0.4  | 65   | 0.3  |
| 2.Significant previous eye trauma               | 52   | 0.4  | 80   | 0.5  | 96   | 0.5  | 41   | 0.2  | 39   | 0.2  |
| 3.Pre-existing non glaucoma field defect        | 2    | 0.0  | 3    | 0.0  | 4    | 0.0  | 4    | 0.0  | 2    | 0.0  |
| 4.Others  | 380  | 3.0  | 827  | 4.9  | 1153 | 6.3  | 668  | 3.6  | 755  | 3.5  |

\*CSME=Clinical Significant Macular Oedema

Number or Percentage may be more than total or 100% as patients might have more than one ocular co-morbidity

Figure 1.2.2.5: Percent Distribution of Patients with Diabetic Retinopathy, Glaucoma or Lens-induced Glaucoma, CSR 2002-2008



#### 1.2.2.6 Pre-operative vision

A high proportion of patients did not have refraction pre-operatively especially in 2002 to 2004. The proportion became less in 2007 and 2008 at 73%.


More than half of the eyes to be operated had unaided vision in the blindness category (2/60-NPL) and up to one-third had refracted vision in the blindness category. These proportions remained unchanged over the years.

Figure 1.2.2.6 showed the bimodal pattern of pre-operative vision which had been persistent over the years. The first peak was at 6/18 and the second peak was at CF/HM. There was a low proportion of patients between 5/60 and 1/60.

Table 1.2.2.6: Distribution of Pre-Operative Vision, CSR 2002-2008

| Year                        | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|-----------------------------|-------|------|-------|------|-------|------|-------|------|-------|------|
| No of patients (N)          | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
|                             | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
| Patients with unaided VA    | 12691 | 99.2 | 16723 | 99.4 | 18222 | 99.1 | 18356 | 99.6 | 21212 | 98.7 |
| Patients with refracted VA  | 700   | 5.5  | 2104  | 12.6 | 2319  | 12.7 | 5071  | 27.8 | 5683  | 26.4 |
| Patients with no refraction | 12098 | 94.5 | 14711 | 87.5 | 16073 | 87.4 | 13355 | 72.5 | 15813 | 73.6 |
| 6/5- Unaided                | 281   | 2.2  | 396   | 2.4  | 523   | 2.9  | 602   | 3.3  | 646   | 3.0  |
| 6/12 Refracted              | 155   | 22.1 | 327   | 15.5 | 396   | 17.1 | 678   | 13.3 | 935   | 16.4 |
| 6/18- Unaided               | 4465  | 35.2 | 6440  | 38.5 | 7235  | 39.7 | 7734  | 42.4 | 9375  | 44.2 |
| 3/60 Refracted              | 374   | 53.4 | 1198  | 56.9 | 1315  | 56.7 | 2375  | 46.9 | 2892  | 50.9 |
| 2/60- Unaided               | 7945  | 62.6 | 9887  | 59.1 | 10464 | 57.4 | 9920  | 54.3 | 11180 | 52.7 |
| NPL Refracted               | 171   | 24.4 | 579   | 27.5 | 608   | 26.2 | 2018  | 39.8 | 1845  | 32.5 |

Figure 1.2.2.6: Distribution of Pre-Operative Vision, CSR 2002-2008



### 1.2.2.7 Target refractive power

The mean target refractive power in 2008 was -0.1D (SD 0.4), with minimum target power at -9.9D and maximum at +9.9D. These findings in 2007 and 2008 demonstrated that most cataract surgeons participated in CSR aimed to give patient either emmetropic or slightly myopic refraction post-operatively.

Table 1.2.2.7(a): Distribution of Target Refractive Power, CSR 2007-2008

| Year             | 2007  | 2008  |
|------------------|-------|-------|
| Operated eye (N) | 11876 | 15083 |
| Mean             | -0.5  | -0.1  |
| SD               | 0.4   | 0.4   |
| Median           | -0.5  | -0.5  |
| Minimum          | -9.0  | -9.9  |
| Maximum          | +5.0  | +9.5  |

Table 1.2.2.7(b): Distribution of Target Refractive Power, CSR 2007-2008

| Year                               | 2007                    |      | 2008                    |      |
|------------------------------------|-------------------------|------|-------------------------|------|
| Target refractive power (Dioptres) | Operated eye<br>N=11876 |      | Operated eye<br>N=15083 |      |
|                                    | No.                     | %    | No.                     | %    |
| -10-(-9.5)                         | 0                       | 0    | 1                       | 0    |
| -9.5-(-9)                          | 2                       | 0    | 1                       | 0    |
| -9-(-8.5)                          | 0                       | 0    | 1                       | 0    |
| -8.5-(-8)                          | 1                       | 0    | 1                       | 0    |
| -8-(-7.5)                          | 2                       | 0    | 3                       | 0    |
| -7.5-(-7)                          | 1                       | 0    | 0                       | 0    |
| -7-(-6.5)                          | 3                       | 0    | 1                       | 0    |
| -6.5-(-5)                          | 1                       | 0    | 2                       | 0    |
| -5-(-4.5)                          | 3                       | 0    | 4                       | 0    |
| -4.5-(-4)                          | 1                       | 0    | 3                       | 0    |
| -4-(-3.5)                          | 7                       | 0.1  | 8                       | 0.1  |
| -3.5-(-3)                          | 6                       | 0.1  | 7                       | 0    |
| -3-(-2.5)                          | 12                      | 0.1  | 22                      | 0.1  |
| -2.5-(-2)                          | 26                      | 0.2  | 21                      | 0.1  |
| -2-(-1.5)                          | 77                      | 0.6  | 48                      | 0.3  |
| -1.5-(-1)                          | 414                     | 3.5  | 373                     | 2.5  |
| -1-(-0.5)                          | 4299                    | 36.2 | 6151                    | 40.8 |
| -0.5-<0                            | 6077                    | 51.2 | 7480                    | 49.6 |
| 0-<0.5                             | 821                     | 6.9  | 731                     | 4.8  |
| 0.5-<1                             | 91                      | 0.8  | 158                     | 1    |
| 1-<1.5                             | 8                       | 0.1  | 31                      | 0.2  |
| 1.5-<2                             | 5                       | 0    | 14                      | 0.1  |
| 2-<2.5                             | 13                      | 0.1  | 10                      | 0.1  |
| 2.5-<3                             | 1                       | 0    | 6                       | 0    |
| 3-<3.5                             | 1                       | 0    | 2                       | 0    |
| 3.5-<4                             | 0                       | 0    | 2                       | 0    |
| 4-<4.5                             | 2                       | 0    | 0                       | 0    |
| 4.5-<5                             | 1                       | 0    | 1                       | 0    |
| 5-<5.5                             | 1                       | 0    | 0                       | 0    |
| 5.5-<6                             | 0                       | 0    | 0                       | 0    |
| 6-<6.5                             | 0                       | 0    | 0                       | 0    |

| Year   | 2007 |   | 2008 |   |
|--------|------|---|------|---|
| 6.5-<7 | 0    | 0 | 0    | 0 |
| 7-<7.5 | 0    | 0 | 0    | 0 |
| 7.5-<8 | 0    | 0 | 0    | 0 |
| 8-<8.5 | 0    | 0 | 0    | 0 |
| 8.5-<9 | 0    | 0 | 0    | 0 |
| 9-<9.5 | 0    | 0 | 0    | 0 |
| 9.5-10 | 0    | 0 | 1    | 0 |

Values outside the +10 and -10 D were excluded from analysis as they would skew the Mean

### 1.3 CATARACT SURGICAL PRACTICES

#### 1.3.1 Number of Cataract Surgeries Registered by SDP, CSR 2002-2008

Data from both the annual census and CSR showed that majority of SDP performed between 100 to 501 cataract surgery.

Table 1.3.1: Range of Cataract Surgeries Registered by SDP per year, CSR 2002-2008

| Year          | 2002   |     | 2003   |     | 2004   |     | 2007   |     | 2008   |     |
|---------------|--------|-----|--------|-----|--------|-----|--------|-----|--------|-----|
| Number of SDP | 29     | 25  | 31     | 32  | 32     | 33  | 33     | 32  | 36     | 36* |
|               | Census | CSR | Census | CSR | Census | CSR | Census | CSR | Census | CSR |
| <100*         | 4      | 1   | 1      | 5   | 2      | 4   | 1      | 3   | 1      | 1   |
| 100-500       | 13     | 15  | 11     | 10  | 14     | 15  | 15     | 14  | 15     | 15  |
| 501-1000      | 7      | 5   | 15     | 14  | 8      | 9   | 8      | 8   | 11     | 11  |
| >1000         | 5      | 4   | 4      | 3   | 8      | 5   | 9      | 7   | 9      | 9   |

\*Four hospitals had less than 50% ascertainment rate


#### 1.3.2 Number of Cataract Surgeries by Month, CSR 2002-2008

The number of cataract surgeries done was lower than average in February and October to December and these patterns remained unchanged. This could be attributed to school holidays, festive seasons and scheduled closure of operating theatres (OT) in MOH hospitals at year-end.

Table 1.3.2: Number of Cataract Surgeries by Month, CSR 2002-2008

| Year               | 2002  |      | 2003  |      | 2004  |      | 2007  |     | 2008  |      |
|--------------------|-------|------|-------|------|-------|------|-------|-----|-------|------|
| No of patients (N) | 12798 |      | 16815 |      | 18392 |      | 18426 |     | 21496 |      |
| Month              | No    | %    | No    | %    | No    | %    | No    | %   | No    | %    |
| January            | 1064  | 8.3  | 1399  | 8.3  | 1265  | 6.9  | 1579  | 8.6 | 1862  | 8.7  |
| February           | 838   | 6.5  | 1197  | 7.1  | 1424  | 7.7  | 1290  | 7.0 | 1653  | 7.7  |
| March              | 1166  | 9.1  | 1389  | 8.3  | 1782  | 9.7  | 1782  | 9.7 | 1812  | 8.4  |
| April              | 986   | 7.7  | 1495  | 8.9  | 1868  | 10.2 | 1625  | 8.8 | 2321  | 10.8 |
| May                | 1018  | 8.0  | 1364  | 8.1  | 1426  | 7.8  | 1618  | 8.8 | 1871  | 8.7  |
| June               | 1127  | 8.8  | 1400  | 8.3  | 1778  | 9.7  | 1476  | 8.0 | 1950  | 9.1  |
| July               | 1207  | 9.4  | 1862  | 11.1 | 1854  | 10.1 | 1808  | 9.8 | 2049  | 9.5  |
| August             | 1210  | 9.5  | 1538  | 9.1  | 1447  | 7.9  | 1814  | 9.8 | 1791  | 8.3  |
| September          | 1184  | 9.3  | 1530  | 9.1  | 1626  | 8.8  | 1486  | 8.1 | 1462  | 6.8  |
| October            | 1346  | 10.5 | 1666  | 9.9  | 1513  | 8.2  | 1376  | 7.5 | 1552  | 7.2  |
| November           | 1003  | 7.8  | 917   | 5.5  | 1077  | 5.9  | 1443  | 7.8 | 1646  | 7.7  |
| December           | 649   | 5.1  | 1058  | 6.3  | 1332  | 7.2  | 1129  | 6.1 | 1527  | 7.1  |


Figure 1.3.2: Number of Cataract Surgeries by Month, CSR 2002-2008



### 1.3.3 Number of cataract surgeries registered by state

The states which performed high number of cataract surgeries were Selangor, Perak, Johor, Penang and Sarawak.

Figure 1.3.3: Number of Cataract Surgeries Registered to NED by State, CSR 2002-2008



\*Wilayah Persekutuan in 2007 and 2008 refer to Putrajaya Hospital only

### 1.3.4 Surgeon Status

Specialists consistently performed more number of cataract surgeries followed by medical officers and gazetted specialists. This is because the numbers of medical officers and gazetted specialists are much less than the number of specialists. This trend has remained unchanged throughout the years.

Table 1.3.4: Surgeon Status, CSR 2002-2008

| Year                 | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|----------------------|-------|------|-------|------|-------|------|-------|------|-------|------|
| No of patients       | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
| Specialist           | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
| Gazetting Specialist | 8763  | 68.5 | 12072 | 71.8 | 13165 | 71.6 | 14327 | 77.8 | 16846 | 78.4 |
| Medical Officer      | 1762  | 13.7 | 1510  | 9.0  | 1757  | 9.6  | 1276  | 6.9  | 1399  | 6.5  |
| Missing              | 2273  | 17.8 | 3233  | 19.2 | 3470  | 18.8 | 2690  | 14.6 | 2697  | 12.5 |
|                      | 0     | 0.0  | 0     | 0.0  | 0     | 0.0  | 133   | 1.0  | 554   | 2.6  |

### 1.3.5 Duration of surgery

The average time taken to perform a cataract surgery was 40.2 min in 2007 and 38.2 min in 2008. The time taken to do phacoemulsification (34.1 min) could be shortened. The time taken to perform a cataract surgery was not significantly different among specialists, gazetted specialists and medical officers.

Table 1.3.5(a): Duration of Surgery by Types of Cataract Surgery in minutes, CSR 2007-2008

| Year            | 2007 |      | 2008 |      |
|-----------------|------|------|------|------|
|                 | Mean | SD   | Mean | SD   |
| All eyes        | 40.2 | 20.6 | 38.2 | 19.6 |
| Phaco           | 36.8 | 19.7 | 34.1 | 17.7 |
| ECCE            | 45.3 | 19.7 | 45.8 | 19.5 |
| Phaco → ECCE    | 57.8 | 20.6 | 44.8 | 24.0 |
| ICCE            | 57.6 | 23.7 | 57.5 | 23.7 |
| Lens Aspiration | 47.8 | 27.2 | 60.0 | 25.6 |

Data entered with extreme values i.e. more than 3 hours and less than 15 minutes are not being analysed as they would skew the data

Table 1.3.5(b): Duration of Surgery by Surgeon Status, CSR 2007-2008

| Year  |                      | 2007 |      | 2008 |      |
|-------|----------------------|------|------|------|------|
|       |                      | Mean | SD   | Mean | SD   |
| Phaco | Specialist           | 36.0 | 19.8 | 35.4 | 17.9 |
|       | Gazetting Specialist | 40.2 | 18.0 | 47.5 | 20.8 |
|       | Medical Officers     | 42.2 | 18.2 | 49.2 | 22.8 |
| ECCE  | Specialist           | 40.2 | 17.6 | 43.9 | 69.5 |
|       | Gazetting Specialist | 45.9 | 17.8 | 54.0 | 71.5 |
|       | Medical Officers     | 53.9 | 20.2 | 63.0 | 89.8 |

### 1.3.6 Distribution of cataract surgery performed under day care setting

The rate of day care cataract surgeries were calculated by excluding children and combined surgeries because surgeries done in these patients require general anaesthesia and thus most probably will be done as in-patient surgery.

Though the proportion of cataract surgery performed as day care has increased over the years, but it remained at 40% and the differences were marked among SDPs. In 2008, four SDPs did not do any day care surgery and five SDPs performed more than 90% surgery as day care. As day care surgery saves cost, SDPs should attempt to do more.

Table 1.3.6(a): Distribution of Cataract Surgeries Performed Under Day Care Setting, CSR 2003-2008

| Year   | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|--|-------|------|-------|------|-------|------|-------|------|-------|------|
| Number of SDPs   | 25*   |      | 32*   |      | 33*   |      | 32    |      | 36    |      |
| Total number of cataract surgery registered to CSR                       | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
| Number of surgery excluding children and combined surgery                | 12445 |      | 15981 |      | 17336 |      | 17402 |      | 19835 |      |
| Number and % of day care surgery excluding children and combined surgery | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
|  | 4887  | 39.3 | 6089  | 38.1 | 6934  | 40.0 | 7297  | 41.9 | 8449  | 42.6 |

\*SDPs in 2002, 2003 and 2004 included private centres and university hospitals

Table 1.3.6(b): Distribution of Cataract Surgery (Excluding Children and Combined Surgery) Performed as Day Care by SDP, CSR 2003-2008

| Year               | 2002 |      | 2003 |      | 2004 |       | 2007 |      | 2008* |      |
|--------------------|------|------|------|------|------|-------|------|------|-------|------|
|                    | No   | %    | No   | %    | No   | %     | No   | %    | No    | %    |
| <b>All Centres</b> | 4887 | 39.3 | 6089 | 38.0 | 6934 | 40.0  | 7297 | 41.9 | 8449  | 42.6 |
| <b>A</b>           | 218  | 24   | 262  | 26.0 | 30   | 70.0  | 91   | 1.3  | 74    | 8.0  |
| <b>B</b>           | -    | -    | -    | -    | -    | -     | 3    | 0.04 | 181   | 99.5 |
| <b>C</b>           | 207  | 98   | 519  | 85.0 | 85   | 15.0  | 317  | 4.34 | 311   | 56.9 |
| <b>E</b>           | 20   | 16   | 139  | 26.0 | 24   | 76.0  | 82   | 1.12 | 25    | 5.5  |
| <b>F</b>           | 0    | 0    | 0    | 0.0  | 2    | 98.0  | -    | -    | 0     | 0.0  |
| <b>G</b>           | 1    | 4    | 27   | 3.0  | 3    | 97.0  | 672  | 9.21 | 896   | 58.1 |
| <b>H</b>           | 10   | 4    | 5    | 2.0  | 2    | 98.0  | 0    | 0    | 2     | 0.5  |
| <b>I</b>           | -    | -    | -    | -    | -    | -     | 1    | 0.01 | 1     | 3.5  |
| <b>J</b>           | 14   | 5    | 26   | 5.0  | 8    | 92.0  | 8    | 0.11 | 17    | 2.5  |
| <b>K</b>           | -    | -    | -    | -    | -    | -     | 0    | 0    | 0     | 0.0  |
| <b>M</b>           | 1    | 3    | 2    | 1.0  | 44   | 56.0  | 61   | 0.84 | 49    | 19.0 |
| <b>N</b>           | 206  | 54   | 100  | 41.0 | 38   | 62.0  | 142  | 2.0  | 194   | 28.0 |
| <b>O</b>           | 875  | 90   | 884  | 92.0 | 92   | 8.0   | 1420 | 19.5 | 1483  | 95.9 |
| <b>P</b>           | -    | -    | NA   | -    | 92   | 8.0   | 15   | 0.2  | 385   | 99.7 |
| <b>Q</b>           | 10   | 2    | 0    | 0.0  | 4    | 96.0  | 2    | 0.03 | 0     | 0.0  |
| <b>R</b>           | 759  | 69   | 759  | 82.0 | 82   | 18.0  | 960  | 13.2 | 1193  | 91.9 |
| <b>S</b>           | 26   | 63   | 68   | 79.0 | 91   | 9.0   | 182  | 2.5  | 201   | 81.7 |
| <b>U</b>           | NA   | NA   | 733  | 84.0 | 88   | 12.0  | 1011 | 13.9 | 995   | 78.8 |
| <b>V</b>           | -    | -    | -    | -    | -    | -     | 313  | 4.29 | 382   | 57.4 |
| <b>W</b>           | 0    | 0    | 0    | 0.0  | 0    | 100.0 | 0    | 0    | 1     | 0.4  |
| <b>X</b>           | -    | -    | -    | -    | -    | -     | 10   | 0.14 | 45    | 13.1 |
| <b>Y</b>           | -    | -    | -    | -    | -    | -     | 1    | 0.01 | 8     | 4.6  |
| <b>Z</b>           | 100  | 10   | 47   | 6.0  | 4    | 96.0  | 48   | 0.7  | 44    | 3.3  |
| <b>AA</b>          | -    | -    | -    | -    | -    | -     | 99   | 1.4  | 230   | 74.4 |
| <b>AB</b>          | 48   | 12   | 130  | 24.0 | 3    | 97.0  | 5    | 0.1  | 2     | 0.4  |
| <b>AC</b>          | 34   | 8    | 175  | 52.0 | 32   | 68.0  | 54   | 0.7  | 46    | 12.7 |
| <b>AD</b>          | 0    | 0    | 1    | 0.4  | 1    | 99.0  | 1    | 0.01 | 0     | 0.0  |
| <b>AE</b>          | 207  | 54   | 166  | 28.0 | 11   | 89.0  | 2    | 0.03 | 66    | 11.5 |
| <b>AF</b>          | -    | -    | -    | -    | -    | -     | 1    | 0.01 | 5     | 1.0  |
| <b>AH</b>          | 21   | 3    | 8    | 1.0  | 2    | 98.0  | 11   | 0.2  | 22    | 1.9  |
| <b>AI</b>          | 345  | 44   | 390  | 53.0 | 57   | 43.0  | 589  | 8.07 | 399   | 69.3 |
| <b>AJ</b>          | 578  | 83   | 544  | 88.0 | 87   | 13.0  | 863  | 11.8 | 893   | 93.6 |

D, L, T and AG were excluded due to low ascertainment rates

Figure 1.3.6(a): Distribution of Cataract Surgery Performed as Day Care by SDP, CSR 2008




Figure 1.3.6(b): Distribution of Cataract Surgery Performed as Day Care and In-patient by SDP (Excluding Surgery Done in Children and Combined Surgery), CSR 2008





Figure 1.3.6(c): Distribution of Cataract Surgeries Performed as Day Care all SDPs (Excluding Surgery Done in Children and Combined Surgery), CSR 2002-2008



### 1.3.7 Distribution of types of cataract surgery

There is an increasing shift from extracapsular cataract extraction (ECCE) to phaco as the more common type of surgery performed. The rate of phaco converted to ECCE, a proxy indicator for competency in performing phaco, stayed constant over the years.

In general, all SDPs demonstrated an increasing trend of phaco (except Hospital E, N and AD). There was no phaco surgery performed in Hospital F and Hospital I.

In general, all SDPs demonstrated a decreasing trend of ECCE (except Hospital E and AD).

Table 1.3.7(a): Distribution of Types of Cataract Surgery, CSR 2002-2008

| Year                    | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|-------------------------|-------|------|-------|------|-------|------|-------|------|-------|------|
| No of patients (N)      | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
|                         | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
| Phacoemulsification     | 5085  | 39.7 | 7674  | 45.6 | 9282  | 50.5 | 11960 | 65.1 | 14781 | 69.1 |
| ECCE                    | 6914  | 54.0 | 8012  | 47.6 | 7830  | 42.6 | 5524  | 30.1 | 5627  | 26.3 |
| Lens Aspiration         | 372   | 2.9  | 435   | 2.6  | 550   | 3.0  | 323   | 1.8  | 340   | 1.6  |
| Phaco Converted to ECCE | 311   | 2.4  | 469   | 2.8  | 454   | 2.5  | 432   | 2.4  | 524   | 2.4  |
| ICCE                    | 81    | 0.6  | 94    | 0.6  | 103   | 0.6  | 141   | 0.8  | 129   | 0.6  |

Figure 1.3.7 Distribution of type of cataract surgery, CSR 2002-2008




Table 1.3.7(b): Distribution of Types of Cataract Surgery by SDP, CSR 2008

| Type of Cataract Surgery |               |     |       |      |      |      |                 |     |                         |      |      |     |
|--------------------------|---------------|-----|-------|------|------|------|-----------------|-----|-------------------------|------|------|-----|
|                          | All Surgeries |     | Phaco |      | ECCE |      | Lens Aspiration |     | Phaco Converted to ECCE |      | ICCE |     |
|                          | No.           | %   | No.   | %    | No.  | %    | No.             | %   | No.                     | %    | No.  | %   |
| All Centres              | 21496         | 100 | 14781 | 69.1 | 5627 | 26.3 | 340             | 1.6 | 524                     | 2.4  | 129  | 0.6 |
| A                        | 986           | 100 | 715   | 72.9 | 247  | 25.2 | 2               | 0.2 | 16                      | 1.6  | 1    | 0.1 |
| B                        | 208           | 100 | 75    | 36.1 | 106  | 51   | 0               | 0   | 26                      | 12.5 | 1    | 0.5 |
| C                        | 573           | 100 | 451   | 79.1 | 95   | 16.7 | 3               | 0.5 | 16                      | 2.8  | 5    | 0.9 |
| E                        | 487           | 100 | 163   | 33.5 | 315  | 64.7 | 5               | 1   | 4                       | 0.8  | 0    | 0   |
| F                        | 137           | 100 | 0     | 0    | 130  | 99.2 | 0               | 0   | 1                       | 0.8  | 0    | 0   |
| G                        | 1723          | 100 | 1434  | 83.6 | 240  | 14   | 10              | 0.6 | 23                      | 1.3  | 8    | 0.5 |
| H                        | 400           | 100 | 303   | 75.9 | 86   | 21.6 | 7               | 1.8 | 3                       | 0.8  | 0    | 0   |
| I                        | 34            | 100 | 0     | 0    | 33   | 97.1 | 1               | 2.9 | 0                       | 0    | 0    | 0   |
| J                        | 739           | 100 | 383   | 51.8 | 302  | 40.9 | 26              | 3.5 | 16                      | 2.2  | 12   | 1.6 |
| K                        | 170           | 100 | 78    | 45.9 | 81   | 47.6 | 5               | 2.9 | 6                       | 3.5  | 0    | 0   |
| M                        | 282           | 100 | 58    | 20.6 | 190  | 67.6 | 3               | 1.1 | 30                      | 10.7 | 0    | 0   |
| N                        | 726           | 100 | 429   | 59.4 | 238  | 33   | 18              | 2.5 | 25                      | 3.5  | 12   | 1.7 |
| O                        | 1681          | 100 | 1335  | 80.3 | 271  | 16.3 | 17              | 1   | 23                      | 1.4  | 16   | 1   |
| P                        | 396           | 100 | 296   | 74.7 | 95   | 24   | 3               | 0.8 | 2                       | 0.5  | 0    | 0   |
| Q                        | 338           | 100 | 236   | 70.7 | 81   | 24.3 | 4               | 1.2 | 11                      | 3.3  | 2    | 0.6 |
| R                        | 1357          | 100 | 1116  | 82.3 | 177  | 13.1 | 22              | 1.6 | 36                      | 2.7  | 5    | 0.4 |
| S                        | 256           | 100 | 166   | 64.8 | 79   | 30.9 | 5               | 2   | 6                       | 2.3  | 0    | 0   |
| U                        | 1429          | 100 | 1291  | 91   | 70   | 4.9  | 18              | 1.3 | 32                      | 2.3  | 8    | 0.6 |
| V                        | 696           | 100 | 521   | 75   | 133  | 19.1 | 19              | 2.7 | 19                      | 2.7  | 3    | 0.4 |
| W                        | 263           | 100 | 0     | 0    | 257  | 97.7 | 5               | 1.9 | 0                       | 0    | 1    | 0.4 |
| X                        | 350           | 100 | 111   | 31.7 | 233  | 66.6 | 1               | 0.3 | 3                       | 0.9  | 2    | 0.6 |
| Y                        | 180           | 100 | 114   | 63.7 | 61   | 34.1 | 1               | 0.6 | 2                       | 1.1  | 1    | 0.6 |
| Z                        | 1376          | 100 | 1293  | 94   | 30   | 2.2  | 25              | 1.8 | 19                      | 1.4  | 8    | 0.6 |
| AA                       | 319           | 100 | 271   | 85.2 | 25   | 7.9  | 4               | 1.3 | 17                      | 5.3  | 1    | 0.3 |
| AB                       | 633           | 100 | 483   | 76.4 | 99   | 15.7 | 18              | 2.8 | 22                      | 3.5  | 10   | 1.6 |
| AC                       | 379           | 100 | 169   | 44.6 | 194  | 51.2 | 10              | 2.6 | 6                       | 1.6  | 0    | 0   |
| AD                       | 317           | 100 | 3     | 1    | 305  | 97.1 | 3               | 1   | 3                       | 1    | 0    | 0   |
| AE                       | 588           | 100 | 358   | 60.9 | 193  | 32.8 | 13              | 2.2 | 23                      | 3.9  | 1    | 0.2 |
| AF                       | 531           | 100 | 354   | 67   | 138  | 26.1 | 8               | 1.5 | 22                      | 4.2  | 6    | 1.1 |
| AH                       | 1217          | 100 | 655   | 53.8 | 499  | 41   | 24              | 2   | 28                      | 2.3  | 11   | 0.9 |
| AI                       | 898           | 100 | 610   | 68.9 | 219  | 24.7 | 7               | 0.8 | 41                      | 4.6  | 8    | 0.9 |
| AJ                       | 1011          | 100 | 702   | 69.4 | 263  | 26   | 24              | 2.4 | 20                      | 2    | 2    | 0.2 |

D, L, T and AG were excluded due to low ascertainment rate

Table 1.3.7(c): Distribution of Phaco by SDP, CSR 2002-2008

| Years              | 2002 |    | 2003 |    | 2004 |    | 2007  |      | 2008  |      |
|--------------------|------|----|------|----|------|----|-------|------|-------|------|
|                    | No.  | %  | No.  | %  | No.  | %  | No.   | %    | No.   | %    |
| <b>All Centres</b> | 5085 | 40 | 7674 | 46 | 9282 | 50 | 11960 | 65.1 | 14781 | 69.1 |
| <b>A</b>           | 263  | 28 | 351  | 33 | 467  | 41 | 240   | 58.4 | 715   | 72.9 |
| <b>B</b>           | -    | -  | -    | -  | -    | -  | 3     | 75   | 75    | 36.1 |
| <b>C</b>           | -    | -  | 240  | 39 | 276  | 49 | 453   | 81.6 | 451   | 79.1 |
| <b>E</b>           |      |    | 350  | 65 | 529  | 78 | 403   | 59.2 | 163   | 33.5 |
| <b>F</b>           | 0    | 0  | 0    | 0  | 0    | 0  | NA    | NA   | 0     | 0    |
| <b>G</b>           | 22   | 7  | 339  | 32 | 293  | 36 | 1117  | 71.4 | 1434  | 83.6 |
| <b>H</b>           | 496  | 46 | 16   | 4  | 35   | 11 | 91    | 28.1 | 303   | 75.9 |
| <b>I</b>           | -    | -  | -    | -  | -    | -  | -     | -    | 0     | 0    |
| <b>J</b>           | 43   | 20 | 209  | 35 | 259  | 41 | 406   | 49.9 | 383   | 51.8 |
| <b>K</b>           | -    | -  | -    | -  | -    | -  | 0     | 0    | 78    | 45.9 |
| <b>M</b>           |      |    | 2    | 1  | 1    | 1  | 24    | 11.4 | 58    | 20.6 |
| <b>N</b>           | 488  | 66 | 74   | 27 | 70   | 30 | 242   | 46.5 | 429   | 59.4 |
| <b>O</b>           | 255  | 49 | 630  | 61 | 742  | 61 | 1152  | 75.9 | 1335  | 80.3 |
| <b>P</b>           | -    | -  | -    | -  | -    | -  | 7     | 46.7 | 296   | 74.7 |
| <b>Q</b>           | 509  | 45 | 398  | 66 | 277  | 76 | 281   | 80.1 | 236   | 70.7 |
| <b>R</b>           | 273  | 57 | 432  | 46 | 577  | 51 | 751   | 68.1 | 1116  | 82.3 |
| <b>S</b>           | 96   | 41 | 9    | 10 | 13   | 11 | 93    | 45.8 | 166   | 64.8 |
| <b>U</b>           | -    | -  | 671  | 68 | 1031 | 79 | 1305  | 92.4 | 1291  | 91   |
| <b>V</b>           | -    | -  | -    | -  | -    | -  | 412   | 68.1 | 521   | 75   |
| <b>W</b>           | 519  | 51 | 1    | 0  | 6    | 2  | 0     | 0    | 0     | 0    |
| <b>X</b>           | -    | -  | -    | -  | -    | -  | 14    | 9.3  | 111   | 31.7 |
| <b>Y</b>           | -    | -  | -    | -  | -    | -  | 64    | 63.4 | 114   | 63.7 |
| <b>Z</b>           | 133  | 32 | 484  | 57 | 579  | 56 | 1418  | 91.9 | 1293  | 94   |
| <b>AA</b>          | -    | -  | -    | -  | -    | -  | 121   | 82.9 | 271   | 85.2 |
| <b>AB</b>          | 153  | 36 | 321  | 58 | 381  | 72 | 410   | 82.5 | 483   | 76.4 |
| <b>AC</b>          | 1    | 1  | 116  | 34 | 176  | 44 | 100   | 35.8 | 169   | 44.6 |
| <b>AD</b>          | 205  | 52 | 1    | 0  | 14   | 7  | 0     | 0    | 3     | 1    |
| <b>AE</b>          | 206  | 49 | 470  | 76 | 199  | 43 | 435   | 64.8 | 358   | 60.9 |
| <b>AF</b>          | -    | -  | -    | -  | -    | -  | 210   | 47.3 | 354   | 67   |
| <b>AH</b>          | 19   | 7  | 323  | 46 | 462  | 57 | 570   | 55   | 655   | 53.8 |
| <b>AI</b>          | 0    | 0  | 203  | 26 | 420  | 46 | 589   | 61.9 | 610   | 68.9 |
| <b>AJ</b>          | 593  | 58 | 377  | 56 | 389  | 44 | 680   | 68   | 702   | 69.4 |

D, L, T and AG were excluded due to low ascertainment rate

Table 1.3.7(d): Distribution of ECCE by SDP, CSR 2002-2008

| Years              | 2002 |    | 2003 |    | 2004 |    | 2007 |      | 2008 |      |
|--------------------|------|----|------|----|------|----|------|------|------|------|
|                    | No.  | %  | No.  | %  | No.  | %  | No.  | %    | No.  | %    |
| <b>All Centres</b> | 6914 | 54 | 8012 | 48 | 7830 | 43 | 5524 | 30.1 | 5627 | 26.3 |
| <b>A</b>           | 649  | 68 | 664  | 62 | 603  | 53 | 160  | 38.9 | 247  | 25.2 |
| <b>B</b>           | -    | -  | -    | -  | -    | -  | 1    | 25   | 106  | 51   |
| <b>C</b>           |      |    | 328  | 53 | 272  | 48 | 83   | 15   | 95   | 16.7 |
| <b>E</b>           |      |    | 135  | 25 | 100  | 15 | 265  | 38.9 | 315  | 64.7 |
| <b>F</b>           | 123  | 95 | 130  | 98 | 119  | 99 | NA   | NA   | 130  | 99.2 |
| <b>G</b>           | 261  | 89 | 669  | 63 | 479  | 59 | 396  | 25.3 | 240  | 14   |
| <b>H</b>           | 513  | 48 | 335  | 92 | 262  | 83 | 223  | 68.8 | 86   | 21.6 |
| <b>I</b>           | -    | -  | -    | -  | -    | -  | -    | -    | 33   | 97.1 |
| <b>J</b>           | 162  | 76 | 323  | 54 | 304  | 48 | 337  | 41.4 | 302  | 40.9 |
| <b>K</b>           | -    | -  | -    | -  | -    | -  | 119  | 95.2 | 81   | 47.6 |
| <b>M</b>           |      |    | 161  | 96 | 139  | 96 | 164  | 77.7 | 190  | 67.6 |
| <b>N</b>           | 208  | 28 | 163  | 59 | 121  | 52 | 243  | 46.7 | 238  | 33   |
| <b>O</b>           | 234  | 45 | 329  | 32 | 404  | 33 | 307  | 20.2 | 271  | 16.3 |
| <b>P</b>           | -    | -  | -    | -  | -    | -  | 7    | 46.7 | 95   | 24   |
| <b>Q</b>           | 557  | 49 | 177  | 29 | 69   | 19 | 49   | 14   | 81   | 24.3 |
| <b>R</b>           | 161  | 34 | 466  | 49 | 486  | 43 | 270  | 24.5 | 177  | 13.1 |
| <b>S</b>           | 123  | 53 | 75   | 86 | 103  | 86 | 104  | 51.2 | 79   | 30.9 |
| <b>U</b>           | NA   | NA | 248  | 25 | 197  | 15 | 44   | 3.1  | 70   | 4.9  |
| <b>V</b>           | -    | -  | -    | -  | -    | -  | 151  | 25   | 133  | 19.1 |
| <b>W</b>           | 449  | 44 | 288  | 93 | 272  | 91 | 372  | 97.1 | 257  | 97.7 |
| <b>X</b>           | -    | -  | -    | -  | -    | -  | 134  | 88.7 | 233  | 66.6 |
| <b>Y</b>           | -    | -  | -    | -  | -    | -  | 32   | 31.7 | 61   | 34.1 |
| <b>Z</b>           | 244  | 59 | 326  | 39 | 385  | 37 | 53   | 3.4  | 30   | 2.2  |
| <b>AA</b>          | -    | -  | -    | -  | -    | -  | 8    | 5.5  | 25   | 7.9  |
| <b>AB</b>          | 232  | 54 | 187  | 34 | 109  | 21 | 57   | 11.5 | 99   | 15.7 |
| <b>AC</b>          | 184  | 98 | 196  | 57 | 194  | 48 | 159  | 57   | 194  | 51.2 |
| <b>AD</b>          | 176  | 45 | 252  | 96 | 176  | 86 | 196  | 97.5 | 305  | 97.1 |
| <b>AE</b>          | 183  | 43 | 125  | 20 | 250  | 55 | 222  | 33.1 | 193  | 32.8 |
| <b>AF</b>          | -    | -  | -    | -  | -    | -  | 210  | 47.3 | 138  | 26.1 |
| <b>AH</b>          | 219  | 82 | 323  | 46 | 292  | 36 | 403  | 38.9 | 499  | 41   |
| <b>AI</b>          | 256  | 98 | 517  | 65 | 435  | 48 | 319  | 33.5 | 219  | 24.7 |
| <b>AJ</b>          | 356  | 35 | 229  | 34 | 403  | 45 | 276  | 27.6 | 263  | 26   |

D, L, T and AG were excluded due to low ascertainment rate

### 1.3.8 Distribution of combined surgery

The proportion of cataract surgery which was performed in combination with VR surgery showed an initial exponential rise from 2002 to 2007. However, the percentage reduced sharply in 2008. The percentage when it was combined with filtering surgery was reduced in 2004 than plateaued and levelled off for 2007 and 2008. Cataract surgery combined with penetrating keratoplasty remained infrequently performed over the years.

Table 1.3.8(a): Distribution of Combined Surgery for all SDPs, CSR 2002-2008

| Year                                      | 2002  |       | 2003  |     | 2004  |      | 2007  |     | 2008  |     |
|---|-------|-------|-------|-----|-------|------|-------|-----|-------|-----|
| No of patients (N)                        | 12798 |       | 16815 |     | 18392 |      | 18426 |     | 21496 |     |
|   | No    | %     | No    | %   | No    | %    | No    | %   | No    | %   |
| All types of combined surgeries           | 375   | 2.9   | 581   | 3.4 | 733   | 4.9  | 891   | 4.8 | 664   | 3.1 |
| <b>Specific types of combined surgery</b> |       |       |       |     |       |      |       |     |       |     |
| Pterygium Surgery                         | 86    | 0.7   | 120   | 0.7 | 147   | 0.8  | 135   | 0.7 | 94    | 0.4 |
| Filtering Glaucoma Surgery                | 148   | 1.2   | 210   | 1.2 | 235   | 1.3  | 131   | 0.7 | 142   | 0.7 |
| Vitreoretinal Surgery                     | 26    | 0.2   | 100   | 0.6 | 186   | 1.0  | 435   | 2.4 | 237   | 1.1 |
| Penetrating Keratoplasty                  | 1     | 0.007 | 0     | 0.0 | 3     | 0.02 | 0     | 0.0 | 3     | 0   |
| Others                                    | 124   | 1.0   | 170   | 1.0 | 149   | 0.8  | 190   | 1.0 | 188   | 0.9 |

Figure 1.3.8(a): Distribution of Combined Surgery for all SDPs, CSR 2002-2008




Table 1.3.8(b): Distribution of Combined Surgery by SDP, CSR 2008

| Combined Surgery |                     |                            |                         |                         |                             |                                |              |  |  |  |  |  |
|------------------|---------------------|----------------------------|-------------------------|-------------------------|-----------------------------|--------------------------------|--------------|--|--|--|--|--|
|                  | All Surgeries<br>No | All Combined Surgery<br>No | Pterygium Surgery<br>No | Filtering Surgery<br>No | Vitreoretinal Surgery<br>No | Penetrating Keratoplasty<br>No | Others<br>No |  |  |  |  |  |
|                  |                     | %                          | %                       | %                       | %                           | %                              | %            |  |  |  |  |  |
| All Centres      | 21496               | 664                        | 94                      | 142                     | 237                         | 3                              | 188          |  |  |  |  |  |
| A                | 986                 | 5.2                        | 8                       | 2                       | 21                          | 0                              | 20           |  |  |  |  |  |
| B                | 208                 | 1                          | 1                       | 0                       | 0                           | 0                              | 1            |  |  |  |  |  |
| C                | 573                 | 3.3                        | 10                      | 8                       | 0                           | 0                              | 1            |  |  |  |  |  |
| E                | 487                 | 0                          | 0                       | 0                       | 0                           | 0                              | 0            |  |  |  |  |  |
| F                | 137                 | 10.2                       | 4                       | 6                       | 0                           | 0                              | 4            |  |  |  |  |  |
| G                | 1723                | 2.3                        | 3                       | 26                      | 1                           | 0                              | 10           |  |  |  |  |  |
| H                | 400                 | 2.5                        | 0                       | 0                       | 0                           | 0                              | 10           |  |  |  |  |  |
| I                | 34                  | 2.9                        | 0                       | 1                       | 0                           | 0                              | 0            |  |  |  |  |  |
| J                | 739                 | 7                          | 3                       | 11                      | 20                          | 0                              | 18           |  |  |  |  |  |
| K                | 170                 | 1.2                        | 0                       | 0                       | 0                           | 0                              | 2            |  |  |  |  |  |
| M                | 282                 | 5.7                        | 2                       | 6                       | 0                           | 0                              | 8            |  |  |  |  |  |
| N                | 726                 | 3.7                        | 12                      | 4                       | 4                           | 0                              | 7            |  |  |  |  |  |
| O                | 1681                | 3.4                        | 1                       | 31                      | 16                          | 0                              | 9            |  |  |  |  |  |
| P                | 396                 | 1                          | 2                       | 0                       | 0                           | 0                              | 2            |  |  |  |  |  |
| Q                | 338                 | 1.5                        | 0                       | 0                       | 1                           | 0                              | 4            |  |  |  |  |  |
| R                | 1357                | 1.8                        | 3                       | 12                      | 1                           | 0                              | 8            |  |  |  |  |  |
| S                | 256                 | 0.4                        | 0                       | 0                       | 0                           | 0                              | 1            |  |  |  |  |  |
| U                | 1429                | 9.4                        | 0                       | 11                      | 109                         | 1                              | 14           |  |  |  |  |  |
| V                | 696                 | 3.3                        | 2                       | 2                       | 1                           | 0                              | 18           |  |  |  |  |  |
| W                | 263                 | 2.3                        | 1                       | 1                       | 0                           | 0                              | 4            |  |  |  |  |  |
| X                | 350                 | 0.3                        | 0                       | 1                       | 0                           | 0                              | 0            |  |  |  |  |  |
| Y                | 180                 | 0.6                        | 0                       | 0                       | 0                           | 0                              | 1            |  |  |  |  |  |
| Z                | 1376                | 0.1                        | 1                       | 0                       | 0                           | 0                              | 0            |  |  |  |  |  |
| AA               | 319                 | 0.6                        | 0                       | 0                       | 0                           | 0                              | 2            |  |  |  |  |  |
| AB               | 633                 | 0.5                        | 2                       | 0                       | 0                           | 0                              | 1            |  |  |  |  |  |
| AC               | 379                 | 2.6                        | 5                       | 2                       | 0                           | 0                              | 3            |  |  |  |  |  |
| AD               | 317                 | 6                          | 8                       | 0                       | 0                           | 0                              | 11           |  |  |  |  |  |
| AE               | 588                 | 0.3                        | 2                       | 0                       | 0                           | 0                              | 0            |  |  |  |  |  |
| AF               | 531                 | 2.3                        | 8                       | 0                       | 0                           | 0                              | 4            |  |  |  |  |  |
| AH               | 1217                | 1.7                        | 0                       | 4                       | 12                          | 0                              | 5            |  |  |  |  |  |
| AI               | 898                 | 2.2                        | 2                       | 6                       | 11                          | 0                              | 1            |  |  |  |  |  |
| AJ               | 1011                | 2.4                        | 7                       | 3                       | 7                           | 2                              | 5            |  |  |  |  |  |

D, L, T and AG were excluded due to low ascertainment rates

### 1.3.9 Anaesthesia in cataract surgery

The number of patients who were being operated under local anaesthesia has increased over the years. The preferred type of local anaesthesia was subtenon injection. However, there was an increase in the usage of topical anaesthesia. The use of peribulbar, retrobulbar and facial block injection for anaesthesia as well as combined LA has decreased over the years.

Table 1.3.9(a): Types of Anaesthesia all SDPs, CSR 2002-2008

| Year   | 2002  |      | 2003  |      | 2004  |      | 2007  |       | 2008  |      |
|--|-------|------|-------|------|-------|------|-------|-------|-------|------|
| No of patients (N)                             | 12798 |      | 16815 |      | 18392 |      | 18426 |       | 21496 |      |
|  | No    | %    | No    | %    | No    | %    | No    | %     | No    | %    |
| General anaesthesia                            | 818   | 6.4  | 1136  | 7.0  | 1379  | 7.3  | 1207  | 6.6   | 1223  | 5.7  |
| Local anaesthesia                              | 11980 | 93.6 | 15679 | 93.2 | 17013 | 92.5 | 17143 | 93.4  | 20188 | 94.3 |
| <b>Type of local anaesthesia</b>               |       |      |       |      |       |      |       |       |       |      |
| Subtenon                                       | 5647  | 47.1 | 8076  | 51.5 | 9260  | 54.4 | 9990  | 58.3  | 11014 | 54.6 |
| Topical  | 1406  | 11.7 | 2819  | 18.0 | 3978  | 23.4 | 4853  | 28.3  | 6680  | 33.1 |
| Peribulbar                                     | 2601  | 21.7 | 2575  | 16.4 | 2940  | 1.3  | 1282  | 7.5   | 1227  | 6.1  |
| Retrobulbar                                    | 3100  | 25.9 | 2952  | 18.8 | 2186  | 12.8 | 1031  | 6.0   | 1182  | 5.9  |
| Intracameral                                   | NA    | NA   | NA    | NA   | NA    | NA   | 249   | 1.5   | 710   | 3.5  |
| Subconjunctival                                | 28    | 0.2  | 141   | 0.9  | 139   | 0.8  | 232   | 1.4   | 251   | 1.2  |
| Facial block                                   | 1348  | 11.3 | 865   | 5.5  | 226   | 1.3  | 20    | 0.1   | 143   | 0.7  |
| Others   | 12    | 0.1  | 0     | 0.0  | 1     | 0.0  | 223   | 1.3   | NA    | NA   |
| Combined local anaesthesia                     | 1983  | 16.6 | 1685  | 10.7 | 1678  | 9.9  | 497   | 2.9   | 537   | 2.7  |
| <b>Types of sedation for patients under LA</b> |       |      |       |      |       |      |       |       |       |      |
| No sedation                                    | 7507  | 62.7 | 12021 | 76.7 | 14031 | 82.5 | 9668  | 56.4* | 11234 | 55.6 |
| Oral sedation alone                            | 3995  | 33.3 | 3354  | 21.4 | 2729  | 16.0 | 2387  | 13.9  | 2923  | 14.5 |
| Intravenous alone                              | 108   | 0.9  | 91    | 0.6  | 144   | 0.8  | 72    | 0.4   | 37    | 0.2  |
| Intravenous plus oral                          | 83    | 0.7  | 53    | 0.3  | 15    | 0.1  | 0.0   | 0.0   | NA    | NA   |
| Intramuscular                                  | 426   | 3.6  | 261   | 1.7  | 104   | 0.6  | 3.0   | 0.02  | 121   | 0.6  |

\*There was a significant percentage of missing values in sedation for 2007; these missing values may be in 'no sedation' category where data were not entered.

Figure 1.3.9: Types of Anaesthesia by All SDPs, CSR 2002-2008




Table 1.3.9(b): Types of Anaesthesia by SDPs, CSR 2008

| Types of Anaesthesia |       |         |      |       |      |
|----------------------|-------|---------|------|-------|------|
|                      | N     | General |      | Local |      |
|                      |       | No.     | %    | No.   | %    |
| <b>All Centres</b>   | 21496 | 1223    | 5.7  | 20188 | 94.3 |
| <b>A</b>             | 986   | 83      | 8.5  | 898   | 91.5 |
| <b>B</b>             | 208   | 1       | 0.5  | 207   | 99.5 |
| <b>C</b>             | 573   | 2       | 0.3  | 570   | 99.7 |
| <b>E</b>             | 487   | 24      | 5    | 459   | 95   |
| <b>F</b>             | 137   | 5       | 3.7  | 131   | 96.3 |
| <b>G</b>             | 1723  | 82      | 4.8  | 1640  | 95.2 |
| <b>H</b>             | 400   | 4       | 1    | 395   | 99   |
| <b>I</b>             | 34    | 4       | 11.8 | 30    | 88.2 |
| <b>J</b>             | 739   | 62      | 8.4  | 677   | 91.6 |
| <b>K</b>             | 170   | 5       | 3    | 164   | 97   |
| <b>M</b>             | 282   | 5       | 1.8  | 276   | 98.2 |
| <b>N</b>             | 726   | 30      | 4.1  | 696   | 95.9 |
| <b>O</b>             | 1681  | 62      | 3.7  | 1604  | 96.3 |
| <b>P</b>             | 396   | 3       | 0.8  | 391   | 99.2 |
| <b>Q</b>             | 338   | 7       | 2.1  | 331   | 97.9 |
| <b>R</b>             | 1357  | 97      | 7.1  | 1260  | 92.9 |
| <b>S</b>             | 256   | 19      | 7.4  | 237   | 92.6 |
| <b>U</b>             | 1429  | 38      | 2.7  | 1368  | 97.3 |
| <b>V</b>             | 696   | 37      | 5.3  | 659   | 94.7 |
| <b>W</b>             | 263   | 15      | 5.7  | 247   | 94.3 |
| <b>X</b>             | 350   | 6       | 1.7  | 344   | 98.3 |
| <b>Y</b>             | 180   | 31      | 17.2 | 149   | 82.8 |
| <b>Z</b>             | 1376  | 34      | 2.5  | 1333  | 97.5 |
| <b>AA</b>            | 319   | 72      | 22.7 | 245   | 77.3 |
| <b>AB</b>            | 633   | 30      | 4.7  | 602   | 95.3 |
| <b>AC</b>            | 379   | 73      | 19.3 | 306   | 80.7 |
| <b>AD</b>            | 317   | 8       | 2.5  | 308   | 97.5 |
| <b>AE</b>            | 588   | 22      | 3.8  | 564   | 96.2 |
| <b>AF</b>            | 531   | 13      | 2.5  | 516   | 97.5 |
| <b>AH</b>            | 1217  | 129     | 10.6 | 1087  | 89.4 |
| <b>AI</b>            | 898   | 60      | 6.7  | 831   | 93.3 |
| <b>AJ</b>            | 1011  | 43      | 4.3  | 966   | 95.7 |

D, L, T and AG were excluded due to low ascertainment rates

Table 1.3.9(c): Types of Local Anaesthesia by SDPs, CSR 2008

| Local Anaesthesia |       |      |             |     |            |     |          |      |                  |     |              |      |         |      |              |     |          |     |
|-------------------|-------|------|-------------|-----|------------|-----|----------|------|------------------|-----|--------------|------|---------|------|--------------|-----|----------|-----|
|                   | All   |      | Retrobulbar |     | Peribulbar |     | Subtenon |      | Sub-conjunctival |     | Facial block |      | Topical |      | Intracameral |     | Combined |     |
|                   | No    | %    | No          | %   | No         | %   | No       | %    | No               | %   | No           | %    | No      | %    | No           | %   | No       | %   |
| All Centres       | 20188 | 1182 | 5.9         | 6.1 | 1227       | 6.1 | 11014    | 54.6 | 251              | 1.2 | 143          | 0.7  | 6680    | 33.1 | 710          | 3.5 | 537      | 2.7 |
| A                 | 898   | 625  | 69.6        | 1   | 0.1        | 109 | 12.1     | 11   | 1.2              | 0   | 0            | 95   | 10.6    | 1    | 0.1          | 0   | 0        | 0   |
| B                 | 207   | 1    | 0.5         | 0   | 0          | 162 | 78.3     | 0    | 0                | 1   | 0.5          | 64   | 30.9    | 24   | 11.6         | 13  | 6.3      | 0   |
| C                 | 570   | 0    | 0           | 0   | 0          | 567 | 99.5     | 0    | 0                | 0   | 0            | 0    | 0       | 0    | 0            | 0   | 0        | 0   |
| E                 | 459   | 1    | 0.2         | 154 | 33.6       | 294 | 64.1     | 0    | 0                | 0   | 0            | 0    | 2       | 0.4  | 4            | 0.9 | 2        | 0.4 |
| F                 | 131   | 43   | 32.8        | 78  | 59.5       | 0   | 0        | 0    | 0                | 108 | 82.4         | 3    | 9.2     | 1    | 0.8          | 1   | 0.8      | 0   |
| G                 | 1640  | 3    | 0.2         | 1   | 0.1        | 921 | 56.2     | 146  | 8.9              | 0   | 0            | 594  | 36.2    | 527  | 32.1         | 435 | 26.5     | 0   |
| H                 | 395   | 4    | 1           | 0   | 0          | 389 | 98.5     | 1    | 0.3              | 0   | 0            | 28   | 93.3    | 0    | 0            | 0   | 0        | 0   |
| I                 | 30    | 11   | 36.7        | 0   | 0          | 0   | 0        | 0    | 0                | 11  | 36.7         | 1    | 0.1     | 0    | 0            | 0   | 0        | 0   |
| J                 | 677   | 1    | 0.1         | 1   | 0.1        | 672 | 99.3     | 0    | 0                | 0   | 0            | 9    | 5.5     | 24   | 14.6         | 10  | 6.1      | 0   |
| K                 | 164   | 0    | 0           | 0   | 0          | 142 | 86.6     | 0    | 0                | 0   | 0            | 1    | 0.4     | 0    | 0            | 0   | 0        | 0   |
| M                 | 276   | 1    | 0.4         | 1   | 0.4        | 270 | 97.8     | 4    | 1.4              | 0   | 0            | 99   | 14.2    | 0    | 0            | 0   | 0        | 0   |
| N                 | 696   | 6    | 0.9         | 0   | 0          | 590 | 84.8     | 14   | 2                | 0   | 0            | 1233 | 76.9    | 0    | 0            | 0   | 0        | 0   |
| O                 | 1604  | 1    | 0.1         | 0   | 0          | 463 | 28.9     | 0    | 0                | 4   | 0.2          | 0    | 3.1     | 0    | 0            | 0   | 0        | 0   |
| P                 | 391   | 2    | 0.5         | 0   | 0          | 352 | 90       | 1    | 0.3              | 0   | 0            | 12   | 1.2     | 0    | 0            | 0   | 0        | 0   |
| Q                 | 331   | 0    | 0           | 0   | 0          | 326 | 98.5     | 0    | 0                | 0   | 0            | 4    | 44.4    | 31   | 2.5          | 20  | 1.6      | 0   |
| R                 | 1260  | 1    | 0.1         | 2   | 0.2        | 687 | 54.5     | 6    | 0.5              | 3   | 0.2          | 560  | 0       | 0    | 0            | 0   | 0        | 0   |
| S                 | 237   | 0    | 0           | 0   | 0          | 236 | 99.6     | 0    | 0                | 0   | 0            | 0    | 0       | 0    | 0            | 0   | 0        | 0   |
| U                 | 1368  | 202  | 14.8        | 3   | 0.2        | 174 | 12.7     | 3    | 0.2              | 0   | 0            | 981  | 71.7    | 13   | 1            | 0   | 0        | 0   |
| V                 | 659   | 0    | 0           | 12  | 1.8        | 375 | 56.9     | 5    | 0.8              | 0   | 0            | 247  | 37.5    | 36   | 5.5          | 17  | 2.6      | 0   |
| W                 | 247   | 9    | 3.6         | 144 | 58.3       | 96  | 38.9     | 0    | 0                | 1   | 0.4          | 0    | 0       | 0    | 0            | 0   | 0        | 0   |
| X                 | 344   | 3    | 0.9         | 1   | 0.3        | 133 | 38.7     | 4    | 1.2              | 1   | 0.3          | 201  | 58.4    | 6    | 1.7          | 4   | 1.2      | 0   |
| Y                 | 149   | 129  | 86.6        | 0   | 0          | 0   | 0        | 20   | 13.4             | 1   | 0.7          | 0    | 0       | 0    | 0            | 0   | 0        | 0   |
| Z                 | 1333  | 3    | 0.2         | 0   | 0          | 801 | 60.1     | 6    | 0.5              | 3   | 0.2          | 501  | 37.6    | 0    | 0            | 0   | 0        | 0   |
| AA                | 245   | 0    | 0           | 0   | 0          | 221 | 90.2     | 1    | 0.4              | 0   | 0            | 15   | 6.1     | 0    | 0            | 0   | 0        | 0   |
| AB                | 602   | 0    | 0           | 0   | 0          | 591 | 98.2     | 3    | 0.5              | 0   | 0            | 102  | 33.3    | 22   | 3.7          | 22  | 3.7      | 0   |
| AC                | 306   | 0    | 0           | 33  | 10.8       | 166 | 54.2     | 0    | 0                | 0   | 0            | 0    | 0       | 0    | 0            | 0   | 0        | 0   |
| AD                | 308   | 0    | 0           | 0   | 0          | 303 | 98.4     | 0    | 0                | 0   | 0            | 0    | 0       | 0    | 0            | 0   | 0        | 0   |
| AE                | 564   | 2    | 0.4         | 0   | 0          | 406 | 72       | 0    | 0                | 0   | 0            | 152  | 27      | 0    | 0            | 0   | 0        | 0   |
| AF                | 516   | 0    | 0           | 0   | 0          | 429 | 83.1     | 0    | 0                | 0   | 0            | 103  | 20      | 0    | 0            | 0   | 0        | 0   |
| AH                | 1087  | 4    | 0.4         | 261 | 24         | 297 | 27.3     | 2    | 0.2              | 0   | 0            | 566  | 52.1    | 0    | 0            | 0   | 0        | 0   |
| AI                | 831   | 27   | 3.2         | 483 | 58.1       | 294 | 35.4     | 15   | 1.8              | 4   | 0.5          | 102  | 12.3    | 5    | 0.6          | 3   | 0.4      | 0   |
| AJ                | 966   | 3    | 0.3         | 7   | 0.7        | 254 | 26.3     | 7    | 0.7              | 3   | 0.3          | 733  | 75.9    | 11   | 1.1          | 10  | 1        | 0   |

- Number or Percentage may be more than total or 100% as patient might have been given more than one type of local anaesthesia

- D, L, T and AG were excluded due to low ascertainment rates

Table 1.3.9(d): Subtenon Anaesthesia by SDPs, CSR 2002-2008

| Years              | 2002 |       | 2003 |       | 2004 |       | 2007 |      | 2008  |      |
|--------------------|------|-------|------|-------|------|-------|------|------|-------|------|
|                    | No.  | %     | No.  | %     | No.  | %     | No.  | %    | No.   | %    |
| <b>All Centres</b> | 5647 | 47.0  | 8076 | 52.0  | 9260 | 54.0  | 9990 | 58.3 | 11014 | 54.6 |
| <b>A</b>           | 86   | 9.0   | 101  | 10.0  | 394  | 37.0  | 35   | 9.5  | 109   | 12.1 |
| <b>B</b>           | -    | -     | -    | -     | -    | -     | 3    | 75   | 162   | 78.3 |
| <b>C</b>           |      |       | 599  | 99.0  | 556  | 99.0  | 545  | 99.6 | 567   | 99.5 |
| <b>E</b>           | -    | -     | 371  | 73.0  | 405  | 66.0  | 422  | 69.5 | 294   | 64.1 |
| <b>F</b>           | 0    | 0.0   | 0    | 0.0   |      |       | NA   | NA   | 0     | 0    |
| <b>G</b>           | 283  | 99.0  | 627  | 68.0  | 463  | 64.0  | 702  | 47.1 | 921   | 56.2 |
| <b>H</b>           | 604  | 60.0  | 344  | 100.0 | 294  | 99.0  | 313  | 98.4 | 389   | 98.5 |
| <b>I</b>           | -    | -     | -    | -     | -    | -     | -    | -    | 0     | 0    |
| <b>J</b>           | 212  | 100.0 | 558  | 99.0  | 577  | 99.0  | 726  | 99.2 | 672   | 99.3 |
| <b>K</b>           | -    | -     | -    | -     | -    | -     | 115  | 100  | 142   | 86.6 |
| <b>M</b>           | -    | -     | 24   | 15.0  | 55   | 39.0  | 208  | 99.5 | 270   | 97.8 |
| <b>N</b>           | 98   | 14.0  | 140  | 59.0  | 120  | 63.0  | 419  | 85.2 | 590   | 84.8 |
| <b>O</b>           | 507  | 99.0  | 400  | 41.0  | 531  | 47.0  | 443  | 30.1 | 463   | 28.9 |
| <b>P</b>           | -    | -     | -    | -     | 2    | 1.0   | 1    | 6.3  | 352   | 90   |
| <b>Q</b>           | 1004 | 95.0  | 585  | 100.0 | 350  | 99.0  | 166  | 49.7 | 326   | 98.5 |
| <b>R</b>           | 2    | 0.0   | 883  | 99.0  | 1036 | 99.0  | 967  | 97.6 | 687   | 54.5 |
| <b>S</b>           | 2    | 1.0   | 73   | 95.0  | 112  | 100.0 | 188  | 98.9 | 236   | 99.6 |
| <b>U</b>           | -    | -     | 467  | 49.0  | 350  | 28.0  | 152  | 11.1 | 174   | 12.7 |
| <b>V</b>           | -    | -     | -    | -     | -    | -     | 522  | 91.7 | 375   | 56.9 |
| <b>W</b>           | 76   | 8.0   | 25   | 9.0   | 23   | 8.0   | 33   | 9.6  | 96    | 38.9 |
| <b>X</b>           | -    | -     | -    | -     | -    | -     | 136  | 92.5 | 133   | 38.7 |
| <b>Y</b>           | -    | -     | -    | -     | -    | -     | 0    | 0    | 0     | 0    |
| <b>Z</b>           | 3    | 1.0   | 40   | 5.0   | 197  | 21.0  | 1103 | 74   | 801   | 60.1 |
| <b>AA</b>          | -    | -     | -    | -     | -    | -     | 98   | 80.3 | 221   | 90.2 |
| <b>AB</b>          | 344  | 85.0  | 1    | 0.0   | 193  | 37.0  | 472  | 99   | 591   | 98.2 |
| <b>AC</b>          | 0    | 0.0   | 240  | 74.0  | 216  | 58.0  | 156  | 71.2 | 166   | 54.2 |
| <b>AD</b>          | 200  | 54.0  | 2    | 1.0   | 68   | 34.0  | 195  | 100  | 303   | 98.4 |
| <b>AE</b>          | 47   | 12.0  | 184  | 33.0  | 249  | 57.0  | 190  | 28.6 | 406   | 72   |
| <b>AF</b>          | -    | -     | -    | -     | -    | -     | 390  | 94.4 | 429   | 83.1 |
| <b>AH</b>          | 207  | 90.0  | 582  | 95.0  | 546  | 80.0  | 468  | 57.1 | 297   | 27.3 |
| <b>AI</b>          | 0    | 0.0   | 175  | 25.0  | 215  | 26.0  | 210  | 24.1 | 294   | 35.4 |
| <b>AJ</b>          | 510  | 53.0  | 292  | 46.0  | 616  | 73.0  | 404  | 42.7 | 254   | 26.3 |

D, L, T and AG were excluded due to low ascertainment rates

Table 1.3.9(e): Topical Anaesthesia by SDPs, CSR 2002-2008

| Year               | 2002 |      | 2003 |      | 2004 |      | 2007 |      | 2008 |      |
|--------------------|------|------|------|------|------|------|------|------|------|------|
|                    | No.  | %    | No.  | %    | No.  | %    | No.  | %    | No.  | %    |
| <b>All Centres</b> | 1406 | 12.0 | 2819 | 18.0 | 3978 | 23.0 | 4853 | 28.3 | 6680 | 33.1 |
| <b>A</b>           | 7    | 1.0  | 1    | 0.0  | 72   | 7.0  | 1    | 0.3  | 95   | 10.6 |
| <b>B</b>           | -    | -    | -    | -    | -    | -    | 3    | 75   | 64   | 30.9 |
| <b>C</b>           | -    | -    | 0    | 0.0  | -    | -    | 1    | 0.2  | 0    | 0    |
| <b>E</b>           | -    | -    | 0    | 0.0  | 1    | 0.0  | 0    | 0    | 2    | 0.4  |
| <b>F</b>           | 0    | 0.0  | 0    | 0.0  | 1    | 1.0  | NA   | NA   | 12   | 9.2  |
| <b>G</b>           | 0    | 0.0  | 183  | 20.0 | 156  | 21.0 | 573  | 38.5 | 594  | 36.2 |
| <b>H</b>           | 33   | 3.0  | 0    | 0.0  | -    | -    | 0    | 0    | 0    | 0    |
| <b>I</b>           | -    | -    | -    | -    | -    | -    | -    | -    | 28   | 93.3 |
| <b>J</b>           | 0    | 0.0  | 0    | 0.0  | 1    | 0.0  | 0    | 0    | 1    | 0.1  |
| <b>K</b>           | -    | -    | -    | -    | -    | -    | 0    | 0    | 9    | 5.5  |
| <b>M</b>           | -    | -    | 0    | 0.0  | -    | -    | 0    | 0    | 1    | 0.4  |
| <b>N</b>           | 380  | 54.0 | 93   | 39.0 | 72   | 38.0 | 75   | 15.2 | 99   | 14.2 |
| <b>O</b>           | 0    | 0.0  | 568  | 58.0 | 600  | 53.0 | 1075 | 73.1 | 1233 | 76.9 |
| <b>P</b>           | -    | -    | -    | -    | 80   | 36.0 | 0    | 0    | 12   | 3.1  |
| <b>Q</b>           | 10   | 1.0  | 0    | 0.0  | 1    | 0.0  | 160  | 47.9 | 4    | 1.2  |
| <b>R</b>           | 92   | 20.0 | 4    | 0.0  | -    | -    | 8    | 0.8  | 560  | 44.4 |
| <b>S</b>           | -    | -    | 0    | 0.0  | -    | -    | 0    | 0    | 0    | 0    |
| <b>U</b>           | -    | -    | 256  | 27.0 | 602  | 47.0 | 983  | 71.5 | 981  | 71.7 |
| <b>V</b>           | -    | -    | -    | -    | -    | -    | 33   | 5.8  | 247  | 37.5 |
| <b>W</b>           | 54   | 6.0  | 1    | 0.0  | -    | -    | 0    | 0    | 0    | 0    |
| <b>X</b>           | -    | -    | -    | -    | -    | -    | 11   | 7.5  | 201  | 58.4 |
| <b>Y</b>           | -    | -    | -    | -    | -    | -    | 0    | 0    | 0    | 0    |
| <b>Z</b>           | 0    | 0.0  | 9    | 1.0  | 197  | 21.0 | 359  | 24.1 | 501  | 37.6 |
| <b>AA</b>          | -    | -    | -    | -    | -    | -    | 27   | 22.1 | 15   | 6.1  |
| <b>AB</b>          | 62   | 15.0 | 94   | 17.0 | 111  | 21.0 | 0    | 0    | 0    | 0    |
| <b>AC</b>          | 1    | 1.0  | 84   | 26.0 | 157  | 42.0 | 63   | 28.8 | 102  | 33.3 |
| <b>AD</b>          | 148  | 40.0 | 0    | 0.0  | 1    | 1.0  | 0    | 0    | 0    | 0    |
| <b>AE</b>          | 4    | 1.0  | 386  | 69.0 | 219  | 50.0 | 469  | 70.6 | 152  | 27   |
| <b>AF</b>          | -    | -    | -    | -    | -    | -    | 27   | 6.5  | 103  | 20   |
| <b>AH</b>          | 0    | 0.0  | 0    | 0.0  | -    | -    | 210  | 25.6 | 566  | 52.1 |
| <b>AI</b>          | 1    | 0.0  | 1    | 0.0  | 2    | 0.0  | 1    | 0.1  | 102  | 12.3 |
| <b>AJ</b>          | 453  | 47.0 | 481  | 76.0 | 788  | 93.0 | 528  | 55.8 | 733  | 75.9 |

D, L, T and AG were excluded due to low ascertainment rates

Table 1.3.9(f): Types of Sedation by among Patients Given Local Anaesthesia by SDPs, CSR 2008

| Table 1.0.6(1). Types of Sedation by among Patients Given Local Anaesthesia by GDTs, GCR 2006 |                                 |             |      |            |      |                   |     |                |      |
|---|---------------------------------|-------------|------|------------|------|-------------------|-----|----------------|------|
|   | Types of sedation               |             |      |            |      |                   |     |                |      |
|   | All Local Anaesthesia<br>a<br>N | No Sedation |      | Oral Alone |      | Intravenous Alone |     | Intra-Muscular |      |
|   |                                 | No.         | %    | No.        | %    | No.               | %   | No.            | %    |
| All Centres   | 20188                           | 11234       | 55.6 | 2923       | 14.5 | 37                | 0.2 | 121            | 0.6  |
| A   | 898                             | 346         | 38.5 | 9          | 1    | 1                 | 0.1 | 0              | 0    |
| B   | 207                             | 109         | 52.7 | 0          | 0    | 0                 | 0   | 0              | 0    |
| C   | 570                             | 567         | 99.5 | 1          | 0.2  | 0                 | 0   | 0              | 0    |
| E   | 459                             | 82          | 17.9 | 356        | 77.6 | 0                 | 0   | 0              | 0    |
| F   | 131                             | 2           | 1.5  | 0          | 0    | 0                 | 0   | 118            | 90.1 |
| G   | 1640                            | 867         | 52.9 | 6          | 0.4  | 8                 | 0.5 | 1              | 0.1  |
| H   | 395                             | 257         | 65.1 | 0          | 0    | 0                 | 0   | 0              | 0    |
| I   | 30                              | 0           | 0    | 1          | 3.3  | 0                 | 0   | 0              | 0    |
| J   | 677                             | 667         | 98.5 | 5          | 0.7  | 2                 | 0.3 | 0              | 0    |
| K   | 164                             | 150         | 91.5 | 11         | 6.7  | 0                 | 0   | 0              | 0    |
| M   | 276                             | 5           | 1.8  | 97         | 35.1 | 0                 | 0   | 0              | 0    |
| N   | 696                             | 667         | 95.8 | 2          | 0.3  | 14                | 2   | 0              | 0    |
| O   | 1604                            | 1544        | 96.3 | 2          | 0.1  | 0                 | 0   | 0              | 0    |
| P   | 391                             | 167         | 42.7 | 0          | 0    | 0                 | 0   | 0              | 0    |
| Q   | 331                             | 324         | 97.9 | 0          | 0    | 0                 | 0   | 0              | 0    |
| R   | 1260                            | 19          | 1.5  | 1124       | 89.2 | 4                 | 0.3 | 0              | 0    |
| S   | 237                             | 206         | 86.9 | 1          | 0.4  | 0                 | 0   | 0              | 0    |
| U   | 1368                            | 375         | 27.4 | 2          | 0.1  | 0                 | 0   | 0              | 0    |
| V   | 659                             | 419         | 63.6 | 0          | 0    | 0                 | 0   | 0              | 0    |
| W   | 247                             | 4           | 1.6  | 57         | 23.1 | 0                 | 0   | 1              | 0.4  |
| X   | 344                             | 335         | 97.4 | 0          | 0    | 0                 | 0   | 0              | 0    |
| Y   | 149                             | 142         | 95.3 | 0          | 0    | 0                 | 0   | 0              | 0    |
| Z   | 1333                            | 936         | 70.2 | 212        | 15.9 | 0                 | 0   | 0              | 0    |
| AA  | 245                             | 74          | 30.2 | 1          | 0.4  | 0                 | 0   | 0              | 0    |
| AB  | 602                             | 1           | 0.2  | 487        | 80.9 | 0                 | 0   | 0              | 0    |
| AC  | 306                             | 51          | 16.7 | 20         | 6.5  | 0                 | 0   | 0              | 0    |
| AD  | 308                             | 11          | 3.6  | 0          | 0    | 1                 | 0.3 | 0              | 0    |
| AE  | 564                             | 395         | 70   | 158        | 28   | 1                 | 0.2 | 0              | 0    |
| AF  | 516                             | 7           | 1.4  | 357        | 69.2 | 2                 | 0.4 | 0              | 0    |
| AH  | 1087                            | 1056        | 97.1 | 2          | 0.2  | 3                 | 0.3 | 0              | 0    |
| AI  | 831                             | 345         | 41.5 | 5          | 0.6  | 1                 | 0.1 | 1              | 0.1  |
| AJ  | 966                             | 919         | 95.1 | 0          | 0    | 0                 | 0   | 0              | 0    |

- Number or Percentage may be more than total or 100% as patient might have more than one type of local Anaesthesia
- D, L, T and AG were excluded due to low ascertainment rates

Table 1.3.9(g): Oral Sedation by SDPs, CSR 2002-2008

| Year               | 2002 |      | 2003 |      | 2004 |      | 2007 |      | 2008 |      |
|--------------------|------|------|------|------|------|------|------|------|------|------|
|                    | No.  | %    | No.  | %    | No.  | %    | No.  | %    | No.  | %    |
| <b>All Centres</b> | 3995 | 33.0 | 3354 | 21.0 | 2729 | 16   | 2387 | 13.9 | 2923 | 14.5 |
| <b>A</b>           | 450  | 50.0 | 601  | 61.0 | 106  | 10.0 | 4    | 1.1  | 9    | 1    |
| <b>B</b>           | -    | -    | -    | -    | -    | -    | 0    | 0    | 0    | 0    |
| <b>C</b>           | -    | -    | 1    | 0.0  | 5    | 1.0  | 0    | 0    | 1    | 0.2  |
| <b>E</b>           |      |      | 0    | 0.0  | 2    | 0.0  | 204  | 33.6 | 356  | 77.6 |
| <b>F</b>           | 0    | 0.0  | 0    | 0.0  | -    | -    | -    | -    | 0    | 0    |
| <b>G</b>           | 119  | 41.0 | 90   | 10.0 | 126  | 17.0 | 7    | 0.5  | 6    | 0.4  |
| <b>H</b>           | 194  | 19.0 | 202  | 59.0 | 202  | 68.0 | 4    | 1.3  | 0    | 0    |
| <b>I</b>           | -    | -    | -    | -    | -    | -    | -    | -    | 1    | 3.3  |
| <b>J</b>           | 2    | 1.0  | 7    | 1.0  | 30   | 5.0  | 5    | 0.7  | 5    | 0.7  |
| <b>K</b>           | -    | -    | -    | -    | -    | -    | 3    | 2.6  | 11   | 6.7  |
| <b>M</b>           | -    | -    | 5    | 3.0  | 24   | 17.0 | 99   | 47.4 | 97   | 35.1 |
| <b>N</b>           | 2    | 0.0  | 9    | 4.0  | -    | -    | 16   | 3.3  | 2    | 0.3  |
| <b>O</b>           | 3    | 1.0  | 3    | 0.0  | 6    | 1.0  | 0    | 0    | 2    | 0.1  |
| <b>P</b>           | -    | -    | -    | -    | 14   | 6.0  | 0    | 0    | 0    | 0    |
| <b>Q</b>           | 653  | 61.0 | 1    | 0.0  | 7    | 2.0  | 4    | 1.2  | 0    | 0    |
| <b>R</b>           | 4    | 1.0  | 555  | 62.0 | 638  | 61.0 | 847  | 85.5 | 1124 | 89.2 |
| <b>S</b>           | 0    | 0.0  | 0    | 0.0  | -    | -    | 0    | 0    | 1    | 0.4  |
| <b>U</b>           | -    | -    | 19   | 2.0  | 10   | 1.0  | 13   | 0.9  | 2    | 0.1  |
| <b>V</b>           | -    | -    | -    | -    | -    | -    | 2    | 0.4  | 0    | 0    |
| <b>W</b>           | 894  | 95.0 | 30   | 11.0 | 98   | 36.0 | 323  | 94.2 | 57   | 23.1 |
| <b>X</b>           | -    | -    | -    | -    | -    | -    | 3    | 2    | 0    | 0    |
| <b>Y</b>           | -    | -    | -    | -    | -    | -    | 0    | 0    | 0    | 0    |
| <b>Z</b>           | 362  | 93.0 | 677  | 85.0 | 529  | 56.0 | 188  | 12.6 | 212  | 15.9 |
| <b>AA</b>          | -    | -    | -    | -    | -    | -    | 1    | 0.8  | 1    | 0.4  |
| <b>AB</b>          | 0    | 0.0  | 344  | 63.0 | 173  | 33.0 | 253  | 53   | 487  | 80.9 |
| <b>AC</b>          | 173  | 97.0 | 1    | 0.0  | 1    | 0.0  | 7    | 3.2  | 20   | 6.5  |
| <b>AD</b>          | 0    | 0.0  | 24   | 9.0  | 27   | 14.0 | 0    | 0    | 0    | 0    |
| <b>AE</b>          | 7    | 2.0  | 0    | 0.0  | -    | -    | 0    | 0    | 158  | 28   |
| <b>AF</b>          | -    | -    | -    | -    | -    | -    | 400  | 96.9 | 357  | 69.2 |
| <b>AH</b>          | 92   | 40.0 | 2    | 0.0  | 3    | 0.0  | 1    | 0.1  | 2    | 0.2  |
| <b>AI</b>          | 211  | 90.0 | 552  | 78.0 | 338  | 41.0 | 3    | 0.3  | 5    | 0.6  |
| <b>AJ</b>          | 1    | 0.0  | 1    | 0.0  | 6    | 1.0  | 0    | 0    | 0    | 0    |

D, L, T and AG were excluded due to low ascertainment rates

Table 1.3.9(h): Intravenous Sedation by SDPs, CSR 2002-2008

| Year               | 2002 |      | 2003 |     | 2004 |     | 2007 |     | 2008 |     |
|--------------------|------|------|------|-----|------|-----|------|-----|------|-----|
|                    | No.  | %    | No.  | %   | No.  | %   | No.  | %   | No.  | %   |
| <b>All Centres</b> | 108  | 1.0  | 91   | 1.0 | 144  | 1.0 | 72   | 0.4 | 37   | 0.2 |
| <b>A</b>           | 21   | 2.0  | 9    | 1.0 | 42   | 4.0 | 1    | 0.3 | 1    | 0.1 |
| <b>B</b>           | -    | -    | -    | -   | -    | -   | 0    | 0   | 0    | 0   |
| <b>C</b>           | -    | -    | 0    | 0.0 | 1    | 0.0 | 0    | 0   | 0    | 0   |
| <b>E</b>           |      |      | 0    | 0.0 | -    | -   | 2    | 0.3 | 0    | 0   |
| <b>F</b>           | 55   | 47.0 | 1    | 1.0 | -    | -   | -    | -   | 0    | 0   |
| <b>G</b>           | 0    | 0.0  | 43   | 5.0 | 22   | 3.0 | 6    | 0.4 | 8    | 0.5 |
| <b>H</b>           | 12   | 1.0  | 0    | 0.0 | -    | -   | 0    | 0   | 0    | 0   |
| <b>I</b>           | -    | -    | -    | -   | -    | -   | -    | -   | 0    | 0   |
| <b>J</b>           | 0    | 0.0  | 0    | 0.0 | -    | -   | 5    | 0.7 | 2    | 0.3 |
| <b>K</b>           | -    | -    | -    | -   | -    | -   | 0    | 0   | 0    | 0   |
| <b>M</b>           | -    | -    | 0    | 0.0 | -    | -   | 0    | 0   | 0    | 0   |
| <b>N</b>           | 2    | 0.0  | 6    | 3.0 | 7    | 4.0 | 7    | 1.4 | 14   | 2   |
| <b>O</b>           | 0    | 0.0  | 1    | 0.0 | -    | -   | 1    | 0.1 | 0    | 0   |
| <b>P</b>           | -    | -    | -    | -   | -    | -   | 0    | 0   | 0    | 0   |
| <b>Q</b>           | 3    | 0.0  | 0    | 0.0 | -    | -   | 0    | 0   | 0    | 0   |
| <b>R</b>           | 0    | 0.0  | 4    | 0.0 | 7    | 1.0 | 3    | 0.3 | 4    | 0.3 |
| <b>S</b>           | 1    | 0.0  | 0    | 0.0 | -    | -   | 0    | 0   | 0    | 0   |
| <b>U</b>           | -    | -    | 8    | 1.0 | 33   | 3.0 | 33   | 2.4 | 0    | 0   |
| <b>V</b>           | -    | -    | -    | -   | -    | -   | 0    | 0   | 0    | 0   |
| <b>W</b>           | 2    | 0.0  | 2    | 1.0 | 2    | 1.0 | 1    | 0.3 | 0    | 0   |
| <b>X</b>           | -    | -    | -    | -   | -    | -   | 0    | 0   | 0    | 0   |
| <b>Y</b>           | -    | -    | -    | -   | -    | -   | 0    | 0   | 0    | 0   |
| <b>Z</b>           | 0    | 0.0  | 1    | 0.0 | -    | -   | 0    | 0   | 0    | 0   |
| <b>AA</b>          | -    | -    | -    | -   | -    | -   | 0    | 0   | 0    | 0   |
| <b>AB</b>          | 0    | 0.0  | 2    | 0.0 | -    | -   | 1    | 0.2 | 0    | 0   |
| <b>AC</b>          | 0    | 0.0  | 0    | 0.0 | -    | -   | 0    | 0   | 0    | 0   |
| <b>AD</b>          | 1    | 0.0  | 0    | 0.0 | -    | -   | 0    | 0   | 1    | 0.3 |
| <b>AE</b>          | 1    | 0.0  | 0    | 0.0 | 1    | 0.0 | 0    | 0   | 1    | 0.2 |
| <b>AF</b>          | -    | -    | -    | -   | -    | -   | 0    | 0   | 2    | 0.4 |
| <b>AH</b>          | 3    | 1.0  | 0    | 0.0 | 7    | 1.0 | 11   | 1.3 | 3    | 0.3 |
| <b>AI</b>          | 0    | 0.0  | 1    | 0.0 | 6    | 1.0 | 1    | 0.1 | 1    | 0.1 |
| <b>AJ</b>          | 0    | 0.0  | 1    | 0.0 | 6    | 1.0 | 0    | 0   | 0    | 0   |

D, L, T and AG were excluded due to low ascertainment rates

### 1.3.10 Intraocular lens implantation

Approximately 98% of patients had IOL implantation. Out of this proportion, 97% had posterior chamber IOL. This trend remained unchanged over the years. The material and type of IOL used in cataract surgery demonstrated a constant shift from PMMA to Acrylic and from non-foldable to foldable. This pattern was consistent with the shift of type of surgery done, from ECCE to phaco. The use of silicone IOL has decreased.

Table 1.3.10(a): Intraocular Lens Implantation, CSR 2002-2008

| Year                     | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |      |
|--------------------------|-------|------|-------|------|-------|------|-------|------|-------|------|
| No of patients (N)       | 12798 |      | 16815 |      | 18392 |      | 18426 |      | 21496 |      |
|                          | No    | %    | No    | %    | No    | %    | No    | %    | No    | %    |
| With IOL                 | 12472 | 97.5 | 16396 | 97.5 | 17944 | 97.6 | 17873 | 97.0 | 21115 | 98.2 |
| Without IOL              | 326   | 2.5  | 419   | 2.5  | 448   | 2.4  | 553   | 3.0  | 375   | 1.7  |
| Not Available            | -     |      | -     |      | -     |      | -     |      | 6     | 0.0  |
| <b>IOL Placement</b>     |       |      |       |      |       |      |       |      |       |      |
| No of IOL                | 12472 |      | 16396 |      | 17944 |      | 17873 |      | 21115 |      |
| PCIOL                    | 12074 | 96.8 | 15957 | 97.3 | 17410 | 97.0 | 17350 | 97.1 | 20342 | 96.3 |
| ACIOL                    | 386   | 3.1  | 404   | 2.5  | 497   | 2.8  | 482   | 2.7  | 454   | 2.2  |
| Scleral Fixated IOL      | 11    | 0.1  | 34    | 0.2  | 34    | 0.2  | 35    | 0.2  | 36    | 0.2  |
| Others                   |       | 0.0  |       | 0.0  | 2     | 0.0  | 6     | 0.0  | 14    | 0.1  |
| Not Available /missing   | 1     | 0.0  | 1     | 0.0  | 1     | 0.0  | -     |      | 269   | 1.3  |
| <b>Materials of IOL</b>  |       |      |       |      |       |      |       |      |       |      |
| No of IOL                | 12472 |      | 16396 |      | 17944 |      | 17873 |      | 21115 |      |
| 1) Acrylic               | 1641  | 13.2 | 4418  | 26.9 | 7105  | 39.6 | 11955 | 66.9 | 15382 | 72.8 |
| 2) PMMA                  | 9161  | 73.5 | 10203 | 62.2 | 9758  | 54.4 | 5547  | 31   | 5300  | 25.1 |
| 3) Silicone              | 1670  | 13.4 | 1776  | 10.8 | 1078  | 6.0  | 97    | 0.5  | 113   | 0.5  |
| 4) Others                | 0     | 0.0  | 4     | 0.0  | 12    | 0.1  | 74    | 0.4  | 19    | 0.1  |
| 4) Not Available/missing | -     |      | 1     | 0.0  | -     |      | 200   | 1.1  | 301   | 1.4  |
| <b>Types of IOL</b>      |       |      |       |      |       |      |       |      |       |      |
| No of IOL                | 12472 |      | 16396 |      | 17944 |      | 17873 |      | 21115 |      |
| 1) Foldable              | 3311  | 26.5 | 6195  | 37.8 | 8186  | 45.6 | 11972 | 67.0 | 15320 | 72.6 |
| 2) Non foldable          | 9161  | 73.5 | 10201 | 62.2 | 9757  | 54.4 | 5590  | 31.3 | 5316  | 25.2 |
| 3) Not Available/missing | -     |      | -     |      | 1     | 0.0  | 311   | 1.7  | 479   | 2.3  |

Figure 1.3.10: Intraocular Lens Implantation, CSR 2002-2008




Table 1.3.10(b): Distribution of IOL Placement by SDPs, CSR 2008

| <b>Cataract Surgery With IOL</b> |       |                       |      |                      |     |                     |     |
|----------------------------------|-------|-----------------------|------|----------------------|-----|---------------------|-----|
|                                  | N     | Posterior Chamber IOL |      | Anterior Chamber IOL |     | Scleral Fixated IOL |     |
|                                  |       | No.                   | %    | No.                  | %   | No.                 | %   |
| <b>All Centres</b>               | 20832 | 20342                 | 97.6 | 454                  | 2.2 | 36                  | 0.2 |
| <b>A</b>                         | 959   | 953                   | 99.4 | 6                    | 0.6 | 0                   | 0   |
| <b>B</b>                         | 207   | 205                   | 99   | 2                    | 1   | 0                   | 0   |
| <b>C</b>                         | 568   | 555                   | 97.7 | 13                   | 2.3 | 0                   | 0   |
| <b>E</b>                         | 476   | 474                   | 99.6 | 2                    | 0.4 | 0                   | 0   |
| <b>F</b>                         | 121   | 119                   | 98.3 | 2                    | 1.7 | 0                   | 0   |
| <b>G</b>                         | 1697  | 1674                  | 98.6 | 23                   | 1.4 | 0                   | 0   |
| <b>H</b>                         | 389   | 380                   | 97.7 | 9                    | 2.3 | 0                   | 0   |
| <b>I</b>                         | 31    | 31                    | 100  | 0                    | 0   | 0                   | 0   |
| <b>J</b>                         | 701   | 690                   | 98.4 | 5                    | 0.7 | 6                   | 0.9 |
| <b>K</b>                         | 163   | 163                   | 100  | 0                    | 0   | 0                   | 0   |
| <b>M</b>                         | 279   | 269                   | 96.4 | 10                   | 3.6 | 0                   | 0   |
| <b>N</b>                         | 685   | 665                   | 97.1 | 20                   | 2.9 | 0                   | 0   |
| <b>O</b>                         | 1638  | 1589                  | 97   | 35                   | 2.1 | 14                  | 0.9 |
| <b>P</b>                         | 385   | 384                   | 99.7 | 1                    | 0.3 | 0                   | 0   |
| <b>Q</b>                         | 335   | 323                   | 96.4 | 12                   | 3.6 | 0                   | 0   |
| <b>R</b>                         | 1320  | 1294                  | 98   | 25                   | 1.9 | 1                   | 0.1 |
| <b>S</b>                         | 246   | 239                   | 97.2 | 7                    | 2.8 | 0                   | 0   |
| <b>U</b>                         | 1345  | 1311                  | 97.5 | 34                   | 2.5 | 0                   | 0   |
| <b>V</b>                         | 677   | 657                   | 97   | 20                   | 3   | 0                   | 0   |
| <b>W</b>                         | 249   | 241                   | 96.8 | 8                    | 3.2 | 0                   | 0   |
| <b>X</b>                         | 345   | 332                   | 96.2 | 13                   | 3.8 | 0                   | 0   |
| <b>Y</b>                         | 171   | 170                   | 99.4 | 1                    | 0.6 | 0                   | 0   |
| <b>Z</b>                         | 1335  | 1303                  | 97.6 | 31                   | 2.3 | 1                   | 0.1 |
| <b>AA</b>                        | 314   | 306                   | 97.5 | 8                    | 2.5 | 0                   | 0   |
| <b>AB</b>                        | 603   | 582                   | 96.5 | 21                   | 3.5 | 0                   | 0   |
| <b>AC</b>                        | 370   | 365                   | 98.6 | 5                    | 1.4 | 0                   | 0   |
| <b>AD</b>                        | 300   | 291                   | 97   | 9                    | 3   | 0                   | 0   |
| <b>AE</b>                        | 588   | 569                   | 96.8 | 19                   | 3.2 | 0                   | 0   |
| <b>AF</b>                        | 511   | 489                   | 95.7 | 22                   | 4.3 | 0                   | 0   |
| <b>AH</b>                        | 1198  | 1153                  | 96.2 | 45                   | 3.8 | 0                   | 0   |
| <b>AI</b>                        | 882   | 850                   | 96.4 | 26                   | 2.9 | 6                   | 0.7 |
| <b>AJ</b>                        | 965   | 958                   | 99.3 | 5                    | 0.5 | 2                   | 0.2 |

D, L, T and AG were excluded due to low ascertainment rates

## 1.4 INTRA-OPERATIVE COMPLICATIONS


### 1.4.1 Intra-operative complications by years

There was an improvement in the rate of intra-operative complications in the year 2008. The rate declined to 7.6% from the cumulative rate of 10.4% in the year 2002. The most common type of complication was PCR followed by vitreous loss and zonular dehiscence. The rates of all the specific types of intra-operative complication have decreased over the years.

Table 1.4.1: Distribution of Type of Intra-operative Complications, CSR 2002-2008

| Year                               | 2002  |      | 2003  |     | 2004  |     | 2007  |      | 2008  |     |
|------------------------------------|-------|------|-------|-----|-------|-----|-------|------|-------|-----|
| No. of patients (N)                | 12798 |      | 16815 |     | 18391 |     | 18380 |      | 21496 |     |
|                                    | No.   | %    | No.   | %   | No.   | %   | No.   | %    | No.   | %   |
| Patient with intra-op complication | 1328  | 10.4 | 1673  | 9.9 | 1730  | 9.4 | 1999  | 10.9 | 1636  | 7.6 |
| <b>Types of complications</b>      |       |      |       |     |       |     |       |      |       |     |
| PCR                                | 773   | 6.0  | 1036  | 6.2 | 1025  | 5.6 | 764   | 4.2  | 798   | 3.7 |
| Vitreous loss                      | 734   | 5.7  | 979   | 5.8 | 994   | 5.4 | 569   | 3.1  | 608   | 2.8 |
| Zonular dehiscence                 | 246   | 1.9  | 327   | 1.9 | 380   | 2.1 | 275   | 1.5  | 322   | 1.5 |
| Drop nucleus                       | 13    | 0.1  | 27    | 0.2 | 34    | 0.2 | 21    | 0.1  | 33    | 0.2 |
| Suprachoroidal haemorrhage         | 5     | 0.0  | 8     | 0.0 | 10    | 0.1 | 9     | 0.0  | 10    | 0   |
| Central corneal oedema             | 56    | 0.4  | 73    | 0.4 | 78    | 0.4 | 58    | 0.3  | 27    | 0.1 |
| Others                             | 274   | 2.1  | 266   | 1.6 | 235   | 1.3 | 350   | 1.9  | 361   | 1.7 |

Figure 1.4.1: Distribution of Specific Type of Intra-operative Complications, CSR 2002-2008




### 1.4.2 Intra-operative complication by type of surgery

Phacoemulsification demonstrated the lowest rate of intra-operative complication, followed by ECCE and lens aspiration. This pattern remained unchanged since 2002. All these three main types of cataract surgeries showed a declining rate of complication over the years. ICCE produced higher rates of intra-operative complications due to the nature of the surgery. On the other hand, the higher rates of complications in 'phaco converted to ECCE' should be interpreted with caution. The surgery was mainly the result of complicated or failed phaco surgery; therefore the rates of complication could have been contributed partly by the complicated phaco surgery itself.

Table 1.4.2(a): Intra-operative Complications by Types of Cataract Surgery, CSR 2002-2008

| Year            | 2002 |      | 2003 |      | 2004 |      | 2007 |      | 2008 |      |
|-----------------|------|------|------|------|------|------|------|------|------|------|
|                 | No   | %    | No   | %    | No   | %    | No   | %    | No   | %    |
| Phaco           | 438  | 8.6  | 667  | 8.7  | 747  | 8.0  | 969  | 8.1  | 753  | 5.1  |
| Phaco→ ECCE     | 128  | 41.2 | 206  | 43.9 | 177  | 39.0 | 225  | 52.1 | 240  | 45.8 |
| ECCE            | 684  | 9.9  | 697  | 8.7  | 680  | 8.7  | 691  | 12.5 | 532  | 9.5  |
| Lens Aspiration | 51   | 13.7 | 50   | 11.5 | 58   | 10.5 | 51   | 15.8 | 31   | 9.1  |
| ICCE            | 27   | 33.3 | 39   | 41.5 | 50   | 48.5 | 63   | 44.7 | 60   | 46.5 |
| Others          | -    | -    | 14   | 10.7 | 18   | 10.5 | -    | -    | 16   | 25.8 |
| Missing         | -    | -    | -    | -    | -    | -    | 9    | 20.0 | 4    | 12.1 |

Figure1.4.2: Intra-operative Complications by Types of Cataract Surgery, CSR 2002-2008



### 1.4.3 Intra-operative complications by combined surgery

Consistent with the previous years' findings, the intra-operative complications were higher in combined surgery when compared to cataract surgery alone. PCR and vitreous loss also remained the most common complications encountered.

Higher complication rates were noted when cataract surgeries were combined with VR, filtering surgery or pterygium surgery. There was a significant proportion of PCR, vitreous loss and zonular dehiscence occurring intra-operatively when the surgery was combined with VR surgeries in 2002. However, it did not reveal any specific trend during the following years.

Table 1.4.3(a): Distribution of Intra-operative Complications by Any Combined Surgery, CSR 2002-2008

| Year                             | 2002 |      | 2003 |      | 2004 |      | 2007 |      | 2008 |      |
|----------------------------------|------|------|------|------|------|------|------|------|------|------|
|                                  | No.  | %    | No.  | %    | No.  | %    | No.  | %    | No.  | %    |
| Number of combined surgery       | 375  | 100  | 581  | 100  | 733  | 100  | 891  | 100  | 664  | 100  |
| Any intra-operative complication | 64   | 17.1 | 105  | 18.1 | 120  | 16.4 | 131  | 14.7 | 89   | 10.0 |
| <b>Types of complications</b>    |      |      |      |      |      |      |      |      |      |      |
| PCR                              | 35   | 9.3  | 60   | 10.3 | 77   | 10.5 | 56   | 6.3  | 54   | 6.1  |
| Vitreous loss                    | 46   | 12.3 | 66   | 11.4 | 72   | 9.8  | 41   | 4.6  | 40   | 4.5  |
| Zonular dehiscence               | 18   | 4.8  | 22   | 3.8  | 23   | 3.1  | 21   | 2.4  | 15   | 1.7  |
| Drop nucleus                     | 3    | 0.8  | 5    | 0.9  | 5    | 0.7  | 4    | 0.4  | 3    | 0.3  |
| Suprachoroidal haemorrhage       | 0    | 0.0  | 0    | 0.0  | 4    | 0.5  | 0    | 0.0  | 0    | 0.0  |
| Central corneal oedema           | 1    | 0.3  | 10   | 1.7  | 4    | 0.5  | 7    | 0.8  | 3    | 0.3  |
| Others                           | 12   | 3.2  | 18   | 3.1  | 16   | 2.2  | 30   | 3.4  | 14   | 1.6  |



Table 1.4.3(d): Distribution of Intra-operative Complications when Combined with VR Surgery, CSR 2002-2008

| Year                         | 2002 |      | 2003 |      | 2004 |      | 2007 |      | 2008 |     |
|------------------------------|------|------|------|------|------|------|------|------|------|-----|
| N                            | No   | %    | No   | %    | No   | %    | No   | %    | No   | %   |
| Any intra-op complication    | 9    | 35.0 | 24   | 24.0 | 25   | 13.0 | 45   | 10.3 | 21   | 8.9 |
| 1.Posterior capsule rupture  | 0    | 0.0  | 4    | 4.0  | 11   | 6.0  | 18   | 4.1  | 17   | 7.2 |
| 2.Vitreous loss              | 5    | 19.0 | 12   | 12.0 | 8    | 5.0  | 11   | 2.5  | 6    | 2.5 |
| 3.Zonular dehiscence         | 0    | 0.0  | 2    | 2.0  | 3    | 2.0  | 6    | 1.4  | 1    | 0.4 |
| 4.Drop nucleus               | 1    | 4.0  | 2    | 2.0  | 3    | 2.0  | 3    | 0.7  | 2    | 0.8 |
| 5.Suprachoroidal haemorrhage | 0    | 0.0  | 0    | 0.0  | 0    | 0.0  | 0    | 0.0  | 0    | 0.0 |
| 6.Central corneal oedema     | 0    | 0.0  | 2    | 2.0  | 1    | 1.0  | 3    | 0.7  | 0    | 0.0 |
| 7.Others                     | 3    | 12.0 | 4    | 4.0  | 2    | 1.0  | 12   | 2.8  | 3    | 1.3 |

#### 1.4.4 Intra-operative complications by types of local anaesthesia

In general, subconjunctival anaesthesia was associated with higher rates of intra-operative complications except for the year 2002 and 2004. The complications were mainly PCR and vitreous loss. However, the higher rates in these eyes could also be due to the occurrence of complication prompting the use of subconjunctival injection as an additional form of anaesthesia.

Table 1.4.4: Intra-operative Complications by Types of Local Anaesthesia, CSR 2008

|                              | All Local Anaesthesia |     | Retrobulbar |     | Peribulbar |      | Subtenon |     | Sub-Conjunctival |     | Facial Block |     | Topical |     | Intracameral |     |
|------------------------------|-----------------------|-----|-------------|-----|------------|------|----------|-----|------------------|-----|--------------|-----|---------|-----|--------------|-----|
|                              | No.                   | %   | No.         | %   | No.        | %    | No.      | %   | No.              | %   | No.          | %   | No.     | %   | No.          | %   |
| Any intra-op complication    | 1517                  | 7.5 | 84          | 7.0 | 124        | 10.0 | 957      | 9.0 | 22               | 9.0 | 11           | 8.0 | 402     | 6.0 | 42           | 6.0 |
| 1.Posterior capsule rupture  | 745                   | 3.7 | 39          | 3.0 | 39         | 3.0  | 468      | 4.0 | 13               | 5.0 | 5            | 3.0 | 227     | 3.0 | 19           | 3.0 |
| 2.Vitreous loss              | 557                   | 2.8 | 15          | 1.0 | 37         | 3.0  | 390      | 4.0 | 9                | 4.0 | 1            | 1.0 | 133     | 2.0 | 15           | 2.0 |
| 3.Zonular dehiscence         | 300                   | 1.5 | 8           | 1.0 | 26         | 2.0  | 205      | 2.0 | 3                | 1.0 | 1            | 1.0 | 68      | 1.0 | 9            | 1.0 |
| 4.Drop nucleus               | 31                    | 0.2 | 3           | 0.0 | 1          | 0.0  | 14       | 0.0 | 0                | 0.0 | 0            | 0.0 | 15      | 0.0 | 3            | 0.0 |
| 5.suprachoroidal haemorrhage | 10                    | 0.0 | 0           | 0.0 | 0          | 0.0  | 8        | 0.0 | 0                | 0.0 | 0            | 0.0 | 2       | 0.0 | 0            | 0.0 |
| 6.Central corneal oedema     | 24                    | 0.1 | 0           | 0.0 | 2          | 0.0  | 21       | 0.0 | 0                | 0.0 | 0            | 0.0 | 1       | 0.0 | 0            | 0.0 |
| 7.Other                      | 338                   | 1.7 | 24          | 2.0 | 40         | 3.0  | 203      | 2.0 | 3                | 1.0 | 5            | 3.0 | 86      | 1.0 | 10           | 1.0 |

Number or percentage may be more than total or 100% as patient might have more than one intra-operative complication.

### 1.4.5 Intra-operative complications by surgeon status

Intra-operative complications were highest in surgeries performed by the gazetted specialists. The rates appeared to be increasing. The complications were mainly PCR and vitreous loss. The rates were lower among Medical Officers most probably due to supervision from seniors or trainers during surgery. Although the occurrence of central corneal oedema and significant damage to iris was low among the specialists, the occurrence of other complications was still relatively high. The high rate of complications could be due to more difficult cases being operated by them. This finding required further observation and analysis.

Table 1.4.5(a): Percentage of Intra-operative Complications by Surgeon Status, CSR 2002-2008

#### (i) Specialist

| Year                             | 2003 |     | 2004 |     | 2007 |      | 2008* |      |
|----------------------------------|------|-----|------|-----|------|------|-------|------|
|                                  | No   | %   | No   | %   | No   | %    | No    | %    |
| Any intra-operative complication | 1144 | 9.5 | 1170 | 8.9 | 1485 | 10.4 | 1144  | 6.8  |
| PCR                              | 199  | 2.7 | 180  | 1.4 | 546  | 3.8  | 538   | 3.2  |
| Vitreous loss                    | 520  | 4.3 | 515  | 3.9 | 405  | 2.8  | 417   | 2.5  |
| Zonular dehiscence               | 151  | 1.3 | 163  | 1.2 | 204  | 1.4  | 232   | 1.4  |
| Drop nucleus                     | 22   | 0.2 | 28   | 0.2 | 20   | 0.1  | 24    | 0.1  |
| Suprachoroidal haemorrhage       | 6    | 0.1 | 8    | 0.1 | 5    | 0.03 | 3     | 0.02 |
| Central corneal oedema           | 42   | 0.4 | 40   | 0.3 | 50   | 0.35 | 19    | 0.11 |
| Others                           | 171  | 1.4 | 158  | 1.2 | 261  | 1.82 | 279   | 1.66 |

\*551 cases are missing in surgeon status and 3 cases are "Not Available"

#### (ii) Gazetting Specialist

| Year                             | 2003 |      | 2004 |      | 2007 |      | 2008* |      |
|----------------------------------|------|------|------|------|------|------|-------|------|
|                                  | No   | %    | No   | %    | No   | %    | No    | %    |
| Any intra-operative complication | 185  | 12.0 | 222  | 13.0 | 175  | 13.7 | 167   | 11.9 |
| PCR                              | 21   | 1.0  | 38   | 2.0  | 85   | 6.7  | 91    | 6.5  |
| Vitreous loss                    | 99   | 8.0  | 97   | 7.0  | 54   | 4.2  | 76    | 5.4  |
| Zonular dehiscence               | 18   | 1.0  | 25   | 1.0  | 24   | 1.9  | 32    | 2.3  |
| Drop nucleus                     | 2    | 0.0  | 4    | 0.0  | 0    | 0.0  | 3     | 0.2  |
| Suprachoroidal haemorrhage       | 2    | 0.1  | 1    | 0.1  | 1    | 0.08 | 1     | 0.1  |
| Central corneal oedema           | 7    | 0.5  | 16   | 0.9  | 5    | 0.39 | 5     | 0.4  |
| Others                           | 27   | 1.8  | 25   | 1.4  | 37   | 2.9  | 37    | 2.9  |


\*551 cases are missing in surgeon status and 3 cases are "Not Available"

(iii) Medical Officer

| Year                             | 2003 |      | 2004 |      | 2007 |      | 2008* |     |
|----------------------------------|------|------|------|------|------|------|-------|-----|
|                                  | No   | %    | No   | %    | No   | %    | No    | %   |
| Any intra-operative complication | 344  | 11.0 | 338  | 10.0 | 330  | 12.3 | 264   | 9.8 |
| PCR                              | 40   | 1.0  | 47   | 1.0  | 126  | 4.7  | 148   | 5.5 |
| Vitreous loss                    | 157  | 6.0  | 148  | 5.0  | 105  | 3.9  | 105   | 3.9 |
| Zonular dehiscence               | 34   | 1.0  | 46   | 1.0  | 43   | 1.6  | 46    | 1.7 |
| Drop nucleus                     | 3    | 0.0  | 2    | 0.0  | 1    | 0.0  | 4     | 0.1 |
| Suprachoroidal haemorrhage       | 0    | -    | 1    | 0.0  | 3    | 0.1  | 4     | 0.1 |
| Central corneal oedema           | 24   | 0.7  | 22   | 0.6  | 2    | 0.1  | 3     | 0.1 |
| Others                           | 68   | 2.1  | 52   | 1.5  | 51   | 1.9  | 51    | 1.9 |

\*551 cases are missing in surgeon status and 3 cases are "Not Available"

Figure 1.4.5: Percentage Distribution of Intra-operative Complications by Surgeon Status, CSR 2003-2008



#### 1.4.6 Rate of posterior capsular rupture by SDPs

There is an obvious variation in PCR rates among SDPs. It ranged from 0% to 11.1% in 2007 and from 0.8% to 6.3% in 2008.

Table 1.4.6(a): Rate of PCR by SDPs, CSR 2007-2008

| Year | 2007           |     |      | 2008           |     |     |
|------|----------------|-----|------|----------------|-----|-----|
|      | No. of surgery | No. | %    | No. of surgery | No. | %   |
| A    | 652            | 10  | 1.5  | 986            | 29  | 2.9 |
| B    | 33             | 0   | 0.0  | 208            | 3   | 1.4 |
| C    | 550            | 20  | 3.6  | 573            | 14  | 2.4 |
| E    | 697            | 18  | 2.6  | 487            | 8   | 1.6 |
| F    | 0              | 0   | 0.0  | 137            | 3   | 2.2 |
| G    | 1556           | 77  | 4.9  | 1723           | 59  | 3.4 |
| H    | 318            | 8   | 2.5  | 400            | 3   | 0.8 |
| I    | 0              | 0   | 0.0  | 34             | 1   | 2.9 |
| J    | 807            | 38  | 4.7  | 739            | 33  | 4.5 |
| K    | 125            | 2   | 1.6  | 170            | 7   | 4.1 |
| M    | 201            | 4   | 2.0  | 282            | 11  | 3.9 |
| N    | 525            | 34  | 6.5  | 726            | 35  | 4.8 |
| O    | 1518           | 87  | 5.7  | 1681           | 106 | 6.3 |
| P    | 18             | 2   | 11.1 | 396            | 7   | 1.8 |
| Q    | 349            | 4   | 1.1  | 338            | 14  | 4.1 |
| R    | 1102           | 92  | 8.3  | 1357           | 77  | 5.7 |
| S    | 199            | 8   | 4.0  | 256            | 8   | 3.1 |
| U    | 1400           | 47  | 3.4  | 1429           | 56  | 3.9 |
| V    | 697            | 43  | 6.2  | 696            | 36  | 5.2 |
| W    | 380            | 10  | 2.6  | 263            | 9   | 3.4 |
| X    | 152            | 10  | 6.6  | 350            | 11  | 3.1 |
| Y    | 100            | 3   | 3.0  | 180            | 9   | 5.0 |
| Z    | 1520           | 28  | 1.8  | 1376           | 28  | 2.0 |
| AA   | 165            | 9   | 5.5  | 319            | 14  | 4.4 |
| AB   | 497            | 23  | 4.6  | 633            | 14  | 2.2 |
| AC   | 278            | 7   | 2.5  | 379            | 10  | 2.6 |
| AD   | 189            | 5   | 2.6  | 317            | 10  | 3.2 |
| AE   | 668            | 19  | 2.8  | 588            | 16  | 2.7 |
| AF   | 443            | 27  | 6.1  | 531            | 28  | 5.3 |
| AH   | 1040           | 40  | 3.8  | 1217           | 34  | 2.8 |
| AI   | 954            | 40  | 4.2  | 898            | 40  | 4.5 |
| AJ   | 998            | 33  | 3.3  | 1011           | 38  | 3.8 |

D, L, T and AG were excluded due to low ascertainment rates

Figure 1.4.6(a): Rate of PCR by SDP, CSR 2007-2008-Bar Chart (National KPI set at < 5%)





Figure 1.4.6(b): Rate of PCR by SDPs, CSR 2007-2008-Radar Chart (National KPI set at < 5%)




### 1.4.7 Rate of posterior capsular rupture by type of cataract surgery

In the year 2002 to 2004, the rate of PCR was higher than ECCE, but in 2007 and 2008, phaco has lower rate of PCR than ECCE. This might reflect learning curve among surgeons when they begin to convert from ECCE to phaco surgery in the early 2000s.

Table 1.4.7 Rate of PCR by Type of Cataract Surgery, CSR 2002-2008

| Year                    | 2002  |      | 2003  |      | 2004  |      | 2007  |      | 2008  |     |
|-------------------------|-------|------|-------|------|-------|------|-------|------|-------|-----|
| No. of patients (N)     | 12798 |      | 16815 |      | 18391 |      | 18380 |      | 21496 |     |
| Total PCR               | 773   |      | 1036  |      | 1013  |      | 764   |      | 790   |     |
|                         | No    | %    | No    | %    | No    | %    | No    | %    | No    | %   |
| Phaco                   | 309   | 6.1  | 489   | 6.4  | 513   | 5.5  | 393   | 3.3  | 432   | 2.9 |
| ECCE                    | 356   | 5.1  | 374   | 4.7  | 356   | 4.5  | 239   | 4.3  | 210   | 3.7 |
| Lens Aspiration         | 32    | 8.6  | 41    | 9.4  | 38    | 6.9  | 18    | 5.6  | 17    | 5   |
| ICCE                    | 3     | 3.7  | 5     | 5.3  | 11    | 10.7 | 15    | 10.6 | 7     | 5.4 |
| Phaco converted to ECCE | 73    | 23.5 | 125   | 26.7 | 95    | 20.9 | 99    | 22.9 | 124   | 24  |

Figure 1.4.7: Rate of PCR by Type of Cataract Surgery, CSR 2002-2008



## 1.5 CATARACT SURGERY OUTCOME

### 1.5.1 Post-operative Complications

Among the patients who were operated on and registered to CSR, all have outcome record submitted in 2002 and 2003 and 95.5% in 2007 and 2008.

Table 1.5.1: Distribution of Cataract Surgery with Post-operative Complication Record, CSR 2002-2008

| Year   | 2002  | 2003  | 2004  | 2007  | 2008  |
|--|-------|-------|-------|-------|-------|
| Total number of cataract surgery registered to CSR       | 12798 | 16815 | 18392 | 18426 | 21496 |
| Cataract surgery with post-operative complication record | 12798 | 16815 | 15996 | 17604 | 20521 |
| Percent ascertainment on post-operative complication (%) | 100   | 100   | 87.0  | 95.5  | 95.5  |

#### 1.5.1.1 Post-operative infectious endophthalmitis

The rate of post-operative infectious endophthalmitis decreased over the years, with 1.1 cases in 1000 cataract surgeries performed in MOH hospitals. This is close to the average international rate of 1 per 1000 cases. The mean duration from the time of surgery to diagnosis of infection for eyes operated in 2007 and 2008 was 3 weeks.

Table 1.5.1.1(a): Rate of Post-operative Infectious Endophthalmitis, CSR 2002-2008

| Year   | 2002  | 2003  | 2004  | 2007  | 2008  |
|--|-------|-------|-------|-------|-------|
| Cataract surgery with post-operative complication records (N)          | 12798 | 16815 | 15996 | 17604 | 20521 |
| Cataract surgery with post-operative infectious endophthalmitis (n)    | 25    | 41    | 25    | 37    | 22    |
| Percentage of cataract surgery with post-operative endophthalmitis (%) | 0.20  | 0.24  | 0.16  | 0.21  | 0.11  |

Figure 1.5.1.1 (a): Rate of Post-operative Infectious Endophthalmitis, CSR 2002-2008






Table 1.5.1.1(b): Time from Surgery to Diagnosis of Post-operative Infectious Endophthalmitis, CSR 2007-2008

| Year   | 2007               | 2008 |
|--|--------------------|------|
| Number of patients with post-operative infective endophthalmitis | 37                 | 22   |
| Time from surgery to diagnosis of infection (day)                | Days               |      |
| Min  | 1                  | 1    |
| Max  | 92                 | 76   |
| Mean   | 21.6               | 20.6 |
| Distribution of patients   | Number of Patients |      |
| Less than 3 days   | 2                  | 5    |
| 3-5 days   | 4                  | 1    |
| 6-14 days  | 8                  | 5    |
| More than 14 days  | 12                 | 9    |
| Missing  | 11                 | 2    |

#### 1.5.1.2 Unplanned return to operating theatre (OT)

Data on unplanned return to OT were available for June to December 2004 and the whole year of 2007 and 2008. The average rate was 0.42% or 4.2 cases per 1000 cataract surgeries.

Among the reasons requiring patients to return to OT; iris prolapse, wound dehiscence and high post-operative IOP showed a decreasing trend. The rate of unplanned return to OT due to problem related to IOL has demonstrated an increase of 4%. The average time for unplanned return to OT was 10 days from surgery.

Table 1.5.1.2(a): Rate for Unplanned Return to OT, CSR 2004-2008

| Year                                     | *2004 |      | 2007  |      | 2008  |      |
|--|-------|------|-------|------|-------|------|
| Patients with outcome records (N)        | 9039  |      | 17604 |      | 20521 |      |
|  | No    | %    | No    | %    | No    | %    |
| Patients with unplanned return to OT (%) | 31    | 0.34 | 87    | 0.50 | 88    | 0.43 |

\* Data in 2004 available only for June-December

Table 1.5.1.2(b): Reasons for Unplanned Return to OT, CSR 2004-2008

| Year                      | *2004 |      | 2007 |      | 2008 |      |
|---------------------------|-------|------|------|------|------|------|
| Reasons                   | No.   | %    | No.  | %    | No.  | %    |
| All eyes                  | 31    | 100  | 87   | 100  | 88   | 100  |
| Iris prolapse             | 10    | 32.3 | 20   | 23   | 12   | 13.6 |
| Wound dehiscence          | 7     | 22.6 | 13   | 14.9 | 7    | 8    |
| High IOP                  | 4     | 12.9 | 5    | 5.7  | 2    | 2.3  |
| IOL related               | 2     | 6.5  | 10   | 11.5 | 14   | 15.9 |
| Infective endophthalmitis | 7     | 22.6 | 12   | 13.8 | 6    | 6.8  |
| Others                    | 9     | 29   | 38   | 43.7 | 48   | 54.5 |

\* Data in 2004 available only for June-December

Figure 1.5.1.2: Reasons for Unplanned Return to OT, CSR 2004-2008




Table 1.5.1.2(c): Time from Surgery to Unplanned Return to OT, CSR 2008

| Post-operative period (day) | N  | Median | Min | Max | Mean | 25 <sup>th</sup> percentile | 75 <sup>th</sup> percentile |
|-----------------------------|----|--------|-----|-----|------|-----------------------------|-----------------------------|
| All cases                   | 88 | 8      | 1   | 58  | 10   | 6                           | 11                          |
| Iris prolapse               | 12 | 7      | 1   | 58  | 12   | 5                           | 11                          |
| Wound dehiscence            | 6  | 8      | 5   | 10  | 8    | 7                           | 9                           |
| High IOP                    | 2  | 9      | 7   | 10  | 9    | 7                           | 10                          |
| IOL related                 | 14 | 9      | 1   | 18  | 9    | 6                           | 12                          |
| Infective endophthalmitis   | 6  | 10     | 5   | 13  | 10   | 7                           | 12                          |
| Others                      | 48 | 8      | 1   | 31  | 9    | 6                           | 11                          |

### 1.5.1.3 Post-operative follow-up period

Most patients were followed up until 8 weeks post-operatively. Patients who had phaco had shortest follow up while those with ICCE had longest follow up.

Table 1.5.1.3(a): Median Follow-up Period for Patients who had only Unaided Vision (in weeks) by Types of Surgery, 2008

| Types of surgery | N     | Median | 25 <sup>th</sup> percentile | 75 <sup>th</sup> percentile |
|------------------|-------|--------|-----------------------------|-----------------------------|
| All surgeries    | 19037 | 8      | 6                           | 11                          |
| Phaco            | 13349 | 7      | 6                           | 10                          |
| ECCE             | 4806  | 9      | 6                           | 12                          |
| Phaco → ECCE     | 479   | 9      | 6                           | 12                          |
| ICCE             | 109   | 10     | 6                           | 12                          |
| Lens aspiration  | 247   | 8      | 6                           | 11                          |

Table 1.5.1.3(b): Median Follow-up Period for Patients who had Refracted Vision (in weeks) by Types of Surgery, 2008

| Types of surgery | N     | Median | 25 <sup>th</sup> percentile | 75 <sup>th</sup> percentile |
|------------------|-------|--------|-----------------------------|-----------------------------|
| All surgeries    | 17216 | 8      | 6                           | 11                          |
| Phaco            | 12043 | 8      | 6                           | 10                          |
| ECCE             | 4408  | 9      | 7                           | 12                          |
| Phaco → ECCE     | 434   | 9      | 6                           | 12                          |
| ICCE             | 91    | 11     | 7                           | 13                          |
| Lens aspiration  | 206   | 9      | 6                           | 11                          |

## 1.5.2 Post-operative Visual Acuity

### 1.5.2.1 Post-operative visual acuity for all patients

Post-operative visual acuity for all patients with and without ocular co-morbidity


- With unaided vision, less than 40% of patients had VA 6/12 or better, about 50% had VA between 6/18-3/60 i.e. low vision category (Table 1.5.2.1).
- With refraction, up to 80% of patients had VA 6/12 or better.

Table 1.5.2.1: Post-operative Visual Acuity for All Patients, CSR 2002-2008


| Year      | 2002    |      |           |      | 2003    |      |           |      | 2004    |      |           |      | 2007    |      |           |      | 2008    |      |           |      |
|-----------|---------|------|-----------|------|---------|------|-----------|------|---------|------|-----------|------|---------|------|-----------|------|---------|------|-----------|------|
|           | Unaided |      | Refracted |      | Unaided |      | Refracted |      | Unaided |      | Refracted |      | Unaided |      | Refracted |      | Unaided |      | Refracted |      |
|           | No      | %    | No        | %    | No      | %    | No        | %    | No      | %    | No        | %    | No      | %    | No        | %    | No      | %    | No        | %    |
| VA        |         |      |           |      |         |      |           |      |         |      |           |      |         |      |           |      |         |      |           |      |
| 6/5       | 9       | 0.1  | 60        | 0.6  | 16      | 0.1  | 91        | 0.7  | 2       | 0.0  | 17        | 0.3  | 3       | 0    | 35        | 0.2  | 9       | 0    | 51        | 0.3  |
| 6/6       | 598     | 4.8  | 2784      | 26.8 | 648     | 4.1  | 3795      | 27.8 | 318     | 4.7  | 1659      | 28.6 | 878     | 5.6  | 4409      | 30.5 | 1126    | 5.9  | 6072      | 35.2 |
| 6/9       | 1968    | 15.7 | 3773      | 36.3 | 2286    | 14.5 | 4857      | 35.6 | 1011    | 15.0 | 2170      | 37.4 | 2806    | 17.8 | 4961      | 34.3 | 3040    | 15.9 | 5714      | 33.1 |
| 6/12      | 2294    | 18.3 | 1759      | 16.9 | 2858    | 18.2 | 2303      | 16.9 | 1230    | 18.3 | 920       | 15.8 | 2717    | 17.2 | 2100      | 14.6 | 3351    | 17.6 | 2577      | 14.9 |
| 6/5-6/12  | 4869    | 38.9 | 8376      | 80.7 | 5808    | 36.9 | 11046     | 81.0 | 2561    | 38.0 | 4766      | 82.1 | 6404    | 40.6 | 11505     | 79.6 | 7526    | 39.4 | 14414     | 83.5 |
| 6/18      | 2308    | 18.5 | 735       | 7.1  | 3046    | 19.4 | 970       | 7.1  | 1244    | 18.5 | 414       | 7.1  | 2893    | 18.3 | 1055      | 7.3  | 3792    | 19.9 | 1012      | 5.9  |
| 6/24      | 1954    | 15.6 | 410       | 4.0  | 2484    | 15.8 | 540       | 4.0  | 1130    | 16.8 | 205       | 3.5  | 2315    | 14.7 | 573       | 4    | 2978    | 15.6 | 607       | 3.5  |
| 6/36      | 1452    | 11.6 | 279       | 2.7  | 1935    | 12.3 | 359       | 2.6  | 761     | 11.3 | 169       | 2.9  | 1687    | 10.7 | 444       | 3.1  | 2018    | 10.6 | 421       | 2.4  |
| 6/60      | 868     | 6.9  | 166       | 1.6  | 1097    | 7.0  | 240       | 1.8  | 489     | 7.3  | 77        | 1.3  | 1126    | 7.1  | 266       | 1.9  | 1300    | 6.8  | 261       | 1.5  |
| 5/60      | 77      | 0.6  | 13        | 0.1  | 124     | 0.8  | 15        | 0.1  | 56      | 0.8  | 7         | 0.1  | 92      | 0.6  | 23        | 0.2  | 116     | 0.6  | 37        | 0.2  |
| 4/6-      | 64      | 0.5  | 13        | 0.1  | 114     | 0.7  | 29        | 0.2  | 40      | 0.6  | 6         | 0.1  | 87      | 0.6  | 35        | 0.2  | 97      | 0.5  | 30        | 0.2  |
| 3/60      | 127     | 1.0  | 43        | 0.4  | 173     | 1.1  | 56        | 0.4  | 73      | 1.1  | 27        | 0.5  | 207     | 1.3  | 80        | 0.6  | 266     | 1.4  | 112       | 0.6  |
| 6/18-3/60 | 6850    | 54.8 | 1659      | 16.0 | 8973    | 57.0 | 2209      | 16.2 | 3793    | 56.3 | 905       | 15.6 | 8407    | 53.3 | 2476      | 17.3 | 10567   | 55.4 | 2480      | 14.3 |
| 2/60      | 128     | 1.0  | 59        | 0.6  | 154     | 1.0  | 43        | 0.3  | 50      | 0.7  | 26        | 0.5  | 158     | 1    | 73        | 0.5  | 186     | 1    | 70        | 0.4  |
| 1/60      | 146     | 1.2  | 54        | 0.5  | 116     | 0.7  | 45        | 0.3  | 76      | 1.1  | 23        | 0.4  | 155     | 1    | 76        | 0.5  | 159     | 0.8  | 60        | 0.3  |
| CF        | 231     | 1.9  | 86        | 0.8  | 345     | 2.2  | 134       | 1.0  | 132     | 2.0  | 35        | 0.6  | 300     | 1.9  | 121       | 0.8  | 295     | 1.5  | 85        | 0.5  |
| HM        | 203     | 1.6  | 105       | 1.0  | 219     | 1.4  | 115       | 0.8  | 87      | 1.3  | 40        | 0.7  | 253     | 1.6  | 149       | 1    | 230     | 1.2  | 84        | 0.5  |
| PL        | 54      | 0.4  | 27        | 0.3  | 77      | 0.5  | 33        | 0.2  | 25      | 0.4  | 6         | 0.1  | 75      | 0.5  | 46        | 0.3  | 53      | 0.3  | 22        | 0.1  |
| NPL       | 31      | 0.3  | 19        | 0.2  | 49      | 0.3  | 20        | 0.2  | 15      | 0.2  | 6         | 0.1  | 34      | 0.2  | 0         | 0    | 32      | 0.2  | 0         | 0    |
|           | 793     | 6.3  | 350       | 3.4  | 960     | 6.1  | 390       | 2.9  | 385     | 5.7  | 136       | 2.3  | 975     | 6.2  | 465       | 3.1  | 955     | 5    | 321       | 1.8  |
| TOTAL     | 12512   |      | 10385     |      | 15741   |      | 13645     |      | 6739    |      | 5807      |      | 15786   |      | 14446     |      | 19048   |      | 17215     |      |

Figure 1.5.2.1 (a) Percent Distribution of Post-operative Unaided and Refracted Vision


2002




2003



2004



2007



2008





Figure 1.5.2.1(b): Post-operative Visual Acuity by Visual Category for All Patients, CSR 2002-2008



#### 1.5.2.2 Post-operative visual acuity for patients without ocular co-morbidity

When patients with ocular co-morbidity were excluded;

- The percentage of patients with unaided VA 6/12 or better remained around 40%.
- The percentage of patients VA 6/12 or better increased to 88% with refraction (Table 1.5.2.2).

These findings might indicate that the unsatisfactory visual outcome were due to refractive error such as inaccurate IOL power related to biometry or surgically induced astigmatism, rather than pre-existing ocular co-morbidity.

The bimodal pattern of pre-op vision was not seen in pattern of post-op vision (compare figure 1.2.2.6: with figure 1.5.2)

Table 1.5.2.2: Post-operative Visual Acuity for Patients without Ocular Co-morbidity, CSR 2002-2008

| Year       | 2002    |      |           |      | 2003    |      |           |      | 2004    |      |           |      | 2007    |      |           |      | 2008    |      |           |      |
|------------|---------|------|-----------|------|---------|------|-----------|------|---------|------|-----------|------|---------|------|-----------|------|---------|------|-----------|------|
|            | Unaided |      | Refracted |      | Unaided |      | Refracted |      | Unaided |      | Refracted |      | Unaided |      | Refracted |      | Unaided |      | Refracted |      |
|            | No      | %    | No        | %    | No      | %    | No        | %    | No      | %    | No        | %    | No      | %    | No        | %    | No      | %    | No        | %    |
| VA         | 7       | 0.1  | 44        | 0.6  | 9       | 0.1  | 70        | 0.8  | 1       | 0.0  | 14        | 0.4  | 3       | 0.0  | 25        | 0.3  | 2       | 0.0  | 23        | 0.3  |
| 6/5        | 501     | 5.6  | 2,229     | 29.9 | 511     | 5.0  | 2,826     | 31.6 | 247     | 5.9  | 1,196     | 32.1 | 667     | 6.2  | 3326      | 33.5 | 561     | 6.2  | 3061      | 36.4 |
| 6/6        | 1,568   | 17.6 | 2,892     | 38.7 | 1,710   | 16.8 | 3,421     | 38.2 | 758     | 18.0 | 1,505     | 40.5 | 2061    | 19.3 | 3574      | 36.0 | 1477    | 16.4 | 2939      | 35.0 |
| 6/9        | 1,780   | 20.0 | 1,260     | 16.9 | 2,074   | 20.4 | 1,595     | 17.8 | 871     | 20.7 | 608       | 16.3 | 2021    | 18.9 | 1473      | 14.8 | 1683    | 18.7 | 1377      | 16.4 |
| 6/12       | 3,856   | 43.4 | 6,425     | 86.1 | 4,304   | 42.2 | 7,912     | 88.4 | 1877    | 44.6 | 3323      | 89.3 | 4752    | 44.4 | 8398      | 84.6 | 3723    | 41.3 | 7400      | 88.1 |
| 6/18       | 1,698   | 19.1 | 444       | 6.0  | 2,072   | 20.3 | 485       | 5.4  | 813     | 19.3 | 216       | 5.8  | 2037    | 19.1 | 634       | 6.4  | 1882    | 20.9 | 411       | 4.9  |
| 6/24       | 1,403   | 15.8 | 240       | 3.2  | 1,634   | 16.0 | 242       | 2.7  | 709     | 16.8 | 90        | 2.4  | 1619    | 15.1 | 351       | 3.5  | 1518    | 16.9 | 254       | 3.0  |
| 6/36       | 1,001   | 11.3 | 136       | 1.8  | 1,162   | 11.4 | 140       | 1.6  | 443     | 10.5 | 55        | 1.5  | 1087    | 10.2 | 234       | 2.4  | 975     | 10.8 | 151       | 1.8  |
| 6/60       | 514     | 5.8  | 74        | 1.0  | 593     | 5.8  | 74        | 0.8  | 240     | 5.7  | 12        | 0.3  | 650     | 6.1  | 113       | 1.1  | 536     | 6.0  | 71        | 0.8  |
| 5/60       | 39      | 0.4  | 6         | 0.1  | 61      | 0.6  | 3         | 0.0  | 26      | 0.6  | 2         | 0.1  | 52      | 0.5  | 8         | 0.1  | 52      | 0.6  | 10        | 0.1  |
| 4/60       | 30      | 0.3  | 3         | 0.0  | 45      | 0.4  | 4         | 0.0  | 13      | 0.3  | 1         | 0.0  | 48      | 0.4  | 13        | 0.1  | 25      | 0.3  | 7         | 0.1  |
| 3/60       | 64      | 0.7  | 18        | 0.2  | 71      | 0.7  | 14        | 0.2  | 20      | 0.5  | 5         | 0.1  | 94      | 0.9  | 26        | 0.3  | 79      | 0.9  | 29        | 0.3  |
| 6/18-3/60  | 4,749   | 53.4 | 921       | 12.3 | 5,638   | 55.3 | 962       | 10.7 | 2264    | 53.8 | 381       | 10.2 | 5587    | 52.3 | 1379      | 13.9 | 5067    | 56.4 | 933       | 11.0 |
| 2/60       | 60      | 0.7  | 22        | 0.3  | 65      | 0.6  | 10        | 0.1  | 18      | 0.4  | 6         | 0.2  | 62      | 0.6  | 25        | 0.3  | 54      | 0.6  | 16        | 0.2  |
| 1/60       | 43      | 0.5  | 18        | 0.2  | 28      | 0.3  | 8         | 0.1  | 14      | 0.3  | 1         | 0.0  | 68      | 0.6  | 23        | 0.2  | 33      | 0.4  | 8         | 0.1  |
| CF         | 94      | 1.1  | 30        | 0.4  | 95      | 0.9  | 36        | 0.4  | 22      | 0.5  | 4         | 0.1  | 120     | 1.1  | 47        | 0.5  | 73      | 0.8  | 23        | 0.3  |
| HM         | 64      | 0.7  | 30        | 0.4  | 37      | 0.4  | 14        | 0.2  | 11      | 0.3  | 5         | 0.1  | 69      | 0.6  | 42        | 0.4  | 31      | 0.3  | 12        | 0.1  |
| PL         | 13      | 0.2  | 10        | 0.1  | 13      | 0.1  | 8         | 0.1  | 5       | 0.1  | 1         | 0.0  | 23      | 0.2  | 13        | 0.1  | 7       | 0.1  | 4         | 0.0  |
| NPL        | 11      | 0.1  | 9         | 0.1  | 10      | 0.1  | 5         | 0.1  | 1       | 0.0  | 0         | 0.0  | 8       | 0.1  | 7         | 0.1  | 7       | 0.1  | 0         | 0.0  |
| 2/60 - NPL | 285     | 3.2  | 119       | 1.58 | 248     | 2.4  | 81        | 0.9  | 71      | 1.7  | 17        | 0.5  | 350     | 3.2  | 157       | 1.6  | 205     | 2.3  | 63        | 0.7  |
| TOTAL      | 8890    | 100  | 7465      | 100  | 10190   | 100  | 8955      | 100  | 4212    | 100  | 3721      | 100  | 10639   | 100  | 9934      | 100  | 8995    | 100  | 8396      | 100  |

Figure 1.5.2.2(a): Post-operative Visual Acuity for Patients without Ocular Co-morbidity, CSR 2003-2008





Figure 1.5.2.2(b): Post-operative Visual Acuity by Visual Category for Patients without Ocular Co-morbidity, CSR 2003-2008



### 1.5.2.3 Post-operative visual acuity 6/12 or better among patients without ocular co-morbidity

Patients who had phacoemulsification had the highest proportion of achieving good visual outcome when compared with other surgeries. The percentage increased from 80.6% in 2002 to 91.3% in 2008. When complication occurred in phacoemulsification which necessitated conversion to ECCE, the visual outcome became less favourable.

The proportion of patients with unaided VA 6/12 or better was less encouraging; with less than 50% in almost all types of surgery throughout the years. These findings indicated that a large number of patients required some forms of visual rehabilitation/correction post-operatively.

Table 1.5.2.3(a): Post-operative Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by Types of Surgery, CSR 2002-2008

| Year            | 2002    |      |      |           |      |    | 2003    |      |    |           |      |    | 2004    |      |      |           |      |    |
|-----------------|---------|------|------|-----------|------|----|---------|------|----|-----------|------|----|---------|------|------|-----------|------|----|
|                 | Unaided |      |      | Refracted |      |    | Unaided |      |    | Refracted |      |    | Unaided |      |      | Refracted |      |    |
|                 | N       | No   | %    | N         | No   | %  | N       | No   | %  | N         | No   | %  | N       | No   | %    | N         | No   | %  |
| All Surgeries   | 12517   | 4869 | 38.9 | 10392     | 8376 | 81 | 9861    | 4181 | 42 | 8683      | 7693 | 89 | 4058    | 1818 | 44.8 | 3604      | 3226 | 90 |
| Phaco           | 5010    | 2490 | 49.7 | 4311      | 3746 | 87 | 4930    | 2524 | 51 | 4411      | 4111 | 93 | 4138    | 2226 | 53.8 | 1974      | 1852 | 94 |
| ECCE            | 6761    | 2177 | 32.2 | 5490      | 4255 | 78 | 4445    | 1507 | 34 | 3840      | 3245 | 85 | 4823    | 1659 | 34.4 | 1479      | 1257 | 85 |
| Phaco ECCE      | 305     | 94   | 30.8 | 255       | 192  | 75 | 311     | 88   | 28 | 289       | 236  | 82 | 347     | 107  | 30.8 | 91        | 72   | 79 |
| Lens Aspiration | 315     | 86   | 27.3 | 237       | 129  | 54 | 123     | 52   | 42 | 100       | 75   | 75 | 145     | 40   | 27.5 | 31        | 23   | 74 |
| ICCE            | 80      | 12   | 15   | 66        | 33   | 50 | 8       | 3    | 38 | 6         | 4    | 67 |         | 7    | 0    | 4         | 2    | 50 |
| Secondary IOL   | 33      | 10   | 30.3 | 26        | 21   | 81 | 42      | 7    | 17 | 36        | 22   | 61 | 97      | 22   | 22.7 | 19        | 15   | 79 |

| Year            | 2007    |      |    |           |      |    | 2008    |      |    |           |      |    |
|-----------------|---------|------|----|-----------|------|----|---------|------|----|-----------|------|----|
|                 | Unaided |      |    | Refracted |      |    | Unaided |      |    | Refracted |      |    |
|                 | N       | No   | %  | N         | No   | %  | N       | No   | %  | N         | No   | %  |
| All Surgeries   | 7130    | 3080 | 43 | 6632      | 5551 | 84 | 8983    | 3719 | 41 | 8390      | 7392 | 88 |
| Phaco           | 4868    | 2332 | 48 | 4508      | 3890 | 86 | 6419    | 3017 | 47 | 5958      | 5440 | 91 |
| ECCE            | 2033    | 675  | 33 | 1910      | 1520 | 80 | 2263    | 629  | 28 | 2158      | 1744 | 81 |
| Phaco ECCE      | 158     | 36   | 23 | 143       | 89   | 62 | 201     | 40   | 20 | 184       | 140  | 76 |
| Lens Aspiration | 62      | 33   | 53 | 59        | 46   | 78 | 74      | 29   | 39 | 66        | 54   | 82 |
| ICCE            | 15      | 2    | 13 | 10        | 4    | 39 | 24      | 4    | 17 | 19        | 11   | 58 |
| Secondary IOL   | -       | NA   | -  | -         | NA   | -  | -       | NA   | -  | -         | NA   | -  |

Figure 1.5.2.3 (a): Post-operative Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by ECCE and Phaco, CSR 2002-2008




Table 1.5.2.3(b): Post-operative Refracted Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by Complications and Types of Surgery, CSR 2008

|  | Types of Cataract Surgery |      |      |                 |     |      |      |      |      |       |      |      |
|--|---------------------------|------|------|-----------------|-----|------|------|------|------|-------|------|------|
|  | All Surgeries             |      |      | Lens Aspiration |     |      | ECCE |      |      | Phaco |      |      |
|  | N                         | No.  | %    | N               | No. | %    | N    | No.  | %    | N     | No.  | %    |
| With intra-op complications<br>No intra-op complications | 8391                      | 7392 | 88.1 | 66              | 54  | 81.8 | 2159 | 1744 | 80.8 | 5958  | 5440 | 91.3 |
|  | 506                       | 352  | 69.6 | 2               | 2   | 100  | 168  | 110  | 65.5 | 253   | 191  | 75.5 |
|  | 7885                      | 7040 | 89.3 | 64              | 52  | 81.3 | 1991 | 1634 | 82.1 | 5705  | 5249 | 92   |
|  |                           |      |      |                 |     |      |      |      |      | 184   | 140  | 76.1 |
|  |                           |      |      |                 |     |      |      |      |      | 73    | 45   | 61.6 |
|  |                           |      |      |                 |     |      |      |      |      | 111   | 95   | 85.6 |
|  |                           |      |      |                 |     |      |      |      |      | 19    | 11   | 57.9 |
|  |                           |      |      |                 |     |      |      |      |      | 8     | 3    | 37.5 |
|  |                           |      |      |                 |     |      |      |      |      | 11    | 8    | 72.7 |



In general, for all types of surgery, the visual outcomes were better in eyes with IOL implantation, foldable IOL and IOL made of Acrylic. This trend remained unchanged throughout the years. Better outcome in acrylic IOL could be because of its main use in phaco surgery which was associated with better visual outcome.

In phacoemulsification, the proportion of patients who could achieve post-operative VA better than 6/12 initially increased among all surgeons. However, it declined in the year 2007 before rising again in 2008. In general, better visual outcomes were observed in phaco and phaco converted to ECCE performed by the specialists. In ECCE, the visual outcomes were comparable between all surgeons and the percentage appeared to be slowly increasing.


Table 1.5.2.3(c): Post-operative Refracted Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by Surgeon Status and Types of Surgery, CSR 2008

|  | Types of Cataract Surgery |      |      |                 |     |      |      |      |      |       |      |      |
|--|---------------------------|------|------|-----------------|-----|------|------|------|------|-------|------|------|
|  | All Surgeries             |      |      | Lens Aspiration |     |      | ECCE |      |      | Phaco |      |      |
|  | N                         | No.  | %    | N               | No. | %    | N    | No.  | %    | N     | No.  | %    |
| N Surgeon Status<br>Specialist<br>Gazetting<br>Specialist<br>Medical Officer | 8356                      | 7360 | 88.1 | 66              | 54  | 81.8 | 2149 | 1735 | 80.7 | 5934  | 5418 | 91.3 |
|  | 6567                      | 5872 | 89.4 | 57              | 47  | 82.5 | 1368 | 1131 | 82.7 | 4981  | 4569 | 91.7 |
|  | 700                       | 580  | 82.9 | 8               | 6   | 75.0 | 170  | 120  | 70.6 | 494   | 438  | 88.7 |
|  | 1089                      | 908  | 83.4 | 1               | 1   | 100  | 611  | 484  | 79.2 | 459   | 411  | 89.5 |
|  |                           |      |      |                 |     |      |      |      |      | 183   | 139  | 76.0 |
|  |                           |      |      |                 |     |      |      |      |      | 143   | 114  | 79.7 |
|  |                           |      |      |                 |     |      |      |      |      | 24    | 15   | 62.5 |
|  |                           |      |      |                 |     |      |      |      |      | 16    | 10   | 62.5 |
|  |                           |      |      |                 |     |      |      |      |      | 19    | 11   | 57.9 |
|  |                           |      |      |                 |     |      |      |      |      | 14    | 9    | 64.3 |
|  |                           |      |      |                 |     |      |      |      |      | 4     | 1    | 25.0 |
|  |                           |      |      |                 |     |      |      |      |      | 1     | 1    | 100  |

ECCE



Phaco → ECCE



In the year 2008, although analysis for each SDP performing ECCE could not be done due to small numbers; in general, the visual outcomes for all SDPs were below the national standards. For phacoemulsification, one SDP performed less than the national standard (Hospital Q = 76.1%).

Table 1.5.2.3(d): Post-operative Refracted Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by SDP and Types of Surgery, CSR 2008

| Type of Cataract Surgery |              |     |               |      |      |                 |      |      |      |      |      |       |      |      |              |      |      |      |     |      |
|--------------------------|--------------|-----|---------------|------|------|-----------------|------|------|------|------|------|-------|------|------|--------------|------|------|------|-----|------|
|                          | All Patients |     | All Surgeries |      |      | Lens Aspiration |      |      | ECCE |      |      | Phaco |      |      | Phaco □ ECCE |      |      | ICCE |     |      |
|                          | N            |     | N             | No.  | %    | N               | No.  | %    | N    | No.  | %    | N     | No.  | %    | N            | No.  | %    | N    | No. | %    |
| All centres              | 11667        |     | 116           | 102  |      | 132             | 96   | 72.7 | 282  | 228  |      | 835   | 764  |      | 267          | 199  | 74.5 | 32   | 17  | 53.1 |
|                          | 590          |     | 24            | 45   | 88.1 | 0               | 0    | 0    | 3    | 2    | 80.8 | 6     | 4    | 91.5 | 12           | 9    | 75   | 0    | 0   | 0    |
|                          | 161          |     | 590           | 514  | 87.1 | 0               | 0    | 0    | 138  | 111  | 80.4 | 440   | 394  | 89.5 | 20           | 17   | 85   | 0    | 0   | 0    |
|                          | 263          |     | 161           | 134  | 83.2 | 0               | 0    | 0    | 84   | 65   | 77.4 | 57    | 52   | 91.2 | 9            | 7    | 77.8 | 1    | 1   | 100  |
|                          | 312          |     | 263           | 234  | 89   | 2               | 1    | 50   | 43   | 29   | 67.4 | 208   | 196  | 94.2 | 3            | 3    | 100  | 0    | 0   | 0    |
|                          | 25           |     | 312           | 292  | 93.6 | 3               | 2    | 66.7 | 195  | 181  | 92.8 | 111   | 106  | 95.5 | 1            | 1    | 100  | 0    | 0   | 0    |
|                          | 877          |     | 25            | 21   | 84   | 0               | 0    | 0    | 21   | 18   | 85.7 | 0     | 0    | 0    | 7            | 4    | 57.1 | 0    | 0   | 0    |
|                          | 293          |     | 875           | 793  | 90.6 | 2               | 0    | 0    | 129  | 110  | 85.3 | 735   | 679  | 92.4 | 3            | 2    | 66.7 | 0    | 0   | 0    |
|                          | 41           |     | 293           | 278  | 94.9 | 5               | 5    | 100  | 59   | 56   | 94.9 | 226   | 215  | 95.1 | 0            | 0    | 0    | 0    | 0   | 0    |
|                          | 327          |     | 18            | 15   | 83.3 | 1               | 0    | 0    | 17   | 15   | 88.2 | 0     | 0    | 0    | 8            | 7    | 87.5 | 0    | 0   | 0    |
|                          | 41           |     | 327           | 282  | 86.2 | 12              | 9    | 75   | 129  | 108  | 83.7 | 178   | 158  | 88.8 | 1            | 1    | 100  | 0    | 0   | 0    |
|                          | 26           |     | 41            | 38   | 92.7 | 0               | 0    | 0    | 21   | 19   | 90.5 | 19    | 18   | 94.7 | 2            | 1    | 50   | 0    | 0   | 0    |
|                          | 150          |     | 26            | 21   | 80.8 | 0               | 0    | 0    | 7    | 4    | 57.1 | 17    | 16   | 94.1 | 22           | 19   | 86.4 | 0    | 0   | 0    |
|                          | 457          |     | 150           | 121  | 80.7 | 1               | 1    | 100  | 90   | 73   | 81.1 | 37    | 28   | 75.7 | 16           | 13   | 81.3 | 4    | 3   | 75   |
|                          | 1005         |     | 457           | 418  | 91.5 | 7               | 6    | 85.7 | 155  | 134  | 86.5 | 275   | 262  | 95.3 | 12           | 7    | 58.3 | 3    | 0   | 0    |
|                          | 266          |     | 998           | 835  | 83.7 | 5               | 3    | 60   | 155  | 108  | 69.7 | 820   | 715  | 87.2 | 1            | 1    | 100  | 0    | 0   | 0    |
|                          | 219          |     | 266           | 254  | 95.5 | 3               | 3    | 100  | 48   | 46   | 95.8 | 214   | 204  | 95.3 | 4            | 1    | 25   | 1    | 1   | 100  |
|                          | 672          |     | 219           | 155  | 70.8 | 2               | 1    | 50   | 55   | 33   | 60   | 155   | 118  | 76.1 | 14           | 9    | 64.3 | 0    | 0   | 0    |
|                          | 109          |     | 672           | 632  | 94   | 8               | 8    | 100  | 49   | 37   | 75.5 | 601   | 578  | 96.2 | 2            | 1    | 50   | 0    | 0   | 0    |
|                          | 182          |     | 109           | 105  | 96.3 | 2               | 2    | 100  | 11   | 10   | 90.9 | 94    | 92   | 97.9 | 16           | 10   | 62.5 | 2    | 1   | 50   |
| 654                      |              | 182 | 165           | 90.7 | 3    | 3               | 100  | 30   | 25   | 83.3 | 146  | 135   | 92.5 | 6    | 4            | 66.7 | 0    | 0    | 0   |      |
| 323                      |              | 651 | 576           | 88.5 | 5    | 1               | 20   | 35   | 20   | 57.1 | 592  | 543   | 91.7 | 0    | 0            | 0    | 1    | 1    | 100 |      |
| 179                      |              | 323 | 298           | 92.3 | 9    | 7               | 77.8 | 25   | 20   | 80   | 283  | 267   | 94.3 | 3    | 3            | 100  | 1    | 0    | 0   |      |
| 273                      |              | 179 | 137           | 76.5 | 2    | 1               | 50   | 176  | 135  | 76.7 | 0    | 0     | 0    | 9    | 8            | 88.9 | 1    | 1    | 100 |      |
| 101                      |              | 273 | 237           | 86.8 | 1    | 1               | 100  | 187  | 155  | 82.9 | 81   | 78    | 96.3 | 11   | 7            | 63.6 | 4    | 2    | 50  |      |
| 779                      |              | 101 | 100           | 99   | 0    | 0               | 0    | 22   | 22   | 100  | 79   | 78    | 98.7 | 0    | 0            | 0    | 0    | 0    | 0   |      |
| 227                      |              | 779 | 667           | 85.6 | 4    | 2               | 50   | 15   | 11   | 73.3 | 750  | 651   | 86.8 | 9    | 3            | 33.3 | 1    | 0    | 0   |      |
| 380                      |              | 226 | 207           | 91.6 | 3    | 2               | 66.7 | 18   | 14   | 77.8 | 195  | 182   | 93.3 | 9    | 8            | 88.9 | 1    | 1    | 100 |      |
|                          |              | 380 | 328           | 86.3 | 14   | 8               | 57.1 | 61   | 39   | 63.9 | 290  | 272   | 93.8 | 11   | 7            | 63.6 | 4    | 2    | 50  |      |


|           |     |     |     |      |    |    |      |     |     |      |     |     |      |    |    |      |   |   |      |
|-----------|-----|-----|-----|------|----|----|------|-----|-----|------|-----|-----|------|----|----|------|---|---|------|
| <b>AC</b> | 198 | 198 | 193 | 97.5 | 2  | 2  | 100  | 83  | 81  | 97.6 | 111 | 108 | 97.3 | 2  | 2  | 100  | 0 | 0 | 0    |
| <b>AD</b> | 100 | 100 | 80  | 80   | 0  | 0  | 0    | 97  | 78  | 80.4 | 2   | 1   | 50   | 1  | 1  | 100  | 0 | 0 | 0    |
| <b>AE</b> | 410 | 410 | 358 | 87.3 | 7  | 5  | 71.4 | 134 | 101 | 75.4 | 256 | 241 | 94.1 | 13 | 11 | 84.6 | 0 | 0 | 0    |
| <b>AF</b> | 295 | 295 | 246 | 83.4 | 3  | 2  | 66.7 | 69  | 44  | 63.8 | 211 | 190 | 90   | 9  | 7  | 77.8 | 2 | 2 | 100  |
| <b>AH</b> | 705 | 705 | 625 | 88.7 | 14 | 12 | 85.7 | 233 | 195 | 83.7 | 439 | 407 | 92.7 | 13 | 9  | 69.2 | 6 | 2 | 33.3 |
| <b>AI</b> | 436 | 432 | 401 | 92.8 | 3  | 3  | 100  | 97  | 91  | 93.8 | 306 | 285 | 93.1 | 22 | 19 | 86.4 | 3 | 3 | 100  |
| <b>AJ</b> | 586 | 586 | 480 | 81.9 | 9  | 5  | 55.6 | 147 | 104 | 70.7 | 415 | 362 | 87.2 | 13 | 9  | 69.2 | 2 | 0 | 0    |

\*D, F, L, T, AD and AG were excluded due to <50% ascertainment rate in CSR and/or <50% ascertainment rate in outcome with refracted vision.

| Country | SDP (%) |
|---------|---------|
| Algeria | 88.1    |
| Algeria | 76.5    |
| Algeria | 70.8    |
| Algeria | 68.5    |
| Algeria | 66.2    |
| Algeria | 64.1    |
| Algeria | 62.3    |
| Algeria | 60.5    |
| Algeria | 58.7    |
| Algeria | 56.9    |

[illegible]

Figure1.5.2.3 (d) Post-op Refracted Visual Acuity 6/12 or Better for Patients without Ocular Co-morbidities by SDP for ECCE, CSR 2008



### 1.5.3 Reasons for no records of visual acuity

The main reason for no records of VA was loss to follow-up.

Table 1.5.3 Reasons for No Records of Visual Acuity, CSR 2002-2008

| Years                 | 2002 |      | 2003 |      | 2004 |      | 2007 |      | 2008 |      |
|-----------------------|------|------|------|------|------|------|------|------|------|------|
| Reasons               | No   | %    | No   | %    | No   | %    | No   | %    | No   | %    |
| All cases             | 1940 | 100  | 1331 | 100  | 1872 | 100  | 1458 | 100  | 1463 | 100  |
| Loss to follow-up     | 1331 | 68.1 | 876  | 65.8 | 1177 | 62.9 | 1078 | 73.9 | 1230 | 84.1 |
| Discharged by doctor  | 396  | 20.4 | 212  | 15.9 | 306  | 1.6  | 32   | 2.2  | 13   | 0.9  |
| Unable to take vision | 69   | 3.6  | 33   | 40.3 | 108  | 5.8  | 49   | 3.4  | 26   | 1.8  |
| Others                | 144  | 7.4  | 210  | 15.8 | 281  | 15.0 | 299  | 20.5 | 194  | 13.3 |

### 1.5.4 Factors contributing to post-operative refracted visual acuity of worse than 6/12

The main contributing factor for post-operative refracted VA worse than 6/12 was pre-existing ocular co-morbidity, followed by high astigmatism and PCO. This trend was the same throughout the years except in the year 2003 when the percentage for high astigmatism was slightly higher. Cystoid macular edema (CMO), corneal decompensation and retinal detachment as the contributing factors remained low over the years. Overall, the trend was decreasing.

When patients with pre-existing ocular co-morbidity were excluded from analysis from the year 2004 onwards, high astigmatism contributed the highest number followed by pre-existing ocular co-morbidity (not detected preoperatively).

Table 1.5.4(a) Factors Contributing to Post-operative Refracted VA of Worse than 6/12 in All Patients, CSR 2002-2008

| Years                            | 2002 |      | 2003 |      | 2004 |      | 2007 |      | 2008 |      |
|----------------------------------|------|------|------|------|------|------|------|------|------|------|
| Factors                          | No   | %    | No   | %    | No   | %    | No   | %    | No   | %    |
| Pre-existing ocular co-morbidity | 818  | 40.7 | 386  | 39.1 | 503  | 47.2 | 904  | 28.8 | 802  | 28.4 |
| High astigmatism                 | 489  | 24.3 | 392  | 39.8 | 321  | 31.1 | 478  | 15.2 | 460  | 16.3 |
| Posterior capsular opacity       | 198  | 9.9  | 152  | 15.4 | 53   | 5.0  | 140  | 4.5  | 112  | 4    |
| Cystoid macular oedema           | 93   | 4.6  | 59   | 6.0  | 33   | 3.1  | 101  | 3.2  | 64   | 2.3  |
| Endophthalmitis                  | 16   | 0.8  | 10   | 1.0  | 6    | 0.6  | 14   | 0.4  | 6    | 0.2  |
| Corneal decompensation           | 37   | 1.8  | 19   | 1.9  | 6    | 0.6  | 28   | 0.9  | 31   | 1.1  |
| Decentered IOL                   | 14   | 0.7  | 1    | 0.1  | 3    | 0.3  | 4    | 0.1  | 6    | 0.2  |
| Retinal detachment               | 27   | 1.3  | 8    | 0.8  | 7    | 0.7  | 67   | 2.1  | 50   | 1.8  |
| Others                           | 302  | 15.0 | 202  | 20.5 | 134  | 12.6 | 620  | 19.8 | 603  | 21.3 |
| Missing/Unavailable              | 14   | 0.7  | 49   | 5.0  | 0    | 0.0  | -    | -    | NA   | NA   |

Figure 1.5.4(a) Factors Contributing to Post-operative Refracted VA of Worse than 6/12 in All Patients, CSR 2002-2008




Table 1.5.4(b) Factors Contributing to Post-operative Refracted VA of Worse than 6/12 Among Patients without Pre-existing Ocular co-morbidity, CSR 2004-2008

| Years                             | 2004 |      | 2007 |      | 2008 |      |
|-----------------------------------|------|------|------|------|------|------|
| Factors                           | No   | %    | No   | %    | No   | %    |
| High astigmatism                  | 197  | 52.0 | 303  | 19.7 | 286  | 20.6 |
| Pre-existing ocular co-morbidity* | 23   | 6.1  | 271  | 17.6 | 229  | 16.5 |
| Posterior capsular opacity        | 20   | 5.3  | 83   | 5.4  | 61   | 4.4  |
| Cystoid macular oedema            | 20   | 5.3  | 52   | 3.4  | 26   | 1.9  |
| Endophthalmitis                   | 4    | 1.0  | 9    | 0.6  | 4    | 0.3  |
| Corneal decompensation            | 3    | 0.8  | 15   | 1.0  | 13   | 0.9  |
| Decentered IOL                    | 2    | 0.5  | 4    | 0.3  | 2    | 0.1  |
| Retinal detachment                | 1    | 0.3  | 18   | 1.2  | 11   | 0.8  |
| Others                            | 76   | 20.0 | 320  | 20.8 | 323  | 23.3 |
| Missing/Unavailable               | NA   | -    | 461  | 30.0 | NA   | -    |

\* not detected before surgery

### 1.5.5 Actual or residual refractive power

Target refractive power is the refractive power aimed by the surgeon for a patient while the actual/residual refractive power or spherical equivalent (SE) is the postoperative refraction results for the same patient. Myopic shift is the shift of the refraction status (actual refraction) towards more negative value as compared to the targeted refraction pre-operatively. It can be the results of surgery induced astigmatism or more anterior placement of IOL in the bag. It can also be due to indentation of eyeball during biometry resulting in shorter axial length. As a whole, data in 2008 showed slight improvement.

- 1) Most surgeons targeted refraction to be near emmetropia (mean -0.1, SD 0.4).
- 2) Slightly less myopic shift for both Phaco and ECCE.

Data for both 2007 and 2008 demonstrated that ECCE produced more myopic shift as compared to phaco.

Table 1.5.5(a) Distribution of Target and Actual Refractive Power in ECCE and Phaco, CSR 2007-2008


|         | Target Refraction |       | Actual Refraction |      |       |       | Actual-Target Refraction |       |
|---------|-------------------|-------|-------------------|------|-------|-------|--------------------------|-------|
|         | All Patient       |       | ECCE              |      | Phaco |       | All Patient              |       |
| Years   | 2007              | 2008  | 2007              | 2008 | 2007  | 2008  | 2007                     | 2008  |
| N       | 11876             | 15083 | 3624              | 4400 | 8343  | 12085 | 8738                     | 12295 |
| Mean    | -0.5              | -0.1  | -1.1              | -0.2 | -0.8  | 0     | -0.5                     | -0.4  |
| SD      | 0.4               | 0.4   | 1.4               | 1.2  | 1.1   | 1.03  | 1.1                      | 1.2   |
| Median  | -0.5              | -0.5  | -1                | -0.2 | -0.7  | 0     | -0.4                     | -0.4  |
| Minimum | -9                | -9.9  | -10               | -8.4 | -10   | -10   | -9.5                     | -9.9  |
| Maximum | 5                 | 9.5   | 9.8               | 10   | 10    | 10    | 5                        | 9     |

Table 1.5.5(b) Percentage Distribution of Target and Actual Refractive Power in ECCE and Phaco, CSR 2007-2008

| Years       | Target Refraction |      |      |      | Actual Refraction |      |      |      |       |      |      |      |
|-------------|-------------------|------|------|------|-------------------|------|------|------|-------|------|------|------|
|             | All Patients      |      |      |      | ECCE              |      |      |      | Phaco |      |      |      |
|             | 2007              |      | 2008 |      | 2007              |      | 2008 |      | 2007  |      | 2008 |      |
| Dioptre (D) | No                | %    | No   | %    | No                | %    | No   | %    | No    | %    | No   | %    |
| -10-<(-9.5) | 0                 | 0.0  | 1    | 0.0  | 0                 | 0.0  | 0    | 0.0  | 0     | 0.0  | 1    | 0.0  |
| -9.5-<(-9)  | 4                 | 0.0  | 1    | 0.0  | 0                 | 0.0  | 1    | 0.0  | 0     | 0.0  | 7    | 0.1  |
| -9-<(-8.5)  | 0                 | 0.0  | 1    | 0.0  | 0                 | 0.0  | 0    | 0.0  | 0     | 0.0  | 1    | 0.0  |
| -8.5-<(-8)  | 1                 | 0.0  | 1    | 0.0  | 0                 | 0.0  | 0    | 0.0  | 0     | 0.0  | 2    | 0.0  |
| -8-<(-7.5)  | 2                 | 0.0  | 3    | 0.0  | 0                 | 0.0  | 0    | 0.0  | 0     | 0.0  | 3    | 0.0  |
| -7.5-<(-7)  | 1                 | 0.0  | 0    | 0.0  | 0                 | 0.0  | 1    | 0.0  | 1     | 0.0  | 11   | 0.1  |
| -7-<(-6.5)  | 3                 | 0.0  | 1    | 0.0  | 0                 | 0.0  | 1    | 0.0  | 0     | 0.0  | 6    | 0.0  |
| -6.5-<(-5)  | 1                 | 0.0  | 2    | 0.0  | 0                 | 0.0  | 3    | 0.1  | 1     | 0.0  | 16   | 0.1  |
| -5-<(-4.5)  | 3                 | 0.0  | 4    | 0.0  | 1                 | 0.0  | 1    | 0.0  | 1     | 0.0  | 15   | 0.1  |
| -4.5-<(-4)  | 2                 | 0.0  | 3    | 0.0  | 3                 | 0.1  | 5    | 0.1  | 3     | 0.0  | 15   | 0.1  |
| -4-<(-3.5)  | 7                 | 0.1  | 8    | 0.1  | 8                 | 0.2  | 7    | 0.2  | 5     | 0.1  | 19   | 0.2  |
| -3.5-<(-3)  | 6                 | 0.0  | 7    | 0.0  | 19                | 0.5  | 15   | 0.3  | 2     | 0.0  | 29   | 0.2  |
| -3-<(-2.5)  | 13                | 0.1  | 22   | 0.1  | 26                | 0.6  | 41   | 0.9  | 7     | 0.1  | 58   | 0.5  |
| -2.5-<(-2)  | 29                | 0.2  | 21   | 0.1  | 65                | 1.6  | 76   | 1.7  | 27    | 0.3  | 80   | 0.7  |
| -2-<(-1.5)  | 77                | 0.6  | 48   | 0.3  | 149               | 3.6  | 203  | 4.6  | 88    | 1.0  | 147  | 1.2  |
| -1.5-<(-1)  | 429               | 3.5  | 373  | 2.5  | 360               | 8.7  | 431  | 9.7  | 277   | 3.1  | 393  | 3.2  |
| -1-<(-0.5)  | 4670              | 37.7 | 6155 | 40.9 | 722               | 17.5 | 763  | 17.2 | 1022  | 11.4 | 1370 | 11.3 |
| -0.5-<0     | 6631              | 53.5 | 7481 | 49.7 | 956               | 23.2 | 956  | 21.6 | 2602  | 29.1 | 3152 | 26.0 |
| 0-<0.5      | 406               | 3.3  | 719  | 4.8  | 860               | 20.8 | 983  | 22.2 | 2551  | 28.5 | 3568 | 29.5 |
| 0.5-<1      | 77                | 0.6  | 145  | 1.0  | 444               | 10.8 | 460  | 10.4 | 1273  | 14.2 | 1738 | 14.3 |
| 1-<1.5      | 12                | 0.1  | 28   | 0.2  | 236               | 5.7  | 228  | 5.1  | 546   | 6.1  | 780  | 6.4  |
| 1.5-<2      | 5                 | 0.0  | 14   | 0.1  | 129               | 3.1  | 98   | 2.2  | 268   | 3.0  | 367  | 3.0  |
| 2-<2.5      | 15                | 0.1  | 10   | 0.1  | 50                | 1.2  | 48   | 1.1  | 117   | 1.3  | 160  | 1.3  |
| 2.5-<3      | 0                 | 0.0  | 6    | 0.0  | 24                | 0.6  | 22   | 0.5  | 59    | 0.7  | 56   | 0.5  |
| 3-<3.5      | 1                 | 0.0  | 2    | 0.0  | 15                | 0.4  | 16   | 0.4  | 28    | 0.3  | 32   | 0.3  |
| 3.5-<4      | 1                 | 0.0  | 2    | 0.0  | 10                | 0.2  | 8    | 0.2  | 17    | 0.2  | 23   | 0.2  |
| 4-<4.5      | 0                 | 0.0  | 0    | 0.0  | 3                 | 0.1  | 3    | 0.1  | 12    | 0.1  | 12   | 0.1  |
| 4.5-<5      | 1                 | 0.0  | 1    | 0.0  | 3                 | 0.1  | 2    | 0.0  | 11    | 0.1  | 4    | 0.0  |
| 5-<5.5      | 0                 | 0.0  | 0    | 0.0  | 3                 | 0.1  | 2    | 0.0  | 3     | 0.0  | 1    | 0.0  |
| 5.5-<6      | 0                 | 0.0  | 0    | 0.0  | 2                 | 0.0  | 1    | 0.0  | 1     | 0.0  | 3    | 0.0  |
| 6-<6.5      | 0                 | 0.0  | 0    | 0.0  | 1                 | 0.0  | 0    | 0.0  | 4     | 0.0  | 2    | 0.0  |
| 6.5-<7      | 0                 | 0.0  | 0    | 0.0  | 2                 | 0.0  | 1    | 0.0  | 4     | 0.0  | 1    | 0.0  |
| 7-<7.5      | 0                 | 0.0  | 0    | 0.0  | 1                 | 0.0  | 3    | 0.1  | 0     | 0.0  | 1    | 0.0  |
| 7.5-<8      | 0                 | 0.0  | 0    | 0.0  | 2                 | 0.0  | 1    | 0.0  | 2     | 0.0  | 3    | 0.0  |
| 8-<8.5      | 0                 | 0.0  | 0    | 0.0  | 1                 | 0.0  | 3    | 0.1  | 3     | 0.0  | 1    | 0.0  |
| 8.5-<9      | 0                 | 0.0  | 0    | 0.0  | 5                 | 0.1  | 1    | 0.0  | 0     | 0.0  | 0    | 0.0  |
| 9-<9.5      | 0                 | 0.0  | 0    | 0.0  | 1                 | 0.0  | 8    | 0.2  | 0     | 0.0  | 0    | 0.0  |
| 9.5-<10     | 0                 | 0.0  | 1    | 0.0  | 5                 | 0.1  | 2    | 0.0  | 4     | 0.0  | 6    | 0.0  |

Eyes with actual refractive power (SE) of more than +10.0D and -10.0D were excluded from analysis

Figure 1.5.5(a) Percentage Distribution of Actual Refractive Power in ECCE and Phaco, CSR 2007-2008




The difference between target and actual refractive power was analysed to assess the disparity between the post-operative refraction and the planned refraction i.e. how far the achieved refraction had deviated from the target. Data in both years demonstrated poor outcome; there was a large disparity between the targeted and the actual refraction. Only ¼ of the patients could achieve what was targetted pre-operatively.

Table 1.5.5(c) Difference in Target and Actual Refractive Power for Patients who had Phacoemulsification Only, CSR 2007-2008

|            | Target Refraction |      |       |      | Actual Refraction |      |       |      | Difference between actual and target refraction (Actual-Target) |      |      |       |
|------------|-------------------|------|-------|------|-------------------|------|-------|------|---|------|------|-------|
| Years      | 2007              |      | 2008  |      | 2007              |      | 2008  |      | 2007  |      | 2008 |       |
| Power (D)  | No                | %    | No    | %    | No                | %    | No    | %    | No  | %    | No   | %     |
| N          | 7975              | 100  | 10660 | 100  | 8342              | 100  | 12154 | 100  | 5782  | 100  | 8803 | 100.0 |
| -5-<(-4.5) | 2                 | 0.0  | 4     | 0.0  | 15                | 0.2  | 13    | 0.1  | 12  | 0.2  | 12   | 0.1   |
| -4.5-<(-4) | 1                 | 0.0  | 3     | 0.0  | 30                | 0.4  | 19    | 0.2  | 14  | 0.2  | 19   | 0.2   |
| -4-<(-3.5) | 5                 | 0.1  | 7     | 0.1  | 49                | 0.6  | 17    | 0.1  | 28  | 0.5  | 18   | 0.2   |
| -3.5-<(-3) | 5                 | 0.1  | 6     | 0.1  | 97                | 1.2  | 20    | 0.2  | 43  | 0.7  | 51   | 0.6   |
| -3-<(-2.5) | 10                | 0.1  | 20    | 0.2  | 200               | 2.4  | 55    | 0.5  | 93  | 1.6  | 103  | 1.2   |
| -2.5-<(-2) | 18                | 0.2  | 16    | 0.2  | 405               | 4.9  | 85    | 0.7  | 176   | 3.0  | 245  | 2.8   |
| -2-<(-1.5) | 51                | 0.6  | 35    | 0.3  | 746               | 8.9  | 164   | 1.3  | 311   | 5.4  | 541  | 6.1   |
| -1.5-<(-1) | 239               | 3.0  | 288   | 2.7  | 1382              | 16.6 | 423   | 3.5  | 595   | 10.3 | 1052 | 12.0  |
| -1-<(-0.5) | 2473              | 31.0 | 4065  | 38.1 | 1771              | 21.2 | 1408  | 11.6 | 994   | 17.2 | 1984 | 22.5  |
| -0.5-<0    | 4512              | 56.6 | 5498  | 51.6 | 1884              | 22.6 | 3167  | 26.1 | 1367  | 23.6 | 2278 | 25.9  |
| 0-<0.5     | 583               | 7.3  | 563   | 5.3  | 1069              | 12.8 | 3534  | 29.1 | 1179  | 20.4 | 1434 | 16.3  |
| 0.5-<1     | 45                | 0.6  | 107   | 1.0  | 399               | 4.8  | 1740  | 14.3 | 573   | 9.9  | 558  | 6.3   |
| 1-<1.5     | 6                 | 0.1  | 23    | 0.2  | 142               | 1.7  | 786   | 6.5  | 225   | 3.9  | 214  | 2.4   |
| 1.5-<2     | 2                 | 0.0  | 7     | 0.1  | 55                | 0.7  | 365   | 3.0  | 73  | 1.3  | 97   | 1.1   |
| 2-<2.5     | 9                 | 0.1  | 6     | 0.1  | 14                | 0.2  | 156   | 1.3  | 32  | 0.6  | 46   | 0.5   |
| 2.5-<3     | 1                 | 0.0  | 4     | 0.0  | 15                | 0.2  | 55    | 0.5  | 14  | 0.2  | 26   | 0.3   |
| 3-<3.5     | 1                 | 0.0  | 0     | 0.0  | 13                | 0.2  | 30    | 0.2  | 13  | 0.2  | 15   | 0.2   |
| 3.5-<4     | 0                 | 0.0  | 1     | 0.0  | 4                 | 0.0  | 22    | 0.2  | 8   | 0.1  | 15   | 0.2   |
| 4-<4.5     | 2                 | 0.0  | 0     | 0.0  | 3                 | 0.0  | 10    | 0.1  | 3   | 0.0  | 12   | 0.1   |
| 4.5-<5     | 0                 | 0.0  | 1     | 0.0  | 4                 | 0.0  | 4     | 0.0  | 3   | 0.0  | 12   | 0.1   |
| 5-<5.5     | 1                 | 0.0  | 0     | 0.0  | 1                 | 0.0  | 1     | 0.0  | 9   | 0.2  | 9    | 0.1   |

Figure 1.5.5(b) Difference in Target and Actual Refractive Power for Patients who had Phacoemulsification Only, CSR 2007-2008



## **Chapter 2**

### **Diabetic Eye Registry**

#### **Contributing Editors**

**Dr Zuraidah Mustari  
Dr Nor Fariza Ngah**

## Chapter 2 DIABETIC EYE REGISTRY

### 2.1 STOCK AND FLOW

#### 2.1.1 Number of cases registered by states

There were 32 SDPs in 2007 and 35 SDPs in 2008. 10,856 diabetic patients who were seen for the first time by eye care providers were registered in 2007 and 12,014 in 2008. When compared to the total number of new diabetic patients seen at MOH Ophthalmology clinics (N=15564 in 2007 and N=19632 in 2008), the ascertainment rate was 69.8% in 2007 and 61.2% in 2008 .

Table 2.1.1 Number of cases of diabetic patients registered to Diabetic Eye Registry (DER)

| States in Malaysia  | Year 2007 (N=10856) |       |      | Year 2008 (N=12014) |       |      | Total |      |
|---------------------|---------------------|-------|------|---------------------|-------|------|-------|------|
|                     | No. of SDP          | No.   | %    | No. of SDP          | No.   | %    | No.   | %    |
| Kedah               | 3                   | 1075  | 9.9  | 3                   | 1068  | 8.9  | 2143  | 9.4  |
| Pulau Pinang        | 2                   | 394   | 3.6  | 2                   | 561   | 4.7  | 955   | 4.2  |
| Perak               | 4                   | 1344  | 12.4 | 4                   | 1646  | 13.7 | 2990  | 13.1 |
| Selangor            | 5                   | 2519  | 23.2 | 5                   | 2357  | 19.6 | 4876  | 21.3 |
| Negeri Sembilan     | 2                   | 791   | 7.3  | 2                   | 599   | 5    | 1390  | 6.1  |
| Melaka              | 1                   | 84    | 0.8  | 1                   | 190   | 1.6  | 274   | 1.2  |
| Johor               | 4                   | 1668  | 15.4 | 4                   | 1442  | 12   | 3110  | 13.6 |
| Kelantan            | 2                   | 621   | 5.7  | 2                   | 563   | 4.7  | 1184  | 5.2  |
| Terengganu          | 1                   | 291   | 2.7  | 1                   | 591   | 4.9  | 882   | 3.9  |
| Pahang              | 1                   | 640   | 5.9  | 2                   | 1131  | 9.4  | 1771  | 7.7  |
| Sabah               | 2                   | 677   | 6.2  | 4                   | 620   | 5.2  | 1297  | 5.6  |
| Sarawak             | 2                   | 169   | 1.6  | 3                   | 668   | 5.7  | 837   | 3.7  |
| Wilayah Persekutuan | 2                   | 583   | 5.4  | 2                   | 578   | 4.8  | 1161  | 5.1  |
| All                 | 31                  | 10856 | 100  | 35                  | 12014 | 100  | 22870 | 100  |

#### 2.1.2 Number of cases registered by month

The average number of cases registered per month was 905 patients in 2007 and 1001 patients in 2008. Lower ascertainment rates were noted in the month of October for both years.

Table 2.1.2 Number of cases registered by month

| Month     | Year 2007 |      | Year 2008 |      | Total   |      |
|-----------|-----------|------|-----------|------|---------|------|
|           | N=10856   |      | N=12014   |      | N=22870 |      |
|           | No.       | %    | No.       | %    | No.     | %    |
| January   | 1021      | 9.4  | 998       | 8.3  | 2019    | 8.8  |
| February  | 800       | 7.4  | 929       | 7.7  | 1729    | 7.6  |
| March     | 1002      | 9.2  | 1125      | 9.4  | 2127    | 9.3  |
| April     | 1006      | 9.3  | 1304      | 10.9 | 2310    | 10.1 |
| May       | 1073      | 9.9  | 865       | 7.2  | 1938    | 8.5  |
| June      | 849       | 7.8  | 930       | 7.7  | 1779    | 7.8  |
| July      | 1110      | 10.2 | 1225      | 10.2 | 2335    | 10.2 |
| August    | 939       | 8.6  | 1276      | 10.6 | 2215    | 9.7  |
| September | 861       | 7.9  | 949       | 7.9  | 1810    | 7.9  |
| October   | 672       | 6.2  | 666       | 5.5  | 1338    | 5.9  |
| November  | 918       | 8.5  | 912       | 7.6  | 1830    | 8    |
| December  | 605       | 5.6  | 835       | 7    | 1440    | 6.3  |
| All       | 10856     | 100% | 12014     | 100% | 22870   | 100% |

## 2.2 CHARACTERISTICS OF PATIENTS

### 2.2.1 Patient demography

The majority of patients registered were between 30 to 60 years, with a mean age of 57.3 years in 2007 and 2008. The age was similar for those with and without diabetic retinopathy (DR) in both years.

More female diabetic patients were screened in 2007 (54.9%) and 2008 (56.2%).

The proportion of patients screened and registered was similar to the national ethnic distributions, i.e. highest in Malay (2007: 54.0%), (2008: 55%), followed by Chinese (2007: 23.2%), (2008: 23.1%), Indians (2007: 18.4%), (2008: 16.4%) and others (2007: 3.6%), (2008: 4.6%). The proportion of those with DR were 39.7% and 41.3% in 2007 and 2008 respectively among Malays, 38.4% and 36.6% in 2007 and 2008 respectively among Chinese, 36.5% and 32.6% in 2007 and 2008 respectively among Indians, 25.1% and 26.3% in 2007 and 2008 respectively among indigenous group and 23.5% and 35.7% in 2007 and 2008 respectively in others.

|                  |                         | Year 2007      |      |                      |      |                   |      | Year 2008      |      |                      |      |                   |      |
|------------------|-------------------------|----------------|------|----------------------|------|-------------------|------|----------------|------|----------------------|------|-------------------|------|
|                  |                         | All<br>N=10856 |      | Without DR<br>N=5558 |      | With DR<br>N=4145 |      | All<br>N=12014 |      | Without DR<br>N=6471 |      | With DR<br>N=4594 |      |
| Age, years       |                         |                |      |                      |      |                   |      |                |      |                      |      |                   |      |
|                  | Mean                    | 57.3           |      | 56.9                 |      | 56.8              |      | 57.3           |      | 56.6                 |      | 57.1              |      |
|                  | SD                      | 11.4           |      | 12.4                 |      | 9.8               |      | 11.5           |      | 12.3                 |      | 9.9               |      |
|                  | Median                  | 58             |      | 57.9                 |      | 57.0              |      | 57.8           |      | 57.5                 |      | 57.2              |      |
| Age group, years |                         | No.            | %    | No.                  | %    | No.               | %    | No.            | %    | No.                  | %    | No.               | %    |
|                  | <30                     | 211            | 1.9  | 170                  | 3.2  | 33                | 0.8  | 222            | 1.8  | 170                  | 2.6  | 44                | 1    |
|                  | 30 - <60                | 6047           | 55.7 | 3101                 | 57.8 | 2583              | 63.2 | 6770           | 56.4 | 3606                 | 55.7 | 2837              | 61.8 |
|                  | >= 60                   | 4541           | 41.9 | 2263                 | 42.2 | 1506              | 36.8 | 5022           | 41.8 | 2695                 | 41.6 | 1713              | 37.3 |
| Gender           |                         |                |      |                      |      |                   |      |                |      |                      |      |                   |      |
|                  | Male                    | 4898           | 45.1 | 2490                 | 44.8 | 1922              | 46.4 | 5261           | 43.8 | 2799                 | 43.3 | 2055              | 44.7 |
|                  | Female                  | 5955           | 54.9 | 3070                 | 55.2 | 2221              | 53.6 | 6753           | 56.2 | 3672                 | 56.7 | 2539              | 55.3 |
| Ethnic           |                         |                |      |                      |      |                   |      |                |      |                      |      |                   |      |
|                  | Malay                   | 5858           | 54   | 2879                 | 51.8 | 2324              | 56.1 | 6612           | 55   | 3366                 | 52   | 2730              | 59.4 |
|                  | Chinese                 | 2523           | 23.2 | 1310                 | 23.6 | 970               | 23.4 | 2781           | 23.1 | 1542                 | 23.8 | 1019              | 22.2 |
|                  | Indian                  | 1996           | 18.4 | 1101                 | 19.7 | 729               | 17.6 | 1972           | 16.4 | 1166                 | 18   | 642               | 14   |
|                  | Orang Asli              | 1              | 0    | 1                    | 0    | 0                 | 0    | 6              | 0    | 3                    | 0    | 2                 | 0    |
|                  | Melanau                 | 106            | 1    | 71                   | 1.3  | 20                | 0.5  | 27             | 0.2  | 23                   | 0.4  | 2                 | 0    |
|                  | Kadazan / Murut / Bajau | 88             | 0.8  | 45                   | 0.8  | 29                | 0.7  | 140            | 1.2  | 88                   | 1.4  | 42                | 0.9  |
|                  | Iban                    | 0              | 0    | 0                    | 0    | 0                 | 0    | 19             | 0.2  | 12                   | 0.2  | 6                 | 0.1  |
|                  | Bidayuh                 | 0              | 0    | 0                    | 0    | 0                 | 0    | 128            | 1.1  | 85                   | 1.3  | 32                | 0.7  |
|                  | Other                   | 200            | 1.8  | 115                  | 2.1  | 47                | 1.1  | 224            | 1.9  | 127                  | 2    | 80                | 1.7  |
|                  | Missing                 | 84             | 0.8  | 39                   | 0.7  | 26                | 0.6  | 105            | 0.9  | 59                   | 0.9  | 39                | 0.8  |

### 2.2.2 Source of Referral

Government primary health care clinics and hospitals were the main source of referrals accounting for 91.7% (2007) and 93.2% (2008) of the referrals. On the contrary, only 2.0% were referred from the private health care providers. From the NHMS data, 20.3% diabetics were being treated by private health care providers. The reasons for low proportion of referral by general practitioners need to be evaluated.

Table 2.2.2 Sources of referral for diabetic patients

| No | Sources of referral                    | Year 2007<br>N=10856 |      | Year 2008<br>N=12014 |      | Total<br>N=22870 |     |
|----|--|----------------------|------|----------------------|------|------------------|-----|
|    |  | No.                  | %    | No.                  | %    | No.              | %   |
| 1  | Government primary health care clinics | 6577                 | 60.6 | 7825                 | 65.1 | 14402            | 63  |
| 2  | Government hospital - MO or physician  | 3377                 | 31.1 | 3370                 | 28.1 | 6747             | 30  |
| 3  | General practitioner                   | 133                  | 1.2  | 113                  | 0.9  | 246              | 1.1 |
| 4  | Private hospital-MO or specialist      | 82                   | 0.8  | 71                   | 0.6  | 153              | 0.7 |
| 5  | Optometrist                            | 14                   | 0.1  | 21                   | 0.2  | 35               | 0.2 |
| 6  | Others                                 | 38                   | 0.4  | 26                   | 0.2  | 64               | 0.3 |

## 2.3 MEDICAL HISTORY AND PRACTICE PATTERN

### 2.3.1 Type of Diabetes

Majority of patients screened in ophthalmology clinics in 2007 and 2008 had type II DM. This reflects the pattern of the diabetic prevalence in Malaysia as shown in NHMS findings where prevalence of DM was 2.4% among those 18 to less than 30 years old and 14.9% among those 30 years and older.

### 2.3.2 Duration of Diabetes

Most of the patients screened (49% in both 2007 and 2008) had diabetes for more than 5 years. As the risk of DR is higher in patients with longer duration of DM, these patients should have their eyes screened at the recommended schedule of at least once a year.

### 2.3.3 Type of Treatment

In 2007 and 2008, eighty percent of the patients were on oral medication whilst 11% were on insulin. This is because most patients were of Type II DM.

### 2.3.4 Systemic co-morbidity

Hypertension (63.4%), hypercholesterolemia (18.1%) and ischemic heart disease (10.3%) were the main systemic co-morbidities found among the diabetic patients registered in both 2007 and 2008. Renal impairment was noted in 5.5% of patients. Only 23.4% of diabetics did not have any form of systemic co-morbidity.

### 2.3.5 Risk Factors

Among patients registered, 9.1% were current smokers in 2007 with an apparent decrease in percentage (5.2%) in 2008.


### 2.3.6 Ocular co-morbidity

Of the 10856 patients registered, 44.2% were found to have cataract and 3.1% had glaucoma in 2007, as compared to 43.4 % ( cataract) and 2.5% (glaucoma) out of a total of 12014 patients registered in 2008.

Table 2.3.6 Past medical and ocular history

|                         |                      | Year 2007 |      | Year 2008 |      | Total |      |
|-------------------------|----------------------|-----------|------|-----------|------|-------|------|
| Types of DM             |                      | No.       | %    | No.       | %    | No.   | %    |
|                         | Type II              | 9995      | 92.0 | 10892     | 90.7 | 20887 | 91.3 |
|                         | Type I               | 571       | 5.3  | 636       | 5.3  | 1207  | 5.3  |
|                         | Pre-diabetic         | -         | -    | 20        | 0.2  | 20    | 0.1  |
|                         | Missing              | 290       | 2.7  | 466       | 3.9  | 756   | 3.3  |
| Duration of DM, years   |                      |           |      |           |      |       |      |
|                         | <5                   | 3612      | 33.3 | 3740      | 31.1 | 7352  | 32.1 |
|                         | 5-10                 | 3355      | 30.8 | 3827      | 31.9 | 7182  | 31.4 |
|                         | >10-20               | 1625      | 15.0 | 1736      | 14.4 | 3361  | 14.7 |
|                         | >20                  | 333       | 3.1  | 368       | 3.1  | 701   | 3.1  |
|                         | Missing              | 1931      | 17.8 | 2343      | 19.5 | 4274  | 18.7 |
| Types of treatment      |                      |           |      |           |      |       |      |
|                         | Diet                 | -         | -    | 494       | 4.1  | 494   | 2.2  |
|                         | Oral medication      | 8958      | 82.0 | 9357      | 77.9 | 18315 | 80   |
|                         | Insulin              | 1393      | 11.8 | 1042      | 8.7  | 2435  | 10.6 |
|                         | Other                | 727       | 6.2  | 636       | 5.3  | 1363  | 6    |
| Systematic Co-morbidity |                      |           |      |           |      |       |      |
|                         | None                 | 2463      | 22.7 | 2898      | 24.1 | 5361  | 23.4 |
|                         | HPT                  | 6935      | 63.9 | 7575      | 63.1 | 14510 | 63.4 |
|                         | Hypercholesterolemia | 1981      | 18.2 | 2155      | 17.9 | 4136  | 18.1 |
|                         | IHD                  | 1203      | 11.1 | 1159      | 9.6  | 2362  | 10.3 |
|                         | Renal Impairment     | 632       | 5.8  | 622       | 5.2  | 1254  | 5.5  |
|                         | CVA                  | 260       | 2.4  | 232       | 1.9  | 492   | 2.2  |
|                         | Amputation           | 70        | 0.6  | 73        | 0.6  | 143   | 0.6  |
|                         | Others               | 1064      | 9.7  | 1018      | 8.5  | 2082  | 9.1  |
| Smoking                 |                      |           |      |           |      |       |      |
|                         | smoking              | 991       | 9.1  | 629       | 5.2  | 1620  | 7.1  |
| Ocular co-morbidity     |                      |           |      |           |      |       |      |
|                         | None                 | 4435      | 40.9 | 5429      | 45.2 | 9864  | 43.1 |
|                         | Cataract             | 4799      | 44.2 | 5122      | 42.6 | 9921  | 43.4 |
|                         | Glaucoma             | 337       | 3.1  | 229       | 1.9  | 566   | 2.5  |
|                         | Rubeosis irides      | 58        | 0.5  | -         | -    | 58    | 0.3  |
|                         | Others               | 445       | 4.1  | 413       | 3.4  | 858   | 3.8  |

Figure 2.3.6 Systemic co-morbidities



*\*multiple checks were allowed for systemic co-morbidity*

### 2.3.7 Pregnancy and eye examination

Among 5927 female patients, 148 (2.5%) were pregnant at the time of first eye examination in 2007 compared to 208(3.1%) among 6753 female patients in 2008. Most of them were seen at the second trimester (41.2%) in 2007 but in 2008 more were seen in the first trimester (43.8%). This could be due to an increased level of awareness to the need for eye screening among pregnant diabetics.

Table 2.3.7 Female diabetic patients who were pregnant

|                    | 2007               |                   | 2008               |                   | Total               |                   |
|--------------------|--------------------|-------------------|--------------------|-------------------|---------------------|-------------------|
|                    | No. of female=5927 |                   | No. of female=6753 |                   | No. of female=12680 |                   |
| Pregnant status    | No.                | % among female    | No.                | % among female    | No.                 | % among female    |
| Pregnant           | 148                | 2.5% among female | 208                | 3.1% among female | 356                 | 2.8% among female |
| Pregnant in female |                    |                   |                    |                   |                     |                   |
| • 1st Trimester    | 54                 | 36.5              | 91                 | 43.8              | 145                 | 40.7              |
| • 2nd Trimester    | 61                 | 41.2              | 76                 | 36.5              | 137                 | 38.5              |
| • 3rd Trimester    | 26                 | 17.6              | 38                 | 18.3              | 64                  | 18                |
| • Missing          | 7                  | 4.7               | 3                  | 1.4               | 10                  | 2.8               |

### 2.3.8 Previous eye examinations

More than two-thirds of the patients; (70.9%) in 2007 and (71.5%) in 2008, never had an eye examination. Among those examined, 71.8% (2007) and 68.4% (2008) had their eye examined in the last one year. The proportion of patients who had never had an eye examination was higher than that noted in NHMS 2006, where 55% never had an eye examination and of the 45% who had eye examination, 32.9% had it done in the last 1 year, 49.7% the last 1 to 2 years and 17.4% in more than 2 years.

Table 2.3.8 Distribution of previous eye examination

|                                  | 2007    |      | 2008    |      | Total   |      |
|----------------------------------|---------|------|---------|------|---------|------|
|                                  | N=10856 |      | N=12014 |      | N=22870 |      |
| Eye examination                  | No.     | %    | No.     | %    | No.     | %    |
| Never had eye examination before | 7700    | 70.9 | 8653    | 72   | 16353   | 71.5 |
| Had eye examination before       | 1869    | 17.2 | 1740    | 14.5 | 3609    | 15.8 |
| • Last 1 year                    | 1342    | 71.8 | 1127    | 64.8 | 2469    | 68.4 |
| • Last 1-2 years                 | 77      | 4.1  | 95      | 5.5  | 172     | 4.8  |
| • > 2 years                      | 1       | 0.1  | 0       | 0    | 1       | 0    |
| • Missing                        | 449     | 24   | 518     | 29.8 | 967     | 26.8 |
| Missing                          | 1287    | 11.8 | 1621    | 13.5 | 2908    | 12.7 |

## 2.4 STATUS OF THE EYES

### 2.4.1 Status of visual acuity

Generally, about 9% (2007 and 2008) of eyes screened were blind, with unaided and presenting VA of worse than 3/60. Eyes with DR had worse vision when compared with eyes without DR.

Table 2.4.1(a) Distribution of unaided visual acuity by eyes

|              | Year 2007            |      |                     |      | Year 2008            |      |                     |      |
|--------------|----------------------|------|---------------------|------|----------------------|------|---------------------|------|
| Unaided VA   | Right Eye<br>N=10856 |      | Left Eye<br>N=10856 |      | Right eye<br>N=12014 |      | Left eye<br>N=12014 |      |
|              | No.                  | %    | No.                 | %    | No.                  | %    | No.                 | %    |
| 6/5          | 4                    | 0    | 5                   | 0    | 4                    | 0    | 9                   | 0.1  |
| 6/6          | 1009                 | 9.3  | 1072                | 9.9  | 1273                 | 10.6 | 1341                | 11.2 |
| 6/9          | 1860                 | 17.1 | 1960                | 18.1 | 2118                 | 17.6 | 2207                | 18.4 |
| 6/12         | 1333                 | 12.3 | 1316                | 12.1 | 1482                 | 12.3 | 1502                | 12.5 |
| 6/5 to 6/12  | 4206                 | 38.7 | 4353                | 40.1 | 4877                 | 40.5 | 5059                | 42.2 |
| 6/18         | 1297                 | 11.9 | 1263                | 11.6 | 1491                 | 12.4 | 1436                | 12   |
| 6/24         | 1176                 | 10.8 | 1162                | 10.7 | 1230                 | 10.2 | 1213                | 10.1 |
| 6/36         | 840                  | 7.7  | 754                 | 6.9  | 870                  | 7.2  | 762                 | 6.3  |
| 6/60         | 612                  | 5.6  | 566                 | 5.2  | 596                  | 5    | 601                 | 5    |
| 5/60         | 61                   | 0.6  | 72                  | 0.7  | 61                   | 0.5  | 81                  | 0.7  |
| 4/60         | 66                   | 0.6  | 73                  | 0.7  | 80                   | 0.7  | 84                  | 0.7  |
| 3/60         | 122                  | 1.1  | 110                 | 1    | 132                  | 1.1  | 138                 | 1.1  |
| 6/18 to 3/60 | 4174                 | 38.4 | 4000                | 36.8 | 4460                 | 37.1 | 4315                | 35.9 |
| 2/60         | 144                  | 1.3  | 142                 | 1.3  | 133                  | 1.1  | 120                 | 1    |
| 1/60         | 168                  | 1.5  | 153                 | 1.4  | 188                  | 1.6  | 179                 | 1.5  |
| CF           | 302                  | 2.8  | 297                 | 2.7  | 359                  | 3    | 335                 | 2.8  |
| HM           | 257                  | 2.4  | 273                 | 2.5  | 268                  | 2.2  | 225                 | 1.9  |
| PL           | 76                   | 0.7  | 82                  | 0.8  | 69                   | 0.6  | 82                  | 0.7  |
| NPL          | 40                   | 0.4  | 37                  | 0.3  | 61                   | 0.5  | 51                  | 0.4  |
| 3/60 to NPL  | 987                  | 9.1  | 984                 | 9.0  | 1078                 | 9    | 992                 | 8.3  |

Table 2.4.1(b) Distribution of presenting visual acuity by eyes

| Presenting VA<br>(with or without<br>glasses) | Year 2007            |      |                     |      | Year 2008            |      |                     |      |
|---|----------------------|------|---------------------|------|----------------------|------|---------------------|------|
|   | Right Eye<br>N=10856 |      | Left Eye<br>N=10856 |      | Right Eye<br>N=12014 |      | Left Eye<br>N=12014 |      |
|   | No.                  | %    | No.                 | %    | No.                  | %    | No.                 | %    |
| 6/5   | 16                   | 0.1  | 15                  | 0.1  | 19                   | 0.2  | 20                  | 0.2  |
| 6/6   | 1636                 | 15.1 | 1679                | 15.5 | 2091                 | 17.4 | 2114                | 17.6 |
| 6/9   | 2942                 | 27.1 | 2856                | 26.3 | 3615                 | 30.1 | 3657                | 30.4 |
| 6/12  | 1433                 | 13.2 | 1555                | 14.3 | 1708                 | 14.2 | 1679                | 14   |
| 6/5 to 6/12                                   | 6027                 | 55.5 | 6105                | 56.2 | 7433                 | 61.9 | 7470                | 62.2 |
| 6/18  | 1207                 | 11.1 | 1155                | 10.6 | 1314                 | 10.9 | 1277                | 10.6 |
| 6/24  | 950                  | 8.8  | 926                 | 8.5  | 835                  | 7    | 860                 | 7.2  |
| 6/36  | 633                  | 5.8  | 565                 | 5.2  | 548                  | 4.6  | 541                 | 4.5  |
| 6/60  | 412                  | 3.8  | 417                 | 3.8  | 370                  | 3.1  | 367                 | 3.1  |
| 5/60  | 48                   | 0.4  | 62                  | 0.6  | 42                   | 0.3  | 68                  | 0.6  |
| 4/60  | 57                   | 0.5  | 62                  | 0.6  | 66                   | 0.5  | 69                  | 0.6  |
| 3/60  | 94                   | 0.9  | 88                  | 0.8  | 79                   | 0.7  | 102                 | 0.8  |
| 6/18 to 3/60                                  | 3401                 | 31.3 | 3275                | 30.2 | 3254                 | 27.1 | 3284                | 27.4 |
| 2/60  | 111                  | 1    | 117                 | 1.1  | 103                  | 0.9  | 98                  | 0.8  |
| 1/60  | 144                  | 1.3  | 136                 | 1.3  | 166                  | 1.4  | 148                 | 1.2  |
| CF  | 292                  | 2.7  | 302                 | 2.8  | 357                  | 3    | 335                 | 2.8  |
| HM  | 256                  | 2.4  | 283                 | 2.6  | 267                  | 2.2  | 237                 | 2    |
| PL  | 76                   | 0.7  | 82                  | 0.8  | 75                   | 0.6  | 80                  | 0.7  |
| NPL   | 45                   | 0.4  | 38                  | 0.4  | 79                   | 0.7  | 58                  | 0.5  |
| 3/60 to NPL                                   | 924                  | 8.5  | 958                 | 8.8  | 1047                 | 8.8  | 956                 | 8    |



## 2.4.2 Status of diabetic retinopathy and maculopathy

Among the patients screened, 60.4% in 2007 and 50.8% in 2008 had no apparent DR in both their eyes. Up to 38.2% in 2007 and 36.1% in 2008 had some form of DR in either eye and 11.9% in 2007 and 9.6% in 2008 had maculopathy.

Among 21712 eyes examined in 2007, 12114 eyes (55.8%) had no apparent DR, 7478 eyes (34.4%) had some form of DR, and 2031 eyes (9.4%) had maculopathy. Up to 4.1% of eyes could not be examined due to poor view of fundus. In comparison to 24,763 eyes examined in 2008, 14,030 eyes (56.7%) had no apparent DR, 8,300 eyes (33.5%) had some form of DR, and 1,969 eyes (8.0%) had maculopathy. Generally, up to 5.0% of eyes could not be examined due to poor view of fundus.

The level of severity of DR among eyes examined showed that 67.3%(2007); 76.8%(2008) had mild to moderate NPDR, 8.6%(2007); 18.7%(2008) had severe NPDR and 18.1%(2007); 11.4%(2008) had PDR, of which 5.9%(2007); 4.8%(2008) was at advanced diabetic eye disease state.

Among 21712 and 24763 eyes examined in 2007 and 2008 respectively showed 15.6 % ( 2007) and 11.5 % ( 2008) had vision threatening DR (PDR and maculopathy).

Table 2.4.2(a) Status of diabetic retinopathy, by individuals

|     |                            | Year 2007 |      | Year 2008 |      | Total   |      |
|-----|----------------------------|-----------|------|-----------|------|---------|------|
|     |                            | N=10856   |      | N=12739   |      | N=23595 |      |
| No. | Diabetic retinopathy types | No.       | %    | No.       | %    | No.     | %    |
| 1   | No diabetic retinopathy    | 6553      | 60.4 | 6471      | 50.8 | 13024   | 55.2 |
| 2   | Diabetic Retinopathy*      | 4145      | 38.2 | 4594      | 36.1 | 8739    | 37   |
| 3   | Maculopathy**              | 1287      | 11.9 | 1225      | 9.6  | 2512    | 10.6 |
| 4   | No view of fundus          | 689       | 6.3  | 297       | 2.3  | 986     | 4.2  |

*\*Diabetic retinopathy: Patients who have any type of diabetic retinopathy including maculopathy.*

*\*\*Maculopathy: patients with maculopathy may also have other types of diabetic retinopathy.*

*The percentage add up to be more than 100% as patient with maculopathy may have other types of diabetic retinopathy.*

Table 2.4.2(b) Status of diabetic retinopathy, by eyes

|                            | Year 2007 |       |          |       |          |       | Year 2008 |       |          |       |          |       |
|----------------------------|-----------|-------|----------|-------|----------|-------|-----------|-------|----------|-------|----------|-------|
|                            | Right Eye |       | Left Eye |       | All Eyes |       | Right Eye |       | Left Eye |       | All Eyes |       |
|                            | No.       | %     | No.      | %     | No.      | %     | No.       | %     | No.      | %     | No.      | %     |
| Diabetic retinopathy types | N=10856   |       | N=10856  |       | N= 21712 |       | N=12394   |       | N=12369  |       | N=24763  |       |
| No diabetic retinopathy    | 6060      | 55.8  | 6054     | 55.8  | 12114    | 55.8  | 6994      | 56.4  | 7036     | 56.9  | 14030    | 56.7  |
| Diabetic Retinopathy*      | 3735      | 34.4  | 3743     | 34.5  | 7478     | 34.4  | 4182      | 33.7  | 4118     | 33.3  | 8300     | 33.5  |
| Maculopathy**              | 1031      | 9.5   | 1000     | 9.2   | 2031     | 9.4   | 1003      | 8.1   | 966      | 7.8   | 1969     | 8.0   |
| No view of fundus          | 474       | 4.4   | 427      | 3.9   | 901      | 4.1   | 623       | 5.0   | 611      | 4.9   | 1234     | 5.0   |
| Total                      | 11300     | 104.1 | 11224    | 103.4 | 22524    | 103.7 | 12802     | 103.2 | 12731    | 102.9 | 25533    | 103.2 |

\*Diabetic retinopathy is patients who have any type of diabetic retinopathy including maculopathy.

\*\*Maculopathy is those with maculopathy, with or without other types of diabetic retinopathy.  
The percentages add up to be more than 100% as patient with maculopathy may have other types of diabetic retinopathy.

Table 2.4.2 (c) Level of severity of diabetic retinopathy by eyes

|                            | Year 2007 |      |          |      |          |      | Year 2008 |      |          |      |          |      |
|----------------------------|-----------|------|----------|------|----------|------|-----------|------|----------|------|----------|------|
|                            | Right Eye |      | Left Eye |      | All Eyes |      | Right Eye |      | Left Eye |      | All Eyes |      |
|                            | No.       | %    | No.      | %    | No.      | %    | No.       | %    | No.      | %    | No.      | %    |
| Diabetic Retinopathy types | N=10856   |      | N=10856  |      | N=21712  |      | N=12394   |      | N=12369  |      | N=24763  |      |
| No diabetic retinopathy    | 6060      | 55.8 | 6054     | 55.8 | 12114    | 55.8 | 6994      | 56.4 | 7036     | 56.9 | 14030    | 56.7 |
| Any diabetic retinopathy   | 3735      | 34.4 | 3743     | 34.5 | 7478     | 34.4 | 4017      | 34.8 | 3950     | 34.3 | 7772     | 34.6 |
| Mild NPDR                  | 1579      | 42.3 | 1573     | 42   | 3152     | 42.2 | 2001      | 49.8 | 1937     | 49.0 | 3938     | 50.7 |
| Moderate NPDR              | 931       | 24.9 | 943      | 25.2 | 1874     | 25.1 | 1031      | 25.7 | 998      | 25.3 | 2029     | 26.1 |
| Severe NPDR                | 336       | 9    | 308      | 8.2  | 644      | 8.6  | 367       | 9.1  | 370      | 9.4  | 737      | 18.7 |
| PDR*                       | 672       | 18   | 681      | 18.2 | 1353     | 18.1 | 438       | 10.9 | 450      | 11.4 | 888      | 11.4 |
| Maculopathy*               | 1031      | 9.5  | 1000     | 9.2  | 2031     | 9.4  | 1003      | 8.1  | 966      | 7.8  | 1969     | 8    |
| *Note : ADED               | 228       | 6.1  | 216      | 5.8  | 444      | 5.9  | 180       | 4.5  | 195      | 4.9  | 375      | 4.8  |

\*multiple checks were allowed for diabetic retinopathy types

## 2.5 TREATMENT PLAN

Majority of patients (83.3%) did not require any intervention and were given follow up appointment in 2007 and 2008. However, 10.2 % (2007) and 8.7 % (2008) of the patients required laser and also 3.1 % (2007) and 0.5% (2008) required vitrectomy at the first visit to ophthalmology clinics. The low vitrectomy percentage could be due to low ascertainment rate or under reporting by SDPs.

Table 2.5 Treatment plans

|  | Year 2007 |      | Year 2008 |      | Total   |      |
|--|-----------|------|-----------|------|---------|------|
| Treatment plans                        | N=10856   |      | N=12014   |      | N=22870 |      |
|  | No.       | %    | No.       | %    | No.     | %    |
| Follow up only                         | 9038      | 83.3 | 10013     | 83.3 | 19051   | 83.3 |
| Need laser                             | 1103      | 10.2 | 1046      | 8.7  | 2149    | 10   |
| Need vitrectomy                        | 332       | 3.1  | 60        | 0.5  | 392     | 1.7  |
| Need further assessment<br>such as FFA | 49        | 0.5  | 43        | 0.4  | 92      | 0.4  |
| Missing                                | 631       | 5.8  | 926       | 7.7  | 1557    | 6.8  |

## **Chapter 3**

### **Contact lens-related corneal ulcer surveillance**

**Contributing Editors**

**Dr Shamala Retnasabapathy  
Dr Chandramalar T. Santhirathelagan**

## CHAPTER 3 CONTACT LENS RELATED CORNEAL ULCER


### 3.1 STOCK AND FLOW

There were a total of 103 cases reported in the year 2007 and 99 cases in 2008. The distribution of cases by month did not reveal any outbreak of contact lens-related keratitis in the MOH Hospitals during the year 2007 and 2008. (Table 3.1)

Table 3.1 Number of cases

| Month     | Year 2007 |      | Year 2008 |      | TOTAL |      |
|-----------|-----------|------|-----------|------|-------|------|
|           | No.       | %    | No.       | %    | No.   | %    |
| January   | 18        | 17.5 | 4         | 4    | 22    | 10.9 |
| February  | 10        | 9.7  | 12        | 12.1 | 22    | 10.9 |
| March     | 11        | 10.7 | 9         | 9.1  | 20    | 9.9  |
| April     | 18        | 17.5 | 4         | 4    | 22    | 10.9 |
| May       | 7         | 6.8  | 6         | 6.1  | 13    | 6.4  |
| June      | 3         | 2.9  | 11        | 11.1 | 14    | 6.9  |
| July      | 11        | 10.7 | 7         | 7.1  | 18    | 8.9  |
| August    | 6         | 5.8  | 5         | 5.1  | 11    | 5.4  |
| September | 6         | 5.8  | 9         | 9.1  | 15    | 7.4  |
| October   | 1         | 1    | 11        | 11.1 | 12    | 5.9  |
| November  | 8         | 7.8  | 10        | 10.1 | 18    | 8.9  |
| December  | 4         | 3.9  | 11        | 11.1 | 15    | 7.4  |
| TOTAL     | 103       | 51.0 | 99        | 49.0 | 202   | 100  |

Figure 3.1 Number of cases



### 3.2 DISTRIBUTION OF CASES BY CENTRE

The three hospitals with the highest number of cases reported in 2007 were Hospital Melaka, Kuala Lumpur and Hospital Sultanah Aminah Johor Bahru. In 2008 Hospital Melaka, Selayang and Sungai Buloh recorded the highest number of cases. (Table 3.2)

Table 3.2 Distribution of cases by centre

| Year 2007            |     |       | Year 2008            |     |       |
|----------------------|-----|-------|----------------------|-----|-------|
| Centre               | No. | %     | Centre               | No. | %     |
| H Ipoh               | 6   | 5.83  | H Ipoh               | 3   | 3.03  |
| H Kuala Lumpur       | 10  | 9.71  | H Kuala Lumpur       | 8   | 8.08  |
| H Kuala Terengganu   | 9   | 8.74  | H Kuala Terengganu   | 6   | 6.06  |
| H Kuching            | 1   | 0.97  | H Kuching            | 5   | 5.05  |
| H Melaka             | 12  | 11.65 | H Melaka             | 11  | 11.11 |
| H Muar               | 2   | 1.94  | H Muar               | 3   | 3.03  |
| H Pulau Pinang       | 2   | 1.94  | H Pulau Pinang       | 4   | 4.04  |
| H Kota Kinabalu      | 1   | 0.97  | H Tuanku Jaafar      | 3   | 3.03  |
| H Tuanku Jaafar      | 2   | 1.94  | H Sibul              | 3   | 3.03  |
| H Sultanah Aminah JB | 8   | 7.77  | H Sultanah Aminah JB | 4   | 4.04  |
| H Sungai Petani      | 1   | 0.97  | H Taiping            | 1   | 1.01  |
| H Taiping            | 2   | 1.94  | H Tawau              | 3   | 3.03  |
| H Teluk Intan        | 1   | 0.97  | H Teluk Intan        | 3   | 3.03  |
| H TAR Klang          | 2   | 1.94  | H TAR Klang          | 4   | 4.04  |
| H Kota Bharu         | 5   | 4.85  | H Putrajaya          | 5   | 5.05  |
| H Putrajaya          | 6   | 5.83  | H Batu Pahat         | 1   | 1.01  |
| H Batu Pahat         | 7   | 6.8   | H Selayang           | 11  | 11.11 |
| H Selayang           | 7   | 6.8   | H Bukit Mertajam     | 2   | 2.02  |
| H Bukit Mertajam     | 1   | 0.97  | HUKM                 | 1   | 1.01  |
| HUKM                 | 5   | 4.85  | H Sri Manjung        | 1   | 1.01  |
| H Sri Manjung        | 4   | 3.88  | H Serdang            | 4   | 4.04  |
| H Serdang            | 5   | 4.85  | H Sg. Buloh          | 8   | 8.08  |
| H Sg. Buloh          | 3   | 2.91  | H Ampang             | 4   | 4.04  |
| H Temerloh           | 1   | 0.97  | H Temerloh           | 1   | 1.01  |
| Total                | 103 | 100   | Total                | 99  | 100   |

Figure 3.2(a) Distribution of cases by centre, 2007





Figure 3.2(b) Distribution of cases by centre, 2008



### 3.3 PATIENTS DEMOGRAPHY


#### 3.3.1 Age

Median age was 25 in 2007 and 24 in 2008.

Table 3.3.1 Distribution of patients by age

|                                  | Year 2007 |      | Year 2008 |      | Total     |      |
|----------------------------------|-----------|------|-----------|------|-----------|------|
| Age, years (N)                   | 103       |      | 99        |      | 202       |      |
| Mean (SD)                        | 26.1(8.1) |      | 26.5(8.8) |      | 26.3(8.4) |      |
| Median                           | 25        |      | 24        |      | 24.5      |      |
| Min                              | 10        |      | 15        |      | 10        |      |
| Max                              | 51        |      | 68        |      | 68        |      |
| Distribution of age group, years | No.       | %    | No.       | %    | No.       | %    |
| 0-<10                            | 0         | 0    | 0         | 0    | 0         | 0    |
| 10-<20                           | 22        | 21.4 | 18        | 18.2 | 40        | 19.8 |
| 20-<30                           | 51        | 49.5 | 53        | 53.5 | 104       | 51.5 |
| 30-<40                           | 24        | 23.3 | 21        | 21.2 | 45        | 22.3 |
| 40-<50                           | 5         | 4.9  | 5         | 5.1  | 10        | 5    |
| 50-<60                           | 1         | 1    | 0         | 0    | 1         | 0.5  |
| 70-<80                           | 0         | 0    | 2         | 2    | 2         | 1    |

Figure 3.3.1 Distribution of patients by age




### 3.3.2 Gender

Majority of the patients were females (71.3%) (Table 3.3.2).

Table 3.3.2 Distribution of patients by gender

| Gender | Year 2007 |      | Year 2008 |      | Total |      |
|--------|-----------|------|-----------|------|-------|------|
|        | No.       | %    | No.       | %    | No.   | %    |
| Male   | 29        | 28.2 | 29        | 29.3 | 58    | 28.7 |
| Female | 74        | 71.8 | 70        | 70.7 | 144   | 71.3 |

Figure 3.3.2 Distribution of patients by gender




### 3.3.3 Ethnic

Among patients with CLRCU seen at MOH Ophthalmology clinics, Malays were the majority.

Table 3.3.3 Distribution of patients by ethnicity

| Ethnic              | Year 2007 |      | Year 2008 |      | Total |      |
|---------------------|-----------|------|-----------|------|-------|------|
|                     | No.       | %    | No.       | %    | No.   | %    |
| Malay               | 74        | 71.8 | 68        | 68.7 | 142   | 70.3 |
| Chinese             | 18        | 17.5 | 16        | 16.2 | 34    | 16.8 |
| Indian              | 8         | 7.8  | 8         | 8.1  | 16    | 7.9  |
| Orang Asli          | 0         | 0    | 0         | 0    | 0     | 0    |
| Melanau             | 1         | 1    | 0         | 0    | 1     | 0.5  |
| Kadazan/Murut/Bajau | 1         | 1    | 5         | 5.1  | 6     | 3    |
| Iban                | 0         | 0    | 0         | 0    | 0     | 0    |
| Bidayuh             | 0         | 0    | 0         | 0    | 0     | 0    |
| Missing             | 1         | 1    | 2         | 2    | 3     | 1.5  |

Figure 3.3.3 Distribution of patients by ethnicity



### 3.4 DATA ON CONTACT LENS RELATED CORNEAL ULCER AT PRESENTATION

Bilateral eye involvement was seen in 6 cases in 2007 and 10 cases in 2008. (Table 3.4.1)

Table 3.4.1 Affected eye(s)

| No. of patients | Year 2007 |       | Year 2008 |       | Total |
|-----------------|-----------|-------|-----------|-------|-------|
|                 | No.       | %     | No.       | %     |       |
| Right           | 56        | 51.38 | 57        | 52.29 | 113   |
| Left eye        | 50        | 45.87 | 50        | 45.87 | 100   |
| Missing         | 3         | 2.75  | 2         | 1.84  | 5     |
| Total           | 109       | 100   | 109       | 100   | 202   |

Trauma was not a predisposing factor in the majority of cases. (Table 3.4.2)

Table 3.4.2 History of trauma

| History of trauma | Year 2007 |      | Year 2008 |      | Total |      |
|-------------------|-----------|------|-----------|------|-------|------|
|                   | No.       | %    | No.       | %    | No.   | %    |
| Yes               | 3         | 2.8  | 5         | 4.6  | 8     | 3.7  |
| No                | 104       | 95.4 | 99        | 90.8 | 203   | 93.1 |
| Missing           | 2         | 1.8  | 5         | 4.6  | 7     | 3.2  |


The majority of the contact lens-related corneal ulcers were seen among those who used monthly disposable contact lens. (Table 3.4.3)

Table 3.4.3 Types of contact lens worn at diagnosis

| No | Types of contact lens | Year 2007 |      | Year 2008 |      | Total |      |
|----|-----------------------|-----------|------|-----------|------|-------|------|
|    |                       | No.       | %    | No.       | %    | No.   | %    |
| 1  | Daily disposable      | 6         | 5.5  | 4         | 3.7  | 10    | 4.5  |
| 2  | Weekly disposable     | 1         | 0.9  | 1         | 0.9  | 2     | 0.9  |
| 3  | 2 weekly disposable   | 3         | 2.8  | 2         | 1.8  | 5     | 2.3  |
| 4  | Monthly disposable    | 92        | 84.4 | 84        | 77.1 | 176   | 79.6 |
| 5  | Extended wear         | 3         | 2.8  | 5         | 4.6  | 8     | 3.6  |
| 6  | Rigid gas permeable   | 0         | 0    | 0         | 0    | 0     | 0    |
| 7  | Others                | 5         | 4.6  | 6         | 5.5  | 11    | 5    |
| 8  | Missing               | 1         | 0.9  | 8         | 7.3  | 9     | 4.1  |

\*multiple checks were allowed for types of contact lens.

Figure 3.4.3 Types of contact lens worn at diagnosis




About a quarter of the cases failed to remove lens before sleep. (Table 3.4.4)

Table 3.4.4 Contact lens wearing pattern at diagnosis

| Wearing pattern | Year 2007 |      | Year 2008 |      | Total |      |
|-----------------|-----------|------|-----------|------|-------|------|
|                 | No        | %    | No        | %    | No    | %    |
| Daily wear      | 70        | 64.2 | 76        | 69.7 | 146   | 67.0 |
| Extended wear   | 32        | 29.4 | 26        | 23.9 | 58    | 26.6 |
| Missing         | 7         | 6.4  | 7         | 6.4  | 14    | 6.4  |

Figure 3.4.4 Contact lens wearing pattern at diagnosis




The most popular choice of contact lens cleaning solution among the cases were from Bausch and Lomb

Table 3.4.5 Types of cleaning solution used at diagnosis

| No | Types of cleaning solution       | Year 2007 |      | Year 2008 |      | Total |      |
|----|----------------------------------|-----------|------|-----------|------|-------|------|
|    |                                  | No        | %    | No        | %    | No.   | %    |
| 1  | Alcon                            | 4         | 3.7  | 4         | 3.7  | 8     | 3.5  |
| 2  | Bausch and Lomb                  | 24        | 22   | 17        | 15.6 | 41    | 18.1 |
| 3  | Allergan (AMO)                   | 12        | 11   | 4         | 3.7  | 16    | 7    |
| 4  | Ciba Vision                      | 0         | 0    | 4         | 3.7  | 4     | 1.8  |
| 5  | Opto-medic                       | 0         | 0    | 1         | 0.9  | 1     | 0.4  |
| 6  | Freskon                          | 3         | 2.8  | 2         | 1.8  | 5     | 2.2  |
| 7  | Sauflon                          | 2         | 1.8  | 7         | 6.4  | 9     | 4    |
| 8  | Multisoft                        | 1         | 0.9  | 2         | 1.8  | 3     | 1.3  |
| 9  | I-Gel                            | 4         | 3.7  | 3         | 2.8  | 7     | 3.1  |
| 10 | Medivue                          | 0         | 0    | 1         | 0.9  | 1     | 0.4  |
| 11 | Normal Saline                    | 4         | 3.7  | 8         | 7.3  | 12    | 5.3  |
| 12 | Simvue                           | 0         | 0    | 0         | 0    | 0     | 0    |
| 13 | Multimate                        | 1         | 0.9  | 1         | 0.9  | 2     | 0.9  |
| 14 | Pharmasafe Multipurpose solution | 3         | 2.8  | 1         | 0.9  | 4     | 1.8  |
| 15 | Tap water                        | 3         | 2.8  | 0         | 0    | 3     | 1.3  |
| 16 | Do not use because of daily wear | 1         | 0.9  | 1         | 0.9  | 2     | 0.9  |
| 17 | Not known                        | 25        | 22.9 | 31        | 28.4 | 56    | 24.7 |
| 18 | Others                           | 24        | 22   | 15        | 13.8 | 39    | 17.2 |
| 19 | Missing                          | 4         | 3.7  | 10        | 9.2  | 14    | 6.2  |

\*multiple checks were allowed for cleaning solution.

Figure 3.4.5 Types of cleaning solution used at diagnosis



About 1/3 of the cases had an unaided vision of 3/60 or worse at the time of presentation.

Table 3.4.6(a) Vision at presentation

| Presenting visual acuity | Unaided, 2007 |             | Best corrected, 2007 |             | Unaided, 2008 |             | Best Corrected, 2008 |             |
|--------------------------|---------------|-------------|----------------------|-------------|---------------|-------------|----------------------|-------------|
|                          | N=109         |             | N=109                |             | N=109         |             | N=109                |             |
|                          | No.           | %           | No.                  | %           | No.           | %           | No.                  | %           |
| • 6/5                    | 0             | 0           | 0                    | 0           | 0             | 0           | 0                    | 0           |
| • 6/6                    | 5             | 4.6         | 13                   | 11.9        | 2             | 1.8         | 5                    | 4.6         |
| • 6/9                    | 7             | 6.4         | 11                   | 10.1        | 5             | 4.6         | 14                   | 12.8        |
| • 6/12                   | 7             | 6.4         | 19                   | 17.4        | 6             | 5.5         | 14                   | 12.8        |
| <b>6/5 to 6/12</b>       | <b>19</b>     | <b>17.4</b> | <b>43</b>            | <b>39.4</b> | <b>13</b>     | <b>11.9</b> | <b>33</b>            | <b>30.3</b> |
| • 6/18                   | 11            | 10.1        | 10                   | 9.2         | 8             | 7.3         | 18                   | 16.5        |
| • 6/24                   | 14            | 12.8        | 6                    | 5.5         | 10            | 9.2         | 7                    | 6.4         |
| • 6/36                   | 6             | 5.5         | 2                    | 1.8         | 12            | 11          | 6                    | 5.5         |
| • 6/60                   | 7             | 6.4         | 2                    | 1.8         | 18            | 16.5        | 3                    | 2.8         |
| • 5/60                   | 1             | 0.9         | 0                    | 0           | 1             | 0.9         | 1                    | 0.9         |
| • 4/60                   | 3             | 2.8         | 1                    | 0.9         | 2             | 1.8         | 0                    | 0           |
| <b>6/18 to 4/60</b>      | <b>42</b>     | <b>38.5</b> | <b>21</b>            | <b>19.2</b> | <b>51</b>     | <b>46.8</b> | <b>35</b>            | <b>32.1</b> |
| • 3/60                   | 3             | 2.8         | 1                    | 0.9         | 3             | 2.8         | 2                    | 1.8         |
| • 2/60                   | 1             | 0.9         | 0                    | 0           | 2             | 1.8         | 0                    | 0           |
| • 1/60                   | 3             | 2.8         | 3                    | 2.8         | 0             | 0           | 0                    | 0           |
| • CF                     | 12            | 11          | 5                    | 4.6         | 7             | 6.4         | 1                    | 0.9         |
| • HM                     | 16            | 14.7        | 9                    | 8.3         | 14            | 12.8        | 12                   | 11          |
| • PL                     | 1             | 0.9         | 1                    | 0.9         | 5             | 4.6         | 2                    | 1.8         |
| • NPL                    | 0             | 0           | 0                    | 0           | 0             | 0           | 0                    | 0           |
| <b>3/60 or worse</b>     | <b>36</b>     | <b>33.1</b> | <b>19</b>            | <b>17.5</b> | <b>31</b>     | <b>28.4</b> | <b>17</b>            | <b>15.6</b> |
| Missing                  | 12            | 11          | 26                   | 23.9        | 14            | 12.9        | 24                   | 22          |

Figure 3.4.6(a) Vision at presentation, January-December 2007





Figure 3.4.6(b) Vision at presentation, January-December 2008




The initial clinical impression of the clinician as to the causative agent of the corneal ulcer was recorded as presumptive causative organism. Eighty seven percent of the cases were presumptively treated as bacterial corneal ulcer.

Table 3.4.7 Presumptive causative organism

| Presumptive causative organism | Year 2007 |      | Year 2008 |      | Total |      |
|--------------------------------|-----------|------|-----------|------|-------|------|
|                                | No.       | %    | No.       | %    | No.   | %    |
| Bacteria                       | 86        | 78.9 | 75        | 68.8 | 161   | 87   |
| Fungus                         | 2         | 1.8  | 9         | 8.3  | 11    | 5.9  |
| Acanthamoeba                   | 5         | 4.6  | 8         | 7.3  | 13    | 7.0  |
| Others                         | 4         | 3.7  | 2         | 1.8  | 6     | 3.2  |
| Missing                        | 14        | 12.8 | 19        | 17.4 | 33    | 17.8 |

\*multiple checks done to the presumptive causative organism were allowed.

Figure 3.4.7 Presumptive causative organism




Cornea scraping was performed in 80% of the eyes. The contact lens and contact lens cleaning solution were sent for microbiological examination in less than half of the cases.

Table 3.4.8 Types of Laboratory investigations

| No | Types of laboratory investigation | Year 2007 |      | Year 2008 |      | Total |      |
|----|-----------------------------------|-----------|------|-----------|------|-------|------|
|    |                                   | No.       | %    | No.       | %    | No.   | %    |
| 1  | Corneal scraping                  | 91        | 83.5 | 84        | 77.1 | 175   | 80.3 |
| 2  | Contact lens                      | 46        | 42.2 | 51        | 46.8 | 97    | 44.5 |
| 3  | Contact lens solution             | 46        | 42.2 | 45        | 41.3 | 91    | 41.7 |
| 4  | PCR for fungus                    | 3         | 2.8  | 2         | 1.8  | 5     | 2.3  |
| 5  | Not sent                          | 5         | 4.6  | 7         | 6.4  | 12    | 5.5  |
| 6  | Missing                           | 8         | 7.3  | 7         | 6.4  | 15    | 6.9  |

\*Multiple checks done to the types of laboratory investigation were allowed.

Figure 3.4.8 Types of Laboratory investigations



The rate of positive culture results for corneal scraping was 37.4% in 2007 and 36.9% in 2008. Bacteria were the most frequently isolated organism from cornea scraping, contact lens and contact lens solution. (Table 3.4.9) Pseudomonas was the most common bacterial isolate from corneal scraping, contact lens and contact lens solution. (Table 3.4.10)

Table 3.4.9 Results of laboratory investigations

|               | Year 2007        |      |              |      |                       |      | Year 2008        |      |              |      |                       |      |
|---------------|------------------|------|--------------|------|-----------------------|------|------------------|------|--------------|------|-----------------------|------|
|               | Corneal scraping |      | Contact lens |      | Contact lens solution |      | Corneal scraping |      | Contact lens |      | Contact lens solution |      |
|               | No.              | %    | No.          | %    | No.                   | %    | No.              | %    | No.          | %    | No.                   | %    |
| Bacteria      | 34               | 37.4 | 26           | 56.5 | 16                    | 34.8 | 31               | 36.9 | 16           | 31.4 | 12                    | 26.7 |
| Acanthamoeba  | 1                | 1.1  | 0            | 0    | 0                     | 0    | 0                | 0    | 0            | 0    | 0                     | 0    |
| Fungal        | 1                | 1.1  | 1            | 2.2  | 0                     | 0    | 2                | 2.4  | 2            | 3.9  | 0                     | 0    |
| Others        | 0                | 0    | 1            | 2.2  | 3                     | 6.5  | 1                | 1.2  | 3            | 5.9  | 1                     | 2.2  |
| Negative      | 46               | 50.5 | 13           | 28.3 | 17                    | 37   | 38               | 45.2 | 18           | 35.3 | 21                    | 46.7 |
| Missing data  | 4                | 4.4  | 1            | 2.2  | 2                     | 4.3  | 1                | 1.2  | 1            | 2    | 2                     | 4.4  |
| Not available | 7                | 7.7  | 5            | 10.9 | 9                     | 19.6 | 11               | 13.1 | 11           | 21.6 | 9                     | 20   |

\*Multiple checks were allowed for corneal scraping, contact lens and contact lens solution.

Figure 3.4.9(a) Results of laboratory investigations, January-December 2007




Figure 3.4.9(b) Results of laboratory investigations, January-December 2008




Table 3.4.10 Bacteria specify for each types of lab investigation

| Bacteria                  | Year 2007 |      | Year 2008 |      | Total |      |
|---------------------------|-----------|------|-----------|------|-------|------|
|                           | No.       | %    | No.       | %    | No.   | %    |
| Corneal scraping (n)      | 34        |      | 31        |      | 65    |      |
| Pseudomonas               | 27        | 79.4 | 28        | 90.3 | 55    | 84.6 |
| Enterobacter              | 3         | 8.8  | 0         | 0    | 3     | 1.3  |
| Staph. epidermidis        | 1         | 2.9  | 0         | 0    | 1     | 1.5  |
| Acinetobacter             | 1         | 2.9  | 0         | 0    | 1     | 1.5  |
| Serratia Marcescens       | 1         | 2.9  | 0         | 0    | 1     | 1.5  |
| Missing                   | 1         | 2.9  | 3         | 9.7  | 4     | 6.2  |
| Contact lens (n)          | 26        |      | 16        |      | 42    |      |
| Pseudomonas               | 20        | 76.9 | 16        | 100  | 36    | 85.7 |
| Enterobacter              | 3         | 11.5 | 0         | 0    | 3     | 7.1  |
| Klebsiella                | 1         | 3.8  | 0         | 0    | 1     | 2.4  |
| Burkholdenia cepacia      | 1         | 3.8  | 0         | 0    | 1     | 2.4  |
| Serratia Marcescens       | 1         | 3.8  | 0         | 0    | 1     | 2.4  |
| Contact lens solution (n) | 16        |      | 12        |      | 28    |      |
| Pseudomonas               | 13        | 81.3 | 12        | 100  | 25    | 89.3 |
| Enterobacter              | 1         | 6.3  | 0         | 0    | 1     | 3.6  |
| Klebsiella                | 1         | 6.3  | 0         | 0    | 1     | 3.6  |
| Coagulase negative        |           |      |           |      |       |      |
| Staphylococcal            | 1         | 6.3  | 0         | 0    | 1     | 3.6  |
| Serratia Marcescens       | 0         | 0    | 0         | 0    | 0     | 0    |

Table 3.4.11 Results of laboratory investigations (PCR)

|              | PCR, Year 2007 |      | PCR, Year 2008 |    |
|--------------|----------------|------|----------------|----|
|              | No.            | %    | No.            | %  |
| Detected     | 0              | 0    | 0              | 0  |
| Not detected | 1              | 33.3 | 1              | 50 |
| Not sent     | 0              | 0    | 1              | 50 |
| Missing      | 2              | 66.7 | 0              | 0  |

### 3.5 OUTCOME BY ONE MONTH AFTER PRESENTATION

About 30% had normal - corrected vision at one month after presentation (Table 3.5.1)

Table 3.5.1 Vision by one month

| Presenting Visual acuity | Year 2007<br>N=109 |              |                |            | Year 2008<br>N=109 |             |                |             |
|--------------------------|--------------------|--------------|----------------|------------|--------------------|-------------|----------------|-------------|
|                          | Unaided            |              | Best corrected |            | Unaided            |             | Best corrected |             |
|                          | No.                | %            | No.            | %          | No.                | %           | No.            | %           |
| • 6/5                    | 1                  | 0.9          | 0              | 0          | 0                  | 0           | 0              | 0           |
| • 6/6                    | 4                  | 3.7          | 22             | 20.2       | 2                  | 1.8         | 13             | 11.9        |
| • 6/9                    | 4                  | 3.7          | 11             | 10.1       | 3                  | 2.8         | 15             | 13.8        |
| • 6/12                   | 10                 | 9.2          | 3              | 2.8        | 4                  | 3.7         | 5              | 4.6         |
| <b>6/5 to 6/12</b>       | <b>19</b>          | <b>17.43</b> | <b>36</b>      | <b>33</b>  | <b>9</b>           | <b>8.3</b>  | <b>33</b>      | <b>30.3</b> |
| • 6/18                   | 8                  | 7.3          | 4              | 3.7        | 11                 | 10.1        | 7              | 6.4         |
| • 6/24                   | 10                 | 9.2          | 3              | 2.8        | 8                  | 7.3         | 2              | 1.8         |
| • 6/36                   | 9                  | 8.3          | 1              | 0.9        | 5                  | 4.6         | 0              | 0           |
| • 6/60                   | 16                 | 14.7         | 1              | 0.9        | 2                  | 1.8         | 0              | 0           |
| • 5/60                   | 2                  | 1.8          | 0              | 0          | 1                  | 0.9         | 0              | 0           |
| • 4/60                   | 0                  | 0            | 0              | 0          | 0                  | 0           | 0              | 0           |
| <b>6/18 to 3/60</b>      | <b>45</b>          | <b>41.3</b>  | <b>9</b>       | <b>8.3</b> | <b>27</b>          | <b>24.7</b> | <b>9</b>       | <b>8.3</b>  |
| • 3/60                   | 1                  | 0.9          | 0              | 0          | 0                  | 0           | 0              | 0           |
| • 2/60                   | 1                  | 0.9          | 0              | 0          | 0                  | 0           | 0              | 0           |
| • 1/60                   | 0                  | 0            | 0              | 0          | 1                  | 0.9         | 0              | 0           |
| • CF                     | 3                  | 2.8          | 1              | 0.9        | 3                  | 2.8         | 1              | 0.9         |
| • HM                     | 3                  | 2.8          | 2              | 1.8        | 2                  | 1.8         | 1              | 0.9         |
| • PL                     | 0                  | 0            | 0              | 0          | 2                  | 1.8         | 1              | 0.9         |
| • NPL                    | 0                  | 0            | 0              | 0          | 0                  | 0           | 0              | 0           |
| <b>3/60 or worse</b>     | <b>8</b>           | <b>7.3</b>   | <b>3</b>       | <b>2.8</b> | <b>8</b>           | <b>7.3</b>  | <b>3</b>       | <b>2.8</b>  |
| Missing                  | 37                 | 33.9         | 61             | 56         | 65                 | 59.6        | 64             | 58.7        |

Figure 3.5.1(a) Vision by one month, 2007





Figure 3.5.1(b) Vision by one month, 2008




Vision status was recorded from patients when both vision at presentation and vision at one month were available. Vision improved in 58.75% of the affected eyes. (Table 3.5.2)

Table 3.5.2 Vision outcomes from presentation to one month after presentation

| Vision outcomes | Year 2007 |      | Year 2008 |      | Total |       |
|-----------------|-----------|------|-----------|------|-------|-------|
|                 | No.       | %    | No.       | %    | No.   | %     |
| Improved        | 26        | 63.4 | 29        | 74.4 | 55    | 68.75 |
| Same            | 11        | 26.8 | 9         | 23.1 | 20    | 25    |
| Worsened        | 4         | 9.8  | 1         | 2.5  | 5     | 6.25  |

Figure 3.5.2 Vision Outcome- from presentation to one month after presentation



In 2008, three cases were complicated by corneal perforation. Two cases were managed by corneal gluing and one by penetrating keratoplasty.

Table 3.5.3 Patients requiring surgical intervention

| No | Surgical intervention    | Year 2007 |   | Year 2008 |     | Total |       |
|----|--------------------------|-----------|---|-----------|-----|-------|-------|
|    |                          | No        | % | No        | %   | No    | %     |
| 1  | Corneal perforation      | 0         | 0 | 3         | 2.8 | 3     | 50    |
| 2  | Penetrating keratoplasty | 0         | 0 | 1         | 0.9 | 1     | 16.67 |
| 3  | Eviseration              | 0         | 0 | 0         | 0   | 0     | 0     |
| 4  | Cornea gluing            | 0         | 0 | 2         | 1.8 | 2     | 33.33 |
| 5  | Other                    | 0         | 0 | 0         | 0   | 0     | 0     |

## **Chapter 4**

### **Glaucoma Registry**

#### **Contributing Editors**

**Dr Ong Poh Yan  
Dr Vivian Gong**

## CHAPTER 4 GLAUCOMA REGISTRY

### 4.1 INTRODUCTION

In 2009, a total of 23 SDPs, consisting of MOH ophthalmology departments collected data for the glaucoma registry. A total of 4481 patients were registered, 3952 (88.2%) were follow up cases and 503 (11.2%) new cases with 26 (0.6%) missing data.

### 4.2 CHARACTERISTICS OF PATIENTS

From the available data, the median age of patients was within the range of 60-69 years. There were 46% male and 54% female. Majority of patients were unemployed (77.4%). The proportion of patients registered differs from the national ethnic distributions; Chinese was the highest (41.5%), followed by Malays (36%), Indians (17.8%) and others (4.7%).

### 4.3 MEDICAL HISTORY

Of the patients registered, 67.7% have systemic co-morbidity. Hypertension and diabetes mellitus were among the most common (Refer Table 1). A total of 113 patients had family history of glaucoma and 55 patients had history of steroid usage.

Table 4.1: Distribution of medical co-morbidity

| Medical co-morbidity | No. of patient |
|----------------------|----------------|
| Diabetes             | 1546 (39.4%)   |
| Hypertension         | 1687 (43.0%)   |
| Hypercholesterolemia | 305 (7.8%)     |
| Cardiac disease      | 287 (7.3%)     |
| Stroke               | 45 (1.1%)      |
| Vasosapatic disease  | 18 (0.5%)      |
| Respiratory disease  | 33 (0.8%)      |

### 4.4 CLINICAL FEATURES

#### 4.4.1 Visual acuity

Among the eyes with recorded visual acuity, 5317 (65.9%) had vision of 6/12 or better, 1746 (21.6%) had low vision (6/18-4/60) while 604 (7.5%) were legally blind and 401 (5%) had no perception to light (Refer Table 2).

#### 4.4.2. Cup disc ratio

More than 76.4% of the eyes had cup disc ratio (CDR) of 0.5 or larger while 18.5% had an advanced stage of glaucomatous cupping (CDR of 0.9 and 1.0) (Refer Table 2).

Table 2: Distribution of visual acuity and cup disc ratio

| VA             | Cup disc ratio |     |     |     |     |     |     |     |     |     |              |         | Total eyes |
|----------------|----------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|--------------|---------|------------|
|                | 1              | 0.9 | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.1 | Undetermined | No view |            |
| 6/12 or better | 280            | 635 | 780 | 747 | 787 | 841 | 436 | 464 | 12  | 4   | 90           | 241     | 5317       |
| 6/18-4/60      | 107            | 227 | 217 | 214 | 296 | 265 | 164 | 163 | 13  | 1   | 31           | 51      | 1749       |
| 3/60-PL        | 51             | 82  | 80  | 78  | 92  | 69  | 56  | 56  | 0   | 0   | 14           | 26      | 604        |
| NPL            | 44             | 64  | 54  | 54  | 54  | 49  | 28  | 26  | 0   | 0   | 8            | 20      | 401        |

#### 4.4.3 Types of Glaucoma

Majority of the eyes (69.1%) had primary type of glaucoma with 10% having secondary glaucoma and 15.6% suspected to have glaucoma. Among the primary type of glaucoma, primary open angle glaucoma was the most common (67.5%) followed by primary angle closure glaucoma (15.5%), ocular hypertension (4.8%), primary angle closure (1.5%), primary angle closure suspect (0.8%) and others (9.9%). As for secondary type of glaucoma, the few common types of glaucoma were post-surgery (15.9%), pseudoexfoliative (14.9%), rubeotic (14.5%), post-trauma (11.7%), Steroid-induced (6.5%) and inflammatory (6%).

#### 4.5 MANAGEMENT OF GLAUCOMA

Medical treatment was the most common mode of management. The eyes were treated either as monotherapy or in combination. The most frequent eye drop prescribed was beta blockers, followed closely by prostaglandin analog and the others were topical CAI, alpha adrenergic and cholinergics (Refer Table 3).

Some eyes had procedures performed either in combination with medical treatment or as a single mode of management. The most common laser performed was laser iridotomy while trabeculectomy was the most frequent surgical operation performed. (Refer Table 4 and Table 5)

Table 4.3: Types of antiglaucoma agents prescribed

| Types of medication  | Right Eye    | Left Eye      |
|----------------------|--------------|---------------|
| Beta blockers        | 2565 (46.8%) | 2505 (46.7%)  |
| Prostaglandin analog | 1814 (33.1%) | 1786 (33.3 %) |
| Alpha adrenergic     | 159 (2.9%)   | 145 (2.7%)    |
| Topical CAI          | 822 (15%)    | 790 (14.7%)   |
| Cholinergics         | 82 (1.5%)    | 83 (1.6%)     |
| Systemic CAI         | 32 (0.6%)    | 40 (0.8%)     |
| Hyperosmotic agents  | 8 (0.1%)     | 6 (0.1%)      |
| Others               | 0            | 6 (0.1%)      |

Table 4: Types of laser procedures performed

| <b>Types of laser</b> | <b>RE (n=436 eyes)</b> | <b>LE (n=407 eyes)</b> |
|-----------------------|------------------------|------------------------|
| Laser iridotomy       | 366 (83.9%)            | 358 (88%)              |
| Laser iridoplasty     | 13 (3.0%)              | 10 (2.4%)              |
| laser trabeculoplasty | 16 (3.7%)              | 12 (2.9%)              |
| TSCPC                 | 34 (7.8%)              | 21 (5.2%)              |
| Endocyclodiode laser  | 2 (0.5%)               | 0                      |
| Others                | 5 (1.1%)               | 6 (1.5%)               |

Table 5: Types of surgical procedures performed

| <b>Types of laser</b>   | <b>RE (n=412 eyes)</b> | <b>LE (n=409 eyes)</b> |
|-------------------------|------------------------|------------------------|
| Trabeculectomy          | 304 (73.8%)            | 301 (73.6%)            |
| Drainage device         | 9 (2.2%)               | 9 (2.2%)               |
| Needling                | 3 (0.7%)               | 4 (1.0%)               |
| Non penetrating surgery | 1 (0.2%)               | 2 (0.5%)               |
| Cryotherapy             | 2 (0.5%)               | 3 (0.7)                |
| Surgical PI             | 30 (7.3%)              | 31 (7.6%)              |
| Trabeculotomy           | 10 (2.4%)              | 13 (3.2%)              |
| Goniotomy               | 0                      | 0                      |
| Others                  | 53 (12.9%)             | 46 (11.2%)             |

## **Chapter 5**

# **Age Related Macular Degeneration Registry**

**Contributing Editor**

**Dr Tara Mary George**

## CHAPTER 5 AGE RELATED MACULAR DEGENERATION REGISTRY

### Introduction

The AMD Registry commenced in August 2008. This data is from the initial period from August 2008 till June 2009 and is a pilot study that contains data on 52 AMD patients with 104 eyes who were seen for the first time at the Medical Retina unit of Hospital Selayang. The mean age of patients was 65.6 years and the mean duration of symptoms was 15.4 months. About thirty-eight percent (38.5%) of eyes of AMD cases presented with VA of 6/5 – 6/12, 23.1% presented with VA 6/24 -3/60 and another 38.5% presented with VA 3/60 or worse. Of these, 50% of eyes had exudative AMD of which 27.2% had disciform scars. Central geographic atrophy was present in 8.6 % of eyes, 14.8 % eyes had polypoidal choroidal vasculopathy and 18.5% eyes had active choroidal neovascularisation.

AMD Registry results show that majority of patients present late to the tertiary referral centre. This indicates that the public awareness on the importance of symptoms of AMD should be emphasized so that patients may be treated at an earlier stage.

### 5.1 PATIENTS DEMOGRAPHY

Table 5.1.1 Demography

| Age, years          |  | N=52 |      |
|---------------------|--|------|------|
| Mean                |  | 65.6 |      |
| SD                  |  | 10.2 |      |
| Median              |  | 68   |      |
| Minimum             |  | 42   |      |
| Maximum             |  | 86   |      |
| Age group, years    |  | No.  | %    |
| Less than 40 yrs    |  | 0    | 0    |
| 40-49 yrs           |  | 5    | 9.6  |
| 50-59 yrs           |  | 8    | 15.4 |
| 60-69 yrs           |  | 22   | 42.3 |
| 70-79 yrs           |  | 13   | 25   |
| 80-89 yrs           |  | 4    | 7.7  |
| >90 yrs             |  | 0    | 0    |
| Gender              |  |      |      |
| Male                |  | 28   | 53.8 |
| Female              |  | 24   | 46.2 |
| Ethnicity           |  |      |      |
| Malay               |  | 23   | 44.2 |
| Chinese             |  | 21   | 40.4 |
| Indian              |  | 7    | 13.5 |
| Orang Asli          |  | 0    | 0    |
| Melanau             |  | 0    | 0    |
| Kadazan/Murut/Bajau |  | 0    | 0    |
| Bidayuh             |  | 0    | 0    |
| Iban                |  | 0    | 0    |
| Other               |  | 1    | 1.9  |
| Missing             |  | 0    | 0    |

### 5.12 Affected eye

|                     | Right eye only |      | Left eye only |      | Both eyes |      |
|---------------------|----------------|------|---------------|------|-----------|------|
|                     | No             | %    | No            | %    | No        | %    |
| No of patients      | 6              | 11.6 | 15            | 28.8 | 31        | 59.6 |
| Total affected eyes | 83             |      |               |      |           |      |

## 5.2 RISK FACTORS

Table 5.2.1 Risk factors by person

|                      | N=52 |      |
|----------------------|------|------|
|                      | No   | %    |
| None                 | 15   | 28.8 |
| DM                   | 14   | 26.9 |
| HPT                  | 22   | 42.3 |
| Past Stroke          | 1    | 1.9  |
| IHD                  | 6    | 11.5 |
| Hypercholesterolemia | 6    | 11.5 |
| Smoking –yes         | 15   | 28.8 |
| Current smoker       | 2    | 13.3 |
| Past smoker          | 7    | 46.7 |

Table 5.2.2 Risk factors in the affected eye

|   | n |
|---|---|
| Had cataract surgery within last 3 months | 1 |
| Eyes with myopia                          | 4 |
| Degree of myopia                          |   |
| < 2d                                      | 0 |
| 2 to 8D                                   | 0 |
| > 8D                                      | 2 |
| Missing                                   | 2 |

## 5.3 QUALITY OF LIFE

Table 5.3 Quality of Life that may be related with the problem

|   | N  | %    |
|---|----|------|
| Currently driving   | 23 | 50   |
| Currently driving and have difficulty during daytime in familiar time | 9  | 39.1 |
| Currently not driving   | 23 | 50   |
| Reason for not driving  |    |      |
| 1) never drive  | 14 | 60.9 |
| 2) gave up because of poor eye sight                                  | 2  | 8.7  |
| 3) others   | 0  | 0    |
| Difficulty reading ordinary print in newspaper                        | 29 | 63   |

## 5.4 MEDICAL HISTORY

Table 5.4 Ocular History of the affected eye

|   | N=82 |      |
|---|------|------|
|   | No   | %    |
| Metamorphopsia                                    | 20   | 16.3 |
| Scotoma   | 34   | 27.6 |
| Blurring of vision                                | 55   | 44.7 |
| Metamorphopsia only                               | 3    | 2.4  |
| Metamorphopsia and scotoma                        | 3    | 2.4  |
| Metamorphopsia and scotoma and blurring of vision | 8    | 6.5  |
| Duration of symptoms (month)                      |      |      |
| Mean  | 34   |      |
| Maximum   | 55   |      |
| Minimum   | 3    |      |

Each eye may have more than one symptom

## 5.5 VISION STATUS

Table 5.6(b) Status of vision in the affected eyes

|                       | Unaided |       | With glasses/ pin hole |       |
|-----------------------|---------|-------|------------------------|-------|
|                       | No      | %     | No                     | %     |
| 6/5                   | 0       | 0.0   | 0                      | 0.0   |
| 6/6                   | 4       | 4.8   | 1                      | 1.2   |
| 6/9                   | 2       | 2.4   | 8                      | 9.6   |
| 6/12                  | 4       | 4.8   | 8                      | 9.6   |
| 6/5 to 6/12           | 10      | 12.05 | 17                     | 20.48 |
| 6/18                  | 7       | 8.4   | 8                      | 9.6   |
| 6/24                  | 11      | 13.3  | 8                      | 9.6   |
| 6/36                  | 8       | 9.6   | 6                      | 7.2   |
| 6/60                  | 7       | 8.4   | 3                      | 3.6   |
| 5/60                  | 2       | 2.4   | 0                      | 0.0   |
| 4/60                  | 0       | 0.0   | 0                      | 0.0   |
| 3/60                  | 1       | 1.2   | 0                      | 0.0   |
| 6/18 to 3/60          | 36      | 43.4  | 25                     | 30.1  |
| 2/60                  | 1       | 1.2   | 1                      | 1.2   |
| 1/60                  | 0       | 0.0   | 0                      | 0.0   |
| CF                    | 23      | 27.7  | 3                      | 3.6   |
| HM                    | 4       | 4.8   | 0                      | 0.0   |
| PL                    | 0       | 0.0   | 0                      | 0.0   |
| NPL                   | 1       | 1.2   | 0                      | 0.0   |
| 2/60 to NPL           | 29      | 34.9  | 4                      | 4.8   |
| Unable to take vision | 8       | 9.6   | 37                     | 44.6  |
| All                   | 83      | 100   | 83                     | 100   |

Table 5.6(c) Status of unaided vision in the affected eyes, by age

| Visual Acuity(VA)     | Age group (in yrs) |       |       |       |     |       |               |       |
|-----------------------|--------------------|-------|-------|-------|-----|-------|---------------|-------|
|                       | 40-59              |       | 60-79 |       | >80 |       | All age group |       |
|                       | No.                | %     | No.   | %     | No. | %     | No.           | %     |
| 6/5                   | 0                  | 0.0   | 0     | 0.0   | 0   | 0.0   | 0             | 0.0   |
| 6/6                   | 3                  | 15.0  | 0     | 0.0   | 1   | 14.3  | 4             | 4.8   |
| 6/9                   | 1                  | 5.0   | 1     | 0.2   | 0   | 0.0   | 2             | 2.4   |
| 6/12                  | 2                  | 10.0  | 2     | 0.4   | 0   | 0.0   | 4             | 4.8   |
| 6/5 to 6/12           | 6                  | 30.0  | 3     | 0.5   | 1   | 14.3  | 10            | 12.0  |
| 6/18                  | 1                  | 5.0   | 6     | 10.7  | 0   | 0.0   | 7             | 8.4   |
| 6/24                  | 2                  | 10.0  | 8     | 14.3  | 1   | 14.3  | 11            | 13.3  |
| 6/36                  | 0                  | 0.0   | 7     | 12.5  | 1   | 14.3  | 8             | 9.6   |
| 6/60                  | 3                  | 15.0  | 4     | 7.1   | 0   | 0.0   | 7             | 8.4   |
| 5/60                  | 0                  | 0.0   | 2     | 3.6   | 0   | 0.0   | 2             | 2.4   |
| 4/60                  | 0                  | 0.0   | 0     | 0.0   | 0   | 0.0   | 0             | 0.0   |
| 3/60                  | 0                  | 0.0   | 1     | 1.8   | 0   | 0.0   | 1             | 1.2   |
| 6/18 to 3/60          | 6                  | 30.0  | 28    | 50.0  | 2   | 28.6  | 36            | 43.4  |
| 2/60                  | 0                  | 0.0   | 1     | 1.8   | 0   | 0.0   | 1             | 1.2   |
| 1/60                  | 0                  | 0.0   | 0     | 0.0   | 0   | 0.0   | 0             | 0.0   |
| CF                    | 3                  | 15.0  | 16    | 28.6  | 4   | 57.1  | 23            | 27.7  |
| HM                    | 1                  | 5.0   | 3     | 5.4   | 0   | 0.0   | 4             | 4.8   |
| PL                    | 0                  | 0.0   | 0     | 0.0   | 0   | 0.0   | 0             | 0.0   |
| NPL                   | 0                  | 0.0   | 1     | 1.8   | 0   | 0.0   | 1             | 1.2   |
| 2/60 to NPL           | 4                  | 20.0  | 21    | 37.5  | 4   | 57.1  | 29            | 34.9  |
| Unable to take vision | 4                  | 20.0  | 4     | 7.1   | 0   | 0.0   | 8             | 9.6   |
| Total patients        | 20                 | 100.0 | 56    | 100.0 | 7   | 100.0 | 83            | 100.0 |

Table 5.6(d) Fundus examination

|   | Affected Eyes<br>N=83 |       |
|---|-----------------------|-------|
|   | No                    | %     |
| Exudative AMD                             | 52                    | 23.4  |
| Non-exudative AMD                         | 27                    | 12.2  |
| Presence of soft drusen                   | 26                    | 11.7  |
| Presence of hard drusen                   | 33                    | 14.9  |
| Presence of Central Geographic Atrophy    | 11                    | 5.0   |
| Presence of Pigment Epithelial Detachment | 27                    | 12.2  |
| Presence of Subretinal Haemorrhage        | 23                    | 10.4  |
| Presence of Disciform scar                | 23                    | 10.4  |
| Total findings seen in affected eyes      | 222                   | 100.0 |

## 5.7 INVESTIGATION

Table 5.7(a) OCT findings in the affected eyes

| OCT Findings                          | Affected Eye<br>N=83 |      |
|---------------------------------------|----------------------|------|
|                                       | N                    | %    |
| Subretinal fluid                      | 24                   | 28.9 |
| Pigment Epithelial detachment         | 27                   | 32.5 |
| Others                                | 18                   | 21.7 |
| Total affected eyes with OCT findings | 69                   |      |

Table: 5.7(b) FFA findings in the affected eyes

| FFA Findings            | Affected eyes with FFA done<br>N=20 |      |
|-------------------------|-------------------------------------|------|
| Had CNV                 | 18                                  |      |
| Had Scar                | 6                                   |      |
| Had PED                 | 2                                   |      |
| For those with CNV      | N=18                                |      |
| Type of CNV             | N                                   | %    |
| • Classic               | 6                                   | 33.3 |
| • Minimally classic     | 1                                   | 5.6  |
| • Predominantly classic | 0                                   | 0.0  |
| • Occult                | 8                                   | 44.4 |
| • Missing               | 3                                   | 16.7 |
| Location of CNV         | N                                   | %    |
| • Subfoveal CNV         | 2                                   | 11.1 |
| • Juxtafoveal CNV       | 3                                   | 16.7 |
| • Extrafoveal CNV       | 2                                   | 11.1 |
| • Missing               | 11                                  | 61.1 |

Table 5.7(c) ICG findings in the affected eyes

| Eyes with ICG Done | Affected eyes<br>n=14 |      |
|--------------------|-----------------------|------|
| ICG findings       | N                     | %    |
| • Polyps           | 10                    | 71.4 |
| • Plaque           | 0                     | 0.0  |
| • No abnormality   | 4                     | 28.6 |

## 5.8 DIAGNOSIS

Table 5.8.1 Diagnosis

| Diagnosis                                    | Affected Eye N=83 |        |
|--|-------------------|--------|
|  | N                 | %      |
| Early AMD                                    | 14                | 15.91  |
| Intermediate AMD                             | 9                 | 10.23  |
| Advanced AMD: Geographical Atrophy           | 7                 | 7.95   |
| Advanced AMD: Disciform Scar                 | 21                | 23.86  |
| Polyopoidal choroidal vasculopathy(PCV)      | 12                | 13.64  |
| Choroidal Neurovascularization(CNV):Active   | 15                | 17.05  |
| Choroidal Neurovascularization(CNV): Treated | 3                 | 3.41   |
| Others                                       | 7                 | 7.95   |
| Total *                                      | 88                | 100.00 |

The total exceeds 83, as there are eyes with more than one diagnosis

Table 5.8.2 Distribution of diagnosis of affected eyes, by age

| Age group   | 40-60 |      | 61-80 |      | >80 |      | All age group |      |
|---|-------|------|-------|------|-----|------|---------------|------|
| Diagnosis   | No.   | %    | No.   | %    | No. | %    | No.           | %    |
| Early AMD   | 5     | 21.7 | 9     | 15.8 | 0   | 0    | 14            | 15.9 |
| Intermediate AMD                                    | 2     | 8.7  | 6     | 10.5 | 1   | 12.5 | 9             | 10.2 |
| Advanced AMD:<br>Geographical Atrophy               | 1     | 4.3  | 5     | 8.8  | 1   | 12.5 | 7             | 8    |
| Advanced AMD:<br>Disciform Scar                     | 1     | 4.3  | 17    | 29.8 | 3   | 37.5 | 21            | 23.9 |
| Polyopoidal choroidal<br>vasculopathy(PCV)          | 6     | 26.1 | 5     | 8.8  | 1   | 12.5 | 12            | 13.6 |
| Choroidal<br>Neurovascularization<br>(CNV):Active   | 4     | 17.4 | 10    | 17.5 | 1   | 12.5 | 15            | 17   |
| Choroidal<br>Neurovascularization<br>(CNV): Treated | 1     | 4.3  | 2     | 3.5  | 0   | 0    | 3             | 3.4  |
| Others  | 3     | 13   | 3     | 5.3  | 1   | 12.5 | 7             | 8    |
| Total   | 23    | 100  | 57    | 100  | 8   | 100  | 88            | 100  |

Table 5.8.3 Risk factors by diagnosis

| DIAGNOSIS                                     | Affected eyes               |      |     |      |             |     |     |     |                      |     |         |      |                  |     |        |      |
|---|-----------------------------|------|-----|------|-------------|-----|-----|-----|----------------------|-----|---------|------|------------------|-----|--------|------|
|   | Proportion with Risk factor |      |     |      |             |     |     |     |                      |     |         |      |                  |     |        |      |
|   | DM                          |      | HPT |      | Past Stroke |     | IHD |     | Hypercholesterolemia |     | Smoking |      | Cataract Surgery |     | Myopia |      |
|   | No.                         | %    | No. | %    | No.         | %   | No. | %   | No.                  | %   | No.     | %    | No.              | %   | No.    | %    |
| Early AMD                                     | 3                           | 14.3 | 3   | 8.1  | 0           | 0   | 0   | 0   | 0                    | 0   | 0       | 0.0  | 0                | 0   | 1      | 14.3 |
| Intermediate AMD                              | 1                           | 4.8  | 7   | 18.9 | 0           | 0   | 1   | 20  | 3                    | 30  | 6       | 23.1 | 0                | 0   | 1      | 14.3 |
| Advanced AMD: Geographical Atrophy            | 3                           | 14.3 | 3   | 8.1  | 0           | 0   | 0   | 0   | 1                    | 10  | 3       | 11.5 | 0                | 0   | 0      | 0.0  |
| Advanced AMD: Disciform Scar                  | 2                           | 9.5  | 9   | 24.3 | 0           | 0   | 1   | 20  | 3                    | 30  | 7       | 26.9 | 0                | 0   | 3      | 42.9 |
| Polyopoidal choroidal vasculopathy (PCV)      | 3                           | 14.3 | 7   | 18.9 | 1           | 100 | 1   | 20  | 0                    | 0   | 3       | 11.5 | 0                | 0   | 0      | 0.0  |
| Choroidal Neurovascularization (CNV);Active   | 7                           | 33.3 | 4   | 10.8 | 0           | 0   | 2   | 40  | 3                    | 30  | 5       | 19.2 | 0                | 0   | 0      | 0.0  |
| Choroidal Neurovascularization (CNV); Treated | 1                           | 4.8  | 1   | 2.7  | 0           | 0   | 0   | 0   | 0                    | 0   | 1       | 3.8  | 1                | 100 | 0      | 0.0  |
| Others  | 1                           | 4.8  | 3   | 8.1  | 0           | 0   | 0   | 0   | 0                    | 0   | 1       | 3.8  | 0                | 0   | 2      | 28.6 |
| Total   | 21                          | 100  | 37  | 100  | 1           | 100 | 5   | 100 | 10                   | 100 | 26      | 100  | 1                | 100 | 7      | 100  |

Table 5.8.4 Diagnosis based on OCT findings

| DIAGNOSIS                                   | Affected eyes<br>OCT findings |      |                               |       |        |      |
|---|-------------------------------|------|-------------------------------|-------|--------|------|
|   | Sub retinal fluid             |      | Pigment Epithelial detachment |       | Others |      |
|   | N                             | %    | N                             | %     | N      | %    |
| Early AMD                                   | 0                             | 0.0  | 0                             | 0.0   | 5      | 27.8 |
| Intermediate AMD                            | 2                             | 8.3  | 6                             | 22.2  | 1      | 5.6  |
| Advanced AMD: Geographical Atrophy          | 0                             | 0.0  | 1                             | 3.7   | 3      | 16.7 |
| Advanced AMD: Disciform Scar                | 4                             | 16.7 | 6                             | 22.2  | 6      | 33.3 |
| Polyopoidal choroidal vasculopathy (PCV)    | 7                             | 29.2 | 5                             | 18.5  | 0      | 0.0  |
| Choroidal Neovascularization (CNV):Active   | 10                            | 41.7 | 8                             | 29.6  | 0      | 0.0  |
| Choroidal Neovascularization (CNV): Treated | 0                             | 0.0  | 0                             | 0.0   | 2      | 11.1 |
| Others                                      | 1                             | 4.2  | 1                             | 3.7   | 1      | 5.6  |
| Total                                       | 24                            | 100  | 27                            | 100.0 | 18     | 100  |

## 5.9 TREATMENTS

Table 5.9.1 Treatment

| Type of treatment         | Affected Eye n= 83 |      |
|---------------------------|--------------------|------|
|                           | N                  | %    |
| No treatment given        | 54                 | 65.1 |
| Treatment given           | 28                 | 33.7 |
| Missing                   | 1                  | 1.2  |
| Type of treatment         | n=28               |      |
| PDT                       | 7                  | 25.0 |
| Anti VEGF                 | 10                 | 35.7 |
| PDT+ Anti VEGF            | 2                  | 7.1  |
| Intravitral triamcinolone | 0                  | 0.0  |
| Argon Laser               | 4                  | 14.3 |
| Others                    | 5                  | 17.9 |

Table 5.9.2 Treatment in affected eyes, by age

| Age Group                  | 40-49 |       | 50-59 |       | 60-69 |       | 70-79 |       | 80-89 |      |
|----------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|------|
| Type of treatment          | No    | %     | No    | %     | No    | No    | %     | No    | %     | No   |
| PDT                        | 6     | 66.7  | 7     | 41.2  | 24    | 61.5  | 13    | 46.4  | 4     | 50   |
| Anti VEGF                  | 2     | 22.2  | 5     | 29.4  | 10    | 25.6  | 8     | 28.6  | 3     | 37.5 |
| PDT+ Anti VEGF             | 1     | 11.1  | 3     | 17.6  | 2     | 5.1   | 1     | 3.6   | 0     | 0    |
| Intra vitral triamcinolone | 0     | 0.0   | 2     | 11.8  | 2     | 5.1   | 5     | 17.9  | 1     | 12.5 |
| Argon Laser                | 0     | 0.0   | 0     | 0.0   | 1     | 2.6   | 1     | 3.6   | 0     | 0    |
| Others                     | 0     | 0.0   | 0     | 0.0   | 0     | 0.0   | 0     | 0.0   | 0     | 0    |
| Total                      | 9     | 100.0 | 17    | 100.0 | 39    | 100.0 | 28    | 100.0 | 8     | 100  |

Table 5.9.2 Treatment by age

| Type of treatment           | Right             |    |       |      |       |      |       |      |       |      |       |      |     |    |   |   |
|-----------------------------|-------------------|----|-------|------|-------|------|-------|------|-------|------|-------|------|-----|----|---|---|
|                             | Age group(in yrs) |    |       |      |       |      |       |      |       |      |       |      |     |    |   |   |
|                             | < 40              |    | 40-49 |      | 50-59 |      | 60-69 |      | 70-79 |      | 80-89 |      | >89 |    |   |   |
| No                          | %                 | No | %     | No   | %     | No   | %     | No   | %     | No   | %     | No   | %   | No | % |   |
| PDT                         | 0                 | 0  | 2     | 66.7 | 4     | 66.7 | 14    | 87.5 | 4     | 44.4 | 2     | 66.7 | 0   | 0  | 0 | 0 |
| Anti VEGF                   | 0                 | 0  | 1     | 33.3 | 2     | 33.3 | 2     | 12.5 | 5     | 55.6 | 1     | 33.3 | 0   | 0  | 0 | 0 |
| PDT+ Anti VEGF              | 0                 | 0  | 1     | 33.3 | 1     | 16.7 | 1     | 6.3  | 1     | 11.1 | 0     | 0    | 0   | 0  | 0 | 0 |
| Intra vitreal triamcinolone | 0                 | 0  | 0     | 0    | 1     | 16.7 | 1     | 6.3  | 2     | 22.2 | 0     | 0    | 0   | 0  | 0 | 0 |
| Argon Laser                 | 0                 | 0  | 0     | 0    | 0     | 0    | 0     | 0    | 1     | 11.1 | 0     | 0    | 0   | 0  | 0 | 0 |
| Others                      | 0                 | 0  | 0     | 0    | 0     | 0    | 0     | 0    | 0     | 0    | 0     | 0    | 0   | 0  | 0 | 0 |

| Type of treatment           | Left              |    |       |    |       |      |       |      |       |    |       |    |     |    |   |   |
|-----------------------------|-------------------|----|-------|----|-------|------|-------|------|-------|----|-------|----|-----|----|---|---|
|                             | Age group(in yrs) |    |       |    |       |      |       |      |       |    |       |    |     |    |   |   |
|                             | < 40              |    | 40-49 |    | 50-59 |      | 60-69 |      | 70-79 |    | 80-89 |    | >89 |    |   |   |
| No                          | %                 | No | %     | No | %     | No   | %     | No   | %     | No | %     | No | %   | No | % |   |
| PDT                         | 0                 | 0  | 4     | 80 | 3     | 50   | 10    | 55.6 | 9     | 75 | 2     | 50 | 0   | 0  | 0 | 0 |
| Anti VEGF                   | 0                 | 0  | 1     | 20 | 3     | 50   | 8     | 44.4 | 3     | 25 | 2     | 50 | 0   | 0  | 0 | 0 |
| PDT+ Anti VEGF              | 0                 | 0  | 0     | 0  | 2     | 33.3 | 1     | 5.6  | 0     | 0  | 0     | 0  | 0   | 0  | 0 | 0 |
| Intra vitreal triamcinolone | 0                 | 0  | 0     | 0  | 1     | 16.7 | 1     | 5.6  | 3     | 25 | 1     | 25 | 0   | 0  | 0 | 0 |
| Argon Laser                 | 0                 | 0  | 0     | 0  | 0     | 0    | 1     | 5.6  | 0     | 0  | 0     | 0  | 0   | 0  | 0 | 0 |
| Others                      | 0                 | 0  | 0     | 0  | 0     | 0    | 0     | 0    | 0     | 0  | 0     | 0  | 0   | 0  | 0 | 0 |

## **Chapter 6**

### **Retinoblastoma Registry**

**Contributing Editor  
Dr Jamalia Rahmat**

## CHAPTER 6 RETINOBLASTOMA REGISTRY

The Retinoblastoma (RB) registry was introduced in November 2008. It started with a retrospective data collection of retinoblastoma patients seen in Hospital Kuala Lumpur, a tertiary referral centre for retinoblastoma from 2005 till 2008.

### 6.1 STOCK AND FLOW

Among the 24 patients registered, 12 were diagnosed in 2007.

Table 6.1 Stock and flow

| Year | No. of confirmed Retinoblastoma Cases |      |
|------|---------------------------------------|------|
|      | No.                                   | %    |
| 2005 | 2                                     | 50   |
| 2006 | 5                                     | 45.5 |
| 2007 | 12                                    | 92.3 |
| 2008 | 5                                     | 83.3 |

### 6.2 PATIENTS DEMOGRAPHY

The mean age at presentation was 2.19 years. The youngest age at presentation was 1 month and the oldest was 5.5 years. About half (45.8%) of these patients were in the age group of 13 to 24 months. There were more boys (70.8%) than girls affected, and the majority were of Malay ethnicity (62.5%), followed by Chinese (12.5%) and Indians (8.3%).

Table 6.2(a) Distribution of patients by age

| Age, years          | N=24 |      |
|---------------------|------|------|
| Mean                | 2.2  |      |
| SD                  | 1.4  |      |
| Median              | 1.8  |      |
| Minimum             | 0.08 |      |
| Maximum             | 5.5  |      |
| Age group, years    | No.  | %    |
| <12months           | 3    | 12.5 |
| 13months - 24months | 11   | 45.8 |
| 25months – 36months | 4    | 16.7 |
| 37months – 48months | 4    | 16.7 |
| 49months – 60months | 1    | 4.2  |
| > 60months          | 1    | 4.2  |

Table 6.2(b) Distribution of patients by gender

| Gender | No | %     |
|--------|----|-------|
| Male   | 17 | 70.83 |
| Female | 7  | 29.17 |

Table 6.3c Distribution of patients by ethnicity

| <b>Ethnicity</b>      | <b>No</b> | <b>%</b> |
|-----------------------|-----------|----------|
| Malay                 | 15        | 62.5     |
| Chinese               | 3         | 12.5     |
| Indian                | 2         | 8.3      |
| Orang Asli            | 1         | 4.2      |
| Melanau               | 0         | 0        |
| Kadazan/ Murut/ Bajau | 0         | 0        |
| Iban                  | 0         | 0        |
| Bidayuh               | 0         | 0        |
| Others                | 3         | 12.5     |

### 6.3 OCULAR HISTORY AND PRESENTATION

The most common feature at presentation was leukocoria. Majority (30.4%) presented between 13 to 24 months of age and 73.9% with 7 to 12 months of history.

Table 6.3.1 Clinical presentation

| <b>Presentation</b> | <b>Number</b> | <b>%</b> |
|---------------------|---------------|----------|
| Leukocoria          | 22            | 91.7     |
| Strabismus          | 2             | 8.3      |
| Proptosis           | 3             | 12.5     |
| Others              | 2             | 8.3      |

Table 6.3.2 Age of onset


|                     | <b>Months (N=23)</b> |          |
|---------------------|----------------------|----------|
| Min                 | 1                    |          |
| Max                 | 53                   |          |
| Mean                | 19.35                |          |
|                     | <b>No</b>            | <b>%</b> |
| Less than 6 months  | 4                    | 17.4     |
| 6 to 12 months      | 5                    | 21.7     |
| 13 to 24 months     | 7                    | 30.4     |
| 24 to 36 months     | 4                    | 17.4     |
| 37 to 48 months     | 2                    | 8.7      |
| More than 48 months | 1                    | 4.3      |

The mean duration of disease from onset of symptoms to presentation was 5.4 months with the majority (73.9%) within 1 to 6 months.

Table 6.3.3 Duration of disease at the time of presentation

|                     | <b>Months (N=23)</b> |          |
|---------------------|----------------------|----------|
| Min                 | 1                    |          |
| Max                 | 17                   |          |
| Mean                | 5.4                  |          |
|                     | <b>No</b>            | <b>%</b> |
| Less than 1 month   | 0                    | 0        |
| 1 to 6 months       | 17                   | 73.9     |
| 7 to 12 months      | 4                    | 17.4     |
| More than 12 months | 2                    | 8.70     |

Figure 6.3.3 Duration of disease at the time of presentation



Of the 24 patients registered, five of them have both eyes affected (20.8%); thus a total of 29 eyes with retinoblastoma.

Five patients (20.8%) presented with bilateral retinoblastoma. Twelve were right eyes and 16 were left eyes.

Table 6.3.4 Eyes affected

|                     | No   | % based on total eyes affected |
|---------------------|------|--------------------------------|
| Right eye only      | 12   | 41.4                           |
| Left eye only       | 17   | 58.6                           |
| Total eyes affected | N=29 |                                |

All patients had no positive family history of retinoblastoma.

Table 6.3.5 Family history of RB

|                | No | %   |
|----------------|----|-----|
| Yes            | 0  | 0   |
| No             | 24 | 100 |
| Missing        | 0  | 0   |
| Total patients | 24 | 100 |

Most eyes were blind at presentation.

Table 6.3.6 Vision Presentation

|                     | No | %     |
|---------------------|----|-------|
| VA better than 6/12 | 1  | 3.4   |
| 6/18 to 3/60        | 7  | 24.1  |
| Worse than 3/60     | 18 | 62.1  |
| Missing             | 3  | 10.3  |
| Total eyes          | 29 | 100.0 |


## 6.4 INVESTIGATION AND CLASSIFICATION

Twenty-three patients; three patients with binocular RB, had CT scan and one patient had MRI done at diagnosis. Based on the CT scan findings, all of the 26 eyes had presence of mass, 24 eyes (92.3%) had calcifications and 5 eyes (19.2%) showed evidence of extraocular extension through CT scan. Two-thirds (65.52%) of the patients presented with Group E Retinoblastoma (based on International Intraocular Retinoblastoma Classification- IIRC)

Table 6.4 Classification of Retinoblastoma based on International Intraocular retinoblastoma Classification (IIRC)

|            | Right eye | % based on right eye | Left eye | % based on left eye | Total in each group | Based on total right and left eye |
|------------|-----------|----------------------|----------|---------------------|---------------------|-----------------------------------|
|            | No        | %                    | No       | %                   | No                  | %                                 |
| Group A    | 1         | 8.3                  | 0        | 0                   | 1                   | 3.4                               |
| Group B    | 0         | 0                    | 0        | 0                   | 0                   | 0                                 |
| Group C    | 1         | 8.3                  | 0        | 0                   | 1                   | 3.4                               |
| Group D    | 4         | 33.3                 | 1        | 5.9                 | 5                   | 17.2                              |
| Group E    | 6         | 50                   | 13       | 76.5                | 19                  | 65.5                              |
| Total eyes | 12        | 100                  | 17       | 100                 | 29                  | 100                               |

Figure 6.4 Classification of Retinoblastoma based on International Intraocular retinoblastoma Classification (IIRC)



## 6.5 MANAGEMENT

Nineteen (76%) of patients had enucleation of the affected eye. Eleven patients (45.8%) had systemic chemotherapy. Two patients had subtenon injection of chemotherapy together with systemic chemotherapy. Focal therapy was given together with chemoreduction. There were no patients who had focal therapy only. No patient had radiotherapy.

Table 6.5 Chemotherapy by patient

|                                     | No of patient | %    |
|-------------------------------------|---------------|------|
| Had Chemotherapy                    | 11            | 45.8 |
| If had chemotherapy                 |               |      |
| • Systemic chemotherapy             | 10            | 90.9 |
| • Subtenon injection                | 2             | 18.2 |
| • Intraviteal injection             | 0             | 0    |
| Those who had Systemic chemotherapy |               |      |
| • Mean cycles given                 | 7.6           |      |
| • Minimum cycle                     | 5             |      |
| • Maximum cycle                     | 9             |      |

### Comment

The RB registry is still new. At present, only patients seen in Hospital Kuala Lumpur are in the registry. We hope to include all patients seen in MOH Ophthalmology departments into the registry.

## **Chapter 7**

### **Ophthalmology Service Census**

#### **Contributing Editors**

**Dr Mariam Ismail  
Dr Goh Pik Pin  
Dr Radzlian Othman  
Dr Elias Hussein**

## CHAPTER 7 OPHTHALMOLOGY SERVICE CENSUS

The census were returned by hard copy form at the end of each year from 2002 to 2006. For 2007 and 2008, census data were entered monthly by the hospitals. Real time online reports both aggregated and by hospitals are available from 2007 onwards.

Table 7.1: Number of ophthalmology departments which have census return

| Year                                | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 |
|-------------------------------------|------|------|------|------|------|------|------|
| Number of Ophthalmology departments | 29   | 32   | 32   | 32   | 34   | 36   | 36   |

Figure 7.1: Number of out-patients visits at Ophthalmology clinics, 2002-2008




Figure 7.2: Number of in- patients admitted to eye wards, 2002-2008





Figure 7.3: Number of ocular operation\* performed, 2002-2008



\*Ocular operations include surgery performed in operating theatre with grade B and C as classified in Fee Acts 1951.

Figure 7.4 Number of cataract surgeries, ECCEs and phacoemulsification performed, 2002-2008




Figure 7.5: Trend of cataract surgeries performed using phacoemulsification and ECCE technique, 2002 to 2008




Figure 7.6: Diabetic patients seen at ophthalmology clinics, 2002-2008




Figure 7.7: Proportion of new patients at eye clinics who came for diabetic eye screening, 2002-2008




Figure 7.8: Number of vitreo-retinal surgery performed at hospitals with vitreoretinal surgeons, 2002-2008




Figure 7.9: Number of refractions performed at ophthalmology clinics, 2002-2008




Figure 7.10: Number of patients with low vision assessments, 2002-2007




Figure 7.11: Number of premature infants screened for retinopathy of prematurity screening, 2002-2008





Figure 7.12: Rate of post- cataract surgery endophthalmitis, 2003-2008



## **Appendix: Case Report Forms**

Office use:  /   
Centre

i) Hospital / Clinic: \_\_\_\_\_ ii) Date : 

|   |   |   |   |   |   |
|---|---|---|---|---|---|
| d | d | m | m | y | y |
|---|---|---|---|---|---|

|  |                              |                         |  |                               |  |                                  |  |   |  |                               |  |  |  |  |  |   |  |   |  |  |  |  |  |         |  |        |  |          |  |         |  |  |  |
|--|------------------------------|-------------------------|--|-------------------------------|--|----------------------------------|--|---|--|-------------------------------|--|--|--|--|--|---|--|---|--|--|--|--|--|---------|--|--------|--|----------|--|---------|--|--|--|
| <b>*1. Patient Name :</b>  |                              |                         |  |                               |  |                                  |  |   |  |                               |  |  |  |  |  |   |  |   |  |  |  |  |  |         |  |        |  |          |  |         |  |  |  |
| <b>*2. Identification Card Number :</b>  |                              | MyKad / MyKid:          |  |                               |  |                                  |  |   |  |                               |  |  |  |  |  |   |  |   |  |  |  |  |  |         |  |        |  |          |  | Old IC: |  |  |  |
| If MyKad/MyKid is not available, please complete the Old IC or Other ID document No. |                              | Other ID document No:   |  |                               |  |                                  |  |   |  |                               |  |  |  |  |  | → |  | Specify type (eg.passport, armed force ID): |  |  |  |  |  |         |  |        |  |          |  |         |  |  |  |
|  |                              | Postcode :              |  |                               |  |                                  |  |   |  | Town / City:                  |  |  |  |  |  |   |  |   |  |  |  |  |  |         |  | State: |  |          |  |         |  |  |  |
| <b>*4a. Date of Birth:</b>   |                              |                         |  |                               |  |                                  |  |   |  |                               |  | <b>*4b. Age at notification:</b> (Auto Calculated)<br>(in years) or (in months if <1 yr old) |  |  |  |   |  |   |  |  |  |  |  | year(s) |  |        |  | month(s) |  |         |  |  |  |
| <b>*5. Gender:</b>   | <input type="radio"/> Male   | <b>6. Ethnic Group:</b> |  | <input type="radio"/> Malay   |  | <input type="radio"/> Indian     |  | <input type="radio"/> Melanau             |  | <input type="radio"/> Iban    |  | <input type="radio"/> Other, specify :   |  |  |  |   |  |   |  |  |  |  |  |         |  |        |  |          |  |         |  |  |  |
|  | <input type="radio"/> Female |                         |  | <input type="radio"/> Chinese |  | <input type="radio"/> Orang Asli |  | <input type="radio"/> Kadazan/Murut/Bajau |  | <input type="radio"/> Bidayuh |  |  |  |  |  |   |  |   |  |  |  |  |  |         |  |        |  |          |  |         |  |  |  |

| <b>*1. Surgery On:</b>   |   |
|--|---|
| <input type="radio"/> First eye<br><input type="radio"/> Second eye →  | Date of first eye surgery: _____<br><br>Intra-op complications: <input type="radio"/> Yes <input type="radio"/> No                          |
| <b>2. Past Ocular Surgery of the Eye to be operated</b>  |   |
| <input type="checkbox"/> None<br><input type="checkbox"/> Vitreoretinal Surgery<br><input type="checkbox"/> Penetrating Keratoplasty | <input type="checkbox"/> Filtering Surgery<br><input type="checkbox"/> Pterygium Excision<br><input type="checkbox"/> Other, specify: _____ |

| <b>3. Cause Of Cataract</b>   |   |
|---|---|
| <input type="radio"/> Primary <span style="background-color: #cccccc; padding: 2px 5px; font-weight: bold;">OR</span>   | <input type="radio"/> Secondary   |
| <div style="background-color: #cccccc; padding: 2px 5px; font-weight: bold; margin-bottom: 5px;">a) If primary:</div> <input type="radio"/> Senile/age related<br><input type="radio"/> Congenital<br><input type="radio"/> Developmental<br><input type="radio"/> Other, _____ | <div style="background-color: #cccccc; padding: 2px 5px; font-weight: bold; margin-bottom: 5px;">b) If Secondary:</div> <input type="radio"/> Trauma<br><input type="radio"/> Drug Induced<br><input type="radio"/> Surgery Induced<br><input type="radio"/> Other, _____ |

|  |  |
|--|--|
| <p><b>a) ANTERIOR SEGMENT:</b></p> <p><input type="checkbox"/> Pterygium involving the cornea</p> <p><input type="checkbox"/> Corneal Opacity</p> <p><input type="checkbox"/> Glaucoma</p> <p><input type="checkbox"/> Chronic Uveitis</p> <p><input type="checkbox"/> Pseudoexfoliation</p> <p><b>Lens Related Complication</b></p> <p><input type="checkbox"/> Phacomorphic</p> <p><input type="checkbox"/> Phacolytic</p> <p><input type="checkbox"/> Subluxated / Dislocated</p> | <p><b>c) POSTERIOR SEGMENT:</b></p> <p><b>Diabetic Retinopathy</b></p> <p><input type="checkbox"/> Non Proliferative Diabetic Retinopathy</p> <p><input type="checkbox"/> Proliferative Diabetic Retinopathy</p> <p><input type="checkbox"/> Maculopathy</p> <p><input type="checkbox"/> Vitreous haemorrhage</p> <p><input type="checkbox"/> ARMD</p> <p><input type="checkbox"/> Other macular disease (includes hole or scar)</p> <p><input type="checkbox"/> Optic nerve disease, any type</p> <p><input type="checkbox"/> Retinal detachment</p> <p><input type="checkbox"/> Cannot be assessed</p> |
| <p><b>b) MISCELLANEOUS:</b></p> <p><input type="checkbox"/> Amblyopia</p> <p><input type="checkbox"/> Significant previous eye trauma</p> <p><input type="checkbox"/> Pre-existing non glaucoma field defect (eg. CVA)</p>   | <p><input type="checkbox"/> Other ocular comorbidity, specify:</p> <p>_____</p>  |

☐ None
 ☐ Renal Failure  
☐ Hypertension
 ☐ Cerebrovascular accident  
☐ Diabetes Mellitus
 ☐ COAD / Asthma  
☐ Ischaemic Heart Disease  
☐ Other, specify:

| Vision                    |       | a) Right   |       | b) Left  |  |
|---------------------------|-------|--|-------|--|--|
| *Unaided :                |       |  |       |  |  |
| With glasses / Pin Hole : |       |  |       |  |  |
| Refracted :               |       |  |       |  |  |
| Refraction :              | Sp:   |  + <input type="text"/> <input type="text"/><br> - <input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/> | Sp:   |  + <input type="text"/> <input type="text"/><br> - <input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/> |  |
|                           | Cy:   | - <input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/>  | Cy:   | - <input type="text"/> <input type="text"/> . <input type="text"/> <input type="text"/>  |  |
|                           | Axis: | <input type="text"/> <input type="text"/> <input type="text"/>   | Axis: | <input type="text"/> <input type="text"/> <input type="text"/>   |  |

|                          |  |            |             |                       |  |  |  |
|--------------------------|--|------------|-------------|-----------------------|--|--|--|
| 1. Date of admission :   | <div> <div>d</div> <div>d</div> <div>m</div> <div>m</div> <div>y</div> <div>y</div> </div> |            |             | 2. Date of Operation: | <div> <div>d</div> <div>d</div> <div>m</div> <div>m</div> <div>y</div> <div>y</div> </div> |  |  |
| 3. Operation :           | Eye  | Type       | Anaesthesia | Team / doctor         |  |  |  |
|                          | <input type="radio"/> Right <input type="radio"/> Left                                     |            |             |                       |  |  |  |
| 4. IOL details :         | Power  | A-Constant | Brand       |                       |  |  |  |
|                          |  |            |             |                       |  |  |  |
| 5. Pre-op Instructions : |  |            |             |                       |  |  |  |

|                       |   |  |  |  |
|-----------------------|---|--|--|--|
| <input type="radio"/> | + |  |  |  |
| <input type="radio"/> | - |  |  |  |

# CATARACT SURGERY REGISTRY (CSR) : OPERATIVE RECORD

**Instruction:** Where check boxes ☐ are provided, check (✓) one or more boxes. Where radio buttons ☐ are provided, check (✓) one box only. \* indicates compulsory field.

|             |  |  |  |
|-------------|--|--|--|
| Office use: |  |  |  |
| Centre:     |  |  |  |

i) Hospital / Clinic :

ii) Patient Name

|                                   |  |   |
|-----------------------------------|--|---|
| iii) Identification Card Number : | MyKad / MyKid: <div style="display: flex; gap: 5px;"> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> </div> | Old IC: <div style="border: 1px solid black; width: 100px; height: 20px;"></div>                                      |
| Other ID document No:             | <div style="border: 1px solid black; width: 150px; height: 20px;"></div>   | Specify type (eg. passport, armed force ID): <div style="border: 1px solid black; width: 150px; height: 20px;"></div> |

If MyKad/MyKid is not available, please complete the Old IC or Other ID document No.

## SECTION 1 : OPERATIVE DATA

1a. Surgeon status: ☐ Specialist ☐ Gazetting specialist ☐ Medical officer

\*3. Date Of Cataract Operation(dd/mm/yy):  /  /

\*1b. Name of Surgeon: \_\_\_\_\_

4a. Time: Start:  (24 hours)

2. Type of Admission: ☐ Day Care ☐ Not Day Care

End:  (24 hours)

4b. Duration of cataract operation: 

auto calculated

| 5. SURGERY   | 6. ANAESTHESIA  | 7. IOL  |
|--|---|---|
| <p><b>*a) Operated Eye:</b></p> <p><input type="radio"/> Right</p> <p><input type="radio"/> Left</p> <p><b>*b) Type:</b></p> <p><input type="radio"/> Phaco</p> <p><input type="radio"/> ECCE</p> <p><input type="radio"/> Phaco converted to ECCE</p> <p><input type="radio"/> ICCE</p> <p><input type="radio"/> Lens aspiration</p> <p><input type="radio"/> Other, specify: _____</p> <p><b>c) Combined:</b></p> <p>(check <input type="checkbox"/> one or more boxes below if perform)</p> <p><input type="checkbox"/> Pterygium surgery</p> <p><input type="checkbox"/> Filtering surgery</p> <p><input type="checkbox"/> Vitreo-retinal surgery</p> <p><input type="checkbox"/> Penetrating Keratoplasty</p> <p><input type="checkbox"/> Other, specify: _____</p> | <p><b>a) Type of Anaesthesia:</b></p> <p><input type="radio"/> General <input type="radio"/> Local</p> <p style="text-align: center;">↓<br/>If local</p> <p>(check <input type="checkbox"/> one or more boxes below)</p> <p><b>(i) Type:</b></p> <p><input type="checkbox"/> Retrobulbar</p> <p><input type="checkbox"/> Peribulbar</p> <p><input type="checkbox"/> Subtenon</p> <p><input type="checkbox"/> Subconjunctival</p> <p><input type="checkbox"/> Facial block</p> <p><input type="checkbox"/> Topical</p> <p><input type="checkbox"/> Intracameral</p> <p><b>(ii) Type of sedation:</b></p> <p><input type="checkbox"/> None</p> <p><input type="checkbox"/> Oral</p> <p><input type="checkbox"/> Intravenous</p> <p><input type="checkbox"/> Intramuscular</p> | <p><b>*a) IOL:</b></p> <p>If Yes -&gt;</p> <p><input type="radio"/> Posterior chamber IOL</p> <p><input type="radio"/> Anterior chamber IOL</p> <p><input type="radio"/> Scleral fixated PCIOL</p> <p><input type="radio"/> IOL planned, but not implanted</p> <p>If No -&gt;</p> <p><input type="radio"/> No IOL was planned or implanted</p> <p><input type="radio"/> Other, specify: _____</p> <p><b>b) Material:</b></p> <p><input type="radio"/> PMMA</p> <p><input type="radio"/> Silicone</p> <p><input type="radio"/> Acrylic → <div style="display: inline-block; border: 1px solid black; padding: 2px; margin-left: 10px;"> <input type="checkbox"/> Hydrophobic <input type="checkbox"/> Hydrophilic         </div></p> <p><input type="radio"/> Other, specify: _____</p> <p><b>c) Type:</b></p> <p><input type="radio"/> Foldable</p> <p><input type="radio"/> Non-Foldable</p> |

**\*8. Intra-Operative Complications** (check ☐ one or more boxes below if present)

- ☐ None
- ☐ Posterior capsule rupture
- ☐ Vitreous Loss
- ☐ Zonular dehiscence
- ☐ Drop nucleus
- ☐ Suprachoroidal haemorrhage
- ☐ Central corneal oedema
- ☐ Other, specify: \_\_\_\_\_

|             |  |  |
|-------------|--|--|
| Office use: |  |  |
| Centre:     |  |  |

# NATIONAL EYE DATABASE (NED)

Office use:  /  Centre:

## MONTHLY OPHTHALMOLOGY SERVICE CENSUS , MOH

Instruction : Please complete the census form by end of each month.

1. Hospital :

2. Month / Year :

Date(dd/mm/yy):

### Section 1 : Outpatient

|  |     |
|--|-----|
| 1. Total Number of Outpatients :   |     |
| 2. Total Number of New Cases :   |     |
| 3. Total Number of Follow Up Cases :   |     |
| 4. Ratio of New Cases vs. Follow Up Cases<br>(auto calculate) : ((3) / (2)) 1: (3/2) | 1 : |
| 5. Total Number of Children Screened for ROP :                                       |     |
| 6. Total Number of Specialists :   |     |
| 7. Ratio of Specialist to Outpatients<br>(auto calculate): ((1) / (6)) 1: (1/6)      | 1 : |

### Section 2 : Inpatient

|  |  |
|--|--|
| 1. Total Number of Inpatients :                                      |  |
| 2. Total Number of Emergency Admission :                             |  |
| 3. Total Number of Elective Admission<br>(auto calculate): (1) - (2) |  |

### Section 3 : Operation

|  |  |
|--|--|
| 1. Total Number of Operations<br>(Category B and C as in Akta Fi 1951) :                   |  |
| 2. Total Number of Vitreoretinal Surgery :   |  |
| 3. Total Number of Corneal Transplant :  |  |
| 4. Total Number of Glaucoma Surgery :  |  |
| 5. Number of Cases With Infectious Endophthalmitis<br>Following Intraocular Surgery :      |  |
| 6. Number of Intraocular Surgeries (excluding<br>surgery for penetrating injury):          |  |
| 7. Percent of post-operative infectious<br>endophthalmitis (auto calculate):((5)/(6)*100%) |  |

### Section 4 : Cataract Service

|  |      |
|--|------|
| 1. Total Number of Cataract Surgery :  |      |
| 2. Total Number of Phacoemulsification :   |      |
| 3. Total Number of ECCE :  |      |
| 4. Total Number of Lens Aspiration :   |      |
| 5. Number of Cataract Surgery in Adults :  |      |
| 6. Number of Cataract Surgery in Adults<br>Performed as Day Care Surgery :                         |      |
| 7. Percentage of Day Care Cataract Surgery in<br>Adult (auto calculate): ((6) / (5)*100)           |      |
| 8. Waiting Time for Cataract Surgery :   | week |
| 9. Total Number of Cataract Surgeons :   |      |
| 10. Ratio of Cataract Surgeon to Number<br>of Cataract Surgery (auto calculate): ((1)/(9)) 1:(1/9) | 1 :  |

### Section 5 : Diabetic Service

|  |  |
|--|--|
| 1. Total Number of New Diabetic Cases Referred : |  |
| 2. Total Number of Diabetic Follow Up cases :    |  |

### Section 6 : Glaucoma Service

|  |    |
|--|----|
| 1. Total Number of New Glaucoma Cases Seen :   |    |
| 2. Total Number of Follow Up Glaucoma Cases Seen:  |    |
| 3. Amount of Glaucoma Drug Prescribed<br>(end of year only)  | RM |
| 4. Total Amount of Ophthalmic Drug Budget :<br>(end of year only)                                    | RM |
| 5. Percentage of Glaucoma Drug Prescribed:<br>(auto calculate): ((3) / (4) * 100) (end of year only) |    |

( SECTION 7- SECTION 11: For centres with this subspecialty service only)

### Section 7 : Vitreo-Retina (VR) Service

|  |  |
|--|--|
| 1. Total Number of New VR Cases Seen :       |  |
| 2. Total Number of Follow Up VR Cases Seen : |  |
| 3. Total Number of VR Surgery Performed :    |  |

### Section 8 : Cornea Service

|  |  |
|--|--|
| 1. Total Number of New Cornea Cases Seen :       |  |
| 2. Total Number of Follow Up Cornea Cases Seen : |  |
| 3. Total Number of Cornea Surgery Performed :    |  |

### Section 9 : Paediatric Ophthalmology Service

|   |  |
|---|--|
| 1. Total Number of New Paediatric Ophthalmology<br>Cases Seen :       |  |
| 2. Total Number of Follow Up Paediatric Ophthalmology<br>Cases Seen : |  |
| 3. Total Number of Paediatric Ophthalmology Surgery<br>Performed :    |  |

### Section 10 : Oculoplastic Service

|   |  |
|---|--|
| 1. Total Number of New Oculoplasty Cases Seen :       |  |
| 2. Total Number of Follow Up Oculoplasty Cases Seen : |  |
| 3. Total Number of Oculoplasty Surgery Performed :    |  |

### Section 11 : Medical Retina Service

|  |  |
|--|--|
| 1. Total number of New Uveitis cases :       |  |
| 2. Total number of Follow Up Uveitis cases : |  |
| 3. Total number of New ARMD cases :          |  |
| 4. Total number of Follow Up ARMD cases :    |  |

### Section 12 : Optometry Service

|   |     |
|---|-----|
| 1. Total Number of Refraction :   |     |
| 2. Total Number of Optometrists :   |     |
| 3. Ratio of Optometrists to Number of Refractions<br>(auto calculate) : ((1)/(2)) 1:(1/2) | 1 : |
| 4. Total Number of Patients With Low Vision<br>(BCVA worse than 6/18 in both eyes) :      |     |
| 5. Total Number of Patients With Blindness (BCVA<br>worse than 3/60 in both eyes) :       |     |
| 6. Total Number of Cases Seen at Low Vision Clinic :                                      |     |
| 7. Total Number of Low Vision Aids Prescribed :   |     |

### Section 13 : Public Health Ophthalmology

| 1. Number of Primary Eye Care (PEC)<br>Training Courses Conducted | No. of<br>Courses | No. of<br>Participants |
|---|-------------------|------------------------|
| a. Medical officers :   |                   |                        |
| b. Paramedic :  |                   |                        |
| c. Jururawat Masyarakat :   |                   |                        |
| 2. Number of CME<br>Session for Dept :                            | a. Doctors :      |                        |
|   | b. Paramedics :   |                        |
| 3. Number of Warga Tua Clinic :                                   |                   |                        |
| 4. Number of District Visit :                                     |                   |                        |
| 5. Number of Screening Programmes :                               |                   |                        |
| 6. Number of Outreach Programmes :                                |                   |                        |

|   |   |
|---|---|
| <b>NATIONAL EYE DATABASE (NED)</b>                | Office use: <span style="border: 1px solid black; display: inline-block; width: 50px; height: 15px;"></span> / <span style="border: 1px solid black; display: inline-block; width: 50px; height: 15px;"></span> Centre: <span style="border: 1px solid black; display: inline-block; width: 100px; height: 15px;"></span> |
| <b>MONTHLY OPHTHALMOLOGY SERVICE CENSUS , MOH</b> |   |

Instruction : Please complete the census form by end of each month.

|                   |   |   |   |   |   |   |
|-------------------|---|---|---|---|---|---|
| 1. Hospital :     |   |   |   |   |   |   |
| 2. Month / Year : | <div style="border: 1px solid black; width: 20px; height: 20px; display: flex; align-items: center; justify-content: center;"> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> </div> | <div style="border: 1px solid black; width: 20px; height: 20px; display: flex; align-items: center; justify-content: center;"> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> </div> | <div style="border: 1px solid black; width: 20px; height: 20px; display: flex; align-items: center; justify-content: center;"> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> </div> | <div style="border: 1px solid black; width: 20px; height: 20px; display: flex; align-items: center; justify-content: center;"> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> </div> | <div style="border: 1px solid black; width: 20px; height: 20px; display: flex; align-items: center; justify-content: center;"> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> </div> | <div style="border: 1px solid black; width: 20px; height: 20px; display: flex; align-items: center; justify-content: center;"> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> <div style="width: 10px; height: 10px; border: 1px solid black;"></div> </div> |
|                   | Date(dd/mm/yy):   |   |   |   |   |   |

**Section 1 : Outpatient**

|   |     |
|---|-----|
| 1. Total Number of Outpatients :  |     |
| 2.Total Number of New Cases :   |     |
| 3. Total Number of Follow Up Cases :  |     |
| 4. Ratio of New Cases to Follow Up Cases<br>(auto calculate) : ((3) / (2)) 1: (3/2) | 1 : |
| 5. Total Number of Children Screened for ROP :                                      |     |
| 6. Total Number of Specialists :  |     |
| 7. Ratio of Specialist to Outpatients<br>(auto calculate): ((1) / (6)) 1: (1/6)     | 1 : |

**Section 2 : Inpatient**

|  |  |
|--|--|
| 1. Total Number of Inpatients :                                      |  |
| 2. Total Number of Emergency Admission :                             |  |
| 3. Total Number of Elective Admission<br>(auto calculate): (1) - (2) |  |

**Section 3 : Operation**

|  |  |
|--|--|
| 1. Total Number of Operations<br>(Category B and C as in Akta Fi 1951) : |  |
| 2. Total Number of Vitreoretinal Surgery :                               |  |
| 3. Total Number of Corneal Transplant :                                  |  |
| 4. Total Number of Glaucoma Surgery :                                    |  |

**Section 4 : Cataract Service**

|   |   |
|---|---|
| 1. Total Number of Cataract Surgery :   |   |
| 2. Total Number of Phacoemulsification :  |   |
| 3. Total Number of ECCE :   |   |
| 4. Total number of ICCE :   |   |
| 5. Total number of Lens Aspiration :  |   |
| 6. Total number of other cataract surgery :   |   |
| 7. Number of cases with Infectious Endophthalmitis following cataract surgery :         |   |
| 8. Rate of post-cataract surgery infectious endophthalmitis (Auto-calculated = 7/1*100) | % |

**Section 5 : Diabetic Service**

|  |  |
|--|--|
| 1. Total Number of New Diabetic Cases Referred : |  |
| 2. Total Number of Diabetic Follow Up cases :    |  |

**Section 6 : Glaucoma Service**

|  |    |
|--|----|
| 1. Total Number of New Glaucoma Cases Seen :   |    |
| 2. Total Number of Follow Up Glaucoma Cases Seen:  |    |
| 3. Total Amount of Glaucoma Drug Prescribed<br>(end of year only)                                    | RM |
| 4. Total Amount of Ophthalmic Drug Budget :<br>(end of year only)                                    | RM |
| 5. Percentage of Glaucoma Drug Prescribed:<br>(auto calculate): ((3) / (4) * 100) (end of year only) |    |

( SECTION 7- SECTION 11: For centres with this subspecialty service only)

**Section 7 : Vitreo-Retina (VR) Service**

|  |  |
|--|--|
| 1. Total Number of New VR Cases Seen :       |  |
| 2. Total Number of Follow Up VR Cases Seen : |  |
| 3. Total Number of VR Surgery Performed :    |  |

**Section 8 : Cornea Service**

|  |  |
|--|--|
| 1. Total Number of New Cornea Cases Seen :       |  |
| 2. Total Number of Follow Up Cornea Cases Seen : |  |
| 3. Total Number of Cornea Surgery Performed :    |  |

**Section 9 : Paediatric Ophthalmology Service**

|  |  |
|--|--|
| 1. Total Number of New Paediatric Ophthalmology Cases Seen :       |  |
| 2. Total Number of Follow Up Paediatric Ophthalmology Cases Seen : |  |
| 3. Total Number of Paediatric Ophthalmology Surgery Performed :    |  |

**Section 10 : Oculoplastic Service**

|   |  |
|---|--|
| 1. Total Number of New Oculoplasty Cases Seen :       |  |
| 2. Total Number of Follow Up Oculoplasty Cases Seen : |  |
| 3. Total Number of Oculoplasty Surgery Performed :    |  |

**Section 11 : Medical Retina Service**

|  |  |
|--|--|
| 1. Total number of New Uveitis cases :       |  |
| 2. Total number of Follow Up Uveitis cases : |  |
| 3. Total number of New ARMD cases :          |  |
| 4. Total number of Follow Up ARMD cases :    |  |

**Section 12 : Optometry Service**

|   |     |
|---|-----|
| 1. Total Number of Optometrists :   |     |
| 2. Total Number of Refraction :   |     |
| 3. Ratio of Optometrists to Number of Refractions<br>(auto calculate) : ((2)/(1)) 1:(2/1)   | 1 : |
| 4. Total number of contact lens patients seen :   |     |
| 5. Orthoptic assessment :   |     |
| 6. Other Visual Function Test :<br>( including all types of visual fields, color vision, Hess chart, A scan, contrast sensitivity, corneal topography, HRT,GDX,OCT, diabetic eye screening, visual assessment in children and electrophysiology tests etc.) |     |
| 7. Total Number of Patients Seen at Low Vision Clinic :   |     |
| 8. Total Number of Low Vision Aids Prescribed :   |     |

**Section 13 : Public Health Ophthalmology**

| 1. Number of Primary Eye Care (PEC) Training Courses Conducted | No. of Courses  | No. of Participants |
|--|-----------------|---------------------|
| a. Medical officers :  |                 |                     |
| b. Paramedic :   |                 |                     |
| c. Jururawat Masyarakat :                                      |                 |                     |
| 2. Number of CME Session for Dept :                            | a. Doctors :    |                     |
|  | b. Paramedics : |                     |
| 3. Number of Warga Tua Clinic :                                |                 |                     |
| 4. Number of District Visit :                                  |                 |                     |
| 5. Number of Screening Programmes :                            |                 |                     |
| 6. Number of Outreach Programmes :                             |                 |                     |

Office use:  /   
Centre:

Where check boxes ☐ are provided, check (✓) one or more boxes. Where radio buttons ☐ are provided, check (✓) one box only. \* indicates compulsory field.

**\*i) Hospital / Clinic:** \_\_\_\_\_ **\*ii) Dr in charge :** \_\_\_\_\_

|  |  |   |  |                   |  |  |  |  |  |  |  |   |   |  |  |   |   |  |  |  |  |  |  |                                      |  |         |  |                                      |         |  |  |  |  |  |  |
|--|--|---|--|-------------------|--|--|--|--|--|--|--|---|---|--|--|---|---|--|--|--|--|--|--|--------------------------------------|--|---------|--|--------------------------------------|---------|--|--|--|--|--|--|
| <b>*1. Patient Name :</b>  |  |   |  |                   |  |  |  |  |  |  |  |   |   |  |  |   |   |  |  |  |  |  |  |                                      |  |         |  |                                      |         |  |  |  |  |  |  |
| <b>*2. Identification Card Number :</b><br><i>If MyKad/MyKid is not available, please complete the Old IC or Other ID document No.</i> |  | MyKad / MyKid:  |  |                   |  |  |  |  |  |  |  |   | - |  |  |   | - |  |  |  |  |  |  |                                      |  |         |  |                                      | Old IC: |  |  |  |  |  |  |
|  |  | Other ID document No:   |  |                   |  |  |  |  |  |  |  |   |   | ➔  |  | Specify type (eg.passport, armed force ID):   |   |  |  |  |  |  |  |                                      |  |         |  |                                      |         |  |  |  |  |  |  |
| <b>*3. Address :</b>   |  | Postcode :  |  |                   |  |  |  |  |  |  |  | Town / City:  |   |  |  |   |   |  |  |  |  |  |  | State:                               |  |         |  |                                      |         |  |  |  |  |  |  |
| <b>*4a. Date of Birth:</b>   |  | <div> <div>d</div> <div>d</div> <div>m</div> <div>m</div> <div>y</div> <div>y</div> </div>  |  |                   |  |  |  |  |  |  |  |   |   | <b>*4b. Age at presentation:</b>               |  |   |   |  |  |  |  |  |  | <div> <div></div> <div></div> </div> |  | year(s) |  | <div> <div></div> <div></div> </div> |         | month(s)   |  |  |  |  |  |
| <b>*5. Gender:</b>   |  | <input type="radio"/> Male<br><input type="radio"/> Female  |  | <b>6. Ethnic:</b> |  | <input type="radio"/> Malay<br><input type="radio"/> Chinese |  | <input type="radio"/> Indian<br><input type="radio"/> Orang Asli |  | <input type="radio"/> Melanau<br><input type="radio"/> Kadazan/Murut/Bajau |  | <input type="radio"/> Iban<br><input type="radio"/> Bidayuh |   | <input type="radio"/> Other, specify:<br>_____ |  |   |   |  |  |  |  |  |  |                                      |  |         |  |                                      |         |  |  |  |  |  |  |
| <b>7. Source of referral :</b>   |  | <input type="radio"/> Government OPD clinic / Klinik Kesihatan / Klinik Des<br><input type="radio"/> Government Hospital - MO or specialist |  |                   |  |  |  |  |  |  |  |   |   |  |  | <input type="radio"/> General Practitioner (GP)<br><input type="radio"/> Private Hospital - MO or specialists |   |  |  |  |  |  |  |                                      |  |         |  |                                      |         | <input type="radio"/> Optometrists/ Optician<br><input type="radio"/> Others, specify: |  |  |  |  |  |

|  |  |  |  |                                  |  |                 |  |                            |  |
|--|--|--|--|----------------------------------|--|-----------------|--|----------------------------|--|
| <b>*1. Date of Presentation:</b>                   |  | <div> <div>d</div> <div>d</div> <div>m</div> <div>m</div> <div>y</div> <div>y</div> </div>   |  | <b>*2. Duration of Symptoms:</b> |  | (days)          |  |                            |  |
| <b>*3. Affected eye :</b>                          |  | <div> <input type="radio"/> Right Eye           <input type="radio"/> Left Eye           <input type="radio"/> Both Eye         </div>   |  |                                  |  |                 |  |                            |  |
| <b>4. Vision at Presentation :</b>                 |  | <b>Right eye</b>   |  |                                  |  | <b>Left eye</b> |  |                            |  |
|  |  | a) Unaided:  |  | b) With glasses / pinhole:       |  | a) Unaided:     |  | b) With glasses / pinhole: |  |
| <b>5. Presumptive causative organism :</b>         |  | <input type="checkbox"/> Bacteria <input type="checkbox"/> Fungus <input type="checkbox"/> Acanthamoeba <input type="checkbox"/> Others, specify: _____  |  |                                  |  |                 |  |                            |  |
| <b>6. Laboratory investigation specimen sent :</b> |  | <input type="checkbox"/> Corneal scraping <input type="checkbox"/> Contact lens <input type="checkbox"/> Contact lens solution <input type="checkbox"/> PCR for fungus <input type="checkbox"/> Not sent   |  |                                  |  |                 |  |                            |  |
| <b>7. Type of Contact Lens :</b>                   |  | <input type="checkbox"/> Daily Disposable <input type="checkbox"/> Weekly Disposable <input type="checkbox"/> 2 weekly Disposable <input type="checkbox"/> Cosmetic coloured contact lens<br><input type="checkbox"/> Extended wear <input type="checkbox"/> Rigid gas permeable <input type="checkbox"/> Monthly Disposable <input type="checkbox"/> Others, specify : _____  |  |                                  |  |                 |  |                            |  |
| <b>8. Brand of Contact lens :</b>                  |  | (e.g. Pure Vision (Bausch & Lomb), Acuvue (Johnson & Johnson), Biomedic (Cooper Vision), Focus Night & Day (Ciba Vision))  |  |                                  |  |                 |  |                            |  |
| <b>9. Wearing Pattern :</b>                        |  | <input type="checkbox"/> Daily Wear (removes before sleep) <input type="checkbox"/> Extended wear (sleeps with lens on)  |  |                                  |  |                 |  |                            |  |
| <b>10. Cleaning Solution :</b>                     |  | <div> <input type="checkbox"/> Alcon           <input type="checkbox"/> Bausch and Lomb           <input type="checkbox"/> Allergan (AMO)           <input type="checkbox"/> Ciba Vision           <input type="checkbox"/> Opto-medic<br/> <input type="checkbox"/> Freskon           <input type="checkbox"/> Sauflon           <input type="checkbox"/> Multisoft           <input type="checkbox"/> I-Gel           <input type="checkbox"/> Medivue<br/> <input type="checkbox"/> Normal Saline           <input type="checkbox"/> Simvue           <input type="checkbox"/> Multimate           <input type="checkbox"/> Pharmasafe Multipurpose solution           <input type="checkbox"/> Tap Water<br/> <input type="checkbox"/> Others, specify : _____           <input type="checkbox"/> Do not use because of daily wear           <input type="checkbox"/> Not known         </div> |  |                                  |  |                 |  |                            |  |
| <b>11. Ocular Trauma :</b>                         |  | <input type="radio"/> Yes, specify: _____ <input type="radio"/> No   |  |                                  |  |                 |  |                            |  |

|                            |  |  |   |                                       |
|----------------------------|--|--|---|---------------------------------------|
| 1. Corneal Scraping :      | <input type="checkbox"/> Negative (No growth)                              | <input type="checkbox"/> Bacterial, specify: _____ | <input type="checkbox"/> Not Sent               | <input type="checkbox"/> Missing data |
|                            | <input type="checkbox"/> Acanthamoeba                                      | <input type="checkbox"/> Fungal, specify: _____    | <input type="checkbox"/> Others, specify: _____ |                                       |
| 2. Contact lens :          | <input type="checkbox"/> Negative (No growth)                              | <input type="checkbox"/> Bacterial, specify: _____ | <input type="checkbox"/> Not Sent               | <input type="checkbox"/> Missing data |
|                            | <input type="checkbox"/> Acanthamoeba                                      | <input type="checkbox"/> Fungal, specify: _____    | <input type="checkbox"/> Others, specify: _____ |                                       |
| 3. Contact lens solution : | <input type="checkbox"/> Negative (No growth)                              | <input type="checkbox"/> Bacterial, specify: _____ | <input type="checkbox"/> Not Sent               | <input type="checkbox"/> Missing data |
|                            | <input type="checkbox"/> Acanthamoeba                                      | <input type="checkbox"/> Fungal, specify: _____    | <input type="checkbox"/> Others, specify: _____ |                                       |
| 4. PCR :                   | <input checked="" type="radio"/> Detected, specify type of organism: _____ |  | <input type="radio"/> Not Detected              | <input type="radio"/> Not Sent        |

|  |  |  |                            |  |                 |  |                            |  |
|--|--|--|----------------------------|--|-----------------|--|----------------------------|--|
| <b>1. Final Diagnosis: (based on lab results and clinical response to treatment)</b> | <input type="checkbox"/> Bacterial, specify: _____ <input type="checkbox"/> Fungal, specify: _____<br><input type="checkbox"/> Acanthamoeba <input type="checkbox"/> Uncertain <input type="checkbox"/> Others, specify: _____ |  |                            |  |                 |  |                            |  |
| <b>2. Vision by 3 months after presentation:</b>                                     | <b>Right eye</b>   |  |                            |  | <b>Left eye</b> |  |                            |  |
|  | a) Unaided:  |  | b) With glasses / pinhole: |  | a) Unaided:     |  | b) With glasses / pinhole: |  |
| <b>3. Corneal Perforation :</b>  | <input type="radio"/> Yes <input type="radio"/> No   |  |                            |  |                 |  |                            |  |
| <b>4. Surgery :</b>  | <input type="checkbox"/> No <input type="checkbox"/> Penetrating keratoplasty <input type="checkbox"/> Eviseration <input type="checkbox"/> Cornea Gluing <input type="checkbox"/> Other, specify: _____                       |  |                            |  |                 |  |                            |  |
| <b>5. Case Referred to other center :</b>  | <input type="radio"/> Yes, specify hospital: _____ <input type="radio"/> No  |  |                            |  |                 |  |                            |  |

Office use:  /  Centre:

Where check boxes ☐ are provided, check (✓) one or more boxes. Where radio buttons ☐ are provided, check (✓) one box only. \* indicates compulsory field.

**\*i) Hospital / Clinic** \_\_\_\_\_ **\*ii) Date of notification (dd/mm/yy)**

|  |  |  |
|--|--|--|
|  |  |  |
|--|--|--|

|   |  |   |  |                         |  |  |  |              |  |   |  |   |  |        |  |   |  |  |  |
|---|--|---|--|-------------------------|--|--|--|--------------|--|---|--|---|--|--------|--|---|--|--|--|
| <b>*1. Patient Name :</b>   |  |   |  |                         |  |  |  |              |  |   |  |   |  |        |  |   |  |  |  |
| <b>*2. Identification Card Number :</b><br><small>If MyKad/MyKid is not available, please complete the Old IC or Other ID document No.</small>  |  | MyKad / MyKid:  |  |                         |  |  |  |              |  |   |  | -    -  |  |        |  | Old IC:   |  |  |  |
|   |  | Other ID document No:   |  |                         |  |  |  |              |  |   |  | → Specify type (eg.passport, armed force ID):       |  |        |  |   |  |  |  |
| <b>3. Residential area :</b>  |  | Postcode :  |  |                         |  |  |  | Town / City: |  |   |  |   |  | State: |  |   |  |  |  |
| <b>*4a. Date of Birth:</b>  |  | <div> <div><div>d</div><div>d</div></div> <div><div>m</div><div>m</div></div> <div><div>y</div><div>y</div></div> </div>  |  |                         |  |  |  |              |  |   |  | <b>*4b. Age of notification:</b><br>Auto Calculated |  |        |  | <div> <div><div></div><div></div></div> <div>year(s)</div> <div><div></div><div></div></div> <div>month(s)</div> </div> |  |  |  |
| <b>*5. Gender:</b>  |  | <input type="radio"/> Male<br><input type="radio"/> Female  |  | <b>6. Ethnic Group:</b> |  | <input type="radio"/> Malay <input type="radio"/> Indian <input type="radio"/> Melanau <input type="radio"/> Iban <input type="radio"/> Other, specify: _____<br><input type="radio"/> Chinese <input type="radio"/> Orang Asli <input type="radio"/> Kadazan/Murut/Bajau <input type="radio"/> Bidayuh    _____ |  |              |  |   |  |   |  |        |  |   |  |  |  |
| <b>7. Source of referral :</b>  |  | <input type="radio"/> Government OPD clinic / Klinik Kesihatan / Klinik Desa <input type="radio"/> General Practitioner (GP) <input type="radio"/> Optometrists/ Optician<br><input type="radio"/> Government Hospital - MO or specialist <input type="radio"/> Private Hospital - MO or specialists <input type="radio"/> Others, specify: _____ |  |                         |  |  |  |              |  |   |  |   |  |        |  |   |  |  |  |
| <b>8. Type of DM :</b>  |  | <input type="radio"/> Type II <input type="radio"/> Type I <input type="radio"/> Pre-diabetic   |  |                         |  |  |  |              |  |   |  | <b>9. Duration of DM :</b>                          |  |        |  | <div> <div><div></div><div></div></div> <div>month(s)</div> <div><div></div><div></div></div> <div>year(s)</div> </div> |  |  |  |
| <b>10. Treatment :</b>  |  | <input type="checkbox"/> Oral Medication only <input type="checkbox"/> Insulin only <input type="checkbox"/> Oral medication and insulin <input type="checkbox"/> Other, specify: _____   |  |                         |  |  |  |              |  |   |  |   |  |        |  |   |  |  |  |
| <b>11. Systemic co-morbidity :</b>  |  |   |  |                         |  |  |  |              |  | <b>12. Risk factors :</b>   |  |   |  |        |  |   |  |  |  |
| <input type="checkbox"/> None <input type="checkbox"/> IHD <input type="checkbox"/> Amputation<br><input type="checkbox"/> HPT <input type="checkbox"/> CVA <input type="checkbox"/> Peripheral neuropathy<br><input type="checkbox"/> Renal Impairment <input type="checkbox"/> Foot ulcer<br><input type="checkbox"/> Hypercholesterolemia <input type="checkbox"/> Anemia <input type="checkbox"/> Other, specify: _____ |  |   |  |                         |  |  |  |              |  | <input type="checkbox"/> Current Smoker<br><br><input type="checkbox"/> Pregnant → If yes, trimester: <input type="radio"/> 1st <input type="radio"/> 2nd <input type="radio"/> 3rd |  |   |  |        |  |   |  |  |  |
| <b>13. Ocular Co-morbidity :</b>  |  |   |  |                         |  |  |  |              |  | <b>14. Has patient had fundus examination before?</b>   |  |   |  |        |  |   |  |  |  |
| <input type="checkbox"/> None <input type="checkbox"/> Glaucoma<br><br><input type="checkbox"/> Cataract <input type="checkbox"/> Other, specify: _____   |  |   |  |                         |  |  |  |              |  | <input type="radio"/> Yes <input type="radio"/> No<br>→ Date of last fundal examination (mm/yy ) : <div><div></div><div></div></div>  |  |   |  |        |  |   |  |  |  |

|   |  |  |  |                                |  |
|---|--|--|--|--------------------------------|--|
| 1. Visual acuity :                              |  | a) Right eye   |  | b) Left eye                    |  |
|   |  | Unaided : <input type="text"/>   | With glasses/<br>Pin hole : <input type="text"/> | Unaided : <input type="text"/> | With glasses /<br>Pin hole: <input type="text"/> |
| *2. Fundus Finding :                            |  |  |  |                                |  |
| a) Right eye:                                   | <input type="radio"/> No view, comments: _____<br><input type="radio"/> No Diabetic Retinopathy<br><input type="radio"/> Has Diabetic Retinopathy (DR)   |  |  |                                |  |
|   | <input type="radio"/> i. Diabetic retinopathy type <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> <input type="radio"/> Mild non proliferative diabetic retinopathy<br/> <input type="radio"/> Moderate non proliferative diabetic retinopathy<br/> <input type="radio"/> Severe non proliferative diabetic retinopathy<br/> <input type="radio"/> Proliferative diabetic retinopathy, including quiescent PDR<br/> <input type="radio"/> Advanced diabetes eye disease               <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> <input type="checkbox"/> Persistent vitreous haemorrhage<br/> <input type="checkbox"/> Tractional retinal detachment                 </div> </div> <input type="radio"/> ii. Maculopathy → <input type="radio"/> Yes <input type="radio"/> No |  |  |                                |  |
| b) Left eye:                                    | <input type="radio"/> No view, comments: _____<br><input type="radio"/> No Diabetic Retinopathy<br><input type="radio"/> Has Diabetic Retinopathy (DR)   |  |  |                                |  |
|   | <input type="radio"/> i. Diabetic retinopathy type <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> <input type="radio"/> Mild non proliferative diabetic retinopathy<br/> <input type="radio"/> Moderate non proliferative diabetic retinopathy<br/> <input type="radio"/> Severe non proliferative diabetic retinopathy<br/> <input type="radio"/> Proliferative diabetic retinopathy, including quiescent PDR<br/> <input type="radio"/> Advanced diabetes eye disease               <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> <input type="checkbox"/> Persistent vitreous haemorrhage<br/> <input type="checkbox"/> Tractional retinal detachment                 </div> </div> <input type="radio"/> ii. Maculopathy → <input type="radio"/> Yes <input type="radio"/> No |  |  |                                |  |
| 3. Fundus photograph taken : (one or both eyes) |  | <input type="radio"/> Yes <input type="radio"/> No   |  |                                |  |
| 4. Plan :                                       |  | <input type="checkbox"/> Routine follow up as scheduled (patient do not need treatment) <input type="checkbox"/> Need further assessment such as FFA<br><input type="checkbox"/> Need procedures → <input type="checkbox"/> Need laser → <div style="border: 1px solid black; padding: 5px; display: inline-block;">           Type of laser : <input type="checkbox"/> Focal laser<br/> <input type="checkbox"/> Pan retinal photocoagulation (PRP)         </div><br><input type="checkbox"/> Need Vitreoretinal surgery <input type="checkbox"/> Need glaucoma procedure for rubeotic glaucoma<br><input type="checkbox"/> Others, state: _____ |  |                                |  |

# GLAUCOMA REGISTRY

Office use:  /   
Centre:

Instruction: This form is to be filled for patient who has glaucoma including glaucoma suspect. Where check boxes ☐ are provided, check (✓) one or more boxes. Where radio buttons ☐ are provided, check (✓) one box only.

i) Hospital : \_\_\_\_\_ ii) Date of notification (dd/mm/yy):    iii) Type of case: ☐ New ☐ Follow-up

## SECTION 1 : PATIENT PARTICULARS

|  |  |   |  |  |  |  |  |   |  |  |  |
|--|--|---|--|--|--|--|--|---|--|--|--|
| 1. Name of Patient :   |  |   |  |  |  |  |  |   |  |  |  |
| 2. Identification Card * Number :  |  | MyKad / MyKid: <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>  |  |  |  |  |  |   |  |  |  |
| If MyKad/MyKid is not available, please complete the Old IC or Other ID document |  | Other ID : (specify) (eg. old IC, passport, armed force, hospital registration No.) <input type="text"/> No. : <input type="text"/>   |  |  |  |  |  |   |  |  |  |
| 3. Address :   |  | Postcode: <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>   |  |  |  | Town / City: <input type="text"/>            |  |   |  | State: <input type="text"/>                        |  |
| 4a. Date of Birth: *   |  | <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>   |  |  |  | 4b. Age at notification: * (Auto Calculated) |  | <input type="text"/> <input type="text"/> year(s) |  | <input type="text"/> <input type="text"/> month(s) |  |
| 5. Gender: *   |  | <input type="radio"/> Male <input type="radio"/> Female         6. Ethnic * Group: <input type="radio"/> Malay <input type="radio"/> Indian <input type="radio"/> Melanau <input type="radio"/> Iban <input type="radio"/> Other, specify : _____<br><input type="radio"/> Chinese <input type="radio"/> Orang Asli <input type="radio"/> Kadazan/Murut/Bajau <input type="radio"/> Bidayuh |  |  |  |  |  |   |  |  |  |
| 7. Occupation: *   |  | <input type="radio"/> Government employed <input type="radio"/> Private employed <input type="radio"/> Self employed <input type="radio"/> Unemployed   |  |  |  |  |  |   |  |  |  |

## SECTION 2 : ASSOCIATE FACTORS \*

|                      |                                   |   |  |   |   |
|----------------------|-----------------------------------|---|--|---|---|
| 1. Medical History : | <input type="checkbox"/> None     | <input type="checkbox"/> Hypertension         | <input type="checkbox"/> Cardiac disease | <input type="checkbox"/> Vasospastic disease  | <input type="checkbox"/> History of steroid therapy |
|                      | <input type="checkbox"/> Diabetes | <input type="checkbox"/> Hypercholesterolemia | <input type="checkbox"/> Stroke          | <input type="checkbox"/> Respiratory diseases | <input type="checkbox"/> Family history of glaucoma |

## SECTION 3 : OCULAR EXAMINATION \*

|                                |  |                           |                                     |                                    |  |                           |   |                                    |                                     |                           |  |                                    |
|--------------------------------|--|---------------------------|-------------------------------------|------------------------------------|--|---------------------------|---|------------------------------------|-------------------------------------|---------------------------|--|------------------------------------|
| 1. Eye(s) affected:            | <input type="radio"/> Right eye only <input type="radio"/> Left eye only <input type="radio"/> Both eyes |                           |                                     |                                    |  |                           |   |                                    |                                     |                           |  |                                    |
|                                | a) OD  |                           |                                     |                                    | b) OS  |                           |   |                                    |                                     |                           |  |                                    |
| 2. VA:                         | (i) : <input type="checkbox"/> Unobtainable  |                           | (ii) Unaided : <input type="text"/> |                                    | (iii) With glasses/pH : <input type="text"/> |                           | (i) : <input type="checkbox"/> Unobtainable |                                    | (ii) Unaided : <input type="text"/> |                           | (iii) With glasses/pH : <input type="text"/> |                                    |
| 3. CUP-DISC RATIO (VERTICAL) : | <input type="radio"/> 0.1  | <input type="radio"/> 0.4 | <input type="radio"/> 0.7           | <input type="radio"/> 1.0          | <input type="radio"/> 0.1                    | <input type="radio"/> 0.4 | <input type="radio"/> 0.7                   | <input type="radio"/> 1.0          | <input type="radio"/> 0.2           | <input type="radio"/> 0.5 | <input type="radio"/> 0.8                    | <input type="radio"/> Undetermined |
|                                | <input type="radio"/> 0.2  | <input type="radio"/> 0.5 | <input type="radio"/> 0.8           | <input type="radio"/> Undetermined | <input type="radio"/> 0.2                    | <input type="radio"/> 0.5 | <input type="radio"/> 0.8                   | <input type="radio"/> Undetermined | <input type="radio"/> 0.3           | <input type="radio"/> 0.6 | <input type="radio"/> 0.9                    | <input type="radio"/> No view      |
|                                | <input type="radio"/> 0.3  | <input type="radio"/> 0.6 | <input type="radio"/> 0.9           | <input type="radio"/> No view      | <input type="radio"/> 0.3                    | <input type="radio"/> 0.6 | <input type="radio"/> 0.9                   | <input type="radio"/> No view      |                                     |                           |  |                                    |

## SECTION 4 : DIAGNOSIS \*

|                |  |                            |  |                                    |  |                            |  |                                    |
|----------------|--|----------------------------|--|------------------------------------|--|----------------------------|--|------------------------------------|
| 1. Diagnosis : | a) OD  |                            |  |                                    | b) OS  |                            |  |                                    |
|                | (i) Primary                                  |                            | (ii) Secondary                               |                                    | (i) Primary                                  |                            | (ii) Secondary                               |                                    |
|                | <input type="radio"/> Congenital             | <input type="radio"/> OHT  | <input type="radio"/> PEX                    | <input type="radio"/> PDS          | <input type="radio"/> Congenital             | <input type="radio"/> OHT  | <input type="radio"/> PEX                    | <input type="radio"/> PDS          |
|                | <input type="radio"/> POAG                   | <input type="radio"/> PACG | <input type="radio"/> Rubecotic              | <input type="radio"/> Inflammatory | <input type="radio"/> POAG                   | <input type="radio"/> PACG | <input type="radio"/> Rubecotic              | <input type="radio"/> Inflammatory |
|                | <input type="radio"/> Glaucoma suspect       | <input type="radio"/> PAC  | <input type="radio"/> Posttraumatic          | <input type="radio"/> Lens induced | <input type="radio"/> Glaucoma suspect       | <input type="radio"/> PAC  | <input type="radio"/> Posttraumatic          | <input type="radio"/> Lens induced |
|                | <input type="radio"/> PAC suspect            |                            | <input type="radio"/> Steroid Induced        | <input type="radio"/> Post Surgery | <input type="radio"/> PAC suspect            |                            | <input type="radio"/> Steroid Induced        | <input type="radio"/> Post Surgery |
|                | <input type="radio"/> Others, specify: _____ |                            | <input type="radio"/> Malignant              | <input type="radio"/> ICE          | <input type="radio"/> Others, specify: _____ |                            | <input type="radio"/> Malignant              | <input type="radio"/> ICE          |
|                |  |                            | <input type="radio"/> Mixed Type             | <input type="radio"/> OHT          |  |                            | <input type="radio"/> Mixed Type             | <input type="radio"/> OHT          |
|                |  |                            | <input type="radio"/> Others, specify: _____ |                                    |  |                            | <input type="radio"/> Others, specify: _____ |                                    |

## SECTION 5 : MANAGEMENT \*

|  |  |  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|--|--|
|  | a) OD  |  |  |  | b) OS  |  |  |  |
| 1. No treatment : (NPL or poor visual potential eye)                       | <input type="radio"/> Yes <input type="radio"/> No   |  |  |  | <input type="radio"/> Yes <input type="radio"/> No   |  |  |  |
| 2. Observation:  | <input type="radio"/> Yes <input type="radio"/> No   |  |  |  | <input type="radio"/> Yes <input type="radio"/> No   |  |  |  |
| 3. Current Medical Therapy<br>Note : fixed combination consider as 2 drugs | Antiglaucoma medication (topical/systemic) :<br><input type="radio"/> Yes <input type="radio"/> No<br><input type="checkbox"/> Beta-blockers <input type="checkbox"/> Alpha-adrenergic <input type="checkbox"/> Systemic CAIs<br><input type="checkbox"/> Prostaglandins <input type="checkbox"/> Hyperosmotic agents<br><input type="checkbox"/> Topical CAIs <input type="checkbox"/> Cholinergics <input type="checkbox"/> Others, specify: _____   |  |  |  | Antiglaucoma medication (topical/systemic) :<br><input type="radio"/> Yes <input type="radio"/> No<br><input type="checkbox"/> Beta-blockers <input type="checkbox"/> Alpha-adrenergic <input type="checkbox"/> Systemic CAIs<br><input type="checkbox"/> Prostaglandins <input type="checkbox"/> Hyperosmotic agents<br><input type="checkbox"/> Topical CAIs <input type="checkbox"/> Cholinergics <input type="checkbox"/> Others, specify: _____   |  |  |  |
| 4. Previous Laser Therapy  | <input type="radio"/> Yes <input type="radio"/> No<br><input type="checkbox"/> Iridotomy <input type="checkbox"/> Trabeculoplasty <input type="checkbox"/> Endocyclodiode<br><input type="checkbox"/> Iridoplasty <input type="checkbox"/> Transcleral Cyclodiode <input type="checkbox"/> Others, specify: _____  |  |  |  | <input type="radio"/> Yes <input type="radio"/> No<br><input type="checkbox"/> Iridotomy <input type="checkbox"/> Trabeculoplasty <input type="checkbox"/> Endocyclodiode<br><input type="checkbox"/> Iridoplasty <input type="checkbox"/> Transcleral Cyclodiode <input type="checkbox"/> Others, specify: _____  |  |  |  |
| 5. Previous Surgery  | <input type="radio"/> Yes <input type="radio"/> No<br><input type="checkbox"/> Trabeculectomy (plain) <input type="checkbox"/> Trabeculectomy (augmented)<br><input type="checkbox"/> Drainage Device <input type="checkbox"/> Cryotherapy<br><input type="checkbox"/> Needling <input type="checkbox"/> Surgical PI only<br><input type="checkbox"/> Non Penetrating Surgery <input type="checkbox"/> Goniotomy<br><input type="checkbox"/> Trabeculotomy <input type="checkbox"/> Others, specify: _____ |  |  |  | <input type="radio"/> Yes <input type="radio"/> No<br><input type="checkbox"/> Trabeculectomy (plain) <input type="checkbox"/> Trabeculectomy (augmented)<br><input type="checkbox"/> Drainage Device <input type="checkbox"/> Cryotherapy<br><input type="checkbox"/> Needling <input type="checkbox"/> Surgical PI only<br><input type="checkbox"/> Non Penetrating Surgery <input type="checkbox"/> Goniotomy<br><input type="checkbox"/> Trabeculotomy <input type="checkbox"/> Others, specify: _____ |  |  |  |

Examined by : ☐ Glaucoma Specialist ☐ Glaucoma Fellow ☐ Other specialist ☐ Medical Officer

|             |  |   |  |         |  |
|-------------|--|---|--|---------|--|
| Office use: |  | / |  | Centre: |  |
|-------------|--|---|--|---------|--|

\* i) Site (machine location) : \_\_\_\_\_ \* iii) Date of fundus photography (dd/mm/yy): 


|  |  |  |
|--|--|--|
|  |  |  |
|--|--|--|

\* ii) Site (where patient is from) : \_\_\_\_\_

|                              |  |  |   |
|------------------------------|--|--|---|
| <b>*iv) Photo taken by :</b> | <input type="radio"/> Family Medication Specialist (FMS) | <input type="radio"/> Medical Assistant (MA) | <input type="radio"/> Jururawat Masyarakat (JM) |
|                              | <input type="radio"/> Doctor (Dr)                        | <input type="radio"/> Staff Nurse (SN)       | <input type="radio"/> Radiographer (Rad)        |

|  |   |  |             |  |                  |  |  |  |  |  |  |  |             |  |             |  |
|--|---|--|-------------|--|------------------|--|--|--|--|--|--|--|-------------|--|-------------|--|
| 1. Patient Name :<br>*   |   |  |             |  |                  |  |  |  |  |  |  |  |             |  |             |  |
| 2. Identification Card<br>* Number :                                 | <div>MyKad / MyKid:</div> <div> <div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div> </div> <div>Old IC:</div> <div> <div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div> </div>  |  |             |  |                  |  |  |  |  |  |  |  |             |  |             |  |
| If MyKad/MyKid not available, please complete the Old IC or Other ID | <div>Other ID document No:</div> <div> <div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div> </div> <div>→ Specify type (eg.passport, armed force ID):</div> <div> <div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div> </div> |  |             |  |                  |  |  |  |  |  |  |  |             |  |             |  |
| 3. Age of notification:<br>*   |   |  | 4. Gender:  | <input type="radio"/> Male<br><br><input type="radio"/> Female | 5. Ethnic Group: | <input type="radio"/> Malay <input type="radio"/> Orang Asli <input type="radio"/> Iban<br><input type="radio"/> Chinese <input type="radio"/> Melanau <input type="radio"/> Bidayuh<br><input type="radio"/> Indian <input type="radio"/> Kadazan/Murut/Bajau <input type="radio"/> Other, specify: _____ |  |  |  |  |  |  |             |  |             |  |
| 6. Type of DM :  | <input type="radio"/> Type II <input type="radio"/> Type I  |  |             |  |                  | 7. Pregnancy :   | <input type="radio"/> Yes <input type="radio"/> No |  |  |  |  |  |             |  |             |  |
| 8. Treatment :   | <input type="radio"/> Oral Medication Only <input type="radio"/> Insulin Only <input type="radio"/> Oral Medication + Insulin <input type="radio"/> Other, specify : _____  |  |             |  |                  |  |  |  |  |  |  |  |             |  |             |  |
| 9. Visual Acuity :<br>*  | a) Right eye  |  | <div></div> |  |                  |  |  |  |  |  |  |  | b) Left eye |  | <div></div> |  |
| 10. Photo Taken :<br>*   | <div> <input type="radio"/> Both eyes<br/> <input type="radio"/> Right eye only<br/> <input type="radio"/> Left eye only         </div> <div>→ If photo of one eye or both eyes are not taken or not saved due to poor quality, reason :</div> <div> <input type="checkbox"/> No Red Reflex    <input type="checkbox"/> No View<br/> <input type="checkbox"/> No Eyeball    <input type="checkbox"/> Other, specify: _____         </div>                       |  |             |  |                  |  |  |  |  |  |  |  |             |  |             |  |

|   |   |
|---|---|
| <b>1. Date of Grading :</b><br>* (dd/mm/yy) <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> |   |
| <div> <div> <b>DIAGNOSIS</b> </div> <div> <b>MANAGEMENT PLAN</b> </div> </div>  |   |
| <input type="checkbox"/> Inadequate view for grading<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye  | <input type="radio"/> Call patient to repeat fundus photo<br><input type="radio"/> Refer eye clinic on :<br><div> <b>a) Date of appointment :</b> (dd/mm/yy)    <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> <b>b) Time of appointment :</b>    <input type="text"/> <input type="text"/> : <input type="text"/> <input type="text"/> </div> |
| <input type="checkbox"/> No apparent diabetic retinopathy :<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye   | Give appointment to repeat fundus photo at KK in :<br><input type="radio"/> One year <input type="radio"/> If pregnant, every 3 months  |
| <input type="checkbox"/> Mild non proliferative diabetic retinopathy :<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye                                | Give appointment to repeat fundus photo at KK in :<br><input type="radio"/> 9 months <input type="radio"/> One year <input type="radio"/> If pregnant, every 3 months   |
| <input type="checkbox"/> Moderate non proliferative diabetic retinopathy :<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye                            | Give appointment to repeat fundus photo at KK in :<br><input type="radio"/> 6 months <input type="radio"/> 9 months <input type="radio"/> If pregnant, every 3 months   |
| <input type="checkbox"/> Severe non proliferative diabetic retinopathy :<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye                              | <b>i. Refer eye clinic on :</b><br><div> <b>a) Date of appointment :</b> (dd/mm/yy)    <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> <b>b) Time of appointment :</b>    <input type="text"/> <input type="text"/> : <input type="text"/> <input type="text"/> </div>  |
| <input type="checkbox"/> Proliferative diabetic retinopathy :<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye   | <b>ii. Treatment planned :</b><br><input type="checkbox"/> Laser <input type="checkbox"/> Fundus Fluorescein Angiography (FFA)  |
| <input type="checkbox"/> Advanced diabetic eye disease :<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye  |   |
| <input type="checkbox"/> Maculopathy :<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye  | <b>i. Refer eye clinic for further assessment on :</b><br><div> <b>a) Date of appointment :</b> (dd/mm/yy)    <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> / <input type="text"/> <input type="text"/> <b>b) Time of appointment :</b>    <input type="text"/> <input type="text"/> : <input type="text"/> <input type="text"/> </div>   |
| <input type="checkbox"/> Glaucoma suspect :<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye   |   |
| <input type="checkbox"/> Age related macular degeneration :<br><input type="checkbox"/> Right eye <input type="checkbox"/> Left eye   | <b>Refer to Optometrists for refraction</b>   |
| <input type="checkbox"/> Other fundus findings :<br><input type="checkbox"/> Right eye, state : _____<br><input type="checkbox"/> Left eye, state : _____                     |   |
| <input type="checkbox"/> Vision worse the 6/12 in either eye  |   |

|  |   |
|--|---|
| <b>Date of referral letter faxed out:</b> (dd/mm/yy) | <div><div></div><div></div></div> / <div><div></div><div></div></div> / <div><div></div><div></div></div>   |
| <b>Patient seen at referring eye clinic</b>          | <div> <input type="radio"/> Yes         <input type="radio"/> No       </div> <div>  <div> <b>a) Date seen :</b><br/>           (dd/mm/yy)         </div> <div><div></div><div></div></div> / <div><div></div><div></div></div> / <div><div></div><div></div></div> </div> |

*Finalized Version 2.1 Last Updated on 25/11/2008*

Page 1 of 1

# RETINOBLASTOMA REGISTRY

Office use:  /   
Centre:

Where check boxes ☐ are provided, check (✓) one or more boxes. Where radio buttons ☐ are provided, check (✓) one box only.

i) Hospital / Clinic:  ii) Dr in charge:  iii) Date of Notification:  /  /

## SECTION A : DEMOGRAPHICS

|                                      |   |   |  |
|--------------------------------------|---|---|--|
| 1. Patient Name :                    |   |   |  |
| 2. Identification Card<br>* Number : | MyKad / MyKid: <input type="text"/> - <input type="text"/> - <input type="text"/> | Old IC: <input type="text"/>                                      |  |
|                                      | Other ID document No: <input type="text"/>  | Specify type (eg. passport, armed force ID): <input type="text"/> |  |
| 3. Address :                         | Postcode <input type="text"/>   | Town / City: <input type="text"/>                                 | State: <input type="text"/>  |
| 4. Contact number :                  | Homephone: <input type="text"/> - <input type="text"/>                            | H/P: <input type="text"/> - <input type="text"/>                  |  |
| 5. Date of Birth:                    | <input type="text"/> d <input type="text"/> m <input type="text"/> y              | 6. Age at presentation:   | <input type="text"/> year(s) <input type="text"/> month(s)   |
| 7. Gender:                           | <input type="radio"/> Male <input type="radio"/> Female                           | 8. Ethnic:  | <input type="radio"/> Malay <input type="radio"/> Indian <input type="radio"/> Melanau <input type="radio"/> Iban <input type="radio"/> Other, specify: <input type="text"/><br><input type="radio"/> Chinese <input type="radio"/> Orang Asli <input type="radio"/> Kadazan/Murut/Bajau <input type="radio"/> Bidayuh |

## SECTION B : OCULAR HISTORY AND PRESENTATION

|  |  |
|--|--|
| 1. Clinical presentation:                  | <input type="checkbox"/> Leukocoria <input type="checkbox"/> Strabismus <input type="checkbox"/> Proptosis <input type="checkbox"/> Others, specify: <input type="text"/>  |
| 2. Age of onset:                           | <input type="text"/> year(s) <input type="text"/> month(s)   |
| 3. Duration of disease:                    | <input type="text"/> month(s)  |
| 4. Eye affected:                           | <input type="radio"/> Right <input type="radio"/> Left <input type="radio"/> Both  |
| 5. Family History:                         | <input type="radio"/> Yes <input type="radio"/> No   |
| 6. Vision at presentation:                 | <div>Right eye</div> <div>Left eye</div>   |
| 6a. Vision:                                | <div>Right eye: Unaided: <input type="text"/> With glasses/pin hole: <input type="text"/></div> <div>Left eye: Unaided: <input type="text"/> With glasses/pin hole: <input type="text"/></div>   |
| 6b. Unable to take vision, appear to have: | <div>Right eye: <input type="radio"/> Normal vision <input type="radio"/> Impaired vision <input type="radio"/> Blind</div> <div>Left eye: <input type="radio"/> Normal vision <input type="radio"/> Impaired vision <input type="radio"/> Blind</div> |

## SECTION C : REFER TO TERTIARY CENTER

|                              |   |
|------------------------------|---|
| 1. Refer to tertiary center: | <input type="radio"/> No <input type="radio"/> Yes → Hospital: <input type="text"/> |
|------------------------------|---|

## SECTION D : INVESTIGATIONS & CLASSIFICATION

|                             |  |
|-----------------------------|--|
| 1. Imaging:                 | <div>Right eye</div> <div>Left eye</div>   |
| a) CT scan:                 | <div>Right eye: <input type="radio"/> No <input type="radio"/> Yes → Presence of mass <input type="checkbox"/> Presence of calcification <input type="checkbox"/> Extraocular extension <input type="checkbox"/> Optic pathway <input type="checkbox"/> Orbit and adnexa <input type="checkbox"/> Intracranial <input type="checkbox"/></div> <div>Left eye: <input type="radio"/> No <input type="radio"/> Yes → Presence of mass <input type="checkbox"/> Presence of calcification <input type="checkbox"/> Extraocular extension <input type="checkbox"/> Optic pathway <input type="checkbox"/> Orbit and adnexa <input type="checkbox"/> Intracranial <input type="checkbox"/></div> |
| b) MRI:                     | <div>Right eye: <input type="radio"/> No <input type="radio"/> Yes → Presence of mass <input type="checkbox"/> Presence of calcification <input type="checkbox"/> Extraocular extension <input type="checkbox"/> Optic pathway <input type="checkbox"/> Orbit and adnexa <input type="checkbox"/> Intracranial <input type="checkbox"/></div> <div>Left eye: <input type="radio"/> No <input type="radio"/> Yes → Presence of mass <input type="checkbox"/> Presence of calcification <input type="checkbox"/> Extraocular extension <input type="checkbox"/> Optic pathway <input type="checkbox"/> Orbit and adnexa <input type="checkbox"/> Intracranial <input type="checkbox"/></div> |
| 2. Genetic testing (blood): | <input type="radio"/> No <input type="radio"/> Yes → <input type="radio"/> +ve <input type="radio"/> -ve   |
| 3. Diagnosis:               | <div>Right eye: <input type="radio"/> Confirmed Retinoblastoma <input type="radio"/> Not Retinoblastoma, other diagnosis: <input type="text"/></div> <div>Left eye: <input type="radio"/> Confirmed Retinoblastoma <input type="radio"/> Not Retinoblastoma, other diagnosis: <input type="text"/></div>   |
|                             | <div>Right eye: <input type="checkbox"/> Congenital cataract <input type="checkbox"/> Retinal Dysplasia <input type="checkbox"/> Others, specify: <input type="text"/></div> <div>Left eye: <input type="checkbox"/> Congenital cataract <input type="checkbox"/> Retinal Dysplasia <input type="checkbox"/> Others, specify: <input type="text"/></div>   |
| 4. Classification:          | <div>Right eye: <input type="radio"/> Group A <input type="radio"/> Group B <input type="radio"/> Group C <input type="radio"/> Group D <input type="radio"/> Group E</div> <div>Left eye: <input type="radio"/> Group A <input type="radio"/> Group B <input type="radio"/> Group C <input type="radio"/> Group D <input type="radio"/> Group E</div>   |

## SECTION E : MANAGEMENT (to be filled up after 3 months)

|   |  |
|---|--|
| 1. Chemotherapy:                        | <div>Right eye</div> <div>Left eye</div>   |
|   | <div>Right eye: <input type="radio"/> No <input type="radio"/> Yes → Systemic Chemotherapy: <input type="text"/> cycles <input type="checkbox"/> Subtenon Injection: <input type="checkbox"/> Ocular chemotherapy injection: <input type="checkbox"/> Intravitreal injection: <input type="checkbox"/></div> <div>Left eye: <input type="radio"/> No <input type="radio"/> Yes → Systemic Chemotherapy: <input type="text"/> cycles <input type="checkbox"/> Subtenon Injection: <input type="checkbox"/> Ocular chemotherapy injection: <input type="checkbox"/> Intravitreal injection: <input type="checkbox"/></div>   |
| 2. Enucleation:                         | <div>Right eye</div> <div>Left eye</div>   |
|   | <div>Right eye: <input type="radio"/> No <input type="radio"/> Yes → HPE Result - Extension of tumour based on HPE results: <input type="checkbox"/> Intracocular (no extraocular extension) <input type="checkbox"/> With extraocular extension <input type="checkbox"/> Lamina cribrosa <input type="checkbox"/> Bruch's membrane <input type="checkbox"/> Superficial choroids <input type="checkbox"/> Deep choroids <input type="checkbox"/> Sclera <input type="checkbox"/> Optic nerve end <input type="checkbox"/></div> <div>Left eye: <input type="radio"/> No <input type="radio"/> Yes → HPE Result - Extension of tumour based on HPE results: <input type="checkbox"/> Intracocular (no extraocular extension) <input type="checkbox"/> With extraocular extension <input type="checkbox"/> Lamina cribrosa <input type="checkbox"/> Bruch's membrane <input type="checkbox"/> Superficial choroids <input type="checkbox"/> Deep choroids <input type="checkbox"/> Sclera <input type="checkbox"/> Optic nerve end <input type="checkbox"/></div> |
| 3. Focal therapy:                       | <input type="radio"/> No <input type="radio"/> Yes → <input type="checkbox"/> Laser <input type="checkbox"/> Cryotherapy   |
| 4. Radiotherapy:                        | <input type="radio"/> No <input type="radio"/> Yes → <input type="checkbox"/> External beam radiation (EBRT) <input type="checkbox"/> Plaque radiotherapy <input type="checkbox"/> Intensity modulated radiotherapy (IMRT)   |
| 5. Traditional complementary medicine : | <input type="radio"/> No <input type="radio"/> Yes   |

## SECTION F : OUTCOME & COMPLICATIONS (to be filled up after 1 year)

|   |  |
|---|--|
| 1. Vision:  | <div>Right eye</div> <div>Left eye</div>   |
| 1a. Vision at the last follow up soon after 1 year: | <div>Right eye: Unaided: <input type="text"/> With glasses/pin hole: <input type="text"/></div> <div>Left eye: Unaided: <input type="text"/> With glasses/pin hole: <input type="text"/></div>   |
| 1b. Unable to take vision, appear to have:          | <div>Right eye: <input type="radio"/> Normal vision <input type="radio"/> Impaired vision <input type="radio"/> Blind</div> <div>Left eye: <input type="radio"/> Normal vision <input type="radio"/> Impaired vision <input type="radio"/> Blind</div>   |
| 2. Remission:                                       | <div>Right eye</div> <div>Left eye</div>   |
|   | <div>Right eye: <input type="radio"/> No regression <input type="radio"/> Partial regression → Type of regression: <input type="checkbox"/> Flat scar <input type="checkbox"/> Fish-flesh <input type="checkbox"/> Complete <input type="checkbox"/> Calcification <input type="checkbox"/> Mixed</div> <div>Left eye: <input type="radio"/> No regression <input type="radio"/> Partial regression → Type of regression: <input type="checkbox"/> Flat scar <input type="checkbox"/> Fish-flesh <input type="checkbox"/> Complete <input type="checkbox"/> Calcification <input type="checkbox"/> Mixed</div> |
| 3. Recurrence:                                      | <input type="radio"/> No <input type="radio"/> Yes → Duration from first time treatment: <input type="text"/> month(s)   |
| 4. Complications:                                   | <div>Right eye: <input type="radio"/> No <input type="radio"/> Yes → Socket / prosthesis related, specify: <input type="text"/> Disease related, specify: <input type="text"/> Chemo related, specify: <input type="text"/> Radiation related, specify: <input type="text"/></div> <div>Left eye: <input type="radio"/> No <input type="radio"/> Yes → Socket / prosthesis related, specify: <input type="text"/> Disease related, specify: <input type="text"/> Chemo related, specify: <input type="text"/> Radiation related, specify: <input type="text"/></div>   |
| 5. Lost to follow up :                              | <input type="radio"/> No <input type="radio"/> Yes   |
| 6. Outcome by 1 year :                              | <input type="radio"/> Alive <input type="radio"/> Death <input type="radio"/> Unknown  |

Office use:  /   
Centre:

Where check boxes ☐ are provided, check (✓) one or more boxes. Where radio buttons ☐ are provided, check (✓) one box only.

ii) Date of Notification : 

|  |  |
|--|--|
|  |  |
|--|--|

 / 

|  |  |
|--|--|
|  |  |
|--|--|

 / 

|  |  |
|--|--|
|  |  |
|--|--|

|  |  |  |  |               |  |  |  |  |  |  |  |   |  |  |  |         |  |         |  |  |  |          |  |
|--|--|--|--|---------------|--|--|--|--|--|--|--|---|--|--|--|---------|--|---------|--|--|--|----------|--|
| 1. Patient Name :<br>*   |  |  |  |               |  |  |  |  |  |  |  |   |  |  |  |         |  |         |  |  |  |          |  |
| 2. Identification Card<br>* Number :   |  | MyKad / MyKid:   |  |               |  |  |  |  |  |  |  |   |  |  |  | Old IC: |  |         |  |  |  |          |  |
| If MyKad/MyKid is not available, please complete the Old IC or Other ID document No. |  | Other ID document No:                                      |  |               |  |  |  | →  |  | Specify type (eg. passport, armed force ID):                               |  |   |  |  |  |         |  |         |  |  |  |          |  |
|  |  |  |  |               |  |  |  |  |  |  |  |   |  |  |  |         |  |         |  |  |  |          |  |
| 3. Address :   |  | Postcode :   |  |               |  |  |  |  |  | Town / City:   |  |   |  |  |  |         |  | State:  |  |  |  |          |  |
| 4. Date of Birth:<br>*   |  |  |  |               |  |  |  | (dd/mm/yy)   |  | 5. Age at presentation:<br>* (Auto calculated)                             |  |   |  |  |  |         |  | year(s) |  |  |  | month(s) |  |
| 6. Gender:<br>*  |  | <input type="radio"/> Male<br><input type="radio"/> Female |  | 7. Ethnicity: |  | <input type="radio"/> Malay<br><input type="radio"/> Chinese |  | <input type="radio"/> Indian<br><input type="radio"/> Orang Asli |  | <input type="radio"/> Melanau<br><input type="radio"/> Kadazan/Murut/Bajau |  | <input type="radio"/> Iban<br><input type="radio"/> Bidayuh |  | <input type="radio"/> Other, specify:<br>----- |  |         |  |         |  |  |  |          |  |

**1. Risk Factors :**

|   |  |   |
|---|--|---|
| <input type="checkbox"/> None                   | <input type="checkbox"/> Ischaemic Heart Disease (IHD)   | <input type="checkbox"/> Cataract surgery within last 3 months prior to onset of symptoms in the affected eye(s)        |
| <input type="checkbox"/> Diabetes Mellitus (DM) | <input type="checkbox"/> Hypercholesterolemia  |   |
| <input type="checkbox"/> Hypertension (HPT)     | <input type="checkbox"/> Smoking → <input type="radio"/> Current <input type="radio"/> Past  | <input type="checkbox"/> Right eye <input type="checkbox"/> Left eye  |
| <input type="checkbox"/> Past Stroke            | <input type="checkbox"/> Myopia - right eye → <input type="checkbox"/> Right eye → <input type="radio"/> < 2 d <input type="radio"/> 2-8 d <input type="radio"/> > 8 d | <input type="checkbox"/> Left eye → <input type="radio"/> < 2 d <input type="radio"/> 2-8 d <input type="radio"/> > 8 d |

|  |  |   |  |  |  |
|--|--|---|--|--|--|
| <b>1. Quality of Life:</b>   |  | <input type="radio"/> Yes → If Yes, do you have difficulty driving during daytime in familiar places? |  | <input type="radio"/> No → If No, reason:  |  |
| <b>i. Are you currently driving, at least once a while ?</b>                                     |  | <input type="radio"/> Yes <input type="radio"/> No  |  | <input type="radio"/> Never drive <input type="radio"/> Others, specify: _____<br><input type="radio"/> Gave up because of poor eye sight      _____ |  |
| <b>ii. Because of your eyesight, do you have difficulty reading ordinary print in newspaper?</b> |  | <input type="radio"/> Yes <input type="radio"/> No  |  |  |  |

| 1 Medical History :            |  | Symptoms   |  |
|--------------------------------|--|--|--|
| i. Metamorphopsia:             | <input type="radio"/> Yes <input type="radio"/> No   | <input type="radio"/> Yes <input type="radio"/> No |  |
| ii. Scotoma:                   | <input type="radio"/> Yes <input type="radio"/> No   | <input type="radio"/> Yes <input type="radio"/> No |  |
| iii. Blurring of vision :      | <input type="radio"/> Yes <input type="radio"/> No   | <input type="radio"/> Yes <input type="radio"/> No |  |
| iv. Duration of symptoms:      | <input type="text"/> Week(s) <input type="text"/> Month(s) <input type="text"/> Year(s)  |  |  |
| v. Previous treatment for AMD: | <input type="radio"/> Yes <input type="radio"/> No <div style="border: 1px dashed black; padding: 5px; display: inline-block; margin-left: 10px;">           If Yes, what treatment:           <div style="display: flex; flex-wrap: wrap; gap: 10px;"> <div><input type="checkbox"/> PDT</div> <div><input type="checkbox"/> PDT+Anti VEGF</div> <div><input type="checkbox"/> Argon Laser</div> <div><input type="checkbox"/> Anti VEGF</div> <div><input type="checkbox"/> Intravitreal Triamcinolone</div> </div> </div> |  |  |

|  |  |  |
|--|--|--|
| 1. Affected eye :  | <input type="radio"/> Right eye <input type="radio"/> Left eye <input type="radio"/> Both eyes             |  |
|  | a) Right eye   | b) Left eye  |
| 2. Vision : (fill in for both affected and non-affected eye) | Unaided: <input type="text"/> With glasses/<br>Pin hole: <input type="text"/>                              | Unaided: <input type="text"/> With glasses/<br>Pin hole: <input type="text"/>                              |
| 3. Fundus Finding :  | a) Right eye   | b) Left eye  |
| i. Type of AMD:  | <input type="radio"/> Exudative <input type="radio"/> Nonexudative   | <input type="radio"/> Exudative <input type="radio"/> Nonexudative   |
| ii. Presence of Drusen:                                      | <input type="radio"/> Yes → <input type="radio"/> Soft <input type="radio"/> Hard <input type="radio"/> No | <input type="radio"/> Yes → <input type="radio"/> Soft <input type="radio"/> Hard <input type="radio"/> No |
| iii. Presence of Central Geographic Atrophy:                 | <input type="radio"/> Yes <input type="radio"/> No   | <input type="radio"/> Yes <input type="radio"/> No   |
| iv. Presence of Pigment Epithelial Detachment:               | <input type="radio"/> Yes <input type="radio"/> No   | <input type="radio"/> Yes <input type="radio"/> No   |
| v. Presence of Subretinal Haemorrhage:                       | <input type="radio"/> Yes <input type="radio"/> No   | <input type="radio"/> Yes <input type="radio"/> No   |
| vi. Presence of Disciform Scar:                              | <input type="radio"/> Yes <input type="radio"/> No   | <input type="radio"/> Yes <input type="radio"/> No   |

|         | a) Right eye   | b) Left eye  |
|---------|--|--|
| 1. OCT: | <input type="radio"/> Done <input type="radio"/> Not Done<br>If done, findings: <input type="checkbox"/> Subretinal Fluid <input type="checkbox"/> Others, specify: <input type="checkbox"/> Pigment Epithelial Detachment   | <input type="radio"/> Done <input type="radio"/> Not Done<br>If done, findings: <input type="checkbox"/> Subretinal Fluid <input type="checkbox"/> Others, specify: <input type="checkbox"/> Pigment Epithelial Detachment   |
| 2. FFA: | <input type="radio"/> Done <input type="radio"/> Not Done<br>If done, findings: <input type="checkbox"/> CNV <input type="checkbox"/> Scar <input type="checkbox"/> PED<br>ii. Type of choroidal neovascularization (CNV): <input type="checkbox"/> Classic <input type="checkbox"/> Minimally classic <input type="checkbox"/> Predominantly classic <input type="checkbox"/> Occult<br>iii. Location of CNV: <input type="radio"/> Subfoveal <input type="radio"/> Juxtafoveal <input type="radio"/> Extrafoveal | <input type="radio"/> Done <input type="radio"/> Not Done<br>If done, findings: <input type="checkbox"/> CNV <input type="checkbox"/> Scar <input type="checkbox"/> PED<br>ii. Type of choroidal neovascularization (CNV): <input type="checkbox"/> Classic <input type="checkbox"/> Minimally classic <input type="checkbox"/> Predominantly classic <input type="checkbox"/> Occult<br>iii. Location of CNV: <input type="radio"/> Subfoveal <input type="radio"/> Juxtafoveal <input type="radio"/> Extrafoveal |
| 3. ICG: | <input type="radio"/> Done <input type="radio"/> Not Done<br>If done, findings: <input type="checkbox"/> Polyps <input type="checkbox"/> Plaque <input type="checkbox"/> No Abnormality  | <input type="radio"/> Done <input type="radio"/> Not Done<br>If done, findings: <input type="checkbox"/> Polyps <input type="checkbox"/> Plaque <input type="checkbox"/> No Abnormality  |

| a) Right eye                                  |   |   | b) Left eye                                   |   |   |
|---|---|---|---|---|---|
| <input type="checkbox"/> Early AMD            | <input type="checkbox"/> Advanced AMD: Disciform Scar                 | <input type="checkbox"/> Others, specify: _____ | <input type="checkbox"/> Early AMD            | <input type="checkbox"/> Advanced AMD: Disciform Scar                 | <input type="checkbox"/> Others, specify: _____ |
| <input type="checkbox"/> Intermediate AMD     | <input type="checkbox"/> Polypoidal choroidal vasculopathy (PCV)      | _____   | <input type="checkbox"/> Intermediate AMD     | <input type="checkbox"/> Polypoidal choroidal vasculopathy (PCV)      | _____   |
| <input type="checkbox"/> Advanced AMD:        | <input type="checkbox"/> Choroidal neovascularization (CNV): Active   | _____   | <input type="checkbox"/> Advanced AMD:        | <input type="checkbox"/> Choroidal neovascularization (CNV): Active   | _____   |
| <input type="checkbox"/> Geographical Atrophy | <input type="checkbox"/> Choroidal neovascularization (CNV): Resolved | _____   | <input type="checkbox"/> Geographical Atrophy | <input type="checkbox"/> Choroidal neovascularization (CNV): Resolved | _____   |

| a) Right eye                |                    |                                    |   |                                      |   | b) Left eye                 |                    |                                    |   |                                      |   |
|-----------------------------|--------------------|------------------------------------|---|--------------------------------------|---|-----------------------------|--------------------|------------------------------------|---|--------------------------------------|---|
| <input type="radio"/> Yes → | Type of treatment: | <input type="checkbox"/> PDT       | <input type="checkbox"/> PDT+Anti VEGF              | <input type="checkbox"/> Argon Laser | <input type="checkbox"/> Others, specify: _____ | <input type="radio"/> Yes → | Type of treatment: | <input type="checkbox"/> PDT       | <input type="checkbox"/> PDT+Anti VEGF              | <input type="checkbox"/> Argon Laser | <input type="checkbox"/> Others, specify: _____ |
| <input type="radio"/> None  |                    | <input type="checkbox"/> Anti VEGF | <input type="checkbox"/> Intravitreal Triamcinolone |                                      |   | <input type="radio"/> None  |                    | <input type="checkbox"/> Anti VEGF | <input type="checkbox"/> Intravitreal Triamcinolone |                                      |   |

☐ Medical officer

# ADVERSE INCIDENT NOTIFICATION FORM - IOL DEFECTS

Office use:  /   
Centre:

Instruction: Where check boxes ☐ are provided, check (✓) one or more boxes. Where radio buttons ☐ are provided, check (✓) one box only.

All health care providers who noted defects on an intraocular lens either before, during or after IOL implantation are encouraged to report to the IOL Defects On-line Notification initiated and coordinated by the National Eye Database (NED). NED is a web-based registry on eye diseases, sponsored by the MOH and Malaysian Society of Ophthalmology. The report will be monitored and reported to the Medical Device Division, MOH for further investigation. A periodic report will also be available on NED website.

\* i) Date of notification:  /  /  (dd/mm/yyyy)

## Section A: Description of an Adverse Event

|   |  |  |  |
|---|--|--|--|
| 1. Date of diagnosis of IOL defect: (dd/mm/yyyy) <input type="text"/> / <input type="text"/> / <input type="text"/> |  | 2. Date of IOL implantation: (dd/mm/yyyy) <input type="text"/> / <input type="text"/> / <input type="text"/> <input type="checkbox"/> Estimated year<br>(If the exact date is not known, please enter 30/06/yyyy and tick the Estimated year checkbox)   |  |
| 3. Type of incident: *  |  | <input type="checkbox"/> IOL Opacification <input type="checkbox"/> Fine deposits on optic <input type="checkbox"/> Early cataract formation subsequent to phakic IOL implantation <input type="checkbox"/> Failure of IOL injector<br><input type="checkbox"/> Crack on optic <input type="checkbox"/> Fracture or detachment of haptic(s) <input type="checkbox"/> Incorrect labeling of IOL, including IOL power <input type="checkbox"/> Others, specify: _____<br><input type="checkbox"/> Lines on optic |  |
| 4. Patient characteristics: *   | a. Age of patient at implantation: <input type="text"/> / <input type="text"/> | b. Current age: <input type="text"/> / <input type="text"/>  | c. Gender: <input type="radio"/> Male <input type="radio"/> Female |
|   | d. Ocular co-morbidity: *  | <input type="checkbox"/> Glaucoma <input type="checkbox"/> Uveitis <input type="checkbox"/> Diabetic retinopathy<br><input type="checkbox"/> Others, specify: _____  |  |
|   | e. Systemic co-morbidity: *  | <input type="checkbox"/> Diabetes mellitus <input type="checkbox"/> Renal failure <input type="checkbox"/> Hypercalcemia<br><input type="checkbox"/> Others, specify: _____  |  |
|   | f. Previous ocular surgery (besides cataract surgery): *                       | <input type="checkbox"/> Glaucoma surgery <input type="checkbox"/> Vitreoretinal surgery<br><input type="checkbox"/> Others, specify: _____  |  |

## Section B: Action Taken

|                    |   |   |
|--------------------|---|---|
| 1. Action taken: * | <input type="checkbox"/> None<br><input type="checkbox"/> Monitoring<br><input type="checkbox"/> Explanation of IOL |   |
|                    | a. Date of explanation: <input type="text"/> / <input type="text"/> / <input type="text"/> (dd/mm/yyyy)             |   |
|                    | b. Replaced with new IOL? <input type="radio"/> Yes <input type="radio"/> No  |   |
|                    | c. Reason(s) for explanation: *   | <input type="checkbox"/> Decrease in best corrected visual acuity <input type="checkbox"/> IOL dislocation<br><input type="checkbox"/> Significant halos / glare / starbursts <input type="checkbox"/> IOL opacification<br><input type="checkbox"/> Significant irregular astigmatism induced <input type="checkbox"/> IOL defect<br><input type="checkbox"/> Diplopia, or other significant visual disturbances <input type="checkbox"/> Others, specify: _____ |

## Section C: Outcome of Incident

|               |  |  |
|---------------|--|--|
| 1. Outcome: * | <input type="checkbox"/> Financial loss - Hospital or individual (e.g. the need to buy new IOL and have another operation)<br><input type="checkbox"/> Distress to the patient | <input type="checkbox"/> Complaint from public<br><input type="checkbox"/> Non-significant |
|---------------|--|--|

## Section D: Details of IOL

|                                     |   |  |   |  |
|-------------------------------------|---|--|---|--|
| 1. IOL company: *                   | <input type="radio"/> Alcon <input type="radio"/> Medennium <input type="radio"/> Freedom IOL <input type="radio"/> The Vision Membrane phakic IOL <input type="radio"/> Not known<br><input type="radio"/> Hoya <input type="radio"/> Ophtec <input type="radio"/> AMO <input type="radio"/> The PRL Phakic Refractive Lens<br><input type="radio"/> ERILENS <input type="radio"/> OII Intracocular Lenses <input type="radio"/> Tekia Inc <input type="radio"/> Eyeonics<br><input type="radio"/> Lenstec <input type="radio"/> Corneal <input type="radio"/> Staar <input type="radio"/> GEL-MED International<br><input type="radio"/> Others, specify: _____ |  |   |  |
| 2. IOL model:                       |   |  |   |  |
| 3i. IOL type:                       | <input type="radio"/> Foldable <input type="radio"/> Non foldable <input type="radio"/> Not known   | 3ii. IOL material:   | <input type="radio"/> Acrysoft hydrophobic <input type="radio"/> Silicon <input type="radio"/> Not known<br><input type="radio"/> Acrysoft hydrophilic <input type="radio"/> PMMA |  |
| 4. Lot No. / Serial No.:            |   |  |   |  |
| 5. IOL Expired date: (if available) | <input type="text"/> / <input type="text"/> / <input type="text"/>  |  |   |  |
| 6. Distributor company:             | a. Name:  |  |   |  |
|                                     | b. Contact address:   |  |   |  |
|                                     | c. Email:   |  |   |  |
|                                     | d. Contact no.:   | <input type="text"/> - <input type="text"/> H/P: <input type="text"/> - <input type="text"/> |   |  |

## Section E: Reporting Person

|                               |   |  |  |
|-------------------------------|---|--|--|
| 1. Reporting person's name: * |   |  |  |
| 2. Position: *                | <input type="radio"/> Doctor <input type="radio"/> Nurse <input type="radio"/> Medical Assistant <input type="radio"/> Others, specify: _____ |  |  |
| 3. Name of facility: *        |   |  |  |
| 4. Email: *                   |   |  |  |
| 5. Contact no: *              | <input type="text"/> - <input type="text"/> H/P: <input type="text"/> - <input type="text"/>  |  |  |

Thank you for reporting an adverse incident concerning an IOL. Our NED manager will be contacting you shortly.

